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 1 
CHAPTER I 
 
BACKGROUND AND LITERATURE REVIEW 
 
Introduction 
Coronaviruses are positive-sense, single-stranded RNA viruses that are important pathogens of 
both humans and animals. Coronaviruses belong to the Coronaviridae family of viruses and were 
first classified as a distinct virus family as a result of human respiratory pathogen research during 
the 1960s (Masters, 2006). In negative-stained electron micrographs, early investigators noted 
the enveloped virion was surrounded by a “fringe of crown-like projections” (Figure 1) (Masters, 
2006). Ultimately, their fundamental observations reminded them of the solar corona and led 
them to propose the name coronaviruses (Almeida et al., 1968). Since their initial discovery, 
coronaviruses have been shown to infect a wide range of mammalian and avian species and are 
notoriously capable of transmission to new hosts (de Wit et al., 2016; Perlman and Netland, 
2009). Primarily, coronaviruses cause respiratory or enteric disease in their hosts and are spread 
by respiratory droplet and fecal-oral routes (Masters, 2006). In humans, approximately 15% of 
all cases of the common cold each year are caused by coronaviruses (Wei et al., 1975; Züst et al., 
2011). In addition, coronaviruses are capable of causing severe and lethal human disease as 
demonstrated by severe acute respiratory syndrome coronavirus (SARS-CoV) and Middle East 
respiratory syndrome coronavirus (MERS-CoV), which have emerged into the human population 
in this century. Currently, no specific antiviral therapies or vaccines exist for human 
coronaviruses, highlighting the need for an increased understanding of coronavirus biology. In 
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Figure 1. Coronavirus virion structure and EM 
 
(A) Schematic representation of a coronavirus virion. Spike (S), nucleocapsid (N), membrane (M), and 
envelope (E) structural proteins are indicated. (B) Negatively stained electron micrograph of avian 
infectious bronchitis virus particles with notable spike protein projections visible. This figure is 
derived from Perlman and Netland, 2009 and Berry and Almeida, 1968 with permission. 
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this dissertation research, I advance our knowledge of coronavirus replication requirements and 
how coronaviruses overcome host defenses.   
 
Coronavirus disease and emergence 
Coronaviruses are widely distributed throughout mammals and birds. Coronavirus infections 
have been observed in humans, mice, dogs, cats, pigs, hedgehogs, cattle, turkeys, chickens, bats, 
whales, and numerous other animals (Leibowitz et al., 2011). Notably, coronaviruses cause 
several veterinary diseases of economic importance (Acheson, 2011). In pigs, transmissible 
gastroenteritis virus (TGEV) and porcine epidemic diarrhea virus (PEDV), as their names imply, 
cause severe diarrhea and dehydration resulting in significant morbidity and mortality. It is 
estimated that PEDV alone causes $900 million to $1.8 billion in economic losses in the United 
States each year (Annamalai et al., 2015). One of the first identified and most studied 
coronaviruses, infectious bronchitis virus, causes respiratory disease in meat-type and egg-laying 
chickens and is one of the foremost causes of economic loss within these industries (Cavanagh, 
2007). Bovine coronavirus causes respiratory and enteric infections in newborn calves and other 
wild ruminants. Further, bovine coronavirus infection can result in clinical syndromes known as 
winter dysentery with hemorrhagic diarrhea and shipping fever in adult cattle (Saif, 2010). In all 
of these examples, mortality rates can approach 100% in newborn animals (Acheson, 2011).  
 
Currently, four coronaviruses are endemic in the human population: human coronaviruses 229E, 
OC43, HKU1, and NL63. All human coronaviruses are proposed to have emerged into the 
human population through zoonotic events. Human coronaviruses 229E and OC43 were 
discovered during the previously mentioned search for the common cold of the 1960s (Garbino 
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et al., 2006; Masters, 2006; Perlman and Netland, 2009). Using molecular clock analysis, 
researchers propose that human coronavirus 229E emerged into the human population between 
approximately 1686-1880 A.D. and is most closely related to coronaviruses isolated from 
alpacas, which may represent intermediate hosts from bats (Crossley et al., 2012; Pfefferle et al., 
2009). Using similar methods, researchers propose human coronavirus OC43 emerged into the 
human population somewhere between 1866-1918 A.D. from cattle (Vijgen et al., 2005). 
Primarily, human coronaviruses 229E and OC43 cause mild upper respiratory tract infections 
and occasionally more severe disease in elderly, infant, and immunocompromised populations 
(Perlman and Netland, 2009).  
 
In November 2002, the first reported case of severe acute respiratory syndrome (SARS) occurred 
in China (de Wit et al., 2016). By February 2003, more than 300 new cases had been reported in 
China, many of which were health care providers. Thereafter, the contagion spread to Hong 
Kong, Vietnam, Canada and several other countries through air travel of infected individuals. In 
March 2003, the World Health Organization established a network to identify the causative agent 
of SARS (de Wit et al., 2016). By April 2003, a novel coronavirus was identified as the 
etiological agent of SARS (Drosten et al., 2003; Ksiazek et al., 2003). Interestingly, the 
characteristic virion morphology observed by researchers in the 1960s, among several other 
identifiers, helped demonstrate that the new human respiratory pathogen was a coronavirus 
(Masters, 2006). By July 2003, SARS-CoV had spread to 27 countries, resulting in more than 
8,000 reported cases and 774 deaths. Subsequent studies demonstrated that SARS-CoV spread 
primarily via respiratory droplets, direct contact, and airborne routes; although, virus was 
isolated from some fecal and urinary samples, which may represent additional routes of 
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transmission (Chan et al., 2004; Gu and Korteweg, 2007; Peiris et al., 2003). Contrary to human 
coronavirus 229E and human coronavirus OC43, SARS-CoV caused severe lower respiratory 
tract infections (Figure 2) (Gu and Korteweg, 2007; Perlman and Netland, 2009). In addition, 
SARS-CoV demonstrated a capacity to cause systemic disease, with evidence of viral pathology 
present in the gastrointestinal tract, liver, kidney, and brain of some cases (Perlman and Netland, 
2009). SARS-CoV patients presented with influenza-like symptoms such as fever, chills, and 
cough (Gu and Korteweg, 2007). Additional common symptoms included malaise, headache, 
and shortness of breath, and less common symptoms included diarrhea and nausea (de Wit et al., 
2016; Gu and Korteweg, 2007). Due to the fact that virus shedding did not occur until after the 
onset of symptoms, the SARS-CoV epidemic was ultimately controlled by quarantine of 
suspected cases and is likely why viral spread was predominately nosocomial in nature (de Wit 
et al., 2016). Fortunately, SARS-CoV is no longer circulating in the human population, and 
numerous studies have sought to determine from where SARS-CoV emerged. An initial study 
demonstrated SARS-CoV could be isolated from palm civets and raccoon dogs. Moreover, 
antibodies against SARS-CoV were detected in Chinese ferret badgers. Interestingly, all of these 
animals are sold in live-animal markets in China, and several animal handlers were also 
seropositive for SARS-CoV, suggesting that these markets may have facilitated the cross- 
species transmission events that led to the SARS-CoV epidemic (de Wit et al., 2016; Guan et al., 
2003; Perlman and Netland, 2009). Yet, there was no indication that SARS-CoV was circulating 
in these animals in the wild and thus, were likely incidental hosts rather than the primary animal 
reservoirs (de Wit et al., 2016; Wang et al., 2006). Additional studies identified viruses that were 
closely related to SARS-CoV in fecal samples of Chinese horseshoe bats (Lau et al., 2005; Li, 
2005). However, these viruses did not use the bat homolog of angiotensin converting enzyme 2 
 
 
 6 
 
 
 
 
 
 
 
 
 
 
Figure 2. SARS-Coronavirus Pathogenesis 
 
The major mechanisms of SARS-CoV pathogenesis are indicated. SARS-CoV infection of 
tracheobronchial and alveolar epithelial cells in the lung results in a cascade of changes that result in 
the clinical symptoms and pathological findings observed. Ultimately, direct viral cytopathic effect, 
infection of immune cells, and an insufficient innate immune response result in severe lung injury, 
dissemination, and disease. This figure is from Gu and Korteweg, 2007 and used with permission.  
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(ACE2), which is the SARS-CoV viral receptor in humans, to infect cells (Becker et al., 2008; 
Ren et al., 2008). In 2013, two novel bat coronaviruses were discovered that are capable of 
infecting humans, civets, and Chinese horseshoe bats using the respective ACE2 receptor from 
each animal to gain cell entry (Ge et al., 2013). These data are the strongest to date that Chinese 
horseshoe bats are the natural reservoir for SARS-CoV and that intermediate animal hosts may 
not be required for direct human transmission. Further, these data indicate that SARS-CoV-like 
viruses are still circulating in bats and could re-emerge into the human population (de Wit et al., 
2016).    
  
After the SARS-CoV epidemic of 2002-2003, increased viral surveillance led to the discovery of 
numerous bat coronaviruses and the identification of two previously unrecognized human 
coronaviruses, human coronavirus NL63 and human coronavirus HKU1. Human coronaviruses 
NL63 and HKU1 were isolated from hospitalized young children with respiratory disease and 
elderly patients with other co-morbidities, respectively (Fouchier et al., 2004; Perlman and 
Netland, 2009; van der Hoek et al., 2004; Woo et al., 2004). Human coronavirus NL63 is 
associated with bronchiolitis, colds, pneumonia, and in children less than three years of age, 
croup. Human coronavirus HKU1 is primarily responsible for colds and pneumonia of varying 
severity.  
 
More recently, in June 2012, another novel coronavirus emerged into the human population. 
MERS-CoV was isolated from a sputum sample of a 60-year-old man that died from acute 
pneumonia and renal failure in Saudi Arabia (Zaki and van Boheemen, 2012). Since that time, 
MERS-CoV has spread by travel of infected persons to more than 27 countries including a 
 
 
 8 
cluster in the United Kingdom and a large outbreak in South Korea involving 186 patients and 16 
hospitals in 2015 (Figure 3) (de Wit et al., 2016; 2017a). As of this publication, 2,143 laboratory-
confirmed cases of MERS-CoV, including at least 750 related deaths, have been reported to the 
World Health Organization (2017b). MERS-CoV infections share many common symptoms with 
SARS-CoV infections. However, MERS-CoV infected patients are more likely to have abnormal 
chest x-rays and to require intensive care. Further, MERS-CoV infection results in a higher 
incidence of acute respiratory distress syndrome, which is likely reflected in the higher mortality 
rate (~35%), compared to SARS-CoV infection (~10%) (de Wit et al., 2016). While MERS-
CoV-like viruses have been isolated in bats, serological studies point to dromedary camels as the 
likely reservoir of MERS-CoV (Drexler et al., 2014; Reusken et al., 2013). MERS-CoV-
neutralizing antibodies have been isolated from dromedary camels in Oman and the Canary 
Islands. However, no viral RNA was recovered from these animals (Reusken et al., 2013). In one 
specific outbreak on a farm in Qatar, MERS-CoV RNA was isolated from three camels that were 
linked to two human cases of MERS-CoV; thus, demonstrating that humans in close contact with 
MERS-CoV infected camels can become infected by the same strain (Figure 3) (Azhar et al., 
2014; Haagmans et al., 2014). In two other studies, infectious MERS-CoVs were isolated from 
dromedary camels in Saudi Arabia and Qatar (Hemida et al., 2014; Raj et al., 2014). In addition, 
there is serological evidence that MERS-CoV or a MERS-CoV-like virus has existed in 
dromedary camel populations of the Middle East, Eastern Africa, and Northern Africa since as 
early as 1983 (Figure 3) (de Wit et al., 2016; Müller et al., 2014). Collectively, these studies 
provide strong evidence for dromedary camels as the reservoir of MERS-CoV. Further, close 
contact between dromedary camels and humans due to cultural practices in these regions 
constitutes a possible explanation for the continued circulation of MERS-CoV. In contrast, 
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Figure 3. MERS-Coronavirus transmission and spread 
 
Serological studies suggest MERS-CoV or a MERS-CoV-like virus have been circulating in 
dromedary camels in the Middle East, Northern Africa, and Eastern Africa since at least 1983 (Gold). 
In Qatar and Saudi Arabia, transmission events between camels and humans have been 
reported. These findings suggest that humans in close contact with MERS-CoV infected 
camels can become infected by the same strain (Red). MERS-CoV has spread to at least 27 
countries due to travel of infected persons from the Middle East (Red arrows). In some cases, this has 
resulted in local outbreaks in traveler destination countries (Blue). This map is adapted from 
www.who.int/emergencies/mers-cov/en/. 
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SARS-CoV, without a sustained intermediate host, was more rapidly contained (de Wit et al., 
2016).   
 
Bat species represent greater than a fifth of the 5,000 known species of mammals and are known 
reservoirs of many human viruses such as Marburg, Hendra, Nipah, and rabies (Calisher et al., 
2006; Huynh et al., 2012). To date, at least 60 novel bat coronaviruses have been identified in 
North America, Europe, Africa, and China by surveillance studies (Dominguez et al., 2007; 
Gloza-Rausch et al., 2008; Perlman and Netland, 2009; Tong et al., 2009; Woo et al., 2007). 
Therefore, it is not surprising that all human coronaviruses are believed to have originated in bats 
with the exception of human coronavirus OC43, which emerged from cattle (Huynh et al., 2012). 
Despite persistent infection with many viruses, bats rarely display clinical symptoms of disease 
(Baker et al., 2013). In fact, as high as 84% of individuals in some Chinese horseshoe bats 
populations have antibodies against SARS-CoV-like viruses. However, SARS-CoV-like virus-
infected bats exhibit no observed pathology (Calisher et al., 2006). Some studies attribute the 
ability of bats to coexist with many viruses in the absence of disease to constitutive expression of 
interferon-alpha (IFN-α) and indirect consequences of flight on the innate immune system 
(Baker et al., 2013; Zhang et al., 2013; Zhou et al., 2016). Regardless, bats are a reservoir for a 
large number of coronaviruses, including SARS-CoV-like and MERS-CoV-like viruses, and will 
continue to pose a threat for the zoonotic spillover of novel coronaviruses into the human 
population (de Wit et al., 2016; Drexler et al., 2014). Moreover, this threat will continue to 
escalate as the human population expands into previously uninhabited or sparely inhabited 
regions of the world.  
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Coronavirus genome organization and replication strategy 
The order Nidovirales consists of four virus families: Arteriviridae, Coronaviridae, 
Mesoniviridae, and Roniviridae. The Coronaviridae family is divided into two subfamilies: 
Torovirinae and Coronavirinae. The subfamily Coronavirinae contains four genera of 
coronaviruses: Alphacoronaviruses, Betacoronaviruses, Gammacoronaviruses, and 
Deltacoronaviruses. Currently, viruses in the Coronavirinae subfamily, which are positive-
sense, single-stranded RNA viruses, contain the largest known genomes for RNA viruses (26-
32kb) (Gorbalenya et al., 2006; Smith et al., 2014). Coronavirus genomes are structurally similar 
to cellular mRNAs since they consist of a 5’-capped RNA molecule with a 3’ poly-(A) tail (Lai 
and Stohlman, 1981; Lai et al., 1982; Masters, 2006). Coronaviruses encode at least 6 open 
reading frames (ORFs) (Perlman and Netland, 2009). The first, ORF1, comprises the first two-
thirds of the coronavirus genome. ORF1 is translated as one of two possible large polyproteins 
(pps), pp1a or pp1ab. Each translation initiation event begins at the 5’ end of pp1a. Due to a -1 
ribosomal frameshift, which is recognized approximately 40% of the time, translation continues 
resulting in pp1ab (Brierley et al., 1987; Plant et al., 2005). Pp1ab encodes 16 non-structural 
proteins (nsps) that are involved in RNA synthesis and RNA modification (Figure 4 and Table 
1). The remaining one-third of the coronavirus genome encodes several accessory proteins that 
are coronavirus species-dependent and four structural proteins: the spike glycoprotein, the 
membrane glycoprotein, the envelope protein, and the nucleocapsid protein (Figure 4 and Table 
1). 
 
A single coronavirus replication cycle begins when the spike glycoprotein on the surface of a 
coronavirus virion binds to the cellular receptor utilized by that particular coronavirus strain 
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Figure 4. Coronavirus genome and nsp14 organization 
 
Coronaviruses encode 16 non-structural proteins within polyprotein 1ab, which comprises 
approximately two-thirds of the coronavirus genome. Nsp14 is a multifunctional protein that encodes 
3’-to-5’ exoribonuclease and N7-methyltransferase activities. The ExoN domain (blue) is located in 
the N-terminal half of the protein whereas the N7-methyltransferase domain (blue hatched) is located 
in the C-terminal half. Nsp14 ExoN activity is conferred by four, invariant active site residues (DE-E-
D). A conserved DxG motif in the N7-methyltransferase domain confers SAM binding and N7-
methyltransferase activity. Three zinc fingers are encoded in CoV nsp14 (gray boxes).  
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Table 1. Coronavirus protein functions 
 
Coronavirus non-structural and structural protein functions are described.  
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(Figure 5). Murine hepatitis virus (MHV), SARS-CoV, and MERS-CoV, the coronaviruses 
studied in our lab, use murine carcinoembryonic antigen-related cell adhesion molecule 1a 
(CEACAM1a), angiotensin-converting enzyme 2 (ACE2), and dipeptidyl peptidase 4 (DPP4), 
respectively, to enter cells (Hemmila et al., 2004; Li et al., 2003; Raj et al., 2013). Upon entry by 
receptor-mediated endocytosis or direct membrane fusion, viral RNA uncoating occurs in the 
cytoplasm (Masters, 2006). The capped 5’ ends of coronavirus genome RNAs are recognized by 
ribosomes and are translated into pp1a and pp1ab (de Wit et al., 2016; Perlman and Netland, 
2009). These polyproteins are proteolytically processed by papain-like proteases 1 and 2 encoded 
in nsp3 and the main protease in nsp5 to generate 16 individual nsps. Data suggest during 
coronavirus replication, nsps 3, 4, and 6 function to modify intracellular membranes derived 
from the rough endoplasmic reticulum to form double membrane vesicles (Kanjanahaluethai et 
al., 2007; Knoops et al., 2008; Oostra et al., 2007; Snijder et al., 2006). Inside double-membrane 
vesicles, coronavirus replication complexes assemble and coronavirus RNA replication occurs 
through two distinct phases: genome replication and subgenomic mRNA synthesis (Masters, 
2006; Smith et al., 2014). The coronavirus replication-transcription complex, which is 
responsible for replicating all viral RNAs, is an intricate, multi-subunit complex comprised of 
several nsps (Smith and Denison, 2013; Smith et al., 2014). Nsp7 and nsp8 form an RNA-
binding, hexadecameric supercomplex that resembles a sliding clamp, which functions to 
increase polymerase processivity (Smith and Denison, 2013; Smith et al., 2014; Subissi et al., 
2014; Zhai et al., 2005). In addition, nsp8 encodes a noncanonical RNA dependent-RNA 
polymerase activity that acts as a primase (Smith and Denison, 2012; Smith et al., 2014; Velthuis 
et al., 2011). Other coronavirus replication-transcription components include nsp9, which binds 
single-stranded RNA; nsp12, the RNA-dependent RNA polymerase; nsp13, which encodes 
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Figure 5. Coronavirus replication cycle 
 
Following receptor-mediated endocytosis, coronavirus spike proteins facilitate membrane fusion and 
viral uncoating. In the cytoplasm of the cell, the positive-sense coronavirus genome is recognized and 
translated by ribosomes. Viral proteases encoded by nsp3 and nsp5 cleave translated polyproteins in 
individual, mature proteins. Coronavirus replication-transcription complexes form on virus-induced 
double-membrane vesicles and coronavirus genomic and subgenomic RNAs are replicated. Viral 
particles are assembled at the ER-Golgi intermediate compartment (ERGIC). Assembled virions are 
released from infected cells through a non-lytic, exocytosis pathway. This figure is adapted from de 
Wit et al., 2016 and is used with permission.  
 
 
 16 
nucleotide triphosphatase and helicase activities; and nsp15, which encodes endonuclease 
activity (Adedeji et al., 2012; Egloff et al., 2004; Ivanov et al., 2004a; Smith et al., 2014). Nsp10 
is a non-enzymatic co-factor that has been demonstrated to interact with nsp14 and nsp16 
(Bouvet et al., 2012; 2010; Decroly et al., 2011a). Coronavirus nsp14 encodes 3’-to-5’ 
exoribonuclease activity (ExoN) and N7-methyltransferase activity (N7-MTase) (Chen et al., 
2009; Minskaia et al., 2006). All data to date support the hypothesis that nsp14 ExoN performs a 
novel proofreading function during replication and may be responsible for expansion of the 
coronavirus genome to such a large size (Gorbalenya et al., 2006; Lauber et al., 2013). 
Moreover, coronavirus nsp14 N7-MTase activity and nsp10-nsp16 complexes are involved in 5’ 
capping of viral RNA (Bouvet et al., 2010; Chen et al., 2009; 2013; Decroly et al., 2008).  
 
From the positive-sense genome RNA, the coronavirus replication-transcription complex 
generates a full-length, negative-sense anti-genome RNA, which is used as a template for 
subsequent positive-sense genome RNA amplification (Figure 6A). In addition, coronavirus 
structural and accessory proteins are expressed as a nested set of subgenomic mRNAs through a 
discontinuous transcription mechanism (Masters, 2006; Sawicki and Sawicki, 1998; 2005; Smith 
et al., 2014)(Figure 6 B-D). First, the coronavirus replication-transcription complex generates 
negative-sense subgenomic RNAs from the 3’ end of the positive-sense genome RNA (Figure       
5B). Each negative-sense subgenomic RNA contains a common 3’ end sequence known as the 
transcriptional regulatory sequence. Upon recognizing the transcriptional regulatory sequence, 
the replication-transcription complex will either read-through the regulatory sequence and 
continue into another subgenomic ORF or dissociate the negative-sense subgenomic RNA from 
the positive-sense RNA genome. This process generates negative-sense subgenomic RNAs of 
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Figure 6. Coronavirus genomic and subgenomic RNA replication 
 
(A) Coronavirus replication-transcription complexes generate a negative-sense genome RNA from a 
positive-sense genome RNA. Negative-sense genome RNAs serve a templates for generating progeny 
positive-sense genome RNAs. (B) Coronavirus replication-transcription complexes generate negative-
sense subgenomic RNAs of varying lengths from positive-sense genome RNAs. (C) Through a 
discontinuous transcription mechanism, negative-sense subgenomic RNAs dissociate from the 3’-end 
of the positive-sense RNA genomes and reassociate through base-pairing interactions at the 5’ leader 
transcription regualatory sequence (TRS) of the positive-sense genome RNA. (D) Negative-sense 
subgenomic RNAs serve as templates for subgenomic positive-sense RNA amplification.  
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varying lengths and thus, varying numbers of subgenomic ORFs. Upon dissociation from the 
positive-sense genome RNA, the replication-transcription complex reassociates with the 5’ 
leader transcriptional regulatory sequence through base pairing interactions at the 5’ end of the 
positive-sense genome RNA and negative-sense subgenomic RNA transcription continues 
through the 5’ end of the genome (Figure 6C). Finally, these negative-sense subgenomic RNAs 
serve as templates for positive-sense subgenomic  mRNA production (Figure 6D). Although 
subgenomic mRNAs may contain more than one ORF, only the 5’ most subgenomic ORF is 
translated. Subgenomic accessory protein ORFs are interspersed between the four structural 
ORFs. The number and function of encoded accessory proteins is dependent on the coronavirus 
strain. Often, coronavirus accessory proteins are not required for viral replication in cell culture 
and many have been described that have innate antagonism roles. Therefore, it is likely that 
coronavirus accessory proteins serve important roles in viral replication in natural host settings 
(Perlman and Netland, 2009). Upon translation of the coronavirus membrane and envelope 
structural proteins, which are transmembrane glycoproteins, they are incorporated into 
assembling virions (de Wit et al., 2016; Masters, 2006; Perlman and Netland, 2009). The 
membrane protein is responsible for giving virions their shape, and the envelope protein is 
important for virion release (Masters, 2006; Perlman and Netland, 2009) Further, the spike 
glycoproteins, which protrude from virions and mediate viral attachment to the host cell and 
membrane fusion, are inserted into the endoplasmic reticulum and are subsequently incorporated 
into assembling virions (de Wit et al., 2016; Masters, 2006). The coronavirus nucleocapsid 
structural protein is an RNA binding protein and interferon antagonist. By encapsidating viral 
RNA, nucleocapsid proteins prevent viral RNA degradation and detection by the host (Perlman 
and Netland, 2009). Virion assembly and genome RNA packaging occur on membranes that bud 
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into the endoplasmic reticulum-Golgi intermediate compartment. Next, vesicles containing 
newly assembled virions migrate and fuse with the plasma membrane to release virus progeny 
(de Wit et al., 2016).  
 
The multiple functions of coronavirus nsp14 
Coronavirus nsp14 is a multifunctional protein that encodes 3’-5’ exoribonuclease (ExoN) and 
N7-methyltransferase (N7-MTase) activities (Figure 4) (Chen et al., 2009; Minskaia et al., 2006). 
The coronavirus nsp14 ExoN and N7-MTase domains are located in the N-terminal and C-
terminal halves of the protein, respectively. Further, two of the three zinc-finger motifs encoded 
by coronavirus nsp14 are located in the ExoN domain and are likely important for binding RNA 
(Ma et al., 2015). Initial biochemical studies of nsp14 ExoN activity demonstrated that ExoN has 
a preference for double-stranded RNA (dsRNA) and the capacity to excise 3’ end 
misincorporated nucleotides (Minskaia et al., 2006). The coronavirus nsp14 ExoN is a member 
of the DE-D-Dh superfamily of DNA and RNA exonucleases, so named for the three motifs of 
four active site residues (Minskaia et al., 2006). SARS-CoV and MHV expressing engineered, 
ExoN-inactivating substitutions at active site residues in Motif I (DE!AA) [ExoN(-)] 
demonstrate an approximately 15-20-fold increase in mutation frequency during viral replication 
(Eckerle et al., 2007; 2010). In addition, ExoN(-) viruses are profoundly sensitive to inhibition 
by RNA mutagens (Case et al., 2017; Eckerle et al., 2007; Graepel et al., 2017; Sexton et al., 
2016; Smith et al., 2013). Thus, coronavirus nsp14 ExoN is the first description of an RNA virus 
encoded proofreading enzyme and nsp14 ExoN activity is required for high-fidelity 
replication(Smith and Denison, 2012; 2013; Smith et al., 2014). Furthermore, a mouse 
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pathogenesis study demonstrated that SARS-CoV ExoN(-) virus is attenuated in vivo but protects 
mice from lethal challenge with WT SARS-CoV (Graham et al., 2012).  
 
Current models place nsp14 as a key component in a multi-subunit coronavirus replication 
complex that includes the nsp12 RNA-dependent-RNA polymerase and nsp10, a non-enzymatic 
co-factor, among several other proteins (Smith and Denison, 2013; Smith et al., 2014). 
Coronavirus nsp10 binds nsp14 and stimulates ExoN activity up to 35-fold (Bouvet et al., 2012). 
In addition, mutations in nsp10 that disrupt binding to nsp14 decrease virus replication fidelity 
(Smith et al., 2015). Relative to DNA-based organisms, RNA viruses have high mutation rates 
and are thought to be limited in genome size due to the lack of proofreading mechanisms 
(Bradwell et al., 2013; Eigen, 1971; Sanjuan et al., 2010; Smith et al., 2014). Thus, the 
acquisition of nsp14 ExoN is thought to be a contributing factor in the expansion of the 
coronavirus genome to allow such a large RNA genome to be faithfully replicated and 
maintained (Gorbalenya et al., 2006; Lauber et al., 2013; Smith and Denison, 2013; Smith et al., 
2014).  
 
Interestingly, outside of the order Nidovirales, the only other known RNA virus-encoded 3’-to-5’ 
exoribonucleases are found in the Arenaviridae family of viruses. Lassa fever virus 
nucleoprotein ExoN is not thought to participate in fidelity regulation, but rather it participates in 
immune evasion by degrading dsRNA and thereby prevents antigen-presenting cell-mediated 
natural killer (NK) cell activation (Hastie et al., 2011; Qi et al., 2010; Russier et al., 2014). 
Recently, in the Alphacoronavirus transmissible gastroenteritis virus (TGEV), an nsp14 ExoN 
zinc finger mutant was shown to generate lower levels of dsRNA compared to wild-type (WT) 
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TGEV. However, in that study viruses with mutations in ExoN active site motifs were non-viable 
and therefore, could not be directly tested for effects on innate immunity (Becares et al., 2016). 
In work described in Chapter III of this dissertation research, I explore my original interests and 
test the hypothesis that coronavirus nsp14 ExoN also functions to antagonize the innate immune 
response.  
 
The coronavirus nsp14 N7-MTase was initially identified in a functional screen, wherein SARS-
CoV nsp14 was capable of complementing N7-MTase deficient yeast (Chen et al., 2009). 
Strikingly, these data also presented evidence than an enzyme encoded by an RNA-based virus 
was capable of complementing the corresponding function of a DNA-based organism (Chen et 
al., 2009). Since the initial discovery, structure-function studies have demonstrated that SARS-
CoV nsp14 N7-MTase activity is mediated by a conserved DxG motif within the MTase domain 
in vitro (Chen et al., 2013; Ma et al., 2015). In addition, all three DxG motif residues were 
required for complete binding of S-adenosyl-L-methionine, the methyl donor for the reaction, 
and full N7-MTase activity in vitro (Bouvet et al., 2010; Chen et al., 2013). Alanine substitution 
of SARS-CoV nsp14 at position D90/E92 in the ExoN domain or at position D331 in the N7-
MTase domain did not affect N7-MTase or ExoN activities in vitro, respectively (Chen et al., 
2009; 2013). However, truncation of as few as 17 residues of the nsp14 C-terminal end of the 
protein ablates ExoN activity. Further, truncation beyond residue 61 from the N-terminal end of 
the protein ablates N7-MTase activity (Chen et al., 2013). Therefore, these data suggest the 
ExoN and N7-MTase domains, but not the respective domain activities of nsp14, are 
interdependent. The nsp10/nsp14 crystal structure further supports these data as the ExoN and 
N7-MTase domains were demonstrated to interact using hydrophobic interactions. Additionally, 
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the nsp10/nsp14 crystal structure suggests that S-adenosyl-L-methionine, and the methyl 
acceptor, guanosine-triphosphate RNA, are held in a highly constricted, hydrophobic pocket 
where conditions are favorable for methyl transfer to occur (Ma et al., 2015). Coronavirus nsp14-
mediated N7-methylation of guanosine triphosphate-RNA to form a cap-0 structure is a 
prerequisite for nsp10/16-mediated 2’O-methylation in vitro (Bouvet et al., 2010). However, the 
requirements of the coronavirus nsp14 N7-MTase during viral replication were not known at the 
beginning of this dissertation. In studies described in Chapter II, I demonstrate that viruses with 
altered N7-MTase activity are attenuated in replication and translation, and that they are detected 
by and sensitive to the innate immune response. 
 
5’ capping of viral and cellular RNA 
Eukaryotic mRNAs possess a methylated 5’ guanosine cap linked to the penultimate nucleotide 
by a 5’-5’ triphosphate bridge (Figure 7) (Shatkin, 1976). The 5’ cap of a cellular mRNA 
functions in RNA stability, pre-mRNA splicing, mRNA export from the nucleus, translation, and 
protection against cellular antiviral defenses (Darnell, 1979). The canonical cellular capping 
process involves three enzymes: 1) an RNA triphosphatase, which is responsible for cleaving the 
γ-phosphate of the nascent transcript, 2) a guanylyltransferase, which transfers a guanosine 
monophosphate moiety to the 5’ diphosphate RNA, and 3) an N7-methyltransferase, which is 
responsible for transferring a methyl group from the methyl donor, S-adenosyl-L-methionine, to         
the N7 position of the guanosine base (Furuichi and Shatkin, 2000). These sequential reactions 
lead to formation of a cap-0 (7-methyl-Gppp) structure, which is thought to be the minimal cap 
determinant required for eukaryotic translation initiation factor E (eIF4E) recognition and 
efficient translation (Figure 7B) (Filipowicz et al., 1976; Marcotrigiano et al., 1997; Schibler and 
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Figure 7. RNA 5’ cap structure and formation 
 
The canonical eukaryotic cell and the hypothesized CoV mRNA capping pathway begins with 
removal of the γ-phosphate of the nascent transcript by an RNA triphosphatase. Next, a guanylytransferase 
transfers a guanosine monophosphate moiety to the 5’-diphosphate-RNA to form a guanosine-triphosphate-RNA 
structure (A). Then, the N7-methyltransferase transfers a methyl group from the methyl donor, S-adenosyl-L-
methionine, to the N7 position of the guanosine base to form a cap-0 structure (B). In CoVs, nsp14 encodes N7-
methyltransferase activity in the C-terminal half of the protein. Finally, a 2’O-methyltransferase adds a methyl 
group to the 2’O position of the ribose sugar of the penultimate nucleotide to form a cap-1 structure (C). CoV 
nsp16, when bound by nsp10, functions as a 2’O-methyltransferase. This figure is adapted from Decroly et al., 
2012 and is used with permission.  
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Perry, 1977). Higher eukaryotes express 2’O-methyltransferases (2’O-MTase) that add a methyl 
group to the ribose 2’O position of the penultimate nucleotide of the cap-0 RNA. This reaction 
results in formation of a cap-1 structure that allows cells to differentiate self from non-self RNAs 
in the cytoplasm (Figure 7C) (Wei et al., 1975; Züst et al., 2011). 
 
Viruses are obligate intracellular parasites, meaning they need host cell machinery and resources 
in order to replicate. Many viruses encode capping enzymes to disguise viral RNAs from the 
cell. Cap structures can be added to viral RNAs by one of the following three mechanisms: 1) 
use of cellular capping machinery, 2) cap snatching, or 3) use of virus encoded capping enzymes. 
The first capping mechanism is utilized by viruses that use cellular RNA polymerase II to 
synthesize their mRNA. Examples include DNA viruses such as those in the Herpesviridae and 
Hepadnaviridae families and by RNA viruses of the Retroviridae family. Viruses of the 
Orthomyxoviridae, Arenaviridae, and Bunyaviridae families utilize the second mechanism, 
which involves stealing 5’ caps from cellular mRNAs via endonucleolytic cleavage. Lastly, 
many viruses encode their own capping enzymes, which can be categorized as either 
conventional, meaning the capping pathway follows that of cellular mRNAs, or unconventional. 
Overall, the diversity of enzymes and mechanisms used by viruses to synthesize capped RNA 
products suggests that there is a strong selective pressure on viruses to cap their RNAs (Decroly 
et al., 2011b).  
 
Coronaviruses encode several enzymes within their large, positive-sense RNA genomes (26-32 
kb) that are implicated in viral RNA capping. The coronavirus genome possesses a 5’ terminal 
cap and 3’ poly-A tail (Lai and Stohlman, 1981; Lai et al., 1982; Masters, 2006). All data to date 
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support the hypothesis that coronavirus genomes are capped using the canonical mRNA capping 
pathway (Bouvet et al., 2010). SARS-CoV nsp13 displays RNA triphosphatase activity in vitro 
(Ivanov et al., 2004b). The coronavirus guanylyltransferase has not been identified but, 
according to the current model, would function to add a guanosine monophosphate to the 
diphosphate RNA product of nsp13. The RNA-dependent RNA polymerase of equine arteritis 
virus and SARS-CoV displays nucleotidylation activity (Lehmann et al., 2015). While further 
study is required to define the function of this activity in viral replication, it is possible that the 
RNA-dependent-RNA-polymerase participates in coronavirus RNA capping. Nsp16 of feline 
coronavirus functions independently as a 2’O-MTase, but SARS-CoV nsp16 requires nsp10 as a 
co-factor for 2’O-MTase activity (Decroly et al., 2008; Grotthuss et al., 2003; Snijder et al., 
2003). SARS-CoVs lacking 2’O-MTase activity are recognized and sequestered by interferon-
induced protein with tetratricopeptide repeats 1 (IFIT1) due to the lack of a cap-1 structure 
(Bouvet et al., 2010; Chen et al., 2011; Daffis et al., 2010; Decroly et al., 2011a; Habjan et al., 
2013; Menachery et al., 2014). In work described in Chapter II of this dissertation, I determine 
the requirements of the MHV nsp14 N7-MTase for viral RNA capping and efficient translation 
during the course of viral infection. In addition, I characterize the innate immune response to 
viruses with ablated nsp14 N7-MTase activity.  
 
Innate immune response to pathogens 
The innate immune response within a mammalian cell is hardwired into the genome and provides 
the first line of defense against an invading pathogen.  The capacity of a cell to distinguish ‘self’ 
from ‘non-self’ is essential for mounting an effective innate immune response. Cells accomplish 
this task in the context of RNA virus infection through the use of pattern recognition receptors, 
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namely retinoic acid-inducible gene like receptors, such as RIG-I and MDA5, and toll-like 
receptors (TLRs), such as TLR3, TLR7, and TLR8 (Brubaker et al., 2015). Pattern recognition 
receptors have evolved to recognize pathogen associated molecular patterns (PAMPs), which are 
conserved features of pathogens. Therefore, while the innate immune response does not afford 
memory to previous infections, it does provide a broadly applicable and robust response to 
infection and initiates the adaptive immune response. In most cases, single- or double-stranded 
RNAs act as the primary PAMPs that are sensed by a cell during RNA virus infection, often 
resulting in the induction of type I interferon (IFN) gene expression and other pro-inflammatory 
antiviral responses (Baum and García-Sastre, 2009). Upon secretion from a cell, IFNs bind to 
cell surface-expressed IFN-α/β receptors (IFNARs) in an autocrine and paracrine manner (Figure 
8). Subsequently, an IFN signaling cascade utilizing the Janus kinase (Jak) and signal transducer 
and activator of transcription (STAT) pathway leads to the induction and expression of hundreds 
of interferon stimulated genes (ISGs) that act to limit or prevent viral replication and spread to 
neighboring cells and tissues. In fact, ISGs targeting every stage of virus replication have been 
described: entry (Mx, TRIM, and IFITM proteins), viral translation and replication (IFIT, 
OAS/RNAse L, and PKR proteins), and viral egress (viperin and tetherin proteins). Further, ISGs 
may act broadly against numerous viruses or may have evolved specifically to counteract a 
single virus family (Schneider et al., 2014).  
 
The 5’ end of an mRNA present in the cytoplasm is assessed by several ISGs as one potential 
mechanism to distinguish self from non-self. RIG-I specifically recognizes 5’ triphosphate-
RNAs, which in the absence of infection, should not be present within the cytoplasm of a cell 
(Decroly et al., 2011a; Hornung et al., 2006). Further, MDA5 recognizes RNA that only 
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Figure 8. Type I interferon signaling pathway 
 
Upon binding of type I interferon to the interferon alpha/beta receptor (IFNAR 1 and 2 heterodimers), 
Janus kinase 1 (JAK1) and tyrosine kinase 2 (TYK2) undergo transphosphorylation and activation. 
Once activated, Jaks phosphorylate IFN receptor chains, leading to the recruitment of STAT proteins. 
Next, STAT proteins become phosphorylated and disassociate from IFN receptors. Phosphorylated 
STAT1 and STAT2 proteins form a heterodimer and interact with interferon regulatory factor 9 
(IRF9), forming what is known collectively as the interferon stimulated gene factor 3 (ISGF3) 
complex. ISGF3 translocates to the nucleus and functions as a transcription factor by binding 
interferon stimulated response elements (ISREs) in the promoter regions of ISGs, resulting in 
transcription of hundreds of genes. This figure is adapted from Schneider et al., 2014. 
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possesses a cap-0 structure or is linked to a protein. In addition, IFIT1 and IFIT2 specialize in 
binding and sequestering 5’ triphosphate-RNA and cap-0 RNA (Decroly et al., 2011a; Züst et al., 
2011). In Chapter II of this dissertation, I determine the requirements of MHV nsp14 N7-MTase 
for viral capping in the context of viral infection and report the ensuing innate immune response 
to viruses with defective capping mechanisms. In Chapter III, I demonstrate that coronaviruses 
lacking ExoN activity are restricted by the IFN-β-mediated innate immune response. In Chapter 
IV, I describe the development of assays and reagents to determine the ISG or ISGs responsible 
for mediating ExoN(-) virus restriction.  
 
Coronavirus innate immune antagonists 
As obligate intracellular parasites, viruses have evolved numerous mechanisms to prevent and 
antagonize innate detection by host cells (Decroly et al., 2011a; Katze et al., 2002). 
Coronaviruses, like many other successful viruses, have evolved numerous mechanisms to 
counter the innate immune response (Perlman and Netland, 2009). Coronaviruses encode many 
IFN antagonists that prevent the induction of IFN. In addition, coronaviruses are also known to 
exhibit a relatively high level of resistance to the effects of IFN pretreatment of cells (Roth-Cross 
et al., 2007). Coronavirus nsp1 antagonizes the innate immune response by degrading host 
mRNAs and suppressing IFN-β expression (Kamitani et al., 2006; Zhang et al., 2015). The nsp3 
of SARS-CoV prevents interferon regulatory factor 3 phosphorylation and NF-κB signaling 
(Devaraj et al., 2007). In addition, SARS-CoV nsp3 encodes deubiquitinating and deISGylating 
activities (Barretto et al., 2005; Rose and Weiss, 2009). Coronavirus viral RNA evades innate 
detection by MDA5 and IFIT1 due to the formation of a 5’ cap-1 structure by encoding N7- and 
2’O-methyltransferases (Case et al., 2016; Chen et al., 2009; Decroly et al., 2008; Menachery et 
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al., 2014; Züst et al., 2011). MHV and MERS-CoV encode 2’-5’ phosphodiesterases that degrade 
2’-5’ oligoadenylates. 2’-5’ oligoadenylates are key signaling molecules generated by 
oligoadenylate synthetase (OAS) in response to innate detection of dsRNA that subsequently 
activate RNase L (Zhao et al., 2012b). Most recently, a coronavirus nsp15 endonuclease 
(EndoU) activity mutant virus was shown to have increased dsRNA levels, suggesting that nsp15 
EndoU functions to reduce dsRNA levels during infection (Kindler et al., 2017). SARS-CoV 
ORF3b and ORF6 accessory proteins prevent IFN induction (Kopecky-Bromberg et al., 2006; 
Perlman and Netland, 2009). In addition, the nucleocapsid protein of SARS-CoV and MHV 
inhibits NF-κB activation and activator protein 1 signaling and PKR function, respectively (He et 
al., 2003; Kopecky-Bromberg et al., 2006; Ye et al., 2007). In work described in Chapter III of 
this dissertation, I present evidence in support of coronavirus nsp14 ExoN activity as an innate 
immune antagonist.  
 
Summary 
Coronavirus genomes are the largest known among single-stranded RNA viruses. The extreme 
size of the coronavirus genome results in a need to reliably replicate the genome without 
accumulating a lethal level of mutations. Coronaviruses have likely solved this issue by devoting 
a considerable portion of their coding space to a large, multi-protein replication complex that 
includes a novel 3’-to-5’ exoribonuclease activity encoded within nsp14. In addition to 3’-to-5’ 
exoribonuclease activity, coronavirus nsp14 encodes an N7-methyltransferase activity that 
participates in viral RNA capping. In this dissertation research, I determine the residues of nsp14 
that are required for N7-MTase activity in replicating virus and that N7-MTase activity is 
required for evading detection by and mediating resistance to the innate immune response. In 
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addition, I investigate the hypothesis that nsp14 ExoN activity is involved in mediating 
resistance to the innate immune response by a potentially novel mechanism. Two highly lethal 
human coronaviruses have emerged into the human population in this century and virus-specific 
therapeutics or vaccines currently do not exist for the treatment of human coronavirus infection. 
Therefore, the development of strategies to attenuate viral replication is critical. This dissertation 
research provides evidence for two potential targets within coronavirus nsp14.   
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Chapter II 
 
MUTAGENESIS OF S-ADENOSYL-L-METHIONINE-BINDING RESIDUES IN 
CORONAVIRUS NSP14 N7-METHYLTRANSFERASE DEMONSTRATES DIFFERING 
REQUIREMENTS FOR GENOME TRANSLATION AND RESISTANCE TO INNATE 
IMMUNITY 
 
Introduction 
At the beginning of this dissertation research, the coronavirus (CoV) non-structural protein 14 
(nsp14) N7-methyltransferase (N7-MTase) had been studied using only recombinantly expressed 
proteins in an in vitro setting. CoV nsp14 N7-MTase activity was originally identified using a 
functional screen in N7-MTase defective yeast and utilized S-adenosyl-L-methionine (SAM) as a 
methyl donor (Chen et al., 2009). Further, a study had demonstrated that nsp14 N7-MTase-
mediated cap-0 formation necessarily preceded nsp10/nsp16 2’O-methyltransferase (2’O-
MTase)-mediated cap-1 formation in vitro. A conserved DxG motif in the nsp14 N7-MTase 
domain was demonstrated to be required for nps14 N7-MTase activity and SAM binding. 
However, the requirement for and the consequences of altered coronavirus N7-MTase activity 
during viral replication were unknown. I hypothesized that coronavirus nsp14 N7-MTase activity 
would be an excellent target for viral attenuation due to the known functions and importance of 
cellular and other viral 5’ caps in translation and viral immune evasion. In this chapter, I used 
site-directed mutagenesis to assess the effect of mutations in the DxG motif of murine hepatitis 
virus (MHV) nsp14 N7-MTase on viral replication. I show that alanine substitution of nsp14 
D330 does not alter viral replication kinetics or increase sensitivity to interferon-β (IFN-β) 
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treatment relative to wild-type (WT) MHV. However, alanine substitution of nsp14 G332 
impaired virus replication, resulting in delayed replication kinetics and decreased peak titer, 
relative to WT MHV. In addition, nsp14 G332A virus displayed increased sensitivity to 
treatment of cells with IFN-β, and nsp14 G332A genomes were translated less efficiently in vitro 
and during infection. These data suggest that residue G332, but not residue D330, is required for 
MHV nsp14 N7-MTase activity, and collectively, that the regulation of coronavirus capping is 
likely more complex in the context of replicating virus than during in vitro biochemical studies 
with isolated proteins. Further, these data demonstrate the requirement for CoV nsp14 N7-MTase 
activity for efficient viral RNA translation and resistance to the innate immune response. I 
performed all experiments and final analysis for the data presented in this chapter. The coauthors 
provided the following contributions: Alison Ashbrook generated bone marrow-derived dendritic 
cells (BMDCs) for some replicates of the figure involving BMDCs and assisted me in generating 
BMDCs for the remaining replicates. 
 
Recovery and replication kinetics of MHV nsp14 N7-MTase mutants 
The DxG SAM-binding motif is conserved among the nsp14 N7-MTase domains of alpha-, beta-
, and gammacoronaviruses (Figure 9A). Mutations in this motif of SARS-CoV nsp14 ablate N7-
MTase activity of purified proteins in vitro (Bouvet et al., 2010; Chen et al., 2009; 2013). To 
determine whether this motif is required for viral replication, I engineered alanine substitutions at 
the DxG SAM-binding motif in the MHV nsp14 N7-MTase domain. Virus containing either a 
D330A or G332A substitution in nsp14 was recovered and sequence confirmed across the nsp14 
coding region. Following infection of DBT cells at an MOI of 1 PFU/cell, nsp14 D330A virus 
replicated with kinetics comparable to WT MHV (Figure 9B). Nsp14 D330A plaque morphology 
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Figure 9. Replication kinetics of viruses with altered N7-MTase SAM-binding residues.  
 
(A) Alignment of GenBank ORF1b sequences of the α-, β-, and γ-CoVs shown demonstrates that 
SAM-binding residues (shaded) are highly conserved. (B) DBT cells were infected with the viruses 
shown at an MOI of 1 PFU/cell. Cell culture supernatants were collected at the indicated times post-
infection, and viral titers were determined by plaque assay. Error bars indicate SEM (n = 6). (C) 
Plaque morphology of the viruses shown following agarose overlay plaque assay and fixation with 
3.7% paraformaldehyde 24 h post-infection.  
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also was similar to that of WT MHV (Figure 9C). In contrast, the nsp14 G332A virus began 
exponential replication 4-6 h later than WT MHV and reached a lower peak titer (1.5 x 104 
PFU/ml) relative to WT MHV (107 PFU/ml) (Figure 9B). The nsp14 G332A virus plaque size 
was also decreased relative to WT MHV (Figure 9C). Thus, despite the requirement of D330 for 
nsp14 N7-MTase activity in vitro (Bouvet et al., 2010; Chen et al., 2009; 2013; Ma et al., 2015), 
my data indicate that the D330A mutation has no detectable effect on MHV replication kinetics 
in cell culture. 
 
Nsp14 D330A or G332A mutations do not significantly influence  
nsp14 ExoN activity 
Coronavirus nsp14 is a multifunctional protein with two known enzymatic activities, a 
proofreading 3’-5’ exoribonuclease activity (ExoN) and N7-MTase activity (Chen et al., 2009; 
Minskaia et al., 2006). Based on in vitro studies, the ExoN and N7-MTase domains of CoV 
nsp14 are interdependent (Chen et al., 2013). This conclusion is supported by the crystal 
structure of nsp14, demonstrating that the ExoN and N7-MTase domains interact through a large 
hydrophobic interface (Ma et al., 2015). In addition, disruption of ExoN (ExoN-) via mutations 
at two active-site residues decreases replication fidelity of MHV and SARS-CoV and renders the 
viruses sensitive to the RNA mutagen 5-fluorouracil (5-FU) (Eckerle et al., 2007; 2010; Smith et 
al., 2013). Thus, 5-FU sensitivity has been shown to be an in vitro indicator of ExoN activity. 
Therefore, I tested whether the D330A or G332A mutations affect ExoN activity by treating cells 
with increasing concentrations of 5-FU or vehicle (DMSO) prior to infection with either nsp14 
D330A or nsp14 G332A virus at an MOI of 0.01 PFU/cell (Figure 10). The nsp14 D330A and 
nsp14 G332A viruses were not significantly altered in 5-FU sensitivity compared with WT MHV 
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Figure 10. N7-MTase mutants display WT-like sensitivity to the RNA mutagen 5-FU.  
 
DBT cells were treated with the indicated concentrations of 5-FU for 30 min prior to infection with the 
viruses shown at an MOI of 0.01 PFU/cell. Medium containing 5-FU or vehicle was added 30 min 
post-infection. After 24 h, cell culture supernatants were collected, and viral titers were determined by 
plaque assay. For each virus, titers were normalized to those following infection of DMSO-treated 
controls. Change in viral titer for nsp14 D330A and nsp14 G332A viruses were not statistically 
significant relative to WT MHV by one-way ANOVA. Error bars indicate SEM (n = 4). 
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(N.S. by One-way ANOVA). In contrast, the ExoN- virus displayed a concentration-dependent 
increase in 5-FU sensitivity. These results indicate that neither D330A nor G332A significantly 
alter ExoN activity during virus replication. 
 
MHV nsp14 G332A is detected by and sensitive to the type I interferon-mediated innate 
immune response 
Coronavirus RNA capping likely follows the conventional capping pathway, with nsp14 N7-
methylation being a prerequisite for 2’O-methylation in vitro (Bouvet et al., 2010). Therefore, 
decreased nsp14 N7-MTase activity should reduce overall 2’O-methylation, thereby increasing 
virus sensitivity to exogenous type I IFN due to recognition by IFIT1 and MDA5 (Habjan et al., 
2013; Menachery et al., 2014). To test this hypothesis, I pretreated DBT cells with murine IFN-β 
prior to infection with WT MHV, nsp16 D130A, an IFN-sensitive positive control due to ablated 
2’O-MTase activity (Daffis et al., 2010; Habjan et al., 2013; Menachery et al., 2014; Smith et al., 
2015), or nsp14 D330A or nsp14 G332A N7-MTase mutant viruses at an MOI of 1 PFU/cell. 
Cell culture supernatants were collected at either 12 or 24 h post-infection, and viral titers were 
determined by plaque assay. As expected, the nsp16 D130A virus was sensitive to IFN-β 
pretreatment (Figure 11A). The nsp14 G332A virus demonstrated a dose-dependent increase in 
IFN-β sensitivity, which became undetectable by plaque assay at IFN-β concentrations greater 
than 75 U/ml (Figure 11A). In contrast, nsp14 D330A virus displayed sensitivity to IFN-β 
comparable to WT MHV (Figure 11B). Because nsp14 D330A displayed replication kinetics and 
resistance to IFN-β pretreatment indistinguishable from WT MHV, it is likely that the D330A 
substitution does not significantly affect N7-MTase activity. Therefore, I focused solely on the 
nsp14 G332A mutant for the remainder of the experiments in this study. 
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Figure 11. Nsp14 G332A virus exhibits increased induction of and sensitivity to IFN-β.  
 
DBT cells were treated for 18 h with the indicated concentrations of mouse IFN-β. Cells were infected 
with WT, nsp16 D130A, or nsp14 G332A virus and incubated for 24 h (A) or infected with WT, 
nsp16 D130A, and nsp14 D330A virus and incubated for 12 h (B). Cell culture supernatants were 
collected, and viral titers were determined by plaque assay. For each panel, error bars represent SEM 
(n = 4). ND = not detectable. C) DBT cells were treated for 18 h with 10 U/ml mouse IFN-β. Cells 
were mock infected or infected with WT, nsp16 D130A, or nsp14 G332A virus at an MOI of 0.1 
PFU/cell. At 12 h post-infection, cell lysates were harvested, total RNA extracted, cDNA generated, 
and IFN-β expression relative to GAPDH determined by qPCR. Error bars indicate SEM (n=9). N.S. = 
not significant, **, P <0.01 by Student’s t-test. (D) BMDCs were infected with either WT or nsp14 
G332A virus at an MOI of 0.01 PFU/cell. At 24 h post-infection, cell culture supernatants were 
collected, and viral titers were determined by plaque assay. Error bars indicate SEM (n = 6). *, P < 
0.05, ***, P < 0.001 by Student’s t-test.  
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In addition to an increased sensitivity to the effects of type I interferon pretreatment, 
coronaviruses lacking 2’O-MTase activity induce higher levels of IFN-β than WT (Habjan et al., 
2013; Menachery et al., 2014; Züst et al., 2011). Therefore, to determine whether nsp14 G332A 
is also recognized by innate sensors and subsequently induces type I interferon expression, I 
pretreated DBT cells with 10 U/mL murine IFN-β for 18 h prior to infection with WT MHV, 
nsp16 D130A, nsp14 G332A viruses at an MOI of 0.1 PFU/cell. At 12 h post-infection, cell 
lysates were collected and the relative expression of IFN-β determined by qPCR (Figure 11C). 
As previously reported, infection with WT MHV marginally induced the expression of IFN-β 
(Roth-Cross et al., 2007) and infection with nsp16 D130A led to an up-regulation of IFN-β 
relative to mock infected cells (Habjan et al., 2013; Menachery et al., 2014; Züst et al., 2011). 
Furthermore, infection with nsp14 G332A led to a significant increase in the expression of IFN-β 
relative to mock and WT MHV infected cells. These data further suggest that nsp14 N7-MTase 
activity precedes nsp16 2’O-MTase activity and the absence of either activity results in innate 
detection of the virus leading to the induction of type I interferon gene expression. 
 
To determine the effect that increased sensitivity to IFN-β has on nsp14 G332A replication, I 
tested whether nsp14 G332A virus replication could be rescued in BMDCs lacking the IFN 
alpha/beta receptor (IFNAR-/-). IFNAR-/- cells lack the capacity to respond to type I IFNs and, 
thus, are incapable of mounting an effective IFN-dependent antiviral response (Katze et al., 
2002). WT or IFNAR-/- BMDCs were infected with WT MHV or nsp14 G332A virus at an MOI 
of 0.01 PFU/cell, cell culture supernatants were collected 24 h post-infection, and viral titers 
were determined by plaque assay. Similar to experiments using DBT cells, nsp14 G332A virus 
replicated poorly in WT BMDCs relative to WT MHV (Figure 11D). Titers of nsp14 G332A 
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virus were increased by approximately 40-fold in IFNAR-/- BMDCs (5.6 x 104 PFU/ml) 
compared with the titers of this virus in WT BMDCs (1.3 x 103 PFU/ml). However, despite the 
increase in viral titers of nsp14 G332A in IFNAR-/- BMDCs, titers were not restored to the level 
of WT MHV in IFNAR-/- BMDCs (3.6 x 106 PFU/ml). These data suggest that the impaired 
replication capacity of nsp14 G332A virus is only in part attributable to IFN sensitivity and, 
instead, this virus may manifest a more general replication defect. 
 
Nsp14 G332A genome translation is delayed during infection 
 Since the absence of the IFNAR was insufficient to restore nsp14 G332A replication, other 
mechanisms, such as decreased genome RNA stability or decreased viral genome translation, 
may contribute to the replication defect of this virus. 5’ capping of cellular mRNAs serves 
several important functions, one of which is to increase RNA stability (Darnell, 1979; Decroly et 
al., 2011a). To test the stability of the nsp14 G332A genome upon entry into the cell, I infected 
DBT cells with WT MHV or nsp14 G332A virus at an MOI of 0.01 PFU/cell in the presence of 
vehicle (DMSO) or 100 µg/ml cycloheximide (CHX). CHX inhibits the translation of input viral 
genomes and prevents expression of the viral RNA dependent RNA polymerase, thereby 
allowing us to quantify the amount of coronavirus RNA present at later time-points relative to 
input. At the indicated times post-infection, cell lysates were collected, spiked with a known 
amount of in vitro transcribed Renilla luciferase, and the amount of viral RNA present relative to 
Renilla luciferase determined by qPCR (Figure 12). At each time-point post-infection for CHX 
treated samples, the level of nsp14 G332A RNA was similar to WT MHV, indicating that nsp14 
G332A replication is not impaired due to decreased genome RNA stability. 
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Figure 12. Nsp14 G332A genomic RNAs are stable.   
 
DBT cells were infected with WT or nsp14 G332A virus at an MOI of 0.01 PFU/cell in the presence 
of vehicle (DMSO) or 100 µg/ml CHX. Cell lysates were harvested at indicated times post-infection, 
spiked with a known amount of in vitro transcribed Renilla luciferase RNA, and total RNA obtained 
by phenol/ chloroform extraction. cDNA was generated by RT-PCR and viral genome copies present 
relative to Renilla luciferase was determined by SYBR Green qPCR using MHV nsp10 and Renilla 
luciferase specific primers. Error bars indicate SEM (n=6).  
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In addition to serving as a precursor for 2’O-methylation, N7-methylated guanosine 5’ caps are 
recognized by eIF4E and required for efficient translation of eukaryotic RNA (Decroly et al., 
2011a; Gebauer et al., 2004). To determine whether the nsp14 G332A mutation impairs viral 
translation efficiency, I first engineered virus encoding FFL as an in-frame N-terminal fusion 
with MHV nsp2 (Freeman et al., 2014) in the ORF1a polyprotein coding sequence of the 
isogenic nsp14 G332A cloned genome. In this setting, FFL-nsp2 is the second protein translated 
from the input viral genome and becomes a reporter for viral protein translation. I infected DBT 
cells with either WT-FFL or nsp14 G332A-FFL virus at an MOI of 0.1 PFU/cell, and lysates 
were prepared at various intervals post-infection to quantify luciferase activity and viral genome 
RNA copy number. Luciferase activity accumulated more slowly following infection by nsp14 
G332A-FFL virus relative to WT-FFL virus (Figure 13A). WT-FFL signal began to decline after 
16 h due to destruction of the cell monolayer. In addition, levels of nsp14 G332A-FFL genomic 
RNA increased more slowly than those of WT-FFL (Figure 13B). By quantifying both luciferase 
activity and viral genome copies, I was able to calculate the kinetics of translation. To determine 
the rate of translation at each time-point post-infection, the ratio of luciferase activity to genome 
copies was determined using data from Figure 13A and 13B. The ratio of luciferase activity to 
genome copies for WT-FFL was highest at early times post-infection (Figure 13C). In contrast, 
the ratio of luciferase activity to genome copies was substantially less for the nsp14 G332A-FFL 
virus at early time-points post-infection compared to WT-FFL and failed to reach peak WT-FFL 
levels. These data demonstrate that nsp14 G332A-FFL virus requires more genomic RNA to 
achieve WT levels of FFL activity, consistent with decreased translation efficiency of the mutant 
virus genome. Therefore, I next determined whether nsp14 G332A-FFL and WT-FFL virions are 
equivalently infectious by measuring the specific infectivity of each virus from infected DBT 
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Figure 13. Nsp14 G332A genomic RNAs are translated with delayed kinetics during infection.  
 
DBT cells were infected with either WT-FFL or nsp14 G332A-FFL virus at an MOI of 0.1 PFU/cell. 
At the times shown post-infection, cell culture supernatants were collected, and lysates were harvested 
and divided equally into two samples. For the first lysate sample, luciferase activity was quantified 
(A). For the remaining lysate sample, RNA was extracted, and genome RNA copies were quantified 
using real-time qRT-PCR with a standard curve and CoV nsp2-specific primers (B). (C) Translation of 
WT-FFL or nsp14 G332A-FFL genomes at the times shown post-infection as determined by luciferase 
activity per genome RNA copy number. Values were normalized to WT-FFL at 6 h post-infection. 
Error bars indicate SEM (n = 4). (D) Viral titers in cell culture supernatants from DBT cells infected 
with either WT-FFL or nsp14 G332A-FFL were determined by plaque assay and the number of 
genome RNA copies present in the input supernatant was determined by one-step real-time qRT-PCR. 
The particle to PFU ratio was calculated by dividing the number of genome RNA copies by viral titers. 
Error bars represent SEM (n = 4). **, P < 0.01 by Student’s t-test.  
 
 
 
 43 
cell culture supernatants. The ratio of nsp14 G332A-FFL particles per PFU was approximately 7-
fold more than WT-FFL (Figure 13D). Thus, packaged nsp14 G332A-FFL genomes were less 
efficient at establishing infection than WT. 
 
Nsp14 G332A-FFL genomes are translated less efficiently than  
WT-FFL genomes in vitro 
 To directly assess the translation capacity of nsp14 G332A-FFL virus genomes, I isolated 
genome RNA from purified virions. Increasing concentrations of genome RNAs were incubated 
with rabbit reticulocyte lysates at 30°C for 1.5 h, and luciferase activity was quantified (Figure 
14A). Compared to WT-FFL genomes, FFL activity in the reticulocyte lysates was significantly 
reduced following incubation with nsp14 G332A-FFL genomes. In addition, I quantified the 
relative translation efficiency of equal amounts of WT-FFL and G332A-FFL genomic RNA over 
time. At all time points tested after 15 min, FFL activity was significantly reduced following 
incubation of reticulocyte lysates with nsp14 G332A-FFL genomes relative to WT-FFL genomes 
(Figure 14B). Taken together, my data indicate that the decreased replication capacity of the 
nsp14 G332A virus is attributable to IFN sensitivity and reduced translation efficiency. 
 
Discussion 
In this study, I engineered recombinant CoVs encoding alanine substitutions in the nsp14 N7-
MTase at the SAM-binding site residues, D330 and G332. I found that the N7-MTase SAM-
binding site mutants are viable and yield drastically different phenotypes during replication. 
Specifically, MHV nsp14 D330A virus replicates indistinguishably from WT MHV in all assays 
conducted, despite the requirement of this residue for SAM binding in vitro (Chen et al., 2013). 
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Figure 14. Purified nsp14 G332A genomic RNA is translated at lower efficiency in vitro.  
 
BHK-R cells were infected at an MOI of 0.001 PFU/cell with either WT-FFL or nsp14 G332A-FFL 
virus. Supernatants were harvested and clarified, and virions were collected by ultracentrifugation. 
Virion pellets were resuspended, TRIzol was added, and virion RNAs were purified using 
phenol/chloroform phase separation. Genome RNA copies were quantified using one-step real-time 
qRT-PCR with a standard curve and CoV nsp2-specific primers. (A) The concentrations of WT-FFL 
or G332A-FFL genomic RNAs shown were translated in vitro at 30°C for 1.5 h, and luciferase activity 
was quantified. Translation values are relative to WT-FFL genomic RNA at 40 ng. Error bars 
represent SEM (n = 4). ***, P < 0.001 by Student’s t-test. (B) Equivalent numbers of either WT-FFL 
or nsp14 G332A-FFL genomic RNAs were translated in vitro for the times shown, and luciferase 
activity was quantified. Error bars represent SEM (n = 6). *, P < 0.05, **, P < 0.01 by Student’s t-test. 
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There is precedent for such a contradiction. A previous study using vesicular stomatitis virus 
identified a SAM-binding residue within the L protein (G1674) that, when altered, does not 
affect viral replication or N7-MTase activity (Li et al., 2005). The structure of the SARS-CoV 
nsp10-nsp14 complex reveals that D331 (D330 in MHV) is in close proximity to the SAM-
binding site, but only G333 (G332 in MHV) directly contacts SAM (Ma et al., 2015). Since in 
vitro N7-MTase activity was assessed only for a SARS-CoV nsp14 D331A/G333A double 
mutant, it is not clear whether nsp14 D331 was required for N7-MTase activity in this study (Ma 
et al., 2015). However, a previous study using both in vitro functional assays and yeast 
complementation reported that SARS-CoV nsp14 D331 is essential for N7-MTase activity (Chen 
et al., 2013). My study examined nsp14 N7-MTase in the context of viral replication. A potential 
difference between my work and previous studies of the CoV nsp14 N7-MTase is the use of 
MHV versus SARS-CoV proteins, respectively. Purified MHV nsp14 N7-MTase is not available 
in my lab for biochemical studies. However, my results will guide future experiments when such 
a system is established. During my study, I attempted to recover SARS-CoV nsp14 D331A, 
I332A, and G333A N7-MTase mutant viruses. However, viable viruses were not recovered after 
at least three attempts for each mutant. Nonetheless, the high conservation of the SAM-binding 
residues makes it unlikely that the differences observed between my work and previous 
biochemical studies are due to profoundly different N7-MTase catalytic mechanisms. 
  
In contrast to nsp14 D330A virus, nsp14 G332A virus replicated with delayed kinetics and 
reached peak titers that were 1000-fold less than those of WT MHV. CoV nsp14 has two 
domains: an N-terminal ExoN domain and a C-terminal N7-MTase domain. Mutations at D331 
in SARS-CoV nsp14 do not affect ExoN activity in vitro (Chen et al., 2009; 2013). However, the 
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effect of altering residue G333 (G332 in MHV) on ExoN activity has not been reported using 
any system. It is unlikely that the G332A mutation in MHV nsp14 influences ExoN activity, as 
nsp14 G332A demonstrated WT-like sensitivity to the RNA mutagen, 5-FU. Even a subtle 
alteration in ExoN activity should result in a detectable change in 5-FU sensitivity, particularly 
since I performed the assay using low-MOI conditions, which would increase mutagen 
incorporation during multi-step replication (Smith et al., 2013; 2015). The lack of enhanced 5-
FU sensitivity for the nsp14 D330A and nsp14 G332A viruses indicates that mutations at these 
SAM-binding residues do not significantly dampen ExoN activity during virus replication. 
Additionally, since nsp14 G332A is resistant to 5-FU treatment, it is unlikely that the G332A 
phenotype is due to nsp14 instability or degradation. 
  
My data indicate that impaired replication of nsp14 G332A virus is likely due to a combination 
of factors, including increased detection by innate immune sensors and decreased translation 
efficiency of viral RNA. Binding of type I IFNs to the IFN receptor leads to expression of many 
IFN-stimulated genes and ultimately the establishment of an antiviral state (Schneider et al., 
2014). Coronavirus RNAs lacking 2’O-methylation are sensed by IFIT1, which is one of the 
most highly up-regulated IFN-stimulated genes following IFN induction (Diamond and Farzan, 
2012). While nsp14 D330A displayed WT-like sensitivity to pretreatment with IFN-β, nsp14 
G332A virus did not replicate following IFN-β pretreatment with doses greater than 75 U/ml. 
However, initial titers were lower for nsp14 G332A. Thus, the concentration-dependent change 
in viral titer following IFN-β pretreatment was similar to the nsp16 D130A virus. The IFN-β 
sensitivity of nsp14 G332A likely results from a reduction in 2’O-methylation of viral RNA due 
to impaired N7-MTase activity. This hypothesis is supported by my data showing that infection 
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with either nsp16 D130A or nsp14 G332A virus results in the induction of IFN-β gene 
expression. In addition, decreased N7-MTase activity due to the G332A mutation results in the 
delayed translation and decreased translation efficiency observed during viral replication and in 
vitro assays. Due to the highly impaired replication capacity of the nsp14 G332A virus, it has not 
been possible to directly determine the cap methylation status of nsp14 G332A virus genomes. 
Nevertheless, my results are consistent with functions of the N7-methylated 5’cap in promoting 
both viral and cellular translation (Filipowicz et al., 1976; Marcotrigiano et al., 1997; Schibler 
and Perry, 1977). Decreased translation efficiency also could explain the lower specific 
infectivity observed for nsp14 G332A virus. Furthermore, it is possible that the delayed 
translation kinetics of nsp14 G332A genomic RNA increases innate sensing of the virus by 
delaying the early expression of multiple CoV IFN antagonists upon entry, resulting in decreased 
replication capacity. 
   
My data provide additional support for a sequential model of CoV RNA capping wherein N7-
methylation precedes 2’O-methylation. In addition, my studies suggest that small-molecule 
inhibitors of the CoV nsp14 N7-MTase would impair virus replication and provide a pathogen-
associated molecular pattern that would be quickly recognized by the innate immune response. 
Given the conservation of these enzymes, such inhibitors may have activity against diverse 
groups of coronaviruses. 
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CHAPTER III 
MURINE HEPATITIS VIRUS NSP14 EXORIBONUCLEASE ACTIVITY IS REQUIRED 
FOR RESISTANCE TO INNATE IMMUNITY 
 
Introduction 
Coronaviruses (CoVs) encode numerous innate immune antagonists that counteract the host 
innate immune response to facilitate efficient viral replication. CoV nsp14 3’-to-5’ 
exoribonuclease (ExoN) activity performs a proofreading function and is required for high-
fidelity replication (Bouvet et al., 2012; Eckerle et al., 2007; Minskaia et al., 2006; Smith et al., 
2013). Further, nsp14 ExoN activity has a preference for dsRNA (Minskaia et al., 2006). The 
CoV nsp14 ExoN is a member of the DE-D-Dh superfamily of DNA and RNA exonucleases, so 
named for the three motifs of four active site residues (Minskaia et al., 2006). Betacoronaviruses 
SARS-CoV and MHV expressing engineered, ExoN-inactivating substitutions at active site 
residues in Motif I (DE!AA) [ExoN(-)] demonstrate increased mutation frequencies and are 
profoundly sensitive to inhibition by RNA mutagens (Eckerle et al., 2007; Smith et al., 2013). 
Additionally, SARS-CoV ExoN(-) virus is attenuated in vivo (Graham et al., 2012). Outside of 
the order Nidovirales, the only other known RNA virus-encoded 3’-to-5’ exoribonucleases are 
found in the Arenaviridae family of viruses. Lassa fever virus nucleoprotein ExoN is not thought 
to participate in fidelity regulation, but rather it participates in immune evasion by degrading 
dsRNA and thereby prevents antigen-presenting cell-mediated NK cell activation (Hastie et al., 
2011; Qi et al., 2010; Russier et al., 2014). 
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Prior to this dissertation research, CoV nsp14 had not been investigated as an innate immune 
antagonist. In Chapter II, I demonstrated CoV nsp14 N7-MTase activity is essential for efficient 
translation of the viral genome and preventing innate detection (Case et al., 2016). In this 
chapter, I demonstrate the CoV ExoN activity is required for resistance to the innate immune 
response. Recently, in the Alphacoronavirus transmissible gastroenteritis virus (TGEV), a 
mutation in the nsp14 ExoN zinc finger was shown to generate lower levels of dsRNA compared 
to wild-type (WT) TGEV. However, in that study viruses with mutations in ExoN active site 
motifs were non-viable and therefore, could not be directly tested for effects on innate immunity 
(Becares et al., 2016). Therefore, I tested the hypothesis that CoV ExoN may also function to 
antagonize the innate immune response. I demonstrate that viruses lacking ExoN activity are 
more sensitive to the effects of IFN pretreatment than WT-MHV. In addition, for viruses lacking 
ExoN activity, replication is restricted in wild-type bone marrow derived macrophages (B6, 
BMMs) but is restored in interferon alpha/beta receptor deficient (IFNAR-/-) BMMs. Despite an 
increased sensitivity to the effects of IFN treatment, MHV ExoN mutants fail to induce 
detectable IFN-β gene expression or RNase L-mediated ribosomal RNA (rRNA) degradation and 
only a limited decrease in viral RNA accumulation is observed. Finally, I demonstrate that 
ExoN(-) virus replicated in the presence of an IFN-β-mediated antiviral state has both a 
decreased specific infectivity and decreased relative fitness compared to untreated ExoN(-) virus. 
Thus, nsp14 ExoN appears to block or correct the restriction of MHV infection by an IFN-
mediated mechanism that may involve damaging nascent viral RNA and affecting subsequent 
infectivity. 
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I performed all experiments and final analyses for the data presented in this chapter with 
exceptions as noted below. The coauthors provided the following contributions: Xiaotao Lu and I 
generated the ExoN(-) P250 virus, Nicole Sexton and Kevin Graepel generated the ExoN(-) 
silent virus stocks used for the co-infection assay, and Clint Smith developed the Taqman probes 
used in viral specific infectivity and co-infection assays. For some replicates, Ruth Elliott 
generated the BMMs and performed viral replication curves. For other replicates involving 
BMMs, Henry Li assisted me in generating the BMMs, and I performed the replication curves. 
 
Viruses lacking ExoN activity are more sensitive to the  
effects of IFN-β than WT-MHV 
Binding of type I interferon to the IFNAR receptor on the cell surface leads to a Jak/STAT 
signaling cascade that ultimately results in the up-regulation and expression of hundreds of 
antiviral ISGs (Schneider et al., 2014). In addition, WT-MHV replication has been shown to be 
relatively resistant to the effects of IFN (Rose et al., 2010; Rose and Weiss, 2009; Roth-Cross et 
al., 2007). To determine whether the ExoN activity of MHV nsp14 was required for resistance to 
IFN, I pretreated murine delayed brain tumor (DBT) cells with increasing concentrations of 
mouse IFN-β for 18 h prior to infecting with WT-MHV or ExoN(-) virus at a multiplicity of 
infection (MOI) of 1 plaque-forming unit (PFU) per cell (Figure 15A). In response to IFN-β 
pretreatment, WT-MHV viral titer decreased by approximately 1 log10 as previously reported 
(Roth-Cross et al., 2007). In contrast, ExoN(-) viral titer demonstrated a dose-dependent decrease 
and resulted in an approximately 3 log10 decrease in viral titer relative to untreated ExoN(-) viral 
titers. The ExoN activity of nsp14 is conferred by active site residues present in 3 different 
motifs within the ExoN domain (Ma et al., 2015). Therefore, to determine whether the observed 
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Figure 15. Viruses lacking ExoN activity are sensitive to IFN-β pretreatment.  
 
(A) DBT cells were pretreated with the indicated concentrations of mouse IFN-β for 18 h and then 
infected with WT-MHV or ExoN(-) virus (A) or WT, ExoN(-), or ExoN3(-) virus (C) at an MOI of 1 
PFU/cell. At 12 h post-infection, cell culture supernatants were collected and the viral titers present 
determined by plaque assay. (B) DBT cells were pretreated with the indicated concentrations of 5-FU 
for 30 min. Following pretreatment, cells were infected with WT, ExoN(-), or ExoN3(-) virus at an 
MOI of 1 PFU/cell for 45 min., inocula were removed, and fresh medium containing vehicle or the 
appropriate concentration of 5-FU were added. Cell culture supernatants were harvested 12 h post-
infection and viral titers were determined by plaque assay. For each panel, the change in viral titer was 
calculated by dividing viral titers following the indicated treatment by the untreated controls and error 
bars indicate SEM (n = 4). Statistical significance compared to WT-MHV is denoted and was 
determined by Student’s t –test. *, P < 0.05, **P < 0.01, *** P < 0.001.   
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increase in sensitivity to IFN-β pretreatment for ExoN(-) virus in Figure 15A was due 
specifically to the absence of ExoN activity in nsp14, I engineered and recovered a virus 
encoding only an aspartic acid to alanine substitution in Motif III [ExoN3(-)]. Previously, we 
have demonstrated that viruses lacking ExoN activity have decreased replication fidelity and are 
sensitive to the RNA mutagen 5-fluorouracil (5-FU) (Smith et al., 2013). Hence, 5-FU sensitivity 
is an in vitro indicator of ExoN activity. Therefore, first, I tested whether ExoN3(-) and ExoN(-) 
demonstrated similar sensitivity to 5-FU to ensure that the ExoN activity of ExoN3(-) virus had 
been ablated. Similar to ExoN(-), ExoN3(-) viral replication in cells treated with increasing 
concentrations of 5-FU demonstrated a dose-dependent decrease in viral titer relative to vehicle 
treated cells (Figure 15B). Further, ExoN(-) and ExoN3(-) displayed similar sensitivities to 
pretreatment with 100 or 500 U/mL IFN-β following infection at an MOI of 1 PFU/cell (Figure 
15C). Thus, these data suggest nsp14 ExoN activity is required for resistance to the effects of 
IFN-β pretreatment.  
 
Increased replication capacity does not confer resistance to the effects of IFN-β 
pretreatment for viruses lacking ExoN activity 
 ExoN(-) virus demonstrates an approximately 2 h delay in exponential replication and a 1 log10 
decrease in peak titer relative to WT-MHV (Eckerle et al., 2007). Therefore, I tested whether the 
IFN sensitivity phenotype observed for ExoN(-) and ExoN3(-) viruses is due to the decreased 
replication capacity of these viruses. To do so, I utilized an ExoN(-) virus developed by our lab 
that has been blindly passaged in DBT cells for 250 passages [ExoN(-) P250]. Over the course of 
passage, the ExoN(-) P250 virus did not revert the engineered ExoN(-) (DE!AA) mutations. In 
addition, ExoN(-) P250 accumulated 171 total mutations (74 non-synonymous mutations) across 
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the genome (Graepel et al., 2017). The replication capacity of the resulting ExoN(-) P250 virus 
exceeds that of WT-MHV (Figure 16A). However, despite increased replication capacity, 
ExoN(-) P250 demonstrated similar sensitivity to IFN-β pretreatment as ExoN(-) virus (Figure 
16A and B). Hence, the IFN-β sensitivity phenotype of viruses lacking ExoN activity is not 
dependent on viral replication capacity but instead, is directly associated with a specific function 
of nsp14 ExoN that is required for efficient replication in the presence of an IFN-β-mediated 
antiviral state.  
 
Nsp14 ExoN activity is required for replication in wild-type B6 BMMs 
 I next wanted to test whether ExoN activity was required for replication in primary innate 
immune cells, such as BMMs. Replication of WT-MHV in primary BMMs is well described, and 
data suggest that wild-type B6 BMMs (B6) express many PRRs and ISGs at a higher basal level 
than many mouse cell lines (Rose and Weiss, 2009; Zhao et al., 2013; 2011). In contrast, BMMs 
lacking the IFNAR receptor (IFNAR-/-) have lower basal and expressed levels of ISGs; thus, 
making B6 and IFNAR-/- BMMs excellent cell types for interrogating the role of ExoN activity 
on viral replication and antagonism of the innate immune response (Zhao et al., 2011). BMMs 
from B6 or IFNAR-/- mice were generated and infected with WT-MHV or ExoN(-) virus at an 
MOI of 1 PFU/cell. Samples were harvested at the indicated time-points, and viral titers were 
determined by plaque assay (Figure 17A). WT-MHV replication increased gradually in both B6 
and IFNAR-/- BMMs at each time-point post-infection. In contrast, ExoN(-) virus replication in 
B6 BMMs was only detectable at 6 and 9 h post-infection. However, when IFNAR-/- BMMs 
were infected with ExoN(-) virus, viral titers were partially restored and increased at each time-
point post-infection. To further test the replication of viruses lacking ExoN activity and the effect 
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Figure 16. Increased replication capacity does not restore virus resistance to IFN-β.  
 
DBT cells were pretreated with the indicated concentrations of mouse IFN-β for 18 h and then infected 
with WT, ExoN(-), or ExoN(-) P250 virus at an MOI of 1 PFU/cell. At 12 h post-infection, cell culture 
supernatants were collected and the viral titers present determined by plaque assay. Raw viral titers 
(A) or the change in viral titers relative to untreated controls (B) are reported. Error bars indicate SEM 
(n = 4). Statistical significance compared to WT-MHV is denoted and was determined by Student’s t –
test. *, P < 0.05, **P < 0.01, *** P < 0.001. 
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Figure 17. Replication of viruses lacking ExoN activity is restricted in wild-type B6 BMMs.  
 
B6 BMMs or IFNAR-/- BMMs were infected with WT-MHV or ExoN(-) virus (A) or WT-MHV or 
ExoN(-) P250 virus (B) at an MOI of 1 PFU/cell. At the indicated times post-infection, cell culture 
supernatant aliquots were collected and the viral titers present were determined by plaque assay.  For 
each panel, error bars represent SEM (n = 6 to 7). ND = not detectable. 
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of an increased replication capacity in BMMs, B6 and IFNAR-/- BMMs were infected with WT-
MHV or ExoN(-) P250 viruses at an MOI of 1 PFU/cell. Similar to the results shown in Figure 
17A, WT-MHV viral titers steadily increased in B6 and IFNAR-/- BMMs at each time-point 
post-infection (Figure 17B). However, similar to ExoN(-) virus, ExoN(-) P250 virus replication 
in B6 BMMs was restricted and not detected beyond 9 h post-infection. In addition, ExoN(-) 
P250 virus replication in IFNAR-/- BMMs was restored to similar levels as WT-MHV. These 
data show that ExoN activity is required for replication in B6 BMMs. Further, they suggest that 
restriction of ExoN(-) or ExoN(-) P250 is mediated by a gene or genes down-stream of IFNAR. 
 
Loss of ExoN activity does not result in the induction of IFN and replication is not rescued 
by RNase L/PKR deficiency 
Upon detection of a pathogen-associated molecular pattern (PAMP) by innate sensors, signaling 
pathways lead to transcription factor activation and nuclear translocation resulting in expression 
of IFN-β mRNA (Schneider et al., 2014). WT-MHV is well known to prevent or delay the 
induction of IFN expression (Rose et al., 2010; Rose and Weiss, 2009). However, ExoN activity 
may help prevent the detection of a PAMP, namely dsRNA, which has been shown to be 
increased in an nsp15 EndoU mutant (Kindler et al., 2017). Therefore, to determine whether the 
loss of ExoN activity resulted in the generation and subsequent detection of a PAMP, I 
determined the level of IFN-β gene expression in DBT cells infected with mock, WT-MHV, 
ExoN(-), or ExoN(-) P250 virus at an MOI of 0.1 PFU/ cell (Figure 18A). In addition, I infected 
DBT cells with Sendai virus (SenV), a positive control and a potent inducer of IFN, at an MOI of 
200 hemagglutination units/ml. SenV infection resulted in IFN expression by 3 h post-infection 
and peaked between 9 and 12 h post-infection prior to returning nearly to mock infected levels 
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Figure 18. Loss of ExoN activity does not result in the generation of a detectable PAMP.  
 
(A) DBT cells were infected with mock, WT, ExoN(-) or ExoN(-) P250 virus at an MOI of 0.1 
PFU/cell or infected with Sendai virus at an MOI of 200 HA units/ml. At the indicated times post-
infection, cell culture supernatants were removed, cell lysates were harvested, total RNA was 
extracted, cDNA was generated, and IFN-β expression relative to GAPDH was determined by qPCR. 
Error bars indicate SEM (n=4). (B) DBT cells were pretreated for 18 h with 0 or 50U/ml mouse IFN-β 
and subsequently infected with WT-MHV or ExoN(-) virus or transfected with 25µg/ml poly I:C. At 
the indicated times post-infection, cell culture supernatants were removed, cell lysates harvested, and 
total RNA extracted. rRNA integrity was assessed using an Agilent Bioanlyzer. One representative 
image is shown for each sample from 2 independent experiments. Images spliced for labeling 
purposes. The averaged RNA integrity values for each condition are reported. (C) B6 BMMs or RL -/- 
/ PKR -/- BMMs were infected with WT-MHV or ExoN(-) virus at an MOI of 1 PFU/cell. At the 
indicated times post-infection, cell culture supernatant aliquots were collected and the viral titers 
present were determined by plaque assay.  Error bars represent SEM (n = 5). ND = not detectable. 
 
 
 58 
by 24 h post-infection, demonstrating that DBT cells are capable of expressing IFN-β. In 
contrast, no CoV infection, regardless of whether intact ExoN activity was present, resulted in 
IFN-β gene expression over mock-infected cells with the exception of WT-MHV at 3 h post-
infection. Further, upon detection of dsRNA by OAS and subsequent activation of RNase L, 
viral and cellular RNAs are degraded as an antiviral mechanism (Schneider et al., 2014). To 
determine whether infection with ExoN(-) virus results in increased dsRNA levels that activate 
the OAS/RNase L pathway, DBT cells were pretreated with 0 or 50 U/ml mouse IFN-β and 
infected with WT-MHV or ExoN(-) virus at an MOI of 1 PFU/cell. As a positive control, DBT 
cells were transfected with 25µg/ml poly I:C, a dsRNA surrogate. At the indicated times post-
infection, cell lysates were harvested, total RNA extracted, and the integrity of cellular rRNA 
determined using a bioanalyzer (Figure 18B). Transfection of DBT cells with poly I:C resulted in 
rRNA degradation, whereas, infection of DBT cells with WT-MHV or ExoN(-) virus did not 
result in rRNA degradation under any tested conditions. Lastly, when B6 or RNase L -/- / PKR -
/- BMMs (RL -/- / PKR -/-) were infected with ExoN(-)virus, replication was restricted (Figure 
18C). In contrast to infection of B6 BMMs, ExoN(-) viral titer from RL -/- / PKR -/- BMMs was 
detectable at 12 and 24 h post-infection. However, viral yield was minimal. These data suggest 
that loss of nsp14 ExoN activity does not lead to the transcriptional activation of IFN-β or a 
notable dsRNA sensor such as OAS/RNase L during infection of DBT cells. In addition, BMMs 
deficient in the antiviral effectors RNase L and PKR were not sufficient to restore ExoN(-) viral 
replication.  
 
IFN treatment does not substantially alter ExoN(-) viral RNA  
accumulation or particle release 
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 Since ExoN activity is required for resistance to IFN but had no effect on IFN induction, I 
sought to discern the stage of viral replication that was restricted by IFN-β treatment. To 
determine the effect of IFN-β pretreatment on viral RNA accumulation, DBT cells were 
pretreated with 0 or 100 U/ml mouse IFN-β for 18 h and subsequently infected with WT-MHV 
or ExoN(-) virus at an MOI of 1 PFU/cell. At the indicated times post-infection, the number of 
genomic RNA copies present were determined by one-step RT-qPCR. IFN-β pretreatment had 
minimal effect on the accumulation of WT-MHV genomic RNA (Figure 19A). Whereas ExoN(-) 
genomic RNA accumulation is delayed relative to WT-MHV (Eckerle et al., 2007), pretreatment 
with IFN-β did not substantially decrease ExoN(-) genomic RNA levels (Figure 19A). In 
addition, I determined the effects of IFN-β pretreatment on the levels of subgenomic viral RNA. 
For both WT-MHV and ExoN(-) viruses, IFN-β pretreatment did not substantially reduce 
subgenomic RNA levels at any time-point (Figure 19B). These data indicate that IFN 
pretreatment did not result in the gross degradation or inhibition of ExoN(-) viral RNA 
accumulation. While slight reductions in viral RNA could explain a small portion of the IFN 
phenotype, these data suggest that decreased replication or transcription is not the primary driver 
of ExoN(-) IFN sensitivity.  
 
Since pretreatment of DBT cells with IFN-β does not grossly alter ExoN(-) viral RNA 
accumulation but does reduce ExoN(-) viral titers, I sought to determine whether IFN 
pretreatment prior to infection resulted in a measurable difference in the number of viral particles 
released from WT-MHV or ExoN(-) infected cells. DBT cells were pretreated with 0 or 100 
U/ml mouse IFN-β for 18 h and subsequently infected with WT-MHV or ExoN(-) virus at an 
MOI of 1 PFU/cell. At 12 h post-infection, cell culture supernatants were harvested and an 
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Figure 19. ExoN(-) viral RNA accumulation and particle release is marginally affected by IFN-β 
pretreatment.  
 
DBT cells were pretreated with 0 or 100U/ml mouse IFN-β for 18 h and subsequently infected with 
WT-MHV or ExoN(-) virus at an MOI of 1 PFU/cell. At the indicated times post-infection, total cell 
lysates were harvested and RNA was extracted. The viral genomic RNA copies present relative to an 
RNA standard were determined by one-step RT-qPCR (A) or cDNA was generated and the 
subgenomic RNA copies relative to GAPDH were determined by qPCR (B). For each panel (A and 
B), error bars represent SEM (n= 6 to 9). DBT cells were pretreated with 0 or 100U/ml mouse IFN-β 
for 18 h and subsequently infected with WT-MHV or ExoN(-) virus at an MOI of 1 PFU/cell. At 12 h 
post-infection, cell culture supernatants were collected. Equivalent volumes of cell culture supernatant 
for each sample were divided into two samples. For the first cell culture supernatant sample, total 
RNA was extracted and the number of virion genome RNA copies present (particles) was determined 
by one-step RT-qPCR (C) or reported as the change in virion genome RNA copies (D). Error bars 
represent SEM (n = 13 to 15). Statistical significance compared to untreated WT-MHV or ExoN(-) 
infection, respectively, is denoted and was determined by Student’s t –test. *** P < 0.001. 
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aliquot of two equal volumes were removed. From the first volume of each sample, RNA was 
extracted and used to perform one-step RT-qPCR to determine the number of genome RNAs 
present, and hence, the number of genome RNA containing particles present in the given volume 
of supernatant (Figure 19C). The second volume was saved for a plaque assay as described 
below. Pretreatment of cells with IFN-β resulted in approximately a 1 log10 decrease in the 
number of supernatant viral particles for both WT-MHV and ExoN(-) viruses compared to the 
number of supernatant viral particles from untreated cells, demonstrating that IFN pretreatment 
affects the release of WT-MHV and ExoN(-) virus particles equally (Figure 19D). Thus, these 
data suggest that IFN pretreatment does not restrict the primary replication of viruses lacking 
ExoN activity, but rather, renders them potentially inadequate for subsequent infection.  
 
ExoN(-) virus progeny generated in the presence of an IFN-induced antiviral state have 
decreased specific infectivity and fitness upon subsequent infection 
While many ISGs antagonize viral replication, some could alter the infectivity of progeny 
particles (Neil and Bieniasz, 2009; Tomaselli et al., 2015). To test whether IFN pretreatment 
affected the infectivity of ExoN(-) viral particles, the remaining cell culture supernatant volume 
described above was used to perform a plaque assay to determine the number of PFUs present 
(data not shown). Using the number of particles determined in Figure 19C and the number of 
PFUs present in an equivalent volume; I calculated the specific infectivity, or particle-to-PFU 
ratio, of each virus generated under each condition (Figure 20A). Regardless of IFN-β 
pretreatment during the initial infection, the specific infectivity of WT-MHV was approximately 
10 particles per 1 PFU upon subsequent infection. Infection of untreated DBT cells with ExoN(-) 
virus resulted in a similar particle to PFU ratio as WT-MHV during subsequent infection. In 
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Figure 20. ExoN(-) viruses generated in the presence of an antiviral state have decreased specific 
infectivity and are less fit relative to untreated.  
 
(A) DBT cells were pretreated with 0 or 100U/ml mouse IFN-β for 18 h and subsequently infected 
with WT-MHV or ExoN(-) virus at an MOI of 1 PFU/cell. At 12 h post-infection, cell culture 
supernatants were collected. Equivalent volumes of cell culture supernatant for each sample were 
divided into two samples. For the first cell culture supernatant sample, total RNA was extracted and 
the number of virion genome RNA copies present (particles) was determined by one-step RT-qPCR 
[Fig. 5C]. For the second cell culture supernatant sample, the viral titer present was determined by 
plaque assay (PFUs) (data not shown). The particle to PFU ratio for each virus and treatment was 
calculated by dividing the number of particles by the number of PFUs. Error bars represent SEM (n = 
13 to 15). (B) DBT cells were pretreated with 0 or 100 U/ml mouse IFN-β for 18 h and subsequently 
infected with WT-MHV or ExoN(-) virus at an MOI of 1 PFU/cell. At 12 h post-infection, cell culture 
supernatants were harvested for each virus and treatment group and the number of virion genome 
RNA copies present (particles) in the supernatant was determined by one-step RT-qPCR. Using the 
determined number of particles, an equivalent number of virus particles from each virus and treatment 
group were mixed with an equal number of WT silent or ExoN(-) silent virus particles. This mixture 
was then used to infect a fresh monolayer of untreated DBT cells. At 24 h post-infection, cell culture 
supernatants were collected, RNA was extracted, and the number of virion genome RNA copies for 
each original virus and treatment group relative to their respective silent standard viruses was 
determined by one-step RT-qPCR and is reported as the change in fitness relative to the silent virus 
standard. Error bars represent SEM (n=6). For each panel, statistical significance compared to 
untreated WT-MHV or ExoN(-) infection, respectively, is denoted and was determined by Student’s t 
–test. *, P < 0.05, *** P < 0.001, n.s.= not significant.  
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contrast, when DBT cells were pretreated with IFN-β prior to initial infection with ExoN(-) 
virus, the resulting specific infectivity of ExoN(-) virus was 100 particles per 1 PFU, a 
significant decrease in specific infectivity. Therefore, ExoN(-) virus generated in the presence of 
an IFN-β-mediated antiviral state requires 10-fold more genome RNA containing particles to 
generate 1 PFU than WT-MHV generated in cells pretreated with or without IFN or ExoN(-) 
virus generated in untreated cells. These data suggest that the IFN-mediated restriction of ExoN(-
) virus in DBT cells occurs at the level of subsequent infection by reducing particle infectivity.    
 
Next, I tested whether the effects of IFN on ExoN(-) viruses were intrinsic to the viruses 
produced. To do so, I performed a co-infection assay, which utilized WT-MHV and ExoN(-) 
viruses harboring 10 silent mutations in the nsp2-coding region (WT silent and ExoN(-) silent, 
respectively) along with WT-MHV and ExoN(-) viruses. The genome RNAs of the silent viruses 
are recognized exclusively by a separate probe than the one used to detect the “WT” nsp2 probe-
binding region of WT-MHV or ExoN(-) viruses (Graepel et al., 2017). Thus, allowing WT silent 
and ExoN(-) silent to act as internal controls for a co-infection assay under identical conditions. 
DBT cells were pretreated with 0 or 100 U/ml mouse IFN-β for 18 h and subsequently infected 
with WT-MHV or ExoN(-) virus at an MOI of 1 PFU/cell. At 12 h post-infection, total cell 
culture supernatants were collected. The number of viral particles present in a representative 
aliquot was determined from purified virion genome RNA by one-step RT-qPCR. In addition, I 
determined the number of genome RNA containing particles in an equivalent volume of WT 
silent or ExoN(-) silent viral p1 stock tubes. Using the calculated number of genome RNA-
containing viral particles, I added an equal number of WT-MHV viral particles generated in the 
absence of IFN pretreatment to WT silent viral particles and an equal number of WT-MHV viral 
 
 
 64 
particles generated in the presence of IFN pretreatment to WT silent viral particles. This same 
set-up was repeated for ExoN(-) viral particles generated in the presence or absence of IFN 
pretreatment with ExoN(-) silent viral particles. Finally, each combination was used to infect a 
fresh monolayer of untreated DBT cells. At 24 h post-co-infection, total cell culture supernatants 
were collected and virion genome RNA was extracted to determine the number of supernatant 
viral particles present from each combination of input viruses by one-step RT-qPCR and is 
reported as the change in fitness relative to the respective silent virus standard (Figure 20B). The 
number of WT-MHV particles generated in the presence of IFN pretreatment was similar to the 
number of WT-MHV particles generated in the absence of IFN pretreatment over the course of 
co-infection, relative to their respective silent standards. However, the number of viral particles 
present from ExoN(-) virus generated in the presence of IFN pretreatment during the course of 
co-infection decreased by approximately 1.5 log10 in comparison with ExoN(-) viral particles 
generated in the absence of IFN pretreatment relative to their respective silent standards. These 
data indicate that a loss in nsp14 ExoN activity sensitizes viruses to IFN pretreatment and 
reduces the infectivity and fitness of progeny during subsequent rounds of infection in the 
absence of an antiviral state.  
 
Discussion 
CoVs encode multiple IFN antagonists that prevent the induction of or mediate resistance to the 
innate immune response; thus, allowing efficient viral replication early during infection (Rose 
and Weiss, 2009). Moreover, an insufficient innate immune response has been proposed to be a 
major contributor of SARS-CoV pathogenesis (Gu and Korteweg, 2007). In this study, I sought 
to determine the contributions of nsp14 ExoN activity in the induction of and resistance to the 
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innate immune response. I demonstrate that ExoN(-) virus is more sensitive to cellular 
pretreatment with IFN-β than WT-MHV. Further, because ExoN3(-) and ExoN(-) P250 viruses 
were also more sensitive to the effects of IFN, I conclude that IFN sensitivity is specifically due 
to a loss of ExoN activity.  
 
Because the ExoN activity of the Lassa fever virus nucleoprotein degrades dsRNA intermediates 
(Hastie et al., 2011; Qi et al., 2010), I hypothesized that CoV nsp14 ExoN could function in a 
similar manner. In fact, since my current study began, CoV nsp14 ExoN activity has also been 
proposed by others to function as an innate immune antagonist (Becares et al., 2016; Kindler and 
Thiel, 2014). If nsp14 ExoN is degrading viral dsRNA, ExoN inactivation should increase 
intracellular dsRNA accumulation, resulting in a concomitant increase in IFN-β expression or 
activation of RNase L during infection. I neither observed IFN-β up-regulation nor RNase L 
activation over the course of ExoN(-) virus infection (Figure 18A and B), and rRNA was intact 
at all time-points tested (Figure 18B). Therefore, at least two possible explanations exist: 1.) 
MHV ExoN does not function to degrade dsRNA or 2.) MHV ExoN does degrade dsRNA, but 
the detection of this PAMP is unchanged during ExoN(-) virus infection due to sufficient 
antagonism by other CoV proteins. Basal OAS expression levels correlate with RNase L 
activation (Birdwell et al., 2016). Thus, I pretreated DBTs with IFN-β to up-regulate OAS and 
RNase L expression. However, rRNA degradation was only observed in cells transfected with 
poly I:C (Figure 18B). Further, nsp15 EndoU and NS2 phosphodiesterase activities were intact 
during all of my experiments. Thus, it is possible that in the absence of nsp14 ExoN activity, 
other CoV innate antagonists were sufficient to prevent innate detection by the cell or prevent the 
induction of a detectable signal in the experiments I performed. However, one would expect the 
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endonucleolytic products of nsp15 to be smaller dsRNAs that could still activate RIG-I or 
MDA5, similar to RNase L products, unless another RNA degradation mechanism were in place 
(Malathi et al., 2007; Schneider et al., 2014). In addition, despite an intact NS2 
phosphodiesterase, nsp15 mutants still activate RNase L-mediated rRNA degradation (Kindler et 
al., 2017). Lastly, when RNaseL -/- / PKR -/- BMMs were infected with ExoN(-) virus, viral 
replication was not rescued, suggesting that RNase L and PKR are not required for ExoN(-) virus 
restriction (Figure 18C). Moreover, these data suggest dsRNA is not detected and the antiviral 
effectors RNaseL and PKR are not activated during ExoN(-) virus infection. 
 
During my study, Becares et al. reported that a TGEV nsp14 zinc-finger mutant modulated the 
innate immune response of swine testis cells by reducing the levels of dsRNA and induction of 
IFN (Becares et al., 2016). Unlike TGEV, Betacoronaviruses such as SARS-CoV and MHV, do 
not induce IFN expression in most cell types (Frieman et al., 2008; Rose and Weiss, 2009; Roth-
Cross et al., 2007) (Figure 18A). Interestingly, TGEV ExoN active site mutants were non-viable; 
although, this is not the first report of non-viable ExoN active site residue mutants in 
Alphacoronaviruses (Becares et al., 2016). In the initial report of CoV nsp14 ExoN activity, 
human CoV 229E ExoN active site mutants were also non-viable, suggesting a common essential 
function for nsp14 ExoN in Alphacoronavirus replication and/or innate antagonism (Minskaia et 
al., 2006). Altogether, the possibility of a common innate immune antagonism function for nsp14 
across Alpha- and Beta-CoVs is apparent but clearly differing requirements exist that may be 
dependent on the CoV genus and cell types used.  
 
My results clearly demonstrate that viruses lacking ExoN activity are more sensitive to IFN-β 
 
 
 67 
pretreatment than WT-MHV in a dose-dependent manner (Figure 15A,C and Figure 16). Further, 
replication of viruses lacking ExoN activity was dependent on the capacity of BMMs to express 
genes downstream of IFNAR signaling (Figure 17). This is due to the fact that B6 and IFNAR-/- 
cells have different levels of basal ISG expression and thus, two very different intracellular 
environments for viral replication to occur (Rose and Weiss, 2009; Zhao et al., 2013; 2011). In 
IFNAR-/- BMMs, ExoN(-) and ExoN(-) P250 virus replication capacity was restored to levels 
approaching or exceeding WT-MHV levels (Figure 17). Further, my specific infectivity (Figure 
20A) and co-infection (Figure 20B) data show that ExoN(-) virus generated in the presence of an 
antiviral state is less viable upon subsequent infection. Altogether, my results suggest that an ISG 
or ISGs is (are) acting on ExoN(-) virus, specifically resulting in progeny that are less viable 
upon subsequent infection. Thus, it will be interesting to determine the specific ISG (or ISGs) 
responsible for mediating the observed restriction. In addition, it will be important to determine 
whether a greater proportion of the incoming ExoN(-) viral particles are strictly non-viable or 
whether cells are now sensing the progeny ExoN(-) viruses and inhibiting replication. My 
specific infectivity data support the possibility that the effects of IFN treatment results in non-
infectious ExoN(-) virus particles, which could potentially compete with infectious ExoN(-) 
virus particles for viral receptors during subsequent entry. Due to the pleiotropic nature of IFN-β, 
more than one mechanism may be acting.  
 
To date, the majority of our understanding of nsp14 ExoN activity is in the context of 
proofreading during CoV replication (Bouvet et al., 2012; Eckerle et al., 2007; Minskaia et al., 
2006; Smith et al., 2013). CoVs lacking ExoN activity demonstrate an increase in mutation 
frequency relative to WT (Eckerle et al., 2007; Smith et al., 2013). Thus, it is possible that 
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ExoN(-) virus replication in IFN pretreated cells results in further alteration of ExoN(-) virus 
mutation frequency. Certainly, an increase or decrease in mutation frequency could impair viral 
replication during a subsequent infection. Moreover, a recent study demonstrated that optimal 
viral replication fidelity is required for poliovirus to overcome tissue-specific innate immune 
responses (Xiao et al., 2017). In addition, IFN pretreatment may up-regulate an ISG that acts to 
hypermutate the large CoV genome in the absence of ExoN activity, rendering viral progeny less 
viable. ISGs that increase viral mutation frequency have been described such as adenosine 
deaminase acting on RNA 1 (ADAR1) and apolipoprotein B mRNA editing enzyme, catalytic 
polypeptide-like 3G (APOBEC3G) (Neil and Bieniasz, 2009; Tomaselli et al., 2015). Further, 
another ISG, SAMHD1, may inhibit HIV replication by limiting nucleotide pools, a known 
contributor to increased viral mutation frequency (Hrecka et al., 2011; Lahouassa et al., 2012; 
Sanjuán and Domingo-Calap, 2016). Moreover, other possible mechanisms outside of altered 
mutation frequency exist. For instance, in the absence of ExoN activity, terminal RNA 
modifications, recombination, and/or replicase protein interactions mediated by nsp14 ExoN may 
be disrupted to a greater extent in the presence of an IFN-β-mediated antiviral state. 
 
Since CoVs encode the largest genome known for RNA viruses, they have the luxury of 
encoding multiple IFN antagonists that limit the capacity of a cell to detect and respond to 
infection. Collectively, my data suggest that MHV nsp14 ExoN activity is a contributor to CoV 
innate immune antagonism. I clearly demonstrate that viruses lacking ExoN activity are more 
sensitive to the effects of an IFN-β-mediated antiviral state. Further, my data reveal a critical role 
for nsp14 ExoN activity in CoV replication and provide additional rationale for targeting nsp14 
ExoN activity as a means of viral attenuation. Our future studies will probe the specific 
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mechanism of restriction for viruses lacking ExoN activity and assess how the requirement of 
ExoN activity for resistance to innate immunity can be utilized for treatment during human 
coronavirus infections.         
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CHAPTER IV 
DETERMINATION OF THE INTERFERON-STIMULATED GENE(S) RESPONSIBLE 
FOR RESTRICTING EXON(-) VIRUS REPLICATION 
 
Introduction 
Prior to this dissertation research, coronavirus (CoV) nonstructural protein 14 (nsp14) 3’-to-5’ 
exoribonuclease (ExoN) activity had been investigated solely in the context of proofreading and 
maintaining viral replication fidelity (Bouvet et al., 2012; Eckerle et al., 2010; Minskaia et al., 
2006; Smith et al., 2013). However, the discovery that arenaviruses also encode an ExoN, which 
functions as an innate immune antagonist, led me to hypothesize that CoV ExoN may act in a 
similar manner (Hastie et al., 2011; Qi et al., 2010). Further, a recent study using transmissible 
gastroenteritis virus, an Alphacoronavirus, nsp14 supports this hypothesis. However, viruses 
lacking ExoN activity were non-viable in that report; thus, preventing the direct study of the role 
of ExoN activity in innate immune antagonism (Becares et al., 2016). In Chapter III of this 
dissertation, I presented the first evidence suggesting that for murine hepatitis virus (MHV), a 
Betacoronavirus, nsp14 ExoN activity is required to confer resistance to the interferon beta 
(IFN-β)-mediated innate immune response. IFN-β pretreatment of cells did not restrict ExoN(-) 
viral RNA replication or particle release compared to wild-type (WT) MHV. Rather, my data 
suggest that viruses lacking ExoN activity that were generated in the presence of an antiviral 
state are specifically incapable of establishing a subsequent infection. Despite my efforts, the 
specific antiviral interferon stimulated gene (ISG) that restricts ExoN(-) virus has yet to be 
determined.  
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Until recently, there were thought to only be 30-40 ISGs. However, today we know the 
expression levels of hundreds of genes are altered in response to interferon (IFN).  (Katze et al., 
2002). The number of genes induced and the relative level of expression is dependent on the 
specific cell-type and stimulus, but the general mechanism for their induction is the same. Upon 
secretion from a cell, type I IFNs bind to interferon alpha/ beta receptors (IFNARs) in an 
autocrine and paracrine manner. Binding triggers an intracellular signaling cascade that 
culminates in the formation of a complex known as interferon stimulated gene factor 3 (ISGF3), 
which is comprised of phosphorylated signal transducer and activator of transcription proteins 1 
and 2 and interferon regulatory factor 9 (IRF9). Next, ISGF3 translocates to the nucleus of the 
cell and binds to interferon-stimulated response elements, facilitating the expression of ISGs. 
ISGs are the workhorses of the antiviral innate immune response (Katze et al., 2002). ISGs may 
act as direct antiviral effectors by targeting a specific stage of viral replication or as positive 
regulators to reinforce the antiviral response. In addition, ISGs can be negative regulators of the 
IFN-mediated innate immune response to limit the duration of the response and prevent 
excessive damage to cells or tissues (Schneider et al., 2014). The specific role of many ISGs in 
controlling viral replication has been described (Katze et al., 2002; Schneider et al., 2014). 
However, the identification of novel ISGs or new roles for previously identified ISGs in response 
to different viral infections is currently a rapidly evolving area in virus research. Accordingly, 
innovative approaches to identify ISGs are needed.  
 
In this chapter, I present preliminary data investigating the contributions of specific antiviral 
ISGs toward restricting ExoN(-) virus infection. In addition, I present the results of an RNA 
sequencing experiment to determine the ISGs up-regulated in DBT cells upon addition of 
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exogenous IFN-β. Lastly, I present the development of a high-throughput screening approach to 
determine the interferon stimulated gene or genes, responsible for restricting ExoN(-) virus 
replication. Data presented in this chapter are from experiments performed and analyzed by me 
with the exceptions mentioned below. In all cases, I designed the experiments and performed all 
final analyses. Ruth Elliot in the Weiss lab performed the WT and ExoN(-) virus replication 
curve in MDA5-/- bone marrow derived macrophages (BMMs). Henry Li generated ADAR1-/- 
A549 cells expressing the MHV CEACAM receptor, the Vanderbilt VANTAGE core performed 
the RNA sequencing, and Xiaotao Lu cloned the ExoN(-) P250 spike into the MHV A-59 G 
fragment used to generate WT and ExoN(-) RFP- ExoN(-) P250S viruses.  
 
ExoN(-) virus demonstrates an increased sensitivity to a fully activated OAS/  
RNase L antiviral response in DBT cells  
The oligoadenylate synthetase/ latent ribonuclease  (OAS/ RNase L) pathway is a major dsRNA 
sensor. Upon detection of viral dsRNA, OAS generates 2’-5’ oligadenylates, which act as 
secondary signaling molecules to activate RNase L. Once RNase L becomes activated, it 
functions to degrade all RNAs, both of cellular and viral origin, inside a cell. The degradation of 
viral RNAs directly limits viral replication, and RNase L RNA products also act to stimulate 
sensors such as MDA5, creating a positive feedback loop (Drappier and Michiels, 2015; Malathi 
et al., 2007; Silverman, 2007). Arenaviruses encode the only ExoN known for RNA viruses 
outside of the order Nidovirales. Studies have demonstrated that the arenavirus ExoN functions 
to antagonize the innate immune response by degrading viral dsRNA intermediates (Hastie et al., 
2011; Qi et al., 2010; Russier et al., 2014). In addition, coronaviruses are known to demonstrate a 
relatively high level of resistance to the innate immune response (Rose and Weiss, 2009). 
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Therefore, I sought to determine whether ExoN functions to degrade dsRNA viral replication 
intermediates and thus, whether viruses lacking ExoN exhibit an increased sensitivity to the 
OAS/ RNase L antiviral response. Previous studies have demonstrated that in order for the OAS/ 
RNase L antiviral response to become fully activated, OAS must be expressed basally or up-
regulated by IFN to a sufficient level and dsRNA must be present (Birdwell et al., 2016; Li et al., 
2016; Marcus and Sekellick, 2001; Zhao et al., 2013). In addition, in this context, viruses that 
were previously refractory to pretreatment with exogenous IFN became sensitive (Marcus and 
Sekellick, 2001). Therefore, I pretreated cells with mock treatment, 100U/ml IFN-β, or 100U/ml 
IFN-β + 25µg poly I:C (a dsRNA surrogate). After pretreatment, I infected cells treated with 
each condition with WT or ExoN(-) virus at a multiplicity of infection (MOI) of 1 plaque 
forming unit (PFU)/ml (Figure 21). In the presence of IFN-β alone, ExoN(-) viral titers were 
decreased by approximately 2.5 log10 compared to untreated. However, in the presence of IFN-β 
+ poly I:C, ExoN(-) viral titers were not detectable. In addition, WT MHV titers in the presence 
of IFN-β + poly I:C were similar to ExoN(-) viral titers in the presence of IFN-β alone. If ExoN 
activity were functioning to also degrade dsRNA, I would expect ExoN(-) virus to be no more 
sensitive to IFN-β + poly I:C than IFN-β alone. Therefore, while it remains possible that ExoN 
functions to degrade dsRNA, it is hard to draw a conclusion from these results alone.  
 
ExoN(-) virus replication is not rescued in MDA5-/- BMMs 
In Figure 17 of Chapter III, I demonstrated that ExoN(-) virus replication is restricted in wild-
type (B6) BMMs. Further, ExoN(-) viral replication was not restored in BMMs deficient in the 
dsRNA effectors RNase L and PKR. These data suggest that in the context of ExoN(-) virus 
replication, dsRNA does not activate RNase L or PKR resulting in decreased viral replication. 
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Figure 21. ExoN(-) virus is more sensitive to a fully activated OAS/ RNase L antiviral response. 
 
DBT cells were pretreated for 18 h with 100 U/ml mouse IFN-β or mock treated. For IFN-β + poly I:C 
treatment, cells were transfected with 25 µg poly I:C and incubated for the final hour of IFN treatment. 
After pretreatment, cells were infected with WT or ExoN(-) viruses at an MOI of 1 PFU/cell. At 12 h 
post-infection, cell culture supernatants were collected and viral titers were determined by plaque 
assay. Values are reported as the change in viral titer relative to untreated viral titers for each 
respective virus. Error bars represent SEM. n=6. 
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Another pattern recognition receptor (PRR) that functions to detect dsRNA during viral infection 
is melanoma differentiation-associated gene 5 (MDA5). MDA5 is a member of the RIG-I-like 
family of PRRs that localizes in the cell cytoplasm and functions to detect long, double-stranded 
RNA as well as cap-0 RNAs (Decroly et al., 2011a; Schneider et al., 2014). MDA5 is positively 
reinforced by IFN expression and upon detection of viral RNA, signals downstream into the 
IFN-mediated antiviral response. To determine if MDA5 is necessary for ExoN(-) virus 
restriction in BMMs, we infected B6 or MDA5-/- BMMs with WT or ExoN(-) MHV at an MOI 
of 1 PFU/cell (Figure 22). Cell culture supernatants were harvested at the indicated times post-
infection and viral titers were determined by plaque assay. My data indicate that ExoN(-) virus 
replication is not affected by MDA5 deficiency. These data are in agreement with my previous 
experiments using RNase L/PKR-/- BMMs and the conclusion presented in Chapter III that 
dsRNA is not detected in viruses lacking ExoN activity. Further, these data corroborate the data 
shown in Figure 18A in Chapter III that suggest ExoN(-) virus replication does not induce IFN-β 
expression. Therefore, all data to date suggest that MHV nsp14 ExoN activity does not function 
to degrade dsRNA during infection.  
 
ADAR1 is not responsible for mediating ExoN(-) virus restriction 
In chapter III of this dissertation, I presented data demonstrating that after ExoN(-) virus 
replicated in the presence of an antiviral state, the viruses produced were less viable and capable 
of establishing a subsequent infection. This observation was highlighted by a decreased specific 
infectivity and decreased replicative fitness exclusively for ExoN(-) virus in IFN-β pretreated 
cells. Therefore, I concluded that CoV ExoN activity is required for resistance to the IFN-β-
mediated innate immune response. In addition, considering the fact that nsp14 ExoN functions as 
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Figure 22. ExoN(-) virus replication is not rescued in MDA5 -/- BMMs.  
 
B6 BMMs or MDA5-/- BMMs were infected with WT-MHV or ExoN(-) virus at an MOI of 1 
PFU/cell. At the indicated times post-infection, cell culture supernatant aliquots were collected and the 
viral titers present were determined by plaque assay. For each panel, error bars represent SEM (n = 3). 
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a proofreading enzyme, I reasoned that an ISG may act to increase or decrease the mutation 
frequency of ExoN(-) virus genomes. One ISG that has been demonstrated to hypermutate viral 
genomes is adenosine deaminase acting on RNA 1 (ADAR1) (Mannion et al., 2014; Piontkivska 
et al., 2017; Schoggins et al., 2011; Tomaselli et al., 2015). ADAR1 is an IFN-inducible protein, 
and previous studies have demonstrated that the hypermutation activity of ADAR1 on viral RNA 
genomes can be pro-viral (in the case of HIV infection) or antiviral (in the case of influenza 
virus). ADAR1 binds dsRNA and deaminates adenosine sequences to inosine (Samuel, 2011; 
Tomaselli et al., 2015). Inosine prefers to base pair with cytosine, resulting in an adenosine to 
guanosine transition (Mannion et al., 2014). Henry Li in the Weiss Lab generously engineered 
A549 cells that were deficient for ADAR1 and express the MHV CEACAM receptor using 
CRISPR/ Cas technology. To determine whether ADAR1 was responsible for mediating ExoN(-) 
virus sensitivity to IFN-β, I performed a replication curve using these cells. I infected WT or 
ADAR1-/- A549 cells with WT or ExoN(-) virus at an MOI of 1 PFU/cell and collected cell 
culture supernatants at the indicated times post-infection (Figure 23). I observed similar viral 
titers for ExoN(-) virus in WT A549 cells and ADAR1-/- A549 cells at each time-point post-
infection. Therefore, I conclude that ADAR1 does not restrict ExoN(-) virus replication in A549 
cells.  
 
Determining the ISGs up-regulated in DBT cells upon treatment with IFN-β 
In Chapter III of this dissertation, I demonstrated that pretreatment of DBT cells with exogenous 
IFN-β restricted ExoN(-) virus replication upon subsequent infection. Treatment with IFN is 
known to alter the expression of hundreds of genes (Katze et al., 2002). However, the specific 
genes and the degree in which they up-regulated is cell-type specific. Therefore, to further 
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Figure 23. ExoN(-) virus replication in ADAR1  p150 -/- A549 cells 
 
WT or ADAR1 p150-/- A549 cells stably expressing the MHV receptor, CEACAM, were infected at 
an MOI of 1 PFU/cell and aliquots of cell culture supernatants were collected at the indicated times 
post-infection. Viral titers present were determined by plaque assay. n=6.  
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understand the environment in which ExoN(-) virus is replicating after pretreatment of DBT cells 
with IFN-β, I performed RNA sequencing on cell lysates from cells pretreated with or without 
mouse IFN-β and analyzed the differential gene expression profile (Figure 24 and Appendix C). 
Uninfected DBT cells were treated with or without mouse IFN-β for 26 h and cell lysates were 
harvested. Upon extraction of total RNA, samples were submitted to the Vanderbilt VANTAGE 
core for mRNA enrichment, cDNA library preparation, and sequencing. After the VANGUARD 
core deconvoluted the sequencing reads, I analyzed the data set to determine genes that were 
statistically up or down-regulated. Over 23,160 annotated murine gene reads were observed. 
Moreover, 3,536 genes were significantly up or down-regulated in IFN treated DBT cells versus 
mock treated DBT cells. Of the 3,500+ differentially expressed genes, 1,607 were up-regulated 
by IFN-β treatment. In addition, antiviral genes such as Irf7, Oas1a, Ifitm3, Bst2 (also known as 
tetherin), Mx2, Ddx58, and Ifit1 were among the most highly up-regulated genes (Figure 24). 
The full list of statistically significant, differentially expressed genes is presented in Appendix C. 
These data demonstrate, and reveal for the first time, the exact cellular environment in which 
ExoN(-) virus is replicating after IFN treatment. Although many genes are differentially 
expressed upon IFN-β pretreatment, these data will allow us to preferentially select genes that 
are now known to be up-regulated in DBT cells during future experiments to elucidate the 
mechanism of ExoN(-) restriction by IFN.  
 
Development of a high-throughput ISG screen to determine the ISG(s) mediating ExoN(-) 
virus restriction in DBT cells 
To this point in this chapter, I have described experiments aimed at determining the specific 
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Figure 24. Statistically up and down-regulated genes in DBT cells upon IFN-β treatment.  
 
DBT cells were pretreated with 0 or 100 U/ml mouse IFN-β for 26 h. After pretreatment, cell culture 
supernatants were removed and total cell lysates were harvested using TRIzol reagent. Total RNA was 
extracted and RNA sequencing performed to identify gene expression profiles. The DeSeq algorithm 
was used to identify statistically differentially expressed genes. Genes that were statistically up or 
down-regulated in IFN-β treated cells relative to untreated cells are plotted with notable genes labeled.  
 
 
 81 
mechanism of ExoN(-) virus restriction when replicated in the presence of IFN-β. While taking a 
targeted approach allows for a quick result, the conclusions that can be made and the limitations 
of isolating a single gene or pathway may not reveal all mechanisms of action. Further, the 
experiments I have performed are based off existing knowledge of ISGs and antiviral pathways 
and may not reveal novel interactions. Most importantly, the ISG or ISGs responsible for 
restricting ExoN(-) virus replication have not been identified by previous methods. Therefore, I 
have developed an unbiased high-throughput screening approach.  
 
Several different high-throughput ISG screening approaches have been developed using ISG 
overexpression constructs, siRNA-mediated knockdown of ISGs, shRNA-mediated knockdown 
of ISGs, or CRISPR-Cas9 directed genome editing (Li et al., 2013; Schneider et al., 2014; 
Schoggins et al., 2011; 2014; Zhao et al., 2012a). Each screening approach has its own caveats 
and limitations. However, the amount of information that can be gathered in a short amount of 
time and subsequently validated make them attractive approaches. The screen I have worked to 
develop is outlined in (Figure 25). The benefits of using this screening approach include but are 
not limited to: 1.) this screen can define the relative contribution of any given ISG in the context 
of an intact IFN response for a desired cell type, 2.) this screen will allow one to identify ISGs 
that are part of a multicomponent complex, and 3.) this screen will allow the differential antiviral 
activities of ISGs against WT and ExoN(-) viruses to be simultaneously determined (Li et al., 
2013). The general concept of the ISG is screen is as follows: 1.) within cells, the expression of a 
single ISG is targeted and knocked down by lentiviral transduction of a green fluorescent protein 
(GFP) and shRNA expressing plasmid, 2.) cells are treated with IFN-β 
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Figure 25. High-throughput ISG screen outline 
 
The workflow of the high-throughput screen I developed is outlined. An shRNA targeting an ISG is 
expressed downstream of a CMV promoter and GFP. 293T cells are co-transfected with shRNA and 
lentiviral packaging plasmids to generated lentiviral pseudoparticles. DBT cells are transduced with 
the lentiviral particles targeting a specific ISG. DBT cells are pretreated with mouse IFN-β for 18 h to 
up-regulate all other ISGs in the cell. DBT cells are infected with an RFP expressing virus of interest 
and viral infection in transduced, GFP+ cells is quantified by flow cytometry.  
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to up-regulate all ISGs (except the expression of the single ISG that has been knocked-down), 3.) 
a red fluorescent protein (RFP) expressing virus of interest is used to infect the transduced cells, 
4.) flow cytometry is used to quickly detect and determine the percentage of successfully 
transduced cells (GFP+) and successfully infected cells (RFP+) for a given well, 5.) the 
contribution of each ISG in the library on viral infection is discernable based on the increase or 
decrease in RFP+ cells relative to controls, which is indicative of viral infection level in a 
particular well. The mouse ISG targeting shRNA plasmid library was kindly shared with me by 
Dr. Michael Diamond and contains shRNAs targeting over 250 known ISGs. The ISGs targeted 
by this library were selected based on published microarray analyses of genes that were induced 
by at least 2-fold upon treatment with IFN-α or IFN-β (Boonyaratanakornkit et al., 2009; Fernald 
et al., 2007; Hayashi et al., 2005; Indraccolo et al., 2007; Li et al., 2013; Pfeffer et al., 2004). In 
this library, each well of a 96-well plate contains a purified pGIPZ lentiviral plasmid that  
encodes GFP and an ISG-targeting shRNA downstream of the human cytomegalovirus promoter. 
Each shRNA plasmid is co-transfected along with pSPAX and pMD2G lentiviral plasmids into a 
packaging cell line, 293T cells. In the 293T cells, each plasmid is expressed, generating 
pseudoviruses that contain the pGIPZ ISG-targeting shRNA as the payload. 293T cell culture 
supernatants containing the pseudoviruses are harvested and placed on the cell type of choice for 
transduction. Cells that are sufficiently transduced by the pseudoviruses will now stably express 
GFP and the downstream ISG-targeting shRNA. The ISG targeted in each well is known due to 
the well location and each well contains only a single shRNA. However, different shRNA 
sequences targeting the same ISG are located in different wells, allowing additional coverage and 
repeated testing of a single ISG. In addition, shRNA plasmids can be combined during 
subsequent experiments to identify multi-component ISG interactions. The ExoN(-) IFN 
 
 
 84 
sensitive phenotype was initially observed in DBT cells. Therefore, I decided to use these cells 
for the ISG screen. To up-regulate all ISGs that are not knocked-down by the shRNA in a 
particular well, IFN-β is added to the DBT cells and incubated for 18h. Next, WT or ExoN(-) 
viruses that have been engineered to express RFP as fusion protein with nsp2 and the ExoN(-) 
P250 virus spike protein (Ex- P250S) are used to infect the transduced, IFN-β treated DBT cells 
(Figure 26A and B). Viruses utilizing the spike protein from the ExoN(-) P250 virus were 
engineered to limit syncytia formation. The ExoN(-) P250S confers a decrease in syncytia 
formation and thus, allows an infected monolayer of cells to become a suspension of single-cells 
during flow cytometry analysis. When 293T cells were transfected for packaging, they were 
routinely 80% GFP+ or greater (data not shown). To validate successful transductions, DBT cells 
were mock transduced or transduced for 3 days using pseudoviruses that contained a non-
silencing control (NSC), or one of five different sequences targeting signal transducer  
and activator of transcription 1 (STAT1) and monitored for GFP fluorescence by flow cytometry 
(Figure 27). For the NSC and each STAT1-targeting shRNA sample, approximately 84-94% of 
cells were successfully transduced. Importantly, the mock transduced cells were 100% GFP-. In 
addition, DBT cells were pretreated with 0 or 250 U/ml mouse IFN-β for 18h and subsequently 
infected with WT or ExoN(-) –RFPnsp2-Ex(-)P250S viruses at an MOI of 0.1 PFU/cell. Cells 
were harvested at 6h and 8h post-infection and analyzed by flow cytometry (Figure 28). IFN-β 
treatment reduced the number of WT-RFP+ cells by 2 and 3-fold at 8h and 6h post-infection, 
respectively. In contrast, IFN-β treatment reduced the number of ExoN(-)-RFP+ cells by 6 and 
6.5-fold at 6h and 8h post-infection, respectively. These data indicate that DBT cells can be 
readily transduced with ISG-targeting shRNAs. In addition, these data demonstrate that WT and 
ExoN(-) –RFPnsp2-Ex(-)P250S virus infected cells are detectable by flow cytometry.  
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Figure 26. Diagram of reporter viruses developed for high-throughput screen 
 
WT or ExoN(-) viruses harboring an RFP fusion protein with nsp2 and expressing the MHV ExoN(-) 
P250 spike (S) protein were developed to detect viral infection levels during high-throughput 
screening experiments.   
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Figure 27. DBT cell transduction efficiency 
 
DBT cells were transduced with lentiviral pseudoparticles encoding a non-silencing control (NSC), 
five different shRNA sequences directed against STAT1 (1-5, respectively), or mock transduced. At 3 
d post-transduction, cells harvested and the percentage of GFP+ cells was determined by flow 
cytometry.  
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Figure 28. Infection of DBT cells with RFP reporter viruses 
 
DBT cells were pretreated with 0 or 250 U/ml mouse IFN-β for 18 h and subsequently infected at an 
MOI of 0.1 PFU/cell with WT-RFPnsp2-Ex(-)P250S or ExoN(-)-RFPnsp2-Ex(-)P250S virus. At the 
indicated times post-infection, cells were harvested and the percentage of RFP+ cells determined by 
flow cytometry.  
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Discussion 
In Chapter III of this dissertation, I demonstrated that CoV nsp14 ExoN activity is required for 
resistance to the innate immune response. My data show that viruses lacking ExoN activity are 
sensitive to pretreatment of cells with IFN-β. Interestingly, the ExoN(-) sensitivity was not 
observed during primary replication in IFN treated cells. Rather, the ExoN(-) viral progeny 
generated in the presence of IFN exhibited decreased viability and fitness during subsequent 
infection. These data suggest that ExoN activity directly or indirectly counteracts one or more 
ISGs during infection.  
 
In this chapter, I sought to determine the specific ISG responsible for mediating restriction of 
ExoN(-) virus. My initial studies tested the hypothesis that ExoN(-) functions to degrade dsRNA, 
which is an obligatory replication intermediate and potent inducer of type I IFN expression. 
Outside of the order Nidovirales, arenaviruses encode the only other known ExoN for RNA 
viruses, which functions to degrade dsRNA (Hastie et al., 2011; Qi et al., 2010). In addition, 
infection with a TGEV zinc finger mutant virus elicited a decreased innate immune response by 
generating lower levels of dsRNA than WT TGEV (Becares et al., 2016). Thus, suggesting a 
novel role for coronavirus nsp14 in innate immune antagonism. However, the experiments 
performed in this chapter are in agreement with the conclusions presented in Chapter III; MHV 
nsp14 ExoN activity does not function to degrade dsRNA. ExoN(-) virus replication was not 
rescued in BMMs deficient in MDA5, a dsRNA sensor. Further, since the effects of IFN-β are 
not observed during primary infection of ExoN(-) virus but rather, during subsequent infection, I 
hypothesized that an ISG could alter ExoN(-) virus mutation frequency. ADAR1 is an RNA 
editing enzyme that is up-regulated by IFN signaling (Katze et al., 2002; Piontkivska et al., 2017; 
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Samuel, 2011; Tomaselli et al., 2015). However, ExoN(-) virus replication in A549 cells 
deficient in ADAR1 was similar to ExoN(-) virus replication in WT A549 cells. Thus, it is 
unlikely ADAR1 is hypermutating MHV genomes in the absence of ExoN activity. It is 
noteworthy that in my A549 replication curves, WT and ADAR1-/- A549 cells were not treated 
with human IFN-β prior to infection. Therefore, assessing the contributions of ADAR1 on 
ExoN(-) replication are limited to basal expression of ADAR1 in WT A549 cells. In separate 
experiments that were not shown, I pretreated WT and ADAR1-/- A549 cells with human IFN-β 
for 24 h prior to infection with WT or ExoN(-) virus. Unfortunately, the results of this 
experiment were not interpretable due to the fact that IFN signaling in ADAR1-/- cells results in 
a cell lethal phenotype that has only recently been described (Li et al., 2017). Therefore, it is 
possible that basal ADAR1 expression in WT A549 cells is not sufficient to inhibit ExoN(-) 
virus replication. To identify ISGs that are differentially expressed in DBT cells upon IFN-β 
pretreatment, we performed RNA sequencing on uninfected cells treated with or without IFN-β. 
Our results revealed that DBT cells generate a robust response to IFN signaling. In future 
experiments, these results with allow us to focus on specific ISGs that are differentially 
expressed by DBT cells.  
 
Due to my previous lack of success using targeted methods, I sought to develop a high-
throughput ISG screen to determine the gene or genes involved in mediating ExoN(-) virus 
restriction. While the screen has yet to be carried out, I have developed the necessary reagents 
and optimized conditions for generating transduced DBT cells expressing an ISG-targeting 
shRNA. In addition, I have generated RFP-tagged viruses that form a limited number of syncytia 
during infection compared to WT MHV. Interestingly, during the studies outlined in Chapter III 
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of this dissertation, IFN-β did not result in a significant decrease in viral RNA levels or an 
overall decrease in the change in particle output for ExoN(-) virus relative to WT MHV (Figure 
19). However, in my preliminary RFP-tagged virus flow cytometry experiments, ExoN(-) –
RFPnsp2-Ex-P250S virus demonstrated a 2-3 fold decrease in RFP+ cells in response to IFN-β 
compared to WT-RFPnsp2-Ex-P250S virus. Although, it is important to note, DBT cells were 
pretreated with 250 U/ml mouse IFN-β for my preliminary flow experiments rather than the 100 
U//ml IFN-β used in the aforementioned experiments presented in Chapter III. For my flow 
cytometry experiments, I started with 250 U/ml IFN-β in an attempt to get the highest fold 
change in viral infection between untreated and treated cells, which would allow for a larger 
dynamic range between ISGs that minimally versus highly affect ExoN(-) virus replication. 
Moreover, experiments in Chapter III detected viral RNAs present, whereas RFP-tagged virus 
flow experiments detected the presence of RFP+ cells; meaning, the cell had been infected and 
the RFP encoded by the viral genome RNA was translated. Thus, when performing the screen, it 
will be important to distinguish not only between RFP+/RFP- cells, but also the difference in 
mean fluorescence intensities among a given population of RFP+ cells. Further, since ExoN(-) 
virus demonstrated reduced replication capacity and fitness upon subsequent infection, the screen 
may need to be altered to measure viral replication upon a subsequent infection of untreated 
cells. Overall, my data suggest CoV nsp14 ExoN activity functions to antagonize the innate 
immune response by a potentially novel mechanism. Thus, it will be exciting to determine the 
specific ISG nsp14 ExoN activity counteracts.  
 
 
 
 
 
 91 
CHAPTER V 
MATERIALS AND METHODS 
 
Virus and cell culture 
 Murine delayed brain tumor (DBT) cells (Chen and Baric, 1996), baby hamster kidney 21 cells 
expressing the MHV receptor (BHK-R) (Yount et al., 2002), and 293T cells were maintained at 
37°C in Dulbecco’s modified Eagle medium (DMEM; Gibco) supplemented to contain 10% fetal 
bovine serum (FBS;Invitrogen), 100 U/ml penicillin and streptomycin (Gibco), and 0.25 µg/ml 
amphotericin B (Corning). BHK-R cells were further supplemented to contain 0.8 mg/ml of 
G418 (Mediatech). Bone-marrow-derived dendritic cells (BMDCs) were maintained in R10 
medium (RPMI 1640 [Gibco] supplemented to contain 10% FBS, 2 mM L-glutamine, 100 µg/ml 
gentamicin [MP Biomedicals], 0.25 µg/ml amphotericin B, 50 µM beta-mercaptoethanol, 20 
ng/ml GM-CSF, and 10 ng/ml IL-4). WT and ADAR1 p150-/- A549 cells were maintained at 
37°C in RPMI 1640 [Gibco] supplemented to contain 10% FBS and 100U/ml penicillin and 
streptomycin (Gibco). Recombinant MHV strain A59 (GenBank accession number AY910861) 
was propagated as described (Yount et al., 2002). 
 
Cloning, recovery, and verification of mutant viruses 
Site-directed mutagenesis was used to engineer point mutations in individual MHV genome 
cDNA fragment plasmids using the MHV infectious clone reverse genetics system (Yount et al., 
2002). ExoN(-) (nsp14 D89A and E91A) has been previously described (Eckerle et al., 2007). To 
generate ExoN(-) P250 virus, sub-confluent monolayers of DBT cells in 25cm2 flasks were 
infected using the ExoN(-) parental stock and blindly passaged for a total of 250 passages 
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(Graepel et al., 2017). For ExoN3(-) virus (nsp14 D272A), nsp14 D330A virus, nsp14 G332A 
virus, and nsp16 D130A virus, site-directed mutagenesis was used to engineer point mutations in 
the MHV genome cDNA F fragment plasmid using the MHV infectious clone reverse genetics 
system (Yount et al., 2002). Viruses encoding firefly luciferase (FFL) fused to nsp2 were 
recovered using MHV A frag-FFL2 (Freeman et al., 2014). RFP expressing WT and ExoN(-) 
viruses were generated using MHV A frag-RFPnsp2, MHV WT or ExoN(-) F frag, and MHV 
ExoN(-) P250S G frag (Eckerle et al., 2007; Graepel et al., 2017). Mutant viruses were recovered 
using BHK-R cells following electroporation of in vitro-transcribed genomic RNA and in some 
instances, overlaid onto DBT cells. All mutagenized plasmids and recovered mutant viruses were 
sequenced (GenHunter Corporation, Nashville, TN) to verify the engineered mutations were 
present and to ensure that no additional mutations were introduced.  
 
Viral replication kinetics 
 Sub-confluent DBT or A549 cell monolayers were infected at a multiplicity of infection (MOI) 
of 1 plaque-forming unit (PFU) per cell at 37°C for 45 min. Inocula were removed, cells were 
washed with 1X PBS, and fresh medium was added. Aliquots were harvested at various times 
post-infection. Viral titer at various intervals was determined by plaque assay (Eckerle et al., 
2007). 
 
5-FU sensitivity assays 
5-fluorouracil (5-FU, Sigma) was prepared as a 200 mM stock solution in DMSO. Sub-confluent 
DBT cells were treated with DMEM supplemented to contain various concentrations of 5-FU or 
DMSO alone at 37°C for 30 min (Smith et al., 2013). After incubation, drug was removed, and 
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cells were infected with virus at an MOI of 0.01 PFU/cell at 37°C for 1 h or at an MOI of 1 
PFU/cell at 37°C for 1 h. Inocula were removed, and cells were incubated in medium containing 
5-FU or DMSO. Cell culture supernatants were collected at 24 h or 12 h post-infection 
corresponding to the respective MOI, and viral titers were determined by plaque assay. 
 
Interferon-β sensitivity assays 
Sub-confluent DBT cells were treated for 18 h with the indicated concentrations of mouse IFN-β 
(PBL Assay Science) prior to infection with virus at a multiplicity of infection (MOI) of 1 
plaque-forming unit (PFU) per cell at 37°C for 45 min. After incubation, inocula were removed, 
cells were washed with PBS, and fresh medium was added. Cell culture supernatants were 
collected at indicated times post-infection, and viral titers were determined by plaque assay 
(Eckerle et al., 2007). 
 
Interferon-β induction assays 
Sub-confluent DBT cells were treated with 10 U/ml mouse IFN-β for 18 h prior to infection with 
mock, WT, nsp14 G332A, or nsp16 D130A virus at an MOI of 0.1 PFU/cell at 37°C for 45 min. 
Alternatively, sub-confluent DBT cells were infected with mock, WT, ExoN(-), or ExoN(-) P250 
virus at an MOI of 0.1 PFU/cell or with Sendai virus (SenV) at an MOI of 200 HA 
(hemagglutination units)/ml at 37°C for 45 min. Inocula were removed, cells were washed with 
PBS, and fresh medium was added. At the indicated times post-infection, cell culture 
supernatants were aspirated and cell lysates were harvested by adding TRIzol reagent. Total 
RNA present in lysates was purified using the phenol/chloroform method. cDNA was generated 
by RT-PCR using 1µg of total RNA as described (Smith et al., 2013). Mouse IFN-β expression 
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levels relative to GAPDH were determined by qPCR using the Applied Biosciences 7500 Real-
Time PCR System with Power SYBR Green PCR Master Mix and IFN-β primers: FWD: 5’-
TCCGCCCTGTAGGTGAGGTTGAT-3’ and REV: 5’-GTTCCTGCTGTGCTTCTCCACCA-3’ 
and GAPDH primers previously reported (Smith et al., 2013). 
 
Generation and infection of BMDCs 
Primary BMDCs were isolated from the hind limbs of WT and IFN-α/β receptor-deficient 
(IFNAR-/-) C57BL/6J mice. Mice were euthanized by isoflurane overdose, and hind limbs were 
resected. Bone marrow cells were collected by flushing the femurs and tibiae with medium. Cells 
were strained through a 70-µm cell strainer, and red blood cells were lysed. Cells were cultured 
at 37°C in R10 medium supplemented to contain 20 ng/ml GM-CSF and 10 ng/ml IL-4. At 3 d 
post-plating, cell culture supernatants were removed and replaced with fresh R10 medium. Six 
days post-plating, cells were lifted using Cellstripper (Corning) and replated with fresh R10 
medium in 24-well plates at a density of 105 cells/well and incubated at 37°C overnight. WT and 
IFNAR-/- BMDCs were infected with virus at an MOI of 0.01 PFU/cell at 37°C for 45 min. 
Inocula were removed, and fresh medium was added. Cell culture supernatants were collected 24 
h post-infection, and viral titers were determined by plaque assay. All experiments with animals 
were performed in accordance with Vanderbilt University School of Medicine Institutional 
Animal Care and Use Committee guidelines. 
 
Generation and infection of BMMs 
Bone-marrow derived macrophages (BMMs) were generated from the hind limbs of WT, 
IFNAR-/-, RNaseL-/-/PKR-/-, or MDA5-/- C57/B6 mice as previously described (Zhao et al., 
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2012b). BMMs were infected with virus at an MOI of 1 PFU/cell at 37°C for 1 h. After 
incubation, inocula were removed, cells were washed with 3 times with PBS, and fresh medium 
was added. At the indicated times post-infection, cell culture supernatant aliquots were collected 
and viral titers determined by plaque assay. 
 
Purification of virions and extraction of RNA 
Virion RNA was purified from sub-confluent T150 flasks of BHK-R cells infected with WT-FFL 
or nsp14 G332A-FFL viruses at an MOI of 0.001 PFU/cell. When CPE was apparent throughout 
the monolayer, cell culture supernatants were collected and pooled into 50 ml conical tubes 
(Corning), clarified by centrifugation at 1,000 x g for 10 min, and stored at -80°C. Upon 
thawing, virus particles in the clarified supernatants were collected by ultra-centrifugation at 
106,750 x g overnight through a 5 ml, 20% (w/w) sucrose cushion in an SW32Ti rotor. The 
pelleted particles were resuspended in 200 µl MSE buffer (10 mM MOPS [pH 6.8], 150 mM 
NaCl, 1 mM EDTA) and incubated at 4°C overnight prior to resuspension by gently pipetting 
several times. Viral RNA was isolated from purified viral particles using TRIzol reagent 
(Invitrogen) and phenol/chloroform extraction.  
 
In vitro translation reactions 
Viral genomic RNAs containing an in-frame firefly luciferase encoding sequence were translated 
at 30°C for various intervals in 10 µl of rabbit reticulocyte lysate (Promega) in the presence of 
both 10 µM amino acid mixture minus leucine and 10 µM amino acid mixture minus methionine. 
 
Firefly luciferase assays 
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 Sub-confluent DBT cells were infected with virus at an MOI of 0.1 PFU/cell. At various 
intervals, cell culture supernatants were removed, cells were washed with PBS, and 100 µl of 
reporter cell lysis buffer (Promega) was added to each well. Cells lysates were frozen at -80°C to 
promote lysis and thawed at room temperature prior to quantifying firefly luciferase activity. 
Luciferase activity from cell lysates or in vitro translation reactions was quantified using a 
Veritas luminometer (Turner Biosystems) and the firefly luciferase assay system (Promega). 
 
Determination of viral specific infectivity 
Sub-confluent monolayers of DBT cells were infected with virus at the indicated MOI at 37°C 
for 45 min. After incubation, inocula were removed, cells were washed with PBS, and fresh 
medium was added. At the indicated times post-infection, cell culture supernatants were 
collected, and viral titers were determined by plaque assay. Supernatants also were used for RNA 
genome isolation by adding 100 µl supernatant to 900 µl TRIzol reagent, chloroform extraction 
by phase separation, and final purification using the PureLink Mini RNA kit (Ambion). Genome 
RNA was quantified using one-step qRT-PCR, and the particle to PFU ratio was calculated. 
 
Determination of rRNA integrity 
Sub-confluent monolayers of DBT cells were treated with 0 or 50 U/ml mouse IFN-β for 18 h 
prior to being infected with virus at an MOI of 1 PFU/cell at 37°C for 45 min. After incubation, 
inocula were removed, cells were washed with PBS, and fresh medium was added. At the 
indicated times post-infection, cell culture supernatants were removed and total RNA was 
harvested by adding 1ml TRIzol reagent. For a positive control, cells were transfected with 
25ug/ml polyI:C (Sigma) using Lipofectamine 2000 (Thermo Fisher Scientific). Total RNA from 
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all samples was purified using the Purelink RNA Mini Purification System (Life Technologies) 
by following the manufacturers instructions. Upon purification, total RNA was analyzed on an 
Agilent Bioanalyzer by the Vanderbilt VANTAGE core facility and the rRNA integrity reported.  
 
Genome RNA stability assay 
Sub–confluent monolayers of DBT-9 cells were infected with virus at an MOI of 0.01 PFU/cell 
at 37°C for 45 min in the presence of DMSO or 100 µg/ml cycloheximide (CHX) (Sigma). 
Inocula were removed, media containing DMSO or 100 µg/ml CHX was added, and cell lysates 
were harvested at indicated times post-infection by removing the cell culture supernatant and 
adding TRIzol reagent. Lysates were spiked with a known amount of in vitro transcribed Renilla 
luciferase RNA and total RNA was obtained by phenol/ chloroform extraction. cDNA was 
generated by RT-PCR and viral genome copies present relative to Renilla luciferase was 
determined by SYBR Green qPCR using nsp10 (Smith et al., 2013) and Renilla luciferase 
specific primers (Habjan et al., 2013). 
 
Quantification of subgenomic RNA by qPCR 
Sub-confluent DBT cells were treated with 0 or 100 U/mL mouse IFN-β for 18 h prior to being 
infected with virus at an MOI of 1 PFU/cell at 37°C for 45 min. After incubation, inocula were 
removed, cells were washed with PBS, and fresh medium was added. At the indicated times 
post-infection, cell culture supernatants were removed and total RNA was harvested by adding 
1ml TRIzol reagent. Total RNA was extracted using the Purelink RNA mini purification system 
by following the manufacturers instructions. cDNA was generated by RT-PCR using 1ug of total 
RNA as previously described (Smith et al., 2013). Primers used to detect subgenomic 
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nucleocapsid and GAPDH gene expression have been reported (Donaldson et al., 2007; Smith et 
al., 2013). Subgenomic (N) expression levels relative to GAPDH were determined using the 
Applied Biosciences 7500 Real-Time PCR System with Power SYBR Green PCR Master Mix.  
 
Quantification of viral genomic RNA by qRT-PCR 
An RNA standard was prepared using the MHV A fragment (Yount et al., 2002) to generate a 
931 nucleotide RNA. First, cDNA was generated by PCR amplification using the primers: 
forward 5’-TAATACGACTCACTATAGGGGGCTATGTGGATTGTTGTGG-3’, which 
initiates with a T7 promoter, and reverse 5’-AATTCTTGACAAGCTCAGGC-3’. RNA for the 
standard curve was prepared using an mMessage mMachine T7 kit (Ambion) and purified using 
an RNeasy Mini kit (Qiagen). A standard curve was generated using 10-fold dilutions from 103 
to 108 copies. A 5’ 6-carboxyfluorescein (FAM)-labeled probe (5’-
TTCTGACAACGGCTACACCCAACG-3’ [Biosearch Technologies]) was used with forward 
(5’-AGAAGGTTACTGGCAACTG-3’) and reverse (5’-TGTCCACGGCTAAATCAAAC-3’) 
primers. Reactions were incubated on ice with enzyme added last. Final volume for reactions 
was 20 µl with 150 nM probe, 900 nM each primer, 2 µl sample RNA, and 10 µl 2X ToughMix, 
one-step, low ROX enzyme mix (Quantas) per reaction. Samples were quantified in duplicate 
using an Applied Biosciences 7500 Real-Time PCR System with the conditions 55°C for 10 min, 
95°C for 5 min, 95°C for 30 s, and 60°C for 1 min, with the last two steps repeated 40 times. The 
standard curve was plotted using GraphPad Prism 6 software, and genomes/µl were calculated. 
 
Co-infection assays 
Sub-confluent monolayers of DBT cells were treated with 0 or 100 U/ml mouse IFN-β for 18 h 
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prior to being infected with virus at an MOI of 1 PFU/cell at 37°C for 45 min. After incubation, 
inocula were removed, cells were washed with PBS, and fresh medium was added. At 12 h post-
infection, cell culture supernatants were removed and 100 µl of supernatant was added to 900 µl 
TRIzol reagent. Viral genome RNA was purified and the number of viral genome RNA copies 
present relative to an RNA standard curve were determined as described above. Based on the 
number of viral genome RNA copies determined by one-step RT-qPCR, an equal number of 
virus particles from each virus and each condition were combined with an equal number of WT 
silent or ExoN(-) silent virus particles, respectively. WT silent and ExoN(-) silent viruses were 
engineered to harbor 10 silent mutations in the probe-binding region of nsp2, allowing separate 
detection from WT-MHV or ExoN(-) virus genomes, respectively, using a separate probe upon 
co-infection (Graepel et al., 2017). Next, a fresh, sub-confluent monolayer of DBT cells were co-
infected with each combination of viruses at 37°C for 45 min. After incubation, inocula were 
removed, cells were washed with PBS, and fresh medium was added. At 24 h post-infection, cell 
culture supernatants were removed and 100 µl of supernatant was added to 900 µl TRIzol 
reagent. Viral genome RNA was purified. The number of viral genome RNA copies of both 
reference and silent viruses were determined relative to the appropriate standard curve. The 
number of viral genome RNA copies relative to the number of silent virus genome RNA copies 
was determined for each virus and condition. Values are reported as the change in fitness relative 
to the silent virus. 
 
RNA sequencing 
RNA sequencing experiments were performed using DBT cells pretreated with 0 or 100U/ml 
mouse IFN-β for 26h. After pretreatment, cell culture supernatants were removed and total cell 
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lysates harvested using TRIzol reagent. Total RNA was extracted using the phenol/chloroform 
method and submitted to the Vanderbilt VANTAGE core for mRNA enrichment and cDNA 
library preparation utilizing stranded mRNA (poly-A-selected) sample preparation kit. 
Sequencing was performed at paired-end 75bp on an Illumina HiSeq 3000. Demultiplexed 
FASTQ files were analyzed by the Vanderbilt VANGUARD core using DESeq2, edgeR, and 
BaySeq algorithms to generate a multi-rank seq, fold change, and p-Value file.   
 
DBT cell RNase L activation assays 
DBT cells were untreated or pretreated with IFN-β for 18h. For IFN-β and polyI:C pretreated 
samples, cells were pretreated with IFN-β for 17h and then transfected with 25µg poly I:C in the 
presence of IFN-β for the final hour prior to infection with WT or ExoN(-) virus at an MOI of 1  
PFU/cell. At 12h post-infection, cell culture supernatants were collected and viral titers were 
determined by plaque assay.  
 
Detection of viral infection by flow cytometry 
In order to determine the percentage of DBT cells infected with WT-RFPnsp2-Ex(-)-P250S or 
ExoN(-)-nsp2-Ex(-)P250S virus by flow cytometry, DBT cells were pretreated with 0 or 250 
U/ml mouse IFN-β for 18h. Next, cells were infected with WT-RFPnsp2-Ex(-)-P250S or ExoN(-
)-nsp2-Ex(-)P250S virus at an MOI of 0.1 PFU/cell. At 6 and 8h post-infection, cell culture 
supernatants were removed and cells were dislodged using Cellstripper (Corning). Cells were 
diluted in MACS wash (PBS, 5% FBS, and 2% EDTA) and RFP expression was analyzed using 
a Fortessa 4-laser flow cytometer (BD Biosciences). Flow cytometry data were analyzed using 
FlowJo software (Treestar).   
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Generation of lentiviral pseudoparticles 
In order to generate lentiviral pseudoparticles, 293T cells were reverse transfected with 100ng 
pSpax, 50ng pMD2G, and 150ng shRNA encoding plasmid using 1.2 µl FuGENE 6 reagent in a 
T.V. of 10 µl serum-free media per well. After plating the DNA/ FuGENE mix, 293T cells were 
added at a density of 2x104 cells in a T.V. of 100 µl per well. At 48 h post-transfection, 293T 
cells were checked for GFP expression and cell culture supernatants were collected and 
respectively pooled. 
 
Transduction of DBT cells 
DBT cells were plated in 96-well flat bottom plates at a density of 0.25x104 cells per well and 
incubated at 37°C. At 24 h post-plating, cell culture supernatants were removed from DBT cells 
and 20 µl of cell culture media supplemented to contain 50 µg/ml polybrene (Millipore) was 
added. Next, 80 µl of lentiviral supernatant was added to respective wells and gently mixed. 
Cells were spinoculated for 30 min. at room temperature at 800x g and incubated overnight at 
37°C. After incubation, cell culture supernatants were carefully removed and replaced with fresh 
cell culture media. Cells were allowed to grow for an additional 2 days and then checked for 
GFP expression. For flow cytometry, cell culture supernatants were removed and cells were 
fixed using 1% paraformaldehyde. GFP expression was analyzed using a Fortessa 4-laser flow 
cytometer (BD Biosciences). Flow cytometry data were analyzed using FlowJo software 
(TreeStar). 
 
Statistical analysis 
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Statistical tests were conduced as described in the respective figure legends using GraphPad 
Prism 6 software (La Jolla, CA). Error bars and the number of replicates for each experiment are 
also listed in respective figure legends. 
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Primers generated for this dissertation research 
Table 2: Primers generated for this dissertation research (IDT) 
Primer Name                        Sequence 5′-3′ 
Quick-change primers for mutant viruses 
Nsp14 D272A Fwd GCTCATGTTGCATCATCTGCGGCTATCATGACCCGGTGT 
Nsp14 D272A Rev ACACCGGGTCATGATAGCCGCAGATGATGCAACATGAGC 
Nsp14 D330A Fwd GGTATGATGTGTGTTATGCAATTGGCAACCCTAAAGG 
Nsp14 D330A Rev CCTTTAGGGTTGCCAATTGCATAACACACATCATACC 
Nsp14 G332A Fwd GGTATGATGTGTGTTATGACATTGCTAACCCTAAAGGTCTTGCC 
Nsp14 G332A Rev GGCAAGACCTTTAGGGTTAGCAATGTCATAACACACATCATACC 
Nsp16 D130A Fwd GGGATCTGATAATTTCTGCGATGTACGACCCTCTTAC 
Nsp16 D130A Rev GTAAGAGGGTCGTACATCGCAGAAATTATCAGATCCC 
 
qPCR primers 
Mouse IFN-β Fwd TCCGCCCTGTAGGTGAGGTTGAT 
Mouse IFN-β Rev GTTCCTGCTGTGCTTCTCCACCA 
Renilla Luc Fwd CGAAAGTTTATGATCCAGAAC 
Renilla Luc Rev AATCATAATAATTAATAAATG 
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Chapter VI 
SUMMARY AND FUTURE DIRECTIONS 
 
Introduction 
Coronaviruses have demonstrated a capacity to infect numerous mammalian and avian species. 
Potentially one of the most important observations made over the past decade and a half of 
coronavirus (CoV) research is that CoVs have and, undoubtedly, will continue to spill over into 
human populations (Perlman and Netland, 2009). When a future cross-species transmission event 
occurs, the disease may be mild, as seen in human coronavirus 229E and OC43 infections, or 
disease may be severe, as seen in SARS-CoV and MERS-CoV patients. Regardless of disease 
severity, specific antiviral therapies are currently not available to treat human CoV infections. 
Thus, it is essential to understand the contributions of conserved CoV proteins in viral replication 
and pathogenesis. One probable reason CoVs are successful pathogens is they encode multiple 
innate immune antagonists within their uniquely large RNA genomes (de Wit et al., 2016; 
Frieman et al., 2008; Perlman and Netland, 2009). Studies have suggested that SARS-CoV 
pathogenesis is due, at least in part, to an insufficient innate immune response (Cheung et al., 
2005; Gu and Korteweg, 2007). In addition, excessive induction of pro-inflammatory cytokines 
and chemokines in SARS-CoV patients, and potentially MERS-CoV patients, suggest that 
dysregulation of the innate immune response is also a major contributor of the observed 
immunopathogenesis associated with these infections (de Wit et al., 2016; Gu and Korteweg, 
2007). Therefore, disarming a conserved CoV antagonist may provide a window of opportunity 
for prospective antiviral therapies or our own immune systems to attenuate viral replication and 
disease.  
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At the beginning of this dissertation research, CoV non-structural protein (nsp) 14 had not been 
investigated as an innate immune antagonist. Rather, it was known that nsp14 3’-to-5’ 
exoribonuclease (ExoN) activity potentially performed a proofreading function during viral RNA 
replication and that nsp14 also encoded N7-methyltransferase (N7-MTase) activity (Bouvet et 
al., 2012; Chen et al., 2009; Minskaia et al., 2006; Smith et al., 2014). The overall goal of this 
dissertation research was to determine whether nsp14 ExoN or N7-MTase activities played a role 
in counteracting the innate immune response. In this chapter, I summarize the main findings of 
my dissertation research and highlight important future directions generated as a result of my 
work.   
 
Coronavirus nsp14 N7-MTase activity is required for efficient viral RNA translation 
In the nucleus, nascent cellular mRNAs are capped at the 5’ end of the RNA molecule (Shatkin, 
1976). The 5’ cap has several important biological roles such as providing RNA stability, 
directing pre-mRNA splicing, and mRNA export from the nucleus (Darnell, 1979; Decroly et al., 
2011b). Moreover, the 5’ cap is critical for recognition by eukaryotic translation initiation factor 
4 E (eIF4E) and thus, efficient translation (Decroly et al., 2011b; Filipowicz et al., 1976; Schibler 
and Perry, 1977). To ensure efficient viral protein translation, viruses have also evolved 
mechanisms in which to cap their RNAs. When I started this dissertation research, it was known 
that CoVs encoded multiple capping enzymes. Further, it had been demonstrated that CoV nsp14 
encoded N7-MTase activity in vitro and that nsp14-mediated N7-methylation of an RNA 
template necessarily preceded CoV nsp10-16 2’O-methylation (Bouvet et al., 2010; Chen et al., 
2009). In addition, it had been demonstrated that CoV nsp14 N7-MTase activity and S-adenosyl-
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L-methionine (SAM) binding was conferred by a conserved DxG motif in the N7-MTase domain 
(Bouvet et al., 2010; Chen et al., 2009; 2013). My dissertation research was the first study to 
investigate the requirements of nsp14 N7-MTase activity during coronavirus replication. My data 
show that alanine substitution of nsp14 residue G332 results in attenuated viral replication and 
decreased viral RNA translation both during viral replication and during in vitro translation of 
purified viral RNA. In direct contrast to existing biochemical data, my data also demonstrate that 
murine hepatitis virus (MHV) nsp14 residue D330 is dispensable for virus replication. In 
addition to the DxG motif, other residues were identified as important for N7-MTase activity in 
recombinant in vitro assays. Mutation of SARS-CoV nsp14 at position R310 or D352 resulted in 
a decrease or total loss of SAM binding and N7-MTase activity (Chen et al., 2013). Future 
studies should address the contributions of these residues in CoV nsp14 N7-MTase activity. In 
fact, the nsp10/nsp14 co-crystal structure suggests SARS-CoV nsp14 R310 contributes positive 
potential for binding the triphosphate portion of the RNA molecule and residue D352 forms 
hydrogen bonds with the O3’ and O2’ atoms of the ribose of SAM (Ma et al., 2015). These 
studies will be important for determining the precise residues of nsp14 that are responsible for 
coordinating the N7-methylation reaction in order to inform cap analog and small molecule 
inhibitor studies.  
 
Coronavirus nsp14 N7-MTase activity is required for evasion of and resistance to the 
innate immune response 
In addition to N7-methylation, the mRNAs of higher eukaryotes are methylated at the 2’O 
position of the ribose sugar of the penultimate nucleotide (Wei et al., 1975). 2’O-methylation 
provides a molecule signature for the cell to discriminate between ‘self’ and ‘non-self’ mRNAs 
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(Daffis et al., 2010; Züst et al., 2011). Not surprisingly, many viruses have evolved to encode 
2’O-methyltransferases (2’O-MTases) in order to subvert this mechanism and thus, mask viral 
RNAs from host innate immune sensors (Daffis et al., 2010; Züst et al., 2011). Innate sensors 
such as MDA5 and IFIT1 have been demonstrated to detect viral RNAs lacking fully capped 
structures and to subsequently function to restrict viral replication (Daffis et al., 2010; Decroly et 
al., 2011b; Habjan et al., 2013; Menachery et al., 2014; Züst et al., 2011). Prior to my 
dissertation research, data suggested that CoVs used the canonical capping pathway to cap viral 
RNAs (Bouvet et al., 2010; Chen et al., 2013). I tested the hypothesis that by ablating CoV N7-
MTase activity, not only should viral RNA translation be delayed/ reduced, but also, that 
downstream 2’O-methylation should be inhibited. In Chapter II, my data demonstrate that CoV 
nsp14 G332A mutant viruses are sensed by the cell, leading to induction of type I interferon 
(IFN). Since G332A virus demonstrated reduced translation in addition to induction of and 
sensitivity to IFN, my data further support the hypothesis and agree with all data to date that 
suggest CoVs use the canonical capping pathway to cap viral RNAs. In previous studies, 2’O-
MTase deficient CoVs and avian metapneuomoviruses were protective against lethal challenge 
(Menachery et al., 2014; Sun et al., 2014). Thus, methyltransferase-defective viruses are 
excellent candidates for live-attenuated vaccines. Future experiments from my work should 
investigate the replication capacity and attenuation of MHV nsp14 D330A and MHV nsp14 
G332A viruses in animal models of disease. While nsp14 D330A mutant virus demonstrated 
WT-like phenotypes in all assays performed in vitro, this virus may be attenuated in vivo. To 
further attenuate virus replication, my data suggest that combining CoV N7-MTase and 2’O-
MTase ablating mutations should provide at least two mechanisms of attenuating viral 
replication. To perform these future studies, I have engineered and recovered MHV nsp14 
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D330A-nsp16 D130A and MHV nsp14 G332A-nsp16D130A mutant viruses but phenotype 
characterization has not begun at this time.  
 
Coronavirus nsp14 ExoN activity is required for counteracting  
the innate immune response 
In Chapter III of this dissertation, I reported my discovery that CoV nsp14 ExoN activity is 
required for resistance to the innate immune response. This study yields exciting new questions 
that will need to be answered to further understand CoV nsp14 ExoN activity and its role in 
innate immunity. Recently, it was demonstrated that loss of CoV nsp15 endonuclease (EndoU) 
activity resulted in increased viral dsRNA levels during replication, suggesting that nsp15 
endonucleolytically cleaves viral dsRNAs to prevent detection by the host (Kindler et al., 2017). 
In addition, a transmissible gastroenteritis virus nsp14 ExoN domain, gain-of-function mutant 
demonstrated decreased dsRNA accumulation during viral replication (Becares et al., 2016). As 
a result, it has been proposed that CoV nsp14 ExoN activity may function to further degrade the 
viral dsRNA products of nsp15 (Becares et al., 2016; Kindler et al., 2017). While my data did not 
reveal a role for MHV nsp14 in degrading dsRNA, this potential function should be further 
evaluated in bone marrow-derived macrophages (BMMs). Viruses lacking ExoN activity did not 
replicate beyond 9 h post-infection in WT BMMs. However, replication of viruses lacking ExoN 
activity was partially or fully restored to WT-MHV levels in IFN alpha/beta receptor deficient 
(IFNAR-/-) BMMs. Therefore, the mechanism of attenuation in WT BMMs should be elucidated 
by assessing viral RNA levels for WT and ExoN(-) viruses during replication in BMMs. In 
murine delayed brain tumor (DBT) cells, ExoN(-) viral RNA was not substantially reduced. 
However, if ExoN(-) virus RNA levels are decreased in WT BMMs, this result would suggest 
 
 
 109 
potentially two different mechanisms of attenuation between DBT cells and BMMs. In addition, 
ExoN(-) virus replication in BMMs should be assessed for the induction of IFN and the secretion 
of pro-inflammatory cytokines. Again, if IFN were induced, this would suggest a potentially 
different mechanism of attenuation for ExoN(-) virus in BMMs in comparison with DBT cells 
within which ExoN(-) virus replication did not induce IFN-β expression.  
 
In DBT cells, my data suggest that ExoN(-) virus is restricted upon subsequent infection of cells 
specifically when the ExoN(-) progeny are generated in the presence of an IFN-β-induced 
antiviral state. Future experiments should be performed to determine if the restricted ExoN(-) 
progeny are purely non-viable or if the incoming ExoN(-) viruses are sensed and restricted by the 
innate immune response of newly infected cells. To facilitate these discoveries, I have developed 
and generated 293T cells stably expressing the MHV viral receptor (MHV-R), murine 
carcinoembryonic antigen-related cell adhesion molecule 1a. Using 293T-MHV-R cells will 
render any potential mouse IFN-β carryover from a primary experiment nonfunctional in 
downstream experiments and will also allow additional approaches for determining whether 
IFN-β generated ExoN(-) progeny are inducing an immune response in recipient cells (for 
instance using an IFN-β-luciferase reporter plasmid). If IFN-β generated ExoN(-) progeny are 
not inducing an innate immune response during subsequent infection, this would suggest that the 
viral genome or an RNA modification is altered during antiviral conditions. Therefore, IFN-β-
generated ExoN(-) virus progeny genomes should be assessed by deep sequencing methods to 
determine if an ISG is further increasing or decreasing ExoN(-) virus mutation frequency. In 
addition, the high-throughput screen developed and described in Chapter IV of this dissertation 
could be used to identify the specific gene or genes responsible. Alternative and complimentary 
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approaches should include but are not limited to crosslinking viral RNA and RNA binding 
proteins in the presence and absence of IFN-β treatment and ExoN activity to identify proteins 
that may be preferentially acting on the ExoN(-) viral genome.  
 
Previously, it was shown that ExoN(-) mouse adapted SARS-CoV (MA-SARS-CoV) is 
attenuated in vivo, and protects mice from lethal challenge (Graham et al., 2012). However, the 
mechanism of attenuation in vivo was presumed to be due to decreased viral replication fidelity 
and was not investigated further. Future experiments with WT and ExoN(-) MA-SARS-CoV 
should be performed in immunocompenent and immunocompromised mice to determine the 
extent of viral dissemination, viral loads in peripheral organs, and to determine IFN-β and pro-
inflammatory cytokine gene expression. Recently, an increased replication fidelity, decreased 
genome recombination strain of poliovirus was demonstrated to be restricted in vivo due to an 
incapacity to overcome tissue specific innate immune responses (Xiao et al., 2017). Therefore, 
analyses of these experiments should focus on the effects of altered fidelity in ExoN(-) viruses as 
well as the contributions of ExoN activity to either directly or indirectly antagonize the innate 
immune response. Together, these studies will further elucidate the requirement of CoV ExoN 
activity in counteracting an immune response and will provide rationale for the development of 
ExoN(-) viruses as live-attenuated vaccines. 
 
Concluding Remarks: nsp14 is the Achilles’ heel of coronaviruses 
Nsp14 encoded ExoN and N7-MTase activities are conserved across coronaviruses (Gorbalenya 
et al., 2006; Lauber et al., 2013). My dissertation research alone suggests that the absence of a 
functional nsp14 can be linked to at least four different mechanisms of viral attenuation: 1) viral 
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protein translation (N7-MTase activity), preventing induction of IFN (N7-MTase activity), 
required for resistance to IFN (N7-MTase and ExoN activities), and required for efficient viral 
replication (ExoN and N7-MTase activities). The research described in this dissertation is my 
small contribution to the overall human understanding of coronaviruses. It is my hope that this 
dissertation research provides the basis and rationale for the development of antiviral therapies 
directed against coronavirus nsp14 to treat or prevent coronavirus infections. Due to the 
conservation of nsp14 activities, such therapies should be broadly applicable to existing or 
emerging coronaviruses of the future.   
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APPENDIX A: 
 
MUTAGENESIS OF S-ADENOSYL-L-METHIONINE-BINDING RESIDUES IN 
CORONAVIRUS NSP14 N7-METHYLTRANSFERASE DEMONSTRATES DIFFERING 
REQUIREMENTS FOR GENOME TRANSLATION AND RESISTANCE TO INNATE 
IMMUNITY 
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Mutagenesis of S-Adenosyl-L-Methionine-Binding Residues in
Coronavirus nsp14 N7-Methyltransferase Demonstrates Differing
Requirements for Genome Translation and Resistance to Innate
Immunity
James Brett Case,a,b Alison W. Ashbrook,b,c Terence S. Dermody,a,b,c Mark R. Denisona,b,c
Departments of Pathology, Microbiology, and Immunologya and Pediatrics,c and Elizabeth B. Lamb Center for Pediatric Research,b Vanderbilt University Medical Center,
Nashville, Tennessee, USA
ABSTRACT
Eukaryotic mRNAs possess a methylated 5=-guanosine cap that is required for RNA stability, efficient translation, and protection
from cell-intrinsic defenses. Many viruses use 5= caps or other mechanisms to mimic a cap structure to limit detection of viral
RNAs by intracellular innate sensors and to direct efficient translation of viral proteins. The coronavirus (CoV) nonstructural
protein 14 (nsp14) is a multifunctional protein with N7-methyltransferase (N7-MTase) activity. The highly conserved S-adeno-
syl-L-methionine (SAM)-binding residues of the DxGmotif are required for nsp14 N7-MTase activity in vitro. However, the re-
quirement for CoVN7-MTase activity and the importance of the SAM-binding residues during viral replication have not been
determined. Here, we engineered mutations in murine hepatitis virus (MHV) nsp14 N7-MTase at residues D330 and G332 and
determined the effects of these mutations on viral replication, sensitivity to mutagen, inhibition by type I interferon (IFN), and
translation efficiency. Virus encoding a G332A substitution in nsp14 displayed delayed replication kinetics and decreased peak
titers relative to wild-type (WT)MHV. In addition, replication of nsp14 G332A virus was diminished following treatment of cells
with IFN-!, and nsp14 G332A genomes were translated less efficiently both in vitro and during viral infection. In contrast, sub-
stitution of alanine at MHV nsp14 D330 did not affect viral replication, sensitivity to mutagen, or inhibition by IFN-! compared
toWTMHV. Our results demonstrate that the conservedMHVN7-MTase SAM-binding-site residues are not required for MHV
viability and suggest that the determinants of CoV N7-MTase activity differ in vitro and during virus infection.
IMPORTANCE
Human coronaviruses, most notably severe acute respiratory syndrome (SARS)-CoV andMiddle East respiratory syndrome
(MERS)-CoV, cause severe and lethal human disease. Since specific antiviral therapies are not available for the treatment of hu-
man coronavirus infections, it is essential to understand the functions of conserved CoV proteins in viral replication. Here, we
show that substitution of alanine at G332 in the N7-MTase domain of nsp14 impairs viral replication, enhances sensitivity to the
innate immune response, and reduces viral RNA translation efficiency. Our data support the idea that coronavirus RNA capping
could be targeted for development of antiviral therapeutics.
Eukaryotic mRNAs possess a methylated 5= guanosine caplinked to the penultimate nucleotide by a 5=-5= triphosphate
bridge (1). The 5= capping of cellular mRNAs functions in RNA
stability, pre-mRNA splicing, mRNA export from the nucleus,
translation, and protection against cellular antiviral defenses (2).
The canonical cellular capping process involves three enzymes:
(i) an RNA triphosphatase (RTPase), which is responsible for
cleaving the !-phosphate of the nascent transcript, (ii) a guanylyl-
transferase (GTase), which transfers a GMP moiety to the 5=
diphosphate RNA, and (iii) an N7-methyltransferase (N7-
MTase), which is responsible for transferring amethyl group from
the methyl donor, S-adenosyl-L-methionine (SAM), to the N7
position of the guanosine base (3). These sequential reactions lead
to formation of a cap-0 (7-methyl-Gppp) structure, which is
thought to be the minimal cap determinant required for eIF4E
recognition and efficient translation (4–6). Higher eukaryotes ex-
press 2=O-methyltransferases (2=O-MTase), which add a methyl
group to the ribose 2=O position of the penultimate nucleotide of
the cap-0 RNA. This reaction results in the formation of a cap-1
structure that allows cells to differentiate self from nonself RNAs
in the cytoplasm (7, 8).
Eukaryotic viruses use host translation machinery, and many
of these viruses encode capping enzymes. The diversity of enzymes
andmechanisms used by viruses to synthesize capped RNA prod-
ucts suggests that there is selective pressure on viruses to cap their
RNAs (9). Coronaviruses (CoVs) encode several enzymes within
their large, positive-sense RNA genomes (27 to 34 kb) that are
implicated in viral RNA capping. The coronavirus genome pos-
sesses a 5= terminal cap and a 3= poly(A) tail (10–12). All data to
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date support the hypothesis that CoV genomes are capped using
the canonical mRNA capping pathway (13). Severe acute respira-
tory syndrome coronavirus (SARS-CoV) nsp13 displays RTPase
activity in vitro (14). The CoV guanylyltransferase has not been
identified but, according to the current model, would function to
add a GMP to the diphosphate RNA product of nsp13. The RNA-
dependent RNA polymerase (RdRp) of equine arteritis virus and
SARS-CoV displays nucleotidylation activity (15). While further
study is required to define the function of this activity in viral
replication, it is possible that the RdRp participates in CoV RNA
capping. nsp16 of feline coronavirus functions independently as a
2=O-MTase (16–18), but SARS-CoV nsp16 requires nsp10 as a
cofactor for 2=O-MTase activity. SARS-CoVs lacking 2=O-MTase
activity are recognized and sequestered by IFIT1 (13, 19–23) due
to the lack of a cap-1 structure.
CoV nsp14 is a multifunctional protein with 3=-5= exoribonu-
clease activity and N7-MTase activity (24, 25). nsp14-mediated
N7-methylation of Gppp-RNA to form a cap-0 structure is a pre-
requisite for nsp10/16-mediated 2=O-methylation in vitro (13). A
conserved DxG motif within the MTase domain is required for
SAM binding in vitro, and alteration of these residues abolishes
MTase activity in vitro (13, 26). However, the requirements of the
CoV nsp14 N7-MTase during viral replication are not known.
Therefore, we assessed the effect of mutations in the DxGmotif of
the MHV nsp14 N7-MTase on viral replication. We show that
substitution of alanine at nsp14 D330 does not alter viral replica-
tion kinetics or increase sensitivity to beta interferon (IFN-!)
treatment relative to wild-type (WT) MHV. However, substitu-
tion of alanine at nsp14G332 impaired virus replication, resulting
in delayed replication kinetics and decreased peak titer relative to
WT MHV. In addition, nsp14 G332A virus displayed increased
sensitivity to treatment of cells with IFN-!, and nsp14 G332A
genomes were translated less efficiently in vitro and during infec-
tion. These data suggest that residue G332, but not residue D330,
is required for MHV nsp14 N7-MTase activity and, collectively,
that the regulation of CoV capping is likely more complex in the
context of replicating virus than during in vitro biochemical stud-
ies with isolated proteins.
MATERIALS AND METHODS
Cells and viruses.Murine delayed brain tumor (DBT) cells (27) and baby
hamster kidney 21 cells expressing theMHV receptor (BHK-R) (28) were
maintained at 37°C in Dulbecco’s modified Eagle medium (DMEM;
Gibco) supplemented to contain 10% fetal bovine serum (FBS; Invitro-
gen), 100 U/ml penicillin and streptomycin (Gibco), and 0.25 "g/ml am-
photericin B (Corning). BHK-R cells were further supplemented to con-
tain 0.8mg/ml ofG418 (Mediatech). Bonemarrow-derived dendritic cells
(BMDCs) were maintained in R10 medium (RPMI 1640 [Gibco] supple-
mented to contain 10% FBS, 2 mM L-glutamine, 100 "g/ml gentamicin
[MP Biomedicals], 0.25 "g/ml amphotericin B, 50 "M beta-mercapto-
ethanol, 20 ng/ml granulocyte-macrophage colony-stimulating factor
[GM-CSF], and 10 ng/ml interleukin-4 [IL-4]). Recombinant MHV
strain A59 (GenBank accession number AY910861) was propagated as
described previously (28).
Cloning, recovery, and verification of mutant viruses. Site-directed
mutagenesis was used to engineer point mutations in individual MHV
genome cDNA fragment plasmids using theMHV infectious clone reverse
genetics system (28). Viruses encoding firefly luciferase (FFL) fused to
nsp2 were recovered using MHV A frag-FFL2 (29). Mutant viruses were
recovered using BHK-R cells following electroporation of in vitro-tran-
scribed genomic RNA. All mutagenized plasmids were sequenced (Gen-
Hunter Corporation, Nashville, TN) to ensure that no additional muta-
tionswere introduced. Recovered viruses alsowere sequenced to verify the
engineered mutations.
Virus replication kinetics. Subconfluent DBT cell monolayers were
infected at a multiplicity of infection (MOI) of 1 PFU per cell at 37°C for
45 min. Inocula were removed, cells were washed with 1# phosphate-
buffered saline (PBS), and fresh medium was added. Aliquots were har-
vested at various times postinfection. Viral titer at various intervals was
determined by plaque assay (30).
5-FU sensitivity assays. 5-Fluorouracil (5-FU; Sigma)was prepared as
a 200 mM stock solution in dimethyl sulfoxide (DMSO). Subconfluent
DBT cells were treated with DMEM supplemented to contain various
concentrations of 5-FU orDMSO alone at 37°C for 30min (31). Drugwas
removed, and cells were infected with virus at an MOI of 0.01 PFU/cell at
37°C for 1 h. Inocula were removed, and cells were incubated in medium
containing 5-FU or DMSO. Cell culture supernatants were collected at 24
h postinfection, and viral titers were determined by plaque assay.
IFN-! sensitivity assays. Subconfluent DBT cells were treated with
various concentrations ofmouse IFN-! (PBLAssay Science) for 18 hprior
to infectionwith virus at anMOI of 1 PFU/cell at 37°C for 45min. Inocula
were removed, cells were washed with PBS, and freshmediumwas added.
Cell culture supernatants were collected at the indicated times postinfec-
tion, and viral titers were determined by plaque assay.
IFN-! induction assays. Subconfluent DBT cells were treated with 10
U/ml mouse IFN-! for 18 h prior to infection with virus at anMOI of 0.1
PFU/cell at 37°C for 45 min. Inocula were removed, cells were washed
with PBS, and freshmediumwas added. At 12 h postinfection, cell culture
supernatants were aspirated and cell lysates were harvested by adding
TRIzol reagent. Total RNA present in lysates was purified using the phe-
nol-chloroform method. cDNA was generated by reverse transcription
(RT)-PCR using 1 "g of total RNA as described previously (31). Mouse
IFN-! expression levels relative to GAPDH (glyceraldehyde-3-phosphate
dehydrogenase) were determined by quantitative real-time PCR (qPCR)
using the Applied Biosciences 7500 real-time PCR system with the Power
SYBR green PCR master mix and the IFN-! primers FWD, 5=-TCCGCC
CTGTAGGTGAGGTTGAT-3=, and REV, 5=-GTTCCTGCTGTGCTTCT
CCACCA-3= and the GAPDH primers previously reported (31).
Generation and infection of BMDCs. Primary BMDCs were isolated
from the hind limbs of WT and IFN-$/! receptor-deficient (IFNAR%/%)
C57BL/6J mice. Mice were euthanized by isoflurane overdose, and hind
limbs were resected. Bone marrow cells were collected by flushing the
femurs and tibiae with medium. Cells were strained through a 70-"m cell
strainer, and red blood cells were lysed. Cells were cultured at 37°C in R10
medium supplemented to contain 20 ng/ml GM-CSF and 10 ng/ml IL-4.
At 3 days postplating, cell culture supernatants were removed and re-
placedwith fresh R10medium. Six days postplating, cells were lifted using
Cellstripper (Corning) and replated with fresh R10 medium in 24-well
plates at a density of 105 cells/well and incubated at 37°C overnight.
WT and IFNAR%/% BMDCs were infected with virus at an MOI of 0.01
PFU/cell at 37°C for 45 min. Inocula were removed, and fresh medium
was added. Cell culture supernatants were collected 24 h postinfection,
and viral titers were determined by plaque assay. All experiments with
animals were performed in accordance with Vanderbilt University
School of Medicine Institutional Animal Care and Use Committee
guidelines.
Purification of virions and extraction of RNA. Virion RNA was pu-
rified from subconfluent T150 flasks of BHK-R cells infected with WT-
FFL or nsp14 G332A-FFL viruses at an MOI of 0.001 PFU/cell. When
cytopathic effect was apparent throughout the monolayer, cell culture
supernatants were collected and pooled into 50-ml conical tubes (Corn-
ing), clarified by centrifugation at 1,000 # g for 10 min, and stored at
%80°C. Upon thawing, virus particles in the clarified supernatants were
collected by ultracentrifugation at 106,750# g overnight through a 5-ml,
20% (wt/wt) sucrose cushion in an SW32Ti rotor. The pelleted particles
were resuspended in 200"l MSE buffer (10mMMOPS [morpholinepro-
panesulfonic acid] [pH 6.8], 150 mMNaCl, 1 mM EDTA) and incubated
CoV N7-MTase in Translation and Innate Immunity
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at 4°C overnight prior to resuspension by gently pipetting several times.
Viral RNA was isolated from purified viral particles using TRIzol reagent
(Invitrogen) and phenol-chloroform extraction.
In vitro translation reactions. Viral genomic RNAs containing an
in-frame firefly luciferase-encoding sequence were translated at 30°C for
various intervals in 10 !l of rabbit reticulocyte lysate (Promega) in the
presence of both 10 !M amino acid mixture without leucine and 10 !M
amino acid mixture without methionine.
Firefly luciferase assays. Subconfluent DBT cells were infected with
virus at an MOI of 0.1 PFU/cell. At various intervals, cell culture super-
natants were removed, cells were washed with PBS, and 100!l of reporter
cell lysis buffer (Promega)was added to eachwell. Cells lysateswere frozen
at "80°C to promote lysis and thawed at room temperature prior to
quantifying firefly luciferase activity. Luciferase activity from cell lysates
or in vitro translation reactions was quantified using a Veritas luminom-
eter (Turner Biosystems) and the firefly luciferase assay system (Pro-
mega).
Determination of specific infectivity. Subconfluent monolayers of
DBT-9 cells were infected with virus at anMOI of 0.1 PFU/cell at 37°C for
45 min. Inocula were removed, fresh medium was added, and cells were
incubated at 37°C for 24 h. Cell culture supernatants were collected, and
viral titers were determined by plaque assay. Supernatants also were used
for RNA genome isolation by addition of 100 !l supernatant to 900 !l
TRIzol reagent, chloroform extraction by phase separation, and final pu-
rification using the PureLinkMini RNA kit (Ambion). Genome RNAwas
quantified using one-step qRT-PCR, and the particle-to-PFU ratio was
calculated.
Genome RNA stability assay. Subconfluent monolayers of DBT-9
cells were infected with virus at an MOI of 0.01 PFU/cell at 37°C for 45
min in the presence ofDMSOor 100!g/ml cycloheximide (CHX; Sigma).
Inocula were removed, medium containing DMSO or 100 !g/ml CHX
was added, and cell lysates were harvested at the indicated times postin-
fection by removing the cell culture supernatant and adding TRIzol re-
agent. Lysates were spiked with a known amount of in vitro-transcribed
Renilla luciferase RNA, and total RNA was obtained by phenol-chloro-
form extraction. cDNA was generated by RT-PCR, and the number of
viral genome copies present relative to Renilla luciferase was determined
by SYBR green qPCR using nsp10 (31) and Renilla luciferase-specific
primers (22).
Quantification of viral genomic RNA by qRT-PCR. An RNA stan-
dard was prepared using the MHV A fragment (28) to generate a 931-
nucleotide RNA. First, cDNA was generated by PCR amplification using
the following primers: forward, 5=-TAATACGACTCACTATAGGGGGC
TATGTGGATTGTTGTGG-3=, which initiates with a T7 promoter, and
reverse, 5=-AATTCTTGACAAGCTCAGGC-3=. RNA for the standard
curve was prepared using an mMessage mMachine T7 kit (Ambion) and
purified using an RNeasy minikit (Qiagen). A standard curve was gener-
ated using 10-fold dilutions from 103 to 108 copies. A 5= 6-carboxyfluo-
rescein (FAM)-labeled probe (5=-TTCTGACAACGGCTACACCCAAC
G-3= [Biosearch Technologies]) was used with forward (5=-AGAAGGTT
ACTGGCAACTG-3=) and reverse (5=-TGTCCACGGCTAAATCAAAC-
3=) primers. Reaction mixtures were incubated on ice with enzyme added
last. The final volume for reactionmixtures was 20!l, with 150 nMprobe,
900 nM each primer, 2 !l sample RNA, and 10 !l 2# ToughMix, one-
step, lowROX enzymemix (Quantas) per reactionmixture. Samples were
quantified in duplicate using an Applied Biosciences 7500 real-time PCR
system under the following conditions: 55°C for 10 min, 95°C for 5 min,
95°C for 30 s, and 60°C for 1min, with the last two steps repeated 40 times.
The standard curve was plotted usingGraphPad Prism 6 software, and the
number of genomes per microliter was calculated.
Statistical analysis. Statistical tests were conducted using GraphPad
Prism 6 software (La Jolla, CA) as indicated in the respective figure leg-
ends.
RESULTS
Recovery and replication kinetics of MHV nsp14 N7-MTase
mutants. The DxG SAM-binding motif is conserved among the
nsp14 N7-MTase domains of alpha-, beta-, and gammacoronavi-
ruses (Fig. 1A).Mutations in thismotif of SARS-CoVnsp14 ablate
N7-MTase activity of purified proteins in vitro (13, 25, 26). To
determine whether this motif is required for viral replication, we
engineered alanine substitutions at the DxG SAM-binding motif
in the MHV nsp14 N7-MTase domain. Virus containing either a
D330A or G332A substitution in nsp14 was recovered, and the
nucleotide sequence of each virus was confirmed across the
nsp14-coding region. Following infection of DBT cells at an MOI
of 1 PFU/cell, nsp14 D330A virus replicated with kinetics compa-
FIG 1 Replication kinetics of viruses with altered N7-MTase SAM-binding
residues. (A) Alignment of GenBank ORF1b sequences of the $-, %-, and
&-CoVs shown demonstrates that SAM-binding residues (highlighted in yel-
low) are highly conserved. (B) DBT cells were infected with the viruses shown
at an MOI of 1 PFU/cell. Cell culture supernatants were collected at the indi-
cated times postinfection, and viral titers were determined by plaque assay.
Error bars indicate standard errors of the means (SEM) (n ' 6). (C) Plaque
morphology of the viruses following agarose overlay plaque assay and fixation
with 3.7% paraformaldehyde 24 h postinfection.
Case et al.
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rable to that of WT MHV (Fig. 1B). nsp14 D330A plaque mor-
phology also was similar to that of WT MHV (Fig. 1C). In con-
trast, the nsp14 G332A virus began exponential replication 4 to 6
h later than WT MHV and reached a lower peak titer (1.5 ! 104
PFU/ml) than that of WT MHV (107 PFU/ml) (Fig. 1B). The
nsp14 G332A virus plaque size was also decreased relative to that
ofWTMHV (Fig. 1C). Thus, despite the requirement of D330 for
nsp14N7-MTase activity in vitro (13, 25, 26, 32), our data indicate
that the D330A mutation has no detectable effect on MHV repli-
cation kinetics in cell culture.
nsp14D330A orG332Amutations do not significantly influ-
encensp14ExoNactivity.Coronavirus nsp14 is amultifunctional
protein with two known enzymatic activities, a proofreading 3=-5=
exoribonuclease activity (ExoN) and N7-MTase activity (24, 25).
Based on in vitro studies, the ExoN and N7-MTase domains of
CoV nsp14 are interdependent (26). This conclusion is supported
by the crystal structure of nsp14, demonstrating that the ExoN
and N7-MTase domains interact through a large hydrophobic in-
terface (32). In addition, disruption of ExoN (ExoN") via muta-
tions at two active-site residues decreases the replication fidelity of
MHVand SARS-CoV and renders the viruses sensitive to the RNA
mutagen 5-fluorouracil (5-FU) (30, 31, 33). Thus, 5-FU sensitivity
has been shown to be an in vitro indicator of ExoN activity. There-
fore, we tested whether the D330A or G332A mutations affect
ExoN activity by treating cells with increasing concentrations of
5-FU or vehicle (DMSO) prior to infection with either nsp14
D330A or nsp14 G332A virus at anMOI of 0.01 PFU/cell (Fig. 2).
The nsp14D330A and nsp14G332A viruses were not significantly
altered in 5-FU sensitivity compared with WT MHV (no signifi-
cant difference by one-way analysis of variance [ANOVA]). In
contrast, the ExoN" virus displayed a concentration-dependent
increase in 5-FU sensitivity. These results indicate that neither
D330A nor G332A significantly alter ExoN activity during virus
replication.
MHV nsp14 G332A is detected by and sensitive to the type I
interferon-mediated innate immune response. Coronavirus
RNA capping likely follows the conventional capping pathway,
with nsp14 N7-methylation being a prerequisite for 2=O-methyl-
ation in vitro (13). Therefore, decreased nsp14 N7-MTase activity
should reduce overall 2=O-methylation, thereby increasing virus
sensitivity to exogenous type I IFN due to recognition by IFIT1
and MDA5 (22, 23). To test this hypothesis, we pretreated DBT
cells with murine IFN-# prior to infection with WTMHV, nsp16
D130A, which is an IFN-sensitive positive-control mutant virus
due to ablated 2=O-MTase activity (19, 22, 23, 34), or nsp14
D330A or nsp14 G332AN7-MTasemutant viruses at anMOI of 1
PFU/cell. Cell culture supernatants were collected at either 12 or
24 h postinfection, and viral titers were determined by plaque
assay. As expected, the nsp16 D130A virus was sensitive to IFN-#
pretreatment (Fig. 3A). The nsp14 G332A virus demonstrated a
dose-dependent increase in IFN-# sensitivity, which became
undetectable by plaque assay at IFN-# concentrations greater
than 75 U/ml (Fig. 3A). In contrast, nsp14 D330A virus dis-
played sensitivity to IFN-# comparable to WT MHV (Fig. 3B).
Because nsp14 D330A displayed replication kinetics and resis-
tance to IFN-# pretreatment indistinguishable from those of
WT MHV, it is likely that the D330A substitution does not
significantly affect N7-MTase activity. Therefore, we focused
solely on the nsp14 G332A mutant for the remainder of the
experiments in this study.
In addition to an increased sensitivity to the effects of type I
interferon pretreatment, coronaviruses lacking 2=O-MTase activ-
ity induce higher levels of IFN-# than do the WT viruses (8, 22,
23). Therefore, to determine whether nsp14 G332A is also recog-
nized by innate sensors and subsequently induces type I interferon
expression, we pretreated DBT cells with 10 U/ml murine IFN-#
for 18 h prior to infection withWTMHV, nsp16D130A, or nsp14
G332A viruses at an MOI of 0.1 PFU/cell. At 12 h postinfection,
cell lysates were collected and the relative expression of IFN-#was
determined by qPCR (Fig. 3C). As previously reported, infection
with WT MHV marginally induced the expression of IFN-# (35)
and infection with nsp16 D130A led to an upregulation of IFN-#
relative to mock-infected cells (8, 22, 23). Furthermore, infection
with nsp14 G332A led to a significant increase in the expression of
IFN-# relative to mock and WT MHV-infected cells. These data
further suggest that nsp14N7-MTase activity precedes nsp16 2=O-
MTase activity and the absence of either activity results in innate
detection of the virus leading to the induction of type I interferon
gene expression.
To determine the effect that increased sensitivity to IFN-# has
on nsp14 G332A replication, we tested whether nsp14 G332A vi-
rus replication could be rescued in BMDCs lacking the IFN-$/#
receptor (IFNAR"/"). IFNAR"/" cells lack the capacity to re-
spond to type I IFNs and are thus incapable of mounting an effec-
tive IFN-dependent antiviral response (36). WT or IFNAR"/"
BMDCs were infected withWTMHV or nsp14 G332A virus at an
MOI of 0.01 PFU/cell, cell culture supernatants were collected 24
h postinfection, and viral titers were determined by plaque assay.
Similar to experiments using DBT cells, nsp14 G332A virus repli-
cated poorly inWTBMDCs relative toWTMHV (Fig. 3D). Titers
of nsp14 G332A virus were increased approximately 40-fold in
IFNAR"/" BMDCs (5.6! 104 PFU/ml) compared with the titers
of this virus inWTBMDCs (1.3! 103 PFU/ml). However, despite
the increase in viral titers of nsp14 G332A in IFNAR"/" BMDCs,
titers were not restored to the level of WT MHV in IFNAR"/"
BMDCs (3.6! 106 PFU/ml). These data suggest that the impaired
FIG 2 N7-MTase mutants display WT-like sensitivity to the RNA mutagen
5-FU. DBT cells were treated with the indicated concentrations of 5-FU for 30
min prior to infection with the viruses shown at an MOI of 0.01 PFU/cell.
Medium containing 5-FU or vehicle was added 30 min postinfection. After 24
h, cell culture supernatants were collected, and viral titers were determined by
plaque assay. For each virus, titers were normalized to those following infec-
tion of DMSO-treated controls. Changes in viral titers for nsp14 D330A and
nsp14 G332A viruses were not statistically significant relative to WTMHV by
one-way ANOVA. Error bars indicate SEM (n% 4).
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replication capacity of nsp14 G332A virus is only in part attribut-
able to IFN sensitivity and, instead, this virusmaymanifest amore
general replication defect.
nsp14 G332A genome translation is delayed during infec-
tion. Since the absence of the IFNAR was insufficient to restore
nsp14 G332A replication, other mechanisms, such as decreased
genome RNA stability or decreased viral genome translation, may
contribute to the replication defect of this virus. The 5= capping of
cellular mRNAs serves several important functions, one of which
is to increase RNA stability (2, 9). To test the stability of the nsp14
G332A genome upon entry into the cell, we infected DBT cells
with WTMHV or nsp14 G332A virus at an MOI of 0.01 PFU/cell
in the presence of vehicle (DMSO) or 100 !g/ml cycloheximide
(CHX). CHX inhibits the translation of input viral genomes and
prevents expression of the viral RNA-dependent RNA polymer-
ase, thereby allowing us to quantify the amount of coronavirus
RNA present at later time points relative to input. At the indicated
times postinfection, cell lysates were collected and spiked with a
known amount of in vitro-transcribed Renilla luciferase, and the
amount of viral RNA present relative to Renilla luciferase was
determined by qPCR (Fig. 4). At each time point postinfection for
FIG 3 nsp14 G332A virus exhibits increased induction of and sensitivity to IFN-". DBT cells were treated for 18 h with the indicated concentrations of mouse
IFN-". Cells were infected withWT, nsp16D130A, or nsp14G332A virus and incubated for 24 h (A) or infected withWT, nsp16D130A, and nsp14D330A virus
and incubated for 12 h (B). Cell culture supernatants were collected, and viral titers were determined by plaque assay. For each panel, error bars represent SEM
(n# 4). ND, not detectable. (C) DBT cells were treated for 18 h with 10 U/ml mouse IFN-". Cells were mock infected or infected with WT, nsp16 D130A, or
nsp14 G332A virus at an MOI of 0.1 PFU/cell. At 12 h postinfection, cell lysates were harvested, total RNA was extracted, cDNA was generated, and IFN-"
expression relative to GAPDHwas determined by qPCR. Error bars indicate SEM (n# 9). N.S., not significant; **, P$ 0.01 by Student’s t test. (D) BMDCs were
infected with either WT or nsp14 G332A virus at an MOI of 0.01 PFU/cell. At 24 h postinfection, cell culture supernatants were collected, and viral titers were
determined by plaque assay. Error bars indicate SEM (n# 6). *, P$ 0.05; ***, P$ 0.001 by Student’s t test.
FIG 4 nsp14 G332A genomic RNAs are stable. DBT cells were infected withWT
or nsp14 G332A virus at an MOI of 0.01 PFU/cell in the presence of vehicle
(DMSO) or 100 !g/ml CHX. Cell lysates were harvested at the indicated times
postinfection and spiked with a known amount of in vitro-transcribed Renilla
luciferaseRNA, and total RNAwas obtained by phenol-chloroformextraction.
cDNA was generated by RT-PCR, and the number of viral genome copies
present relative to Renilla luciferase was determined by SYBR green qPCR
using MHV nsp10 and Renilla luciferase-specific primers. Error bars indicate
SEM (n# 6).
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CHX-treated samples, the level of nsp14 G332A RNA was similar
to that of WT MHV, indicating that nsp14 G332A replication is
not impaired due to decreased genome RNA stability.
In addition to serving as a precursor for 2=O-methylation, N7-
methylated guanosine 5= caps are recognized by eIF4E and re-
quired for efficient translation of eukaryotic RNA (9, 37). To
determine whether the nsp14 G332A mutation impairs viral
translation efficiency, we first engineered virus encoding FFL as an
in-frame N-terminal fusion with MHV nsp2 (29) in the open
reading frame 1a (ORF1a) polyprotein coding sequence of the
isogenic nsp14 G332A cloned genome. In this setting, FFL-nsp2 is
the second protein translated from the input viral genome and
becomes a reporter for viral protein translation.We infected DBT
cells with eitherWT-FFL or nsp14 G332A-FFL virus at anMOI of
0.1 PFU/cell, and lysates were prepared at various intervals postin-
fection to quantify luciferase activity and viral genome RNA copy
number. Luciferase activity accumulated more slowly following
infection by nsp14 G332A-FFL virus relative to WT-FFL virus
(Fig. 5A). The WT-FFL signal began to decline after 16 h due to
destruction of the cell monolayer. In addition, levels of nsp14
G332A-FFL genomic RNA increased more slowly than those of
WT-FFL (Fig. 5B). By quantifying both luciferase activity and viral
genome copies, we were able to calculate the kinetics of transla-
tion. To determine the rate of translation at each time point
postinfection, the ratio of luciferase activity to genome copies was
determined using data shown in Fig. 5A and B. The ratio of lucif-
erase activity to genome copies for WT-FFL was highest at early
times postinfection (Fig. 5C). In contrast, the ratio of luciferase
activity to genome copies was substantially less for the nsp14
G332A-FFL virus at early time points postinfection than for WT-
FFL and failed to reach peak WT-FFL levels. These data demon-
strate that nsp14G332A-FFL virus requiresmore genomicRNA to
achieve the WT levels of FFL activity, consistent with decreased
translation efficiency of the mutant virus genome. Therefore, we
next determined whether nsp14 G332A-FFL andWT-FFL virions
are equivalently infectious by measuring the specific infectivity of
each virus from infected DBT cell culture supernatants. The ratio
of nsp14 G332A-FFL particles per PFU was approximately 7-fold
more thanWT-FFL (Fig. 5D). Thus, packaged nsp14 G332A-FFL
genomes were less efficient at establishing infection than the WT.
nsp14 G332A-FFL genomes are translated less efficiently
thanWT-FFL genomes in vitro. To directly assess the translation
capacity of nsp14 G332A-FFL virus genomes, we isolated genome
RNA from purified virions. Increasing concentrations of genome
RNAs were incubated with rabbit reticulocyte lysates at 30°C for
1.5 h, and luciferase activity was quantified (Fig. 6A). Compared
to WT-FFL genomes, FFL activity in the reticulocyte lysates was
significantly reduced following incubation with nsp14 G332A-
FIG5 nsp14G332A genomic RNAs are translatedwith delayed kinetics during infection. DBT cells were infectedwith eitherWT-FFL or nsp14G332A-FFL virus
at an MOI of 0.1 PFU/cell. At the times shown postinfection, cell culture supernatants were collected, and lysates were harvested and divided equally into two
samples. For the first lysate sample, luciferase activity was quantified (A). For the remaining lysate sample, RNA was extracted, and genome RNA copies were
quantified using real-time qRT-PCRwith a standard curve and CoV nsp2-specific primers (B). (C) Translation ofWT-FFL or nsp14 G332A-FFL genomes at the
times shown postinfection as determined by luciferase activity per genome RNA copy number. Values were normalized to WT-FFL at 6 h postinfection. Error
bars indicate SEM (n! 4). (D) Viral titers in cell culture supernatants from DBT cells infected with either WT-FFL or nsp14 G332A-FFL were determined by
plaque assay, and the number of genomeRNAcopies present in the input supernatantwas determined by one-step real-time qRT-PCR. The particle-to-PFU ratio
was calculated by dividing the number of genome RNA copies by the viral titers. Error bars represent SEM (n! 4). **, P" 0.01 by Student’s t test.
CoV N7-MTase in Translation and Innate Immunity
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FFL genomes. In addition, we quantified the relative translation
efficiency of equal amounts of WT-FFL and nsp14 G332A-FFL
genomicRNAover time. At all timepoints tested after 15min, FFL
activity was significantly reduced following incubation of reticu-
locyte lysates with nsp14G332A-FFL genomes relative toWT-FFL
genomes (Fig. 6B). Taken together, our data indicate that the de-
creased replication capacity of the nsp14 G332A virus is attribut-
able to IFN sensitivity and reduced translation efficiency.
DISCUSSION
In this study, we engineered recombinant CoVs encoding alanine
substitutions in the nsp14N7-MTase at the SAM-binding-site res-
idues, D330 and G332. We found that the N7-MTase SAM-bind-
ing-site mutants are viable and yield drastically different pheno-
types during replication. Specifically, MHV nsp14 D330A virus
replicates indistinguishably from WT MHV in all assays con-
ducted, despite the requirement of this residue for SAMbinding in
vitro (26). There is precedent for such a contradiction. A previous
study using vesicular stomatitis virus identified a SAM-binding
residue within the L protein (G1674) that, when altered, does not
affect viral replication or N7-MTase activity (38). The structure of
the SARS-CoV nsp10-nsp14 complex reveals that D331 (D330 in
MHV) is in close proximity to the SAM-binding site, but only
G333 (G332 in MHV) directly contacts SAM (32). Since in vitro
N7-MTase activity was assessed only for a SARS-CoV nsp14
D331A/G333A double mutant, it is not clear whether nsp14 D331
was required for N7-MTase activity in this study (32). However, a
previous study using both in vitro functional assays and yeast com-
plementation reported that SARS-CoVnsp14D331 is essential for
N7-MTase activity (26). Our study examined nsp14 N7-MTase in
the context of viral replication. A potential difference between our
work and previous studies of the CoV nsp14 N7-MTase is the use
of MHV versus SARS-CoV proteins, respectively. Purified MHV
nsp14 N7-MTase is not available in our lab for biochemical stud-
ies. However, our results will guide future experiments when such
a system is established. During our study, we attempted to recover
SARS-CoV nsp14 D331A, I332A, and G333A N7-MTase mutant
viruses. However, viable viruses were not recovered after at least
three attempts for each mutant. Nonetheless, the high conserva-
tion of the SAM-binding residues makes it unlikely that the dif-
ferences observed between our work and previous biochemical
studies are due to profoundly different N7-MTase catalytic mech-
anisms.
In contrast to nsp14 D330A virus, nsp14 G332A virus repli-
cated with delayed kinetics and reached peak titers that were
1,000-fold less than those of WT MHV. CoV nsp14 has two do-
mains: an N-terminal ExoN domain and a C-terminal N7-MTase
domain. Mutations at D331 in SARS-CoV nsp14 do not affect
ExoN activity in vitro (25, 26). However, the effect of altering
residue G333 (G332 in MHV) on ExoN activity has not been re-
ported using any system. It is unlikely that the G332Amutation in
MHV nsp14 influences ExoN activity, as nsp14 G332A demon-
strated WT-like sensitivity to the RNA mutagen 5-FU. Even a
subtle alteration in ExoN activity should result in a detectable
change in 5-FU sensitivity, particularly since we performed the
assay using low-MOI conditions, which would increase mutagen
incorporation during multistep replication (31, 34). The lack of
enhanced 5-FU sensitivity for the nsp14 D330A and nsp14 G332A
viruses indicates thatmutations at these SAM-binding residues do
not significantly dampen ExoN activity during virus replication.
Additionally, since nsp14 G332A is resistant to 5-FU treatment, it
is unlikely that the G332A phenotype is due to nsp14 instability or
degradation.
Our data indicate that impaired replication of nsp14 G332A
virus is likely due to a combination of factors, including increased
detection by innate immune sensors and decreased translation
efficiency of viral RNA. Binding of type I IFNs to the IFN receptor
leads to expression of many IFN-stimulated genes and ultimately
the establishment of an antiviral state (39). Coronavirus RNAs
lacking 2=O-methylation are sensed by IFIT1, which is one of the
most highly upregulated IFN-stimulated genes following IFN in-
duction (40).While nsp14D330AdisplayedWT-like sensitivity to
pretreatment with IFN-!, nsp14 G332A virus did not replicate
following IFN-! pretreatment with doses of"75 U/ml. However,
initial titers were lower for nsp14 G332A. Thus, the concentra-
tion-dependent change in viral titer following IFN-! pretreat-
ment was similar to that for the nsp16 D130A virus. The IFN-!
sensitivity of nsp14 G332A likely results from a reduction in 2=O-
methylation of viral RNA due to impaired N7-MTase activity.
FIG 6 Purified nsp14 G332A genomic RNA is translated at lower efficiency in
vitro. BHK-R cells were infected at an MOI of 0.001 PFU/cell with either WT-
FFLor nsp14G332A-FFL virus. Supernatantswere harvested and clarified, and
virions were collected by ultracentrifugation. Virion pellets were resuspended,
TRIzol was added, and virion RNAs were purified using phenol-chloroform
phase separation. Genome RNA copies were quantified using one-step real-
time qRT-PCR with a standard curve and CoV nsp2-specific primers. (A) The
concentrations of WT-FFL or nsp14 G332A-FFL genomic RNAs shown were
translated in vitro at 30°C for 1.5 h, and luciferase activity was quantified.
Translation values are relative to WT-FFL genomic RNA at 40 ng. Error bars
represent SEM (n # 4). ***, P $ 0.001 by Student’s t test. (B) Equivalent
numbers of either WT-FFL or nsp14 G332A-FFL genomic RNAs were trans-
lated in vitro for the times shown, and luciferase activity was quantified. Error
bars represent SEM (n# 6). *, P$ 0.05; **, P$ 0.01 by Student’s t test.
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This hypothesis is supported by our data showing that infection
with either nsp16 D130A or nsp14 G332A virus results in the
induction of IFN-! gene expression. In addition, decreased N7-
MTase activity due to the G332A mutation results in the delayed
translation and decreased translation efficiency observed during
viral replication and in vitro assays. Due to the highly impaired
replication capacity of the nsp14 G332A virus, it has not been
possible to directly determine the capmethylation status of nsp14
G332A virus genomes. Nevertheless, our results are consistent
with functions of the N7-methylated 5=cap in promoting both
viral and cellular translation (4–6). Decreased translation effi-
ciency also could explain the lower specific infectivity observed for
nsp14 G332A virus. Furthermore, it is possible that the delayed
translation kinetics of nsp14 G332A genomic RNA increases in-
nate sensing of the virus by delaying the early expression of mul-
tiple CoV IFN antagonists upon entry, resulting in decreased rep-
lication capacity.
Our data provide additional support for a sequential model of
CoV RNA capping wherein N7-methylation precedes 2=O-meth-
ylation. In addition, our studies suggest that small-molecule in-
hibitors of the CoV nsp14 N7-MTase would impair virus replica-
tion and provide a pathogen-associated molecular pattern that
would be quickly recognized by the innate immune response.
Given the conservation of these enzymes, such inhibitors may
have activity against diverse groups of coronaviruses.
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ABSTRACT Coronaviruses (CoVs) are positive-sense RNA viruses that infect numerous
mammalian and avian species and are capable of causing severe and lethal disease in
humans. CoVs encode several innate immune antagonists that counteract the host in-
nate immune response to facilitate efficient viral replication. CoV nonstructural protein
14 (nsp14) encodes 3=-to-5= exoribonuclease activity (ExoN), which performs a proofread-
ing function and is required for high-fidelity replication. Outside of the order Nidovirales,
arenaviruses are the only RNA viruses that encode an ExoN, which functions to degrade
double-stranded RNA (dsRNA) replication intermediates. In this study, we tested the hy-
pothesis that CoV ExoN also functions to antagonize the innate immune response. We
demonstrate that viruses lacking ExoN activity [ExoN(!)] are sensitive to cellular pre-
treatment with interferon beta (IFN-!) in a dose-dependent manner. In addition, ExoN(!)
virus replication was attenuated in wild-type bone marrow-derived macrophages (BMMs)
and partially restored in interferon alpha/beta receptor-deficient (IFNAR!/!) BMMs.
ExoN(!) virus replication did not result in IFN-! gene expression, and in the presence of
an IFN-!-mediated antiviral state, ExoN(!) viral RNA levels were not substantially re-
duced relative to those of untreated samples. However, ExoN(!) virus generated from
IFN-!-pretreated cells had reduced specific infectivity and decreased relative fitness, sug-
gesting that ExoN(!) virus generated during an antiviral state is less viable to establish a
subsequent infection. Overall, our data suggest murine hepatitis virus (MHV) ExoN activ-
ity is required for resistance to the innate immune response, and antiviral mechanisms
affecting the viral RNA sequence and/or an RNA modification act on viruses lacking
ExoN activity.
IMPORTANCE CoVs encode multiple antagonists that prevent or disrupt an efficient
innate immune response. Additionally, no specific antiviral therapies or vaccines cur-
rently exist for human CoV infections. Therefore, the study of CoV innate immune
antagonists is essential for understanding how CoVs overcome host defenses and to
maximize potential therapeutic interventions. Here, we sought to determine the con-
tributions of nsp14 ExoN activity in the induction of and resistance to the innate im-
mune response. We show that viruses lacking nsp14 ExoN activity are more sensitive
than wild-type MHV to restriction by exogenous IFN-! and that viruses produced in
the presence of an antiviral state are less capable of establishing a subsequent viral
infection. Our results support the hypothesis that murine hepatitis virus ExoN activ-
ity is required for resistance to the innate immune response.
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The innate immune response within a mammalian cell is the first line of defenseagainst an invading pathogen. However, as obligate intracellular parasites, viruses
have evolved numerous mechanisms to prevent and antagonize innate detection by
host cells. Coronaviruses (CoVs), which are the largest known positive-sense, single-
stranded RNA viruses, encode several type I interferon (IFN) antagonists. Many of these
antagonists prevent the induction of IFN, while others mediate resistance to the effects
of IFN (1–3). Upon secretion from a cell, IFNs bind to cell surface-expressed IFN-!/"
receptors (IFNARs) in an autocrine and paracrine manner. Subsequently, an IFN signal-
ing cascade utilizing the Janus kinase and signal transducer and activator of the
transcription pathway leads to the induction and expression of hundreds of interferon-
stimulated genes (ISGs) that act to limit or prevent viral replication and spread (4).
However, during CoV infection, nonstructural protein 1 (nsp1) antagonizes the innate
immune response by degrading host mRNAs and suppressing IFN-" expression (5, 6).
The nsp3 of severe acute respiratory syndrome coronavirus (SARS-CoV) prevents IRF3
phosphorylation and NF-#B signaling (7). In addition, SARS-CoV nsp3 encodes deubiq-
uitinating and deISGylating activities (3, 8). CoV RNA evades innate detection by pattern
recognition receptors (PRRs), such as MDA5, and antiviral effectors, such as IFIT1,
through formation of a 5= cap-1 structure by encoding N7-methyltransferase and
2=O-methyltransferase activities within nsp14 and nsp16, respectively (9, 10). Murine
hepatitis virus (MHV) and Middle East respiratory syndrome coronavirus (MERS-CoV)
encode 2=-5= phosphodiesterases that degrade 2=-5= oligoadenylates, which are key
signaling molecules generated by oligoadenylate synthetase (OAS) in response to
innate detection of double-stranded RNA (dsRNA) that subsequently activate RNase L
(11). Most recently, a CoV nsp15 endonuclease activity (EndoU) mutant virus was shown
to have increased dsRNA levels, suggesting that nsp15 EndoU reduces dsRNA levels
during infection (12).
CoV nsp14 encodes 3=-to-5= exoribonuclease (ExoN) and N7-methyltransferase
(N7-MTase) activities (9, 13). CoV nsp14 N7-MTase activity is essential for efficient
translation of the viral genome and preventing innate detection (14). In addition,
initial biochemical studies of nsp14 ExoN activity demonstrated that ExoN has a
preference for dsRNA and the capacity to excise 3=-end misincorporated nucleo-
tides (13). Moreover, nsp14 ExoN activity is required for high-fidelity replication. The
CoV nsp14 ExoN is a member of the DE-D-Dh superfamily of DNA and RNA
exonucleases, so named for the three motifs of four active-site residues (13).
Betacoronaviruses SARS-CoV and MHV expressing engineered, ExoN-inactivating
substitutions at active-site residues in motif I (DE¡AA) [ExoN(!)] demonstrate
increased mutation frequencies and are profoundly sensitive to inhibition by RNA
mutagens (15, 16). Additionally, SARS-CoV ExoN(!) virus is attenuated in vivo (17).
Interestingly, outside the order Nidovirales, the only other known RNA virus-
encoded 3=-to-5= exoribonucleases are found in the Arenaviridae family of viruses.
Lassa fever virus nucleoprotein ExoN is not thought to participate in fidelity
regulation; rather, it participates in immune evasion by degrading dsRNA and
thereby prevents antigen-presenting cell-mediated NK cell activation (18–20). Re-
cently, in the Alphacoronavirus transmissible gastroenteritis virus (TGEV), a mutation
in the nsp14 ExoN zinc finger was shown to generate lower levels of dsRNA than
wild-type (WT) TGEV. However, in that study viruses with mutations in ExoN
active-site motifs were nonviable and therefore could not be directly tested for
effects on innate immunity (21).
Here, we demonstrate that viruses lacking ExoN activity were more sensitive to the
effects of IFN pretreatment than WT MHV. In addition, for viruses lacking ExoN activity,
replication was restricted in wild-type bone marrow-derived macrophages (B6 BMMs)
but restored in IFNAR-deficient (IFNAR!/!) BMMs. Despite an increased sensitivity to
the effects of IFN treatment, MHV ExoN mutants failed to induce detectable IFN-" gene
expression or RNase L-mediated rRNA degradation, and only a limited decrease in viral
RNA accumulation was observed. Finally, ExoN(!) virus replicated in the presence of an
IFN-"-mediated antiviral state had both a decreased specific infectivity and decreased
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relative fitness compared to that of untreated ExoN(!) virus. Thus, nsp14 ExoN appears
to block or correct the restriction of MHV infection by an IFN-mediated mechanism that
may involve damaging nascent viral RNA and affecting subsequent infectivity.
(This article was submitted to an online preprint archive [42].)
RESULTS
Viruses lacking ExoN activity are more sensitive to the effects of IFN-! than WT
MHV. Binding of type I interferon to the IFNAR receptor on the cell surface leads to a
Jak/STAT signaling cascade that ultimately results in the upregulation and expression
of hundreds of antiviral ISGs (4). In addition, WT MHV replication has been shown to be
relatively resistant to the effects of IFN (1, 3, 22). To determine whether the ExoN
activity of MHV nsp14 was required for resistance to IFN, we pretreated murine delayed
brain tumor (DBT) cells with increasing concentrations of mouse IFN-! for 18 h prior to
infection with WT MHV or ExoN(!) virus at a multiplicity of infection (MOI) of 1 PFU per
cell (Fig. 1A). In response to IFN-! pretreatment, WT MHV viral titer decreased by
approximately 1 log10, as previously reported (1). In contrast, ExoN(!) viral titer
demonstrated a dose-dependent decrease and resulted in an approximately 3-log10
decrease in viral titer relative to untreated ExoN(!) viral titers. The ExoN activity of
nsp14 is conferred by active-site residues present in 3 different motifs within the ExoN
domain (23). Therefore, to determine whether the observed increase in sensitivity to
IFN-! pretreatment for ExoN(!) virus shown in Fig. 1A was due specifically to the
absence of ExoN activity in nsp14, we engineered and recovered a virus encoding only
an aspartic acid-to-alanine substitution in motif III [ExoN3(!)]. Previously, we demon-
strated that viruses lacking ExoN activity have decreased replication fidelity and are
sensitive to the RNA mutagen 5-fluorouracil (5-FU) (16). Hence, 5-FU sensitivity is an
in vitro indicator of ExoN activity. Therefore, first, we tested whether ExoN3(!) and
ExoN(!) demonstrated similar sensitivity to 5-FU to ensure that the ExoN activity of
ExoN3(!) virus had been ablated. Similar to that of ExoN(!), ExoN3(!) viral replication
in cells treated with increasing concentrations of 5-FU demonstrated a dose-dependent
decrease in viral titer relative to vehicle-treated cells (Fig. 1B). Further, ExoN(!) and
ExoN3(!) displayed similar sensitivities to pretreatment with 100 or 500 U/ml IFN-!
following infection at an MOI of 1 PFU/cell (Fig. 1C). Thus, these data suggest nsp14
ExoN activity is required for resistance to the effects of IFN-! pretreatment.
Increased replication capacity does not confer resistance to the effects of IFN-!
pretreatment for viruses lacking ExoN activity. ExoN(!) virus demonstrates an
approximately 2-h delay in exponential replication and a 1-log10 decrease in peak titer
relative to WT MHV (15). Therefore, we tested whether the IFN sensitivity phenotypes
observed for ExoN(!) and ExoN3(!) viruses are due to the decreased replication
capacity of these viruses. To do so, we utilized an ExoN(!) virus developed by our
laboratory that has been blindly passaged in DBT cells for 250 passages [ExoN(!) P250].
Over the course of passage, the ExoN(!) P250 virus did not revert the engineered
ExoN(!) (DE¡AA) mutations. In addition, ExoN(!) P250 accumulated 171 total muta-
tions (74 nonsynonymous mutations) across the genome (24). The replication capacity
of the resulting ExoN(!) P250 virus exceeds that of WT MHV (Fig. 2A). However, despite
increased replication capacity, ExoN(!) P250 demonstrated sensitivity to IFN-! pre-
treatment similar to that of ExoN(!) virus (Fig. 2A and B). Hence, the IFN-! sensitivity
phenotype of viruses lacking ExoN activity is not dependent on viral replication
capacity but instead is directly associated with a specific function of nsp14 ExoN that
is required for efficient replication in the presence of an IFN-!-mediated antiviral state.
nsp14 ExoN activity is required for replication in wild-type B6 BMMs. We next
wanted to test whether ExoN activity was required for replication in primary innate
immune cells, such as BMMs. Replication of WT MHV in primary BMMs is well described,
and data suggest that wild-type B6 BMMs express many PRRs and ISGs at a higher basal
level than many mouse cell lines (3, 25, 26). In contrast, BMMs lacking the IFNAR
receptor (IFNAR!/!) have lower basal and expressed levels of ISGs, making B6 and
IFNAR!/! BMMs excellent cell types for interrogating the role of ExoN activity on viral
nsp14 ExoN Activity Is Required for Resistance to IFN Journal of Virology
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FIG 1 Viruses lacking ExoN activity are sensitive to IFN-! pretreatment. (A) DBT cells were pretreated with
the indicated concentrations of mouse IFN-! for 18 h and then infected with WT MHV or ExoN(!) virus
(A) or WT, ExoN(!), or ExoN3(!) virus (C) at an MOI of 1 PFU/cell. At 12 h postinfection, cell culture
supernatants were collected and the viral titers determined by plaque assay. (B) DBT cells were
pretreated with the indicated concentrations of 5-FU for 30 min. Following pretreatment, cells were
infected with WT, ExoN(!), or ExoN3(!) virus at an MOI of 1 PFU/cell for 45 min, inocula were removed,
and fresh medium containing vehicle or the appropriate concentration of 5-FU was added. Cell culture
(Continued on next page)
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replication and antagonism of the innate immune response (25). BMMs from B6 or
IFNAR!/! mice were generated and infected with WT MHV or ExoN(!) virus at an MOI
of 1 PFU/cell. Samples were harvested at the indicated time points, and viral titers were
determined by plaque assay (Fig. 3A). WT MHV replication increased gradually in both
B6 and IFNAR!/! BMMs at each time point postinfection. In contrast, ExoN(!) virus
replication in B6 BMMs was detectable only at 6 and 9 h postinfection. However, when
IFNAR!/! BMMs were infected with ExoN(!) virus, viral titers were partially restored
and increased at each time point postinfection. To further test the replication of viruses
lacking ExoN activity and the effect of an increased replication capacity in BMMs, B6
and IFNAR!/! BMMs were infected with WT MHV or ExoN(!) P250 viruses at an MOI
of 1 PFU/cell. Similar to the results shown in Fig. 3A, WT MHV viral titers steadily
increased in B6 and IFNAR!/! BMMs at each time point postinfection (Fig. 3B).
However, similar to that of ExoN(!) virus, ExoN(!) P250 virus replication in B6 BMMs
was restricted and not detected beyond 9 h postinfection. In addition, ExoN(!) P250
virus replication in IFNAR!/! BMMs was restored to levels similar to those of WT MHV.
These data show that ExoN activity is required for replication in B6 BMMs. Further, they
suggest that restriction of ExoN(!) or ExoN(!) P250 is mediated by a gene or genes
downstream of IFNAR.
Loss of ExoN activity does not result in the induction of IFN and replication is
not rescued by RNase L/PKR deficiency. Upon detection of a pathogen-associated
molecular pattern (PAMP) by innate sensors, signaling pathways lead to transcription
factor activation and nuclear translocation, resulting in expression of IFN-! mRNA (4).
WT MHV is well known to prevent or delay the induction of IFN expression (3, 22).
However, ExoN activity may help prevent the detection of a PAMP, namely, dsRNA,
which has been shown to be increased in an nsp15 EndoU mutant (12). Therefore, to
determine whether the loss of ExoN activity resulted in the generation and subsequent
detection of a PAMP, we determined the level of IFN-! gene expression in DBT cells
either mock infected or infected with WT MHV, ExoN(!), or ExoN(!) P250 virus at an
MOI of 0.1 PFU/cell (Fig. 4A). In addition, we infected DBT cells with Sendai virus (SenV),
a positive control and a potent inducer of IFN, at an MOI of 200 hemagglutinin (HA)
FIG 1 Legend (Continued)
supernatants were harvested 12 h postinfection, and viral titers were determined by plaque assay. For
each panel, the change in viral titer was calculated by dividing viral titers following the indicated
treatment by the untreated controls, and error bars indicate standard errors of the means (SEM) (n " 4).
Statistical significance compared to WT MHV is denoted and was determined by Student’s t test. *, P #
0.05; **, P # 0.01; ***, P # 0.001.
FIG 2 Increased replication capacity does not restore virus resistance to IFN-!. DBT cells were pretreated
with the indicated concentrations of mouse IFN-! for 18 h and then infected with WT, ExoN(!), or
ExoN(!) P250 virus at an MOI of 1 PFU/cell. At 12 h postinfection, cell culture supernatants were
collected and the viral titers determined by plaque assay. Raw viral titers (A) or the change in viral titers
relative to untreated controls (B) are reported. Error bars indicate SEM (n " 4). Statistical significance
compared to WT MHV is denoted and was determined by Student’s t test. *, P # 0.05; **, P # 0.01; ***,
P # 0.001.
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units/ml. SenV infection resulted in IFN expression by 3 h postinfection and peaked
between 9 and 12 h postinfection before returning nearly to mock-infected levels by
24 h postinfection, demonstrating that DBT cells are capable of expressing IFN-!. In
contrast, no CoV infection, regardless of whether or not intact ExoN activity was
present, resulted in IFN-! gene expression over that of mock-infected cells, with the
exception of WT MHV at 3 h postinfection. Further, upon detection of dsRNA by OAS
and subsequent activation of RNase L, viral and cellular RNAs are degraded as an
antiviral mechanism (4). To determine whether infection with ExoN(!) virus results in
increased dsRNA levels that activate the OAS/RNase L pathway, DBT cells were pre-
treated with 0 or 50 U/ml mouse IFN-! and infected with WT MHV or ExoN(!) virus at
an MOI of 1 PFU/cell. As a positive control, DBT cells were transfected with 25 "g/ml
poly(I·C), a dsRNA surrogate. At the indicated times postinfection, cell lysates were
FIG 3 Replication of viruses lacking ExoN activity is restricted in wild-type B6 BMMs. B6 BMMs or
IFNAR!/! BMMs were infected with WT MHV or ExoN(!) virus (A) or WT MHV or ExoN(!) P250 virus (B)
at an MOI of 1 PFU/cell. At the indicated times postinfection, cell culture supernatant aliquots were
collected and the viral titers present were determined by plaque assay. For each panel, error bars
represent SEM (n " 6 to 7). ND, not detectable.
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FIG 4 Loss of ExoN activity does not result in the generation of a detectable PAMP. (A) DBT cells were mock
infected or infected with WT, ExoN(!), or ExoN(!) P250 virus at an MOI of 0.1 PFU/cell or infected with Sendai
virus at an MOI of 200 HA units/ml. At the indicated times postinfection, cell culture supernatants were
removed, cell lysates were harvested, total RNA was extracted, cDNA was generated, and IFN-! expression
relative to that of GAPDH was determined by qPCR. Error bars indicate SEM (n " 4). (B) DBT cells were
pretreated for 18 h with 0 or 50 U/ml mouse IFN-! and subsequently infected with WT MHV or ExoN(!) virus
or transfected with 25 "g/ml poly(I·C). At the indicated times postinfection, cell culture supernatants were
removed, cell lysates harvested, and total RNA extracted. rRNA integrity was assessed using an Agilent
Bioanalyzer. One representative image is shown for each sample from 2 independent experiments. Images
were spliced for labeling purposes. The averaged RNA integrity (RIN) values for each condition are reported.
(C) B6 BMMs or RL !/!/PKR !/! BMMs were infected with WT MHV or ExoN(!) virus at an MOI of 1 PFU/cell.
At the indicated times postinfection, cell culture supernatant aliquots were collected and the viral titers
present were determined by plaque assay. Error bars represent SEM (n " 5). ND, not detectable.
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harvested, total RNA extracted, and the integrity of cellular rRNA determined using a
bioanalyzer (Fig. 4B). Transfection of DBT cells with poly(I·C) resulted in rRNA degrada-
tion, whereas infection of DBT cells with WT MHV or ExoN(!) virus did not result in
rRNA degradation under any tested conditions. Lastly, when B6 or RNase L!/!/PKR!/!
(RL!/!/PKR!/!) BMMs were infected with ExoN(!) virus, replication was restricted (Fig.
4C). In contrast to infection of B6 BMMs, ExoN(!) viral titer from RL!/!/PKR!/! BMMs
was detectable at 12 and 24 h postinfection. However, viral yield was minimal. These
data suggest that loss of nsp14 ExoN activity does not lead to the transcriptional
activation of IFN-! or a notable dsRNA sensor such as OAS/RNase L during infection of
DBT cells. In addition, BMMs deficient in the antiviral effectors RNase L and PKR were
not sufficient to restore ExoN(!) viral replication.
IFN treatment does not substantially alter ExoN(!) viral RNA accumulation or
particle release. Since ExoN activity is required for resistance to IFN but had no effect
on IFN induction, we sought to discern the stage of viral replication that was restricted
by IFN-! treatment. To determine the effect of IFN-! pretreatment on viral RNA
accumulation, DBT cells were pretreated with 0 or 100 U/ml mouse IFN-! for 18 h and
subsequently infected with WT MHV or ExoN(!) virus at an MOI of 1 PFU/cell. At the
indicated times postinfection, the number of genomic RNA copies present was deter-
mined by one-step reverse transcription-quantitative PCR (RT-qPCR). IFN-! pretreat-
ment had minimal effect on the accumulation of WT MHV genomic RNA (Fig. 5A).
Whereas ExoN(!) genomic RNA accumulation is delayed relative to that of WT MHV
(15), pretreatment with IFN-! did not substantially decrease ExoN(!) genomic RNA
levels (Fig. 5A). In addition, we determined the effects of IFN-! pretreatment on the
levels of subgenomic viral RNA. For both WT MHV and ExoN(!) viruses, IFN-! pretreat-
ment did not substantially reduce subgenomic RNA levels at any time point (Fig. 5B).
These data indicate that IFN pretreatment did not result in the gross degradation or
inhibition of ExoN(!) viral RNA accumulation. While slight reductions in viral RNA could
explain a small portion of the IFN phenotype, these data suggest that decreased
replication or transcription is not the primary driver of ExoN(!) IFN sensitivity.
Since pretreatment of DBT cells with IFN-! does not grossly alter ExoN(!) viral RNA
accumulation but does reduce ExoN(!) viral titers, we sought to determine whether
IFN pretreatment prior to infection resulted in a measurable difference in the number
of viral particles released from WT MHV- or ExoN(!)-infected cells. DBT cells were
pretreated with 0 or 100 U/ml mouse IFN-! for 18 h and subsequently infected with WT
MHV or ExoN(!) virus at an MOI of 1 PFU/cell. At 12 h postinfection, cell culture
supernatants were harvested and aliquots of two equal volumes were removed. From
the first volume of each sample, RNA was extracted and used to perform one-step
RT-qPCR to determine the number of genome RNAs present and, hence, the number of
genome RNA-containing particles present in the given volume of supernatant (Fig. 5C).
The second volume was saved for a plaque assay as described below. Pretreatment of
cells with IFN-! resulted in an approximately 1-log10 decrease in the number of
supernatant viral particles for both WT MHV and ExoN(!) viruses compared to the
number of supernatant viral particles from untreated cells, demonstrating that IFN
pretreatment affects the release of WT MHV and ExoN(!) virus particles equally (Fig.
5D). Thus, these data suggest that IFN pretreatment does not restrict the primary
replication of viruses lacking ExoN activity but rather renders them inadequate for
subsequent infection.
ExoN(!) virus progeny generated in the presence of an IFN-induced antiviral
state have decreased specific infectivity and fitness upon subsequent infection.
While many ISGs antagonize viral replication, some could alter the infectivity of
progeny particles (27, 28). To test whether IFN pretreatment affected the infectivity of
ExoN(!) viral particles, the remaining cell culture supernatant volume described above
was used to perform a plaque assay to determine the number of PFU present (data not
shown). Using the number of particles determined in Fig. 5C and the number of PFU
present in an equivalent volume, we calculated the specific infectivity, or particle-to-
PFU ratio, of each virus generated under each condition (Fig. 6A). Regardless of IFN-!
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pretreatment during the initial infection, the specific infectivity of WT MHV was
approximately 10 particles per 1 PFU upon subsequent infection. Infection of untreated
DBT cells with ExoN(!) virus resulted in a particle-to-PFU ratio similar to that for WT
MHV during subsequent infection. In contrast, when DBT cells were pretreated with
IFN-! prior to initial infection with ExoN(!) virus, the resulting specific infectivity of
ExoN(!) virus was 100 particles per 1 PFU, a significant decrease in specific infectivity.
Therefore, ExoN(!) virus generated in the presence of an IFN-!-mediated antiviral state
requires 10-fold more genome RNA-containing particles to generate 1 PFU than WT
MHV generated in cells pretreated with or without IFN or ExoN(!) virus generated in
FIG 5 ExoN(!) viral RNA accumulation and particle release is marginally affected by IFN-! pretreatment. DBT cells were pretreated with
0 or 100 U/ml mouse IFN-! for 18 h and subsequently infected with WT MHV or ExoN(!) virus at an MOI of 1 PFU/cell. At the indicated
times postinfection, total cell lysates were harvested and RNA was extracted. The viral genomic RNA copies present relative to an RNA
standard were determined by one-step RT-qPCR (A), or cDNA was generated and the subgenomic RNA copies relative to those of GAPDH
were determined by qPCR (B). For each of panels A and B, error bars represent SEM (n " 6 to 9). DBT cells were pretreated with 0 or 100
U/ml mouse IFN-! for 18 h and subsequently infected with WT MHV or ExoN(!) virus at an MOI of 1 PFU/cell. At 12 h postinfection, cell
culture supernatants were collected. Equivalent volumes of cell culture supernatant for each sample were divided into two samples. For
the first cell culture supernatant sample, total RNA was extracted and the number of virion genome RNA copies present (particles) was
determined by one-step RT-qPCR (C) or reported as the change in virion genome RNA copies (D). Error bars represent SEM (n " 13 to 15).
Statistical significance compared to untreated WT MHV or ExoN(!) infection, respectively, is denoted and was determined by Student’s
t test. ***, P # 0.001.
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untreated cells. These data suggest that the IFN-mediated restriction of ExoN(!) virus
in DBT cells occurs at the level of subsequent infection by reducing particle infectivity.
We next tested whether the effects of IFN on ExoN(!) viruses were intrinsic to the
viruses produced. To do so, we performed a coinfection assay that utilized WT MHV and
ExoN(!) viruses harboring 10 silent mutations in the nsp2 coding region (WT silent and
ExoN(!) silent, respectively) along with WT MHV and ExoN(!) viruses. The genome
RNAs of the silent viruses are recognized exclusively by a probe separate from the one
used to detect the nsp2 probe-binding region of WT MHV or ExoN(!) virus (24),
allowing WT silent and ExoN(!) silent viruses to act as internal controls for a coinfection
assay under identical conditions. DBT cells were pretreated with 0 or 100 U/ml mouse
IFN-! for 18 h and subsequently infected with WT MHV or ExoN(!) virus at an MOI of
1 PFU/cell. At 12 h postinfection, total cell culture supernatants were collected. The
number of viral particles present in a representative aliquot was determined from
purified virion genome RNA by one-step RT-qPCR. In addition, we determined the
number of genome RNA-containing particles in an equivalent volume of WT silent or
ExoN(!) silent viral p1 stock tubes. Using the calculated number of genome RNA-
containing viral particles, we added an equal number of WT MHV viral particles
generated in the absence of IFN pretreatment to WT silent viral particles and an equal
number of WT MHV viral particles generated in the presence of IFN pretreatment to WT
silent viral particles. This same setup was used for ExoN(!) viral particles generated in
the presence or absence of IFN pretreatment with ExoN(!) silent viral particles. Finally,
each combination was used to infect a fresh monolayer of untreated DBT cells. At 24 h
FIG 6 ExoN(!) viruses generated in the presence of an antiviral state have decreased specific infectivity and
are less fit relative to untreated virus. (A) DBT cells were pretreated with 0 or 100 U/ml mouse IFN-! for 18 h
and subsequently infected with WT MHV or ExoN(!) virus at an MOI of 1 PFU/cell. At 12 h postinfection,
cell culture supernatants were collected. Equivalent volumes of cell culture supernatant for each sample
were divided into two samples. For the first cell culture supernatant sample, total RNA was extracted and
the number of virion genome RNA copies present (particles) was determined by one-step RT-qPCR (Fig. 5C).
For the second cell culture supernatant sample, the viral titer present was determined by plaque assay
(PFU) (data not shown). The particle-to-PFU ratio for each virus and treatment was calculated by dividing
the number of particles by the number of PFU. Error bars represent SEM (n " 13 to 15). (B) DBT cells were
pretreated with 0 or 100 U/ml mouse IFN-! for 18 h and subsequently infected with WT MHV or ExoN(!)
virus at an MOI of 1 PFU/cell. At 12 h postinfection, cell culture supernatants were harvested for each virus
and treatment group, and the number of virion genome RNA copies present (particles) in the supernatant
was determined by one-step RT-qPCR. Using the determined number of particles, an equivalent number of
virus particles from each virus and treatment group were mixed with an equal number of WT silent or
ExoN(!) silent virus particles. This mixture then was used to infect a fresh monolayer of untreated DBT cells.
At 24 h postinfection, cell culture supernatants were collected, RNA was extracted, and the number of virion
genome RNA copies for each original virus and treatment group relative to their respective silent standard
viruses was determined by one-step RT-qPCR and is reported as the change in fitness relative to the silent
virus standard. Error bars represent SEM (n " 6). For each panel, statistical significance compared to
untreated WT MHV or ExoN(!) infection is denoted and was determined by Student’s t test. *, P# 0.05; ***,
P # 0.001; n.s., not significant.
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postcoinfection total cell culture supernatants were collected and virion genome RNA
was extracted to determine the number of supernatant viral particles present from each
combination of input viruses by one-step RT-qPCR and is reported as the change in
fitness relative to the respective silent virus standard (Fig. 6B). The number of WT MHV
particles generated in the presence of IFN pretreatment was similar to the number of
WT MHV particles generated in the absence of IFN pretreatment over the course of
coinfection, relative to their respective silent standards. However, the number of viral
particles present from ExoN(!) virus generated in the presence of IFN pretreatment
during the course of coinfection decreased by approximately 1.5 log10 compared with
ExoN(!) viral particles generated in the absence of IFN pretreatment relative to their
respective silent standards. These data indicate that a loss in nsp14 ExoN activity
sensitizes viruses to IFN pretreatment and reduces the infectivity and fitness of progeny
during subsequent rounds of infection in the absence of an antiviral state.
DISCUSSION
CoVs encode multiple IFN antagonists that prevent the induction of or mediate
resistance to the innate immune response, allowing efficient viral replication early
during infection (3). Moreover, an insufficient innate immune response has been
proposed to be a major contributor to SARS-CoV pathogenesis (29). In this study, we
sought to determine the contributions of nsp14 ExoN activity to the induction of and
resistance to the innate immune response. We demonstrate that ExoN(!) virus is more
sensitive to cellular pretreatment with IFN-! than WT MHV. Further, because ExoN3(!)
and ExoN(!) P250 viruses also were more sensitive to the effects of IFN, we conclude
that IFN sensitivity is specifically due to a loss of ExoN activity.
Because the ExoN activity of the Lassa fever virus nucleoprotein degrades dsRNA
intermediates (18, 19), we hypothesized that CoV nsp14 ExoN could function in a similar
manner. In fact, since our current study began, CoV nsp14 ExoN activity also has been
proposed by others to function as an innate immune antagonist (21, 30). If nsp14 ExoN
is degrading viral dsRNA, ExoN inactivation should increase intracellular dsRNA accu-
mulation, resulting in a concomitant increase in IFN-! expression or activation of RNase
L during infection. We observed neither IFN-! upregulation nor RNase L activation over
the course of ExoN(!) virus infection (Fig. 4A and B), and rRNA was intact at all time
points tested (Fig. 4B). Therefore, at least two possible explanations exist: (i) MHV ExoN
does not function to degrade dsRNA or (ii) MHV ExoN does degrade dsRNA, but the
detection of this PAMP is unchanged during ExoN(!) virus infection due to sufficient
antagonism by other CoV proteins. Basal OAS expression levels correlate with RNase L
activation (31). Thus, we pretreated DBTs with IFN-! to upregulate OAS and RNase L
expression. However, rRNA degradation was observed only in cells transfected with
poly(I·C) (Fig. 4B). Further, nsp15 EndoU and NS2 phosphodiesterase activities were
intact during all of our experiments. Thus, it is possible that in the absence of nsp14
ExoN activity, other CoV innate antagonists were sufficient to prevent innate detection
by the cell or prevent the induction of a detectable signal in the experiments we
performed. However, one would expect the endonucleolytic products of nsp15 to be
smaller dsRNAs that could still activate RIG-I or MDA5, similar to RNase L products,
unless another RNA degradation mechanism were in place (4, 32). In addition, despite
an intact NS2 phosphodiesterase, nsp15 mutants still activate RNase L-mediated rRNA
degradation (12). Lastly, when RL!/!/PKR!/! BMMs were infected with ExoN(!) virus,
viral replication was not rescued, suggesting that RNase L and PKR are not required for
ExoN(!) virus restriction (Fig. 4C). Moreover, these data suggest dsRNA is not detected
and the antiviral effectors RNase L and PKR are not activated during ExoN(!) virus
infection.
During our study, Becares et al. reported that a TGEV nsp14 zinc finger mutant
modulated the innate immune response of swine testis cells by reducing the levels of
dsRNA and induction of IFN (21). Unlike TGEV, betacoronaviruses such as SARS-CoV and
MHV do not induce IFN expression in most cell types (1–3) (Fig. 4A). Interestingly, TGEV
ExoN active-site mutants were nonviable, although this is not the first report of
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nonviable ExoN active-site residue mutants in alphacoronaviruses (21). In the initial
report of CoV nsp14 ExoN activity, human CoV 229E ExoN active-site mutants were also
nonviable, suggesting a common essential function for nsp14 ExoN in Alphacoronavirus
replication and/or innate antagonism (13). Altogether, the possibility of a common
innate immune antagonism function for nsp14 across alpha- and beta-CoVs is apparent,
but clearly differing requirements exist that may be dependent on the CoV genus and
cell types used.
Our results clearly demonstrate that viruses lacking ExoN activity are more sensitive
to IFN-! pretreatment than WT MHV in a dose-dependent manner (Fig. 1A and C and
2). Further, replication of viruses lacking ExoN activity was dependent on the capacity
of BMMs to express genes downstream of IFNAR signaling (Fig. 3). This is due to the fact
that B6 and IFNAR!/! cells have different levels of basal ISG expression and, thus, two
very different intracellular environments for viral replication to occur (3, 25, 26). In
IFNAR!/! BMMs, ExoN(!) and ExoN(!) P250 virus replication capacity was restored to
levels approaching or exceeding WT MHV levels (Fig. 3). Further, our specific infectivity
(Fig. 6A) and coinfection (Fig. 6B) data show that ExoN(!) virus generated in the
presence of an antiviral state is less viable upon subsequent infection. Altogether, our
results suggest that an ISG(s) is acting on ExoN(!) virus, specifically resulting in
progeny that are less viable upon subsequent infection. Thus, it will be interesting to
determine the specific ISG or ISGs responsible for mediating the observed restriction. In
addition, it will be important to determine whether a greater proportion of the
incoming ExoN(!) viral particles are strictly nonviable or whether cells are now sensing
the progeny ExoN(!) viruses and inhibiting replication. Our specific infectivity data
support the possibility that the effects of IFN treatment results in noninfectious
ExoN(!) virus particles, which could compete with infectious ExoN(!) virus particles for
viral receptors during subsequent entry. Due to the pleiotropic nature of IFN-!, more
than one mechanism may be acting.
To date, the majority of our understanding of nsp14 ExoN activity is in the context
of proofreading during CoV replication (13, 15, 16, 33). CoVs lacking ExoN activity
demonstrate an increase in mutation frequency relative to that of the WT (15, 16). Thus,
it is possible that ExoN(!) virus replication in IFN-pretreated cells results in further
alteration of ExoN(!) virus mutation frequency. Certainly, an increase or decrease in
mutation frequency could impair viral replication during a subsequent infection. More-
over, a recent study demonstrated that optimal viral replication fidelity is required for
poliovirus to overcome tissue-specific innate immune responses (34). In addition, IFN
pretreatment may upregulate an ISG that acts to hypermutate the large CoV genome
in the absence of ExoN activity, rendering viral progeny less viable. ISGs that increase
viral mutation frequency have been described, such as adenosine deaminase acting on
RNA 1 (ADAR1) and apolipoprotein B mRNA editing enzyme, catalytic polypeptide-like
3G (APOBEC3G) (27, 28). Further, another ISG, SAMHD1, may inhibit HIV replication by
limiting nucleotide pools, a known contributor to increased viral mutation frequency
(35–37). Moreover, other possible mechanisms outside of altered mutation frequency
exist. For instance, in the absence of ExoN activity, terminal RNA modifications, recom-
bination, and/or replicase protein interactions mediated by nsp14 ExoN may be dis-
rupted to a greater extent in the presence of an IFN-!-mediated antiviral state.
Since CoVs encode the largest genome known for RNA viruses, they have the luxury
of encoding multiple IFN antagonists that limit the capacity of a cell to detect and
respond to infection. Collectively, our data suggest that MHV nsp14 ExoN activity is a
contributor to CoV innate immune antagonism. We clearly demonstrate that viruses
lacking ExoN activity are more sensitive to the effects of an IFN-!-mediated antiviral
state. Further, our data reveal a critical role for nsp14 ExoN activity in CoV replication
and provide additional rationale for targeting nsp14 ExoN activity as a means of viral
attenuation. Our future studies will probe the specific mechanism of restriction for
viruses lacking ExoN activity and assess how the requirement of ExoN activity for
resistance to innate immunity can be utilized for treatment during human coronavirus
infections.
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MATERIALS AND METHODS
Cell culture. Murine delayed brain tumor (DBT) cells (38) and baby hamster kidney 21 cells
expressing the MHV receptor (BHK-R) (39) were maintained at 37°C in Dulbecco’s modified Eagle medium
(DMEM; Gibco) supplemented with 10% fetal bovine serum (FBS; Invitrogen), 100 U/ml penicillin and
streptomycin (Gibco), and 0.25 !g/ml amphotericin B (Corning). BHK-R cells were further supplemented
with 0.8 mg/ml of G418 (Mediatech).
Cloning, recovery, and verification of mutant viruses. Recombinant MHV strain A59 (GenBank
accession number AY910861) has been previously described (39). ExoN(!) (nsp14 D89A and E91A) has
been previously described (15). To generate ExoN(!) P250 virus, subconfluent monolayers of DBT cells
in 25-cm2 flasks were infected using the ExoN(!) parental stock and blindly passaged for a total of 250
passages (24). For ExoN3(!) virus (nsp14 D272A), site-directed mutagenesis was used to engineer point
mutations in the MHV genome cDNA F fragment plasmid using the MHV infectious clone reverse
genetics system (39). ExoN3(!) mutant virus was recovered using BHK-R cells following electroporation
of in vitro-transcribed genomic RNA. Recovered ExoN3(!) virus was sequenced (GenHunter Corporation,
Nashville, TN) to verify the engineered mutations were present and to ensure that no additional
mutations were introduced.
IFN-! sensitivity assays. Subconfluent DBT cells were treated for 18 h with the indicated concen-
trations of mouse IFN-" (PBL Assay Science) prior to infection with virus at a multiplicity of infection (MOI)
of 1 PFU per cell at 37°C for 45 min. After incubation, inocula were removed, cells were washed with
phosphate-buffered saline (PBS), and fresh medium was added. Cell culture supernatants were collected
at 12 h postinfection, and viral titers were determined by plaque assay (15).
5-FU sensitivity assays. Subconfluent DBT cells were treated with DMEM supplemented to contain
the indicated concentrations of 5-fluorouracil (5-FU; Sigma) or dimethyl sulfoxide (DMSO) alone at 37°C
for 30 min. After incubation, drug was removed and cells were infected with virus at an MOI of 1 PFU/cell
at 37°C for 1 h. Inocula were removed, and cells were incubated in medium containing 5-FU or DMSO.
Cell culture supernatants were collected at 12 h postinfection, and viral titers were determined by plaque
assay.
Virus replication kinetics. Bone marrow-derived macrophages (BMMs) were generated from the
hind limbs of WT, IFNAR!/!, or RL!/!/PKR!/! C57/B6 mice as previously described (11). BMMs were
infected with virus at an MOI of 1 PFU/cell at 37°C for 1 h. After incubation, inocula were removed, cells
were washed 3 times with PBS, and fresh medium was added. At the indicated times postinfection, cell
culture supernatant aliquots were collected and viral titers determined by plaque assay.
IFN-! induction assays. Subconfluent DBT cells were mock infected or infected with WT, ExoN(!),
or ExoN(!) P250 virus at an MOI of 0.1 PFU/cell or with Sendai virus (SenV) at an MOI of 200 HA units/ml
at 37°C for 45 min. Inocula were removed, cells were washed with PBS, and fresh medium was added.
At the indicated times postinfection, cell culture supernatants were removed and cell lysates were
harvested by adding 1 ml TRIzol reagent. Total RNA present in the lysates was purified using the
phenol-chloroform method. cDNA was generated by reverse transcriptase PCR (RT-PCR) using 1 !g of
total RNA as previously described (16). Mouse IFN-" expression levels were determined relative to that
for glyceraldehyde-3-phosphate dehydrogenase (GAPDH) by qPCR using the Applied Biosciences 7500
real-time PCR system with Power SYBR green PCR master mix and IFN-" primers (FWD, 5=-TCCGCCCTG
TAGGTGAGGTTGAT-3=; REV, 5=-GTTCCTGCTGTGCTTCTCCACCA-3=) and GAPDH primers previously re-
ported (16).
Determination of rRNA integrity. Subconfluent monolayers of DBT cells were treated with 0 or 50
U/ml mouse IFN-" for 18 h prior to being infected with virus at an MOI of 1 PFU/cell at 37°C for 45 min.
After incubation, inocula were removed, cells were washed with PBS, and fresh medium was added. At
the indicated times postinfection, cell culture supernatants were removed and total RNA was harvested
by adding 1 ml TRIzol reagent. For a positive control, cells were transfected with 25 !g/ml poly(I:C)
(Sigma) using Lipofectamine 2000 (Thermo Fisher Scientific). Total RNA from all samples was purified
using the PureLink RNA mini purification system (Life Technologies) by following the manufacturer’s
instructions. Upon purification, total RNA was analyzed on an Agilent Bioanalyzer by the Vanderbilt
VANTAGE core facility and the rRNA integrity reported.
Quantification of viral genomic RNA by one-step RT-qPCR. The quantification of viral genomic
RNA has been previously described (14). Briefly, an RNA standard was prepared using the MHV A
fragment (39), and a standard curve was generated using 10-fold dilutions from 103 to 108 copies. A 5=
6-carboxyfluorescein (FAM)-labeled probe (5=-TTCTGACAACGGCTACACCCAACG-3= [Biosearch Technolo-
gies]) was used with forward (5=-AGAAGGTTACTGGCAACTG-3=) and reverse (5=-TGTCCACGGCTAAATCA
AAC-3=) nsp2 specific primers. The final volume for each reaction mixture was 20 !l with 150 nM probe,
900 nM each primer, 2 !l sample RNA, and 10 !l 2" ToughMix, one-step, low-ROX enzyme mix (Quanta
Bio) per reaction. Samples were quantified using an Applied Biosciences 7500 real-time PCR system with
conditions of 55°C for 10 min, 95°C for 5 min, 95°C for 30 s, and 60°C for 1 min, with the last two steps
repeated 40 times. The standard curve was plotted using GraphPad Prism 6 software, and genomes per
microliter were calculated.
Quantification of subgenomic RNA by qPCR. Subconfluent DBT cells were treated with 0 or 100
U/ml mouse IFN-" for 18 h prior to being infected with virus at an MOI of 1 PFU/cell at 37°C for 45 min.
After incubation, inocula were removed, cells were washed with PBS, and fresh medium was added. At
the indicated times postinfection, cell culture supernatants were removed and total RNA was harvested
by adding 1 ml TRIzol reagent. Total RNA was extracted using the PureLink RNA mini purification system
by following the manufacturer’s instructions. cDNA was generated by RT-PCR using 1 !g of total RNA as
previously described (16). Primers used to detect subgenomic nucleocapsid and GAPDH gene expression
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have been reported (16, 40). Subgenomic expression levels relative to GAPDH were determined using the
Applied Biosciences 7500 real-time PCR system with Power SYBR green PCR master mix.
Determination of specific infectivity. The quantification of virus-specific infectivity has been
previously described (14, 24, 41). Briefly, subconfluent monolayers of DBT cells were infected with virus
at an MOI of 1 PFU/cell at 37°C for 45 min. After incubation, inocula were removed, cells were washed
with PBS, and fresh medium was added. At 12 h postinfection, cell culture supernatants were collected,
and viral titers were determined by plaque assay. Supernatants also were used for RNA genome isolation
by adding 100 !l supernatant to 900 !l TRIzol reagent, chloroform extraction by phase separation, and
final purification using the PureLink RNA mini purification system. Genome RNA was quantified using
one-step RT-qPCR as described above, and the particle-to-PFU ratio was calculated.
Coinfection assay. Subconfluent monolayers of DBT cells were treated with 0 or 100 U/ml mouse
IFN-" for 18 h prior to being infected with virus at an MOI of 1 PFU/cell at 37°C for 45 min. After
incubation, inocula were removed, cells were washed with PBS, and fresh medium was added. At 12 h
postinfection, cell culture supernatants were removed and 100 !l of supernatant was added to 900 !l
TRIzol reagent. Viral genome RNA was purified, and the number of viral genome RNA copies present
relative to an RNA standard curve was determined as described above. Based on the number of viral
genome RNA copies determined by one-step RT-qPCR, equal numbers of virus particles from each
virus and each condition were combined with an equal number of WT silent or ExoN(!) silent virus
particles, respectively. WT silent and ExoN(!) silent viruses were engineered to harbor 10 silent
mutations in the probe-binding region of nsp2, allowing separate detection from WT MHV or
ExoN(!) virus genomes, respectively, using a separate probe upon coinfection (24). A fresh,
subconfluent monolayer of DBT cells next was coinfected with each combination of viruses at 37°C
for 45 min. After incubation, inocula were removed, cells were washed with PBS, and fresh medium
was added. At 24 h postinfection, cell culture supernatants were removed and 100 !l of supernatant
was added to 900 !l TRIzol reagent. Viral genome RNA was purified. The number of viral genome
RNA copies of both reference and silent viruses were determined relative to the appropriate
standard curve. The number of viral genome RNA copies relative to the number of silent virus
genome RNA copies was determined for each virus and condition. Values are reported as the change
in fitness relative to the silent virus.
Statistical analysis. Statistical tests were applied as noted in the respective figure legends and were
determined using GraphPad Prism 6 software (La Jolla, CA).
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Gene Log2 Fold Change pValue Gene Log2 Fold Change pValue
ENSMUSG00000025498    Irf7    -4.724135798 0 ENSMUSG00000026222    Sp100    -0.705276261 1.22E-08
ENSMUSG00000028268    Gbp3    -3.909806849 0 ENSMUSG00000022216    Psme1    -0.691133394 7.73E-26
ENSMUSG00000052776    Oas1a -3.372201251 3.38E-187 ENSMUSG00000038393    Txnip -0.685904569 2.13E-14
ENSMUSG00000046718    Bst2    -3.241894357 0 ENSMUSG00000041642    Kif21b -0.678424039 3.74E-08
ENSMUSG00000035692    Isg15    -3.214844637 4.94E-204 ENSMUSG00000037997    Parp11    -0.665638164 9.37E-10
ENSMUSG00000027514    Zbp1    -3.209775701 0 ENSMUSG00000021453    Gadd45g -0.664847689 2.09E-13
ENSMUSG00000001123    Lgals9    -3.00395842 6.97E-207 ENSMUSG00000021281    Tnfaip2    -0.661824392 1.34E-12
ENSMUSG00000028037    Ifi44    -2.836579535 4.38E-118 ENSMUSG00000057143    Trim12c -0.659266823 1.17E-07
ENSMUSG00000025492    Ifitm3    -2.830792551 0 ENSMUSG00000029446    Psph -0.650094495 1.02E-24
ENSMUSG00000033880    Lgals3bp -2.788878802 1.32E-280 ENSMUSG00000032596    Uba7    -0.647982126 1.38E-07
ENSMUSG00000024308    Tapbp -2.396669443 2.11E-228 ENSMUSG00000026104    Stat1    -0.646126754 1.16E-10
ENSMUSG00000024338    Psmb8    -2.237581537 1.82E-72 ENSMUSG00000002983    Relb -0.639256053 2.37E-08
ENSMUSG00000029561    Oasl2    -2.204782831 8.42E-80 ENSMUSG00000091373    Gm8810    -0.636135233 2.33E-07
ENSMUSG00000066861    Oas1g -2.201822243 1.61E-70 ENSMUSG00000029752    Asns -0.63304898 2.51E-71
ENSMUSG00000040483    Xaf1    -2.174360841 1.64E-166 ENSMUSG00000005667    Mthfd2    -0.627734176 2.10E-43
ENSMUSG00000068246    Apol9b -2.169814146 3.08E-72 ENSMUSG00000060950    Trmt61a -0.627404205 1.43E-14
ENSMUSG00000027313    Chac1    -2.105040676 3.67E-110 ENSMUSG00000027071    P2rx3    -0.611724629 6.30E-08
ENSMUSG00000057346    Apol9a -2.069572242 7.12E-68 ENSMUSG00000040010    Slc7a5    -0.610944125 1.28E-40
ENSMUSG00000027078    Ube2l6    -2.022067931 1.13E-63 ENSMUSG00000085156    Gm11974    -0.604955404 3.38E-10
ENSMUSG00000033355    Rtp4        -1.93170957 8.50E-57 ENSMUSG00000010095    Slc3a2    -0.602497421 1.83E-46
ENSMUSG00000062488    Ifit3b -1.918709202 6.85E-54 ENSMUSG00000024330    Col11a2    -0.602210223 7.23E-09
ENSMUSG00000074896    Ifit3    -1.897224158 2.12E-54 ENSMUSG00000020638    Cmpk2    -0.595525932 1.76E-06
ENSMUSG00000023341    Mx2    -1.830166471 3.56E-49 ENSMUSG00000086841    2410006H16Rik -0.594815543 3.24E-18
ENSMUSG00000032715    Trib3    -1.735709686 2.59E-119 ENSMUSG00000037321    Tap1    -0.594485032 1.69E-06
ENSMUSG00000030107    Usp18    -1.715782616 2.90E-43 ENSMUSG00000026628    Atf3    -0.588443036 1.66E-06
ENSMUSG00000032661    Oas3    -1.677240108 1.33E-41 ENSMUSG00000090272    Mndal -0.583872268 2.80E-06
ENSMUSG00000030921    Trim30a -1.608580593 5.26E-40 ENSMUSG00000034394    Lif -0.581453743 2.21E-13
ENSMUSG00000064215    Ifi27    -1.594532605 6.82E-83 ENSMUSG00000034855    Cxcl10    -0.579790866 3.28E-06
ENSMUSG00000040296    Ddx58    -1.497769143 4.36E-69 ENSMUSG00000039236    Isg20    -0.576563844 4.57E-12
ENSMUSG00000040253    Gbp7    -1.455014505 3.12E-32 ENSMUSG00000037580    Gch1    -0.568643872 3.57E-06
ENSMUSG00000067212    H2-T23    -1.41660395 1.03E-35 ENSMUSG00000049502    Dtx3l -0.568495207 8.33E-11
ENSMUSG00000046879    Irgm1    -1.393861453 2.42E-56 ENSMUSG00000024261    Syt4    -0.565727767 9.30E-45
ENSMUSG00000028270    Gbp2    -1.359860823 7.41E-28 ENSMUSG00000028480    Glipr2    -0.562138562 1.05E-12
ENSMUSG00000032690    Oas2    -1.358630825 7.08E-30 ENSMUSG00000079492    Gm11127    -0.558931441 5.81E-06
ENSMUSG00000069874    Irgm2    -1.311312445 5.84E-26 ENSMUSG00000035773    Kiss1r -0.558109772 4.41E-09
ENSMUSG00000028179    Cth -1.294791171 3.00E-28 ENSMUSG00000050022    Amz1    -0.555297334 8.34E-06
ENSMUSG00000056116    H2-T22    -1.263191437 4.67E-39 ENSMUSG00000029605    Oas1b -0.553693315 2.54E-08
ENSMUSG00000070327    Rnf213    -1.255026518 4.65E-52 ENSMUSG00000035828    Pim3    -0.544658293 1.48E-20
ENSMUSG00000038507    Parp12    -1.189084475 7.87E-28 ENSMUSG00000031026    Trim66    -0.53533792 1.56E-05
ENSMUSG00000010358    Ifi35    -1.133070153 6.17E-29 ENSMUSG00000001918    Slc1a5    -0.533027915 9.88E-21
ENSMUSG00000024339    Tap2    -1.130790166 1.22E-22 ENSMUSG00000053560    Ier2    -0.532651729 2.01E-10
ENSMUSG00000078853    Igtp -1.114359946 3.78E-20 ENSMUSG00000030785    Cox6a2    -0.528097766 2.68E-06
ENSMUSG00000061232    H2-K1    -1.111859931 9.89E-58 ENSMUSG00000040569    Slc26a7    -0.526673336 2.50E-06
ENSMUSG00000068245    Phf11d -1.110359135 7.28E-22 ENSMUSG00000032591    Mst1    -0.526051496 1.37E-05
ENSMUSG00000034459    Ifit1    -1.102356162 2.10E-19 ENSMUSG00000034765    Dusp5    -0.523621742 1.95E-11
ENSMUSG00000028838    Extl1    -1.084286501 3.58E-24 ENSMUSG00000030717    Nupr1    -0.523004681 8.60E-08
ENSMUSG00000038539    Atf5    -1.060307455 1.75E-65 ENSMUSG00000031202    Rab39b -0.520345651 5.85E-06
ENSMUSG00000078921    Tgtp2    -1.02205456 4.36E-17 ENSMUSG00000020812    1810032O08Rik -0.518137428 1.10E-05
ENSMUSG00000028893    Sesn2    -1.021164465 2.61E-32 ENSMUSG00000079442    St6galnac4    -0.518116226 4.08E-10
ENSMUSG00000026946    Nmi -1.002540294 8.71E-16 ENSMUSG00000058402    Zfp420    -0.515839498 9.99E-06
ENSMUSG00000035929    H2-Q4    -0.985299947 5.78E-21 ENSMUSG00000000275    Trim25    -0.513042293 1.65E-18
ENSMUSG00000079017    Ifi27l2a -0.980916864 2.37E-15 ENSMUSG00000039997    Ifi203    -0.50994698 8.32E-10
ENSMUSG00000021186    Fbln5    -0.966474479 6.60E-15 ENSMUSG00000039646    Vasn -0.509256476 1.88E-10
ENSMUSG00000040328    Olfr56    -0.94778222 3.48E-15 ENSMUSG00000097971    Gm26917    -0.505393546 2.02E-16
ENSMUSG00000079197    Psme2    -0.910405618 3.75E-40 ENSMUSG00000023947    Nfkbie -0.500582635 2.80E-05
ENSMUSG00000027737    Slc7a11    -0.90358632 4.03E-24 ENSMUSG00000106734    RP24-328P2.5    -0.494310756 1.36E-05
ENSMUSG00000040618    Pck2    -0.88890164 6.40E-36 ENSMUSG00000028982    Slc25a33    -0.492376703 2.79E-07
ENSMUSG00000028542    Slc6a9    -0.876158045 2.21E-20 ENSMUSG00000036390    Gadd45a -0.492249446 2.96E-05
ENSMUSG00000091705    H2-Q2    -0.875159717 7.10E-13 ENSMUSG00000041736    Tspo -0.488420416 3.26E-15
ENSMUSG00000038418    Egr1    -0.873642464 2.59E-25 ENSMUSG00000052837    Junb -0.486222164 3.26E-18
ENSMUSG00000002325    Irf9    -0.872219199 6.38E-14 ENSMUSG00000041313    Slc7a1    -0.484255738 1.79E-38
ENSMUSG00000032315    Cyp1a1    -0.870902277 2.55E-13 ENSMUSG00000035385    Ccl2    -0.480624279 9.83E-05
ENSMUSG00000020142    Slc1a4    -0.85060697 6.52E-22 ENSMUSG00000023045    Soat2    -0.478286138 1.80E-05
ENSMUSG00000022906    Parp9    -0.847818949 1.63E-20 ENSMUSG00000042659    Arrdc4    -0.475350083 1.95E-07
ENSMUSG00000086290    Snhg12    -0.83175718 5.86E-22 ENSMUSG00000016995    Matn4        -0.475077075 8.09E-14
ENSMUSG00000060802    B2m -0.82329657 4.06E-163 ENSMUSG00000040613    Apobec1    -0.473519152 3.96E-05
ENSMUSG00000025408    Ddit3    -0.820755284 1.05E-14 ENSMUSG00000037465    Klf10    -0.47348131 7.09E-17
ENSMUSG00000047735    Samd9l -0.813601853 5.85E-12 ENSMUSG00000015837    Sqstm1    -0.473155973 2.55E-45
ENSMUSG00000063268    Parp10    -0.7968143 1.62E-16 ENSMUSG00000074063    Osgin1    -0.472305601 5.10E-05
ENSMUSG00000041827    Oasl1    -0.790413126 9.76E-11 ENSMUSG00000029298    Gbp9    -0.470761267 3.66E-07
ENSMUSG00000021583    Erap1    -0.770028937 4.64E-20 ENSMUSG00000024587    Nars -0.464190485 5.81E-47
ENSMUSG00000025140    Pycr1    -0.765033822 4.42E-11 ENSMUSG00000031897    Psmb10    -0.455947243 3.34E-06
ENSMUSG00000026896    Ifih1    -0.75917511 6.63E-11 ENSMUSG00000041028    Ghitm -0.451357192 9.46E-24
ENSMUSG00000026601    Axdnd1    -0.751693172 1.07E-10 ENSMUSG00000026456    Cyb5r1    -0.450884348 5.64E-08
ENSMUSG00000060519    Tor3a -0.747553172 2.19E-21 ENSMUSG00000029377    Ereg -0.448251906 2.75E-06
ENSMUSG00000040264    Gbp2b -0.744142123 7.04E-10 ENSMUSG00000042165    Gm9774        -0.447684049 4.36E-05
ENSMUSG00000002227    Mov10    -0.742445398 4.34E-19 ENSMUSG00000032841    Prr5l -0.446607587 0.0003377
ENSMUSG00000031700    Gpt2    -0.73816388 1.82E-24 ENSMUSG00000060183    Cxcl11    -0.445924471 3.96E-07
ENSMUSG00000078920    Ifi47    -0.733725432 3.12E-10 ENSMUSG00000054520    Sh3bp2    -0.445395699 2.41E-09
ENSMUSG00000024066    Xdh -0.718714938 1.96E-10 ENSMUSG00000038046    Rnmtl1    -0.442034467 1.70E-06
ENSMUSG00000027580    Helz2    -0.710939534 1.01E-11 ENSMUSG00000054855    Rnd1    -0.441608928 0.0002466
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ENSMUSG00000015312    Gadd45b -0.440513883 1.40E-07 ENSMUSG00000095687    Rnaset2a -0.363588439 0.0034009
ENSMUSG00000037428    Vgf -0.440133256 8.74E-05 ENSMUSG00000074754    Gm561    -0.363495143 0.0010328
ENSMUSG00000073418    C4b -0.43967142 0.0001181 ENSMUSG00000079008    Gm14124    -0.363196871 0.0001083
ENSMUSG00000029009    Mthfr -0.439198878 4.39E-06 ENSMUSG00000060002    Chpt1    -0.362344927 4.51E-05
ENSMUSG00000034437    Gm9761    -0.437812742 0.0004387 ENSMUSG00000021481    Zfp346    -0.36224828 0.0001425
ENSMUSG00000044948    Cfap43    -0.437424819 7.29E-09 ENSMUSG00000044576    Gareml -0.361467013 0.0017918
ENSMUSG00000031355    Arhgap6    -0.435219497 5.94E-06 ENSMUSG00000006930    Hap1    -0.360790056 0.0001558
ENSMUSG00000029816    Gpnmb -0.434784079 3.30E-50 ENSMUSG00000020256    Aldh1l2    -0.359269187 2.49E-26
ENSMUSG00000063765    Chadl -0.434352508 2.43E-07 ENSMUSG00000036181    Hist1h1c -0.356692769 0.0041802
ENSMUSG00000044037    Als2cl -0.429509449 3.71E-05 ENSMUSG00000023809    Rps6ka2    -0.354972163 0.0007458
ENSMUSG00000068794    Col28a1    -0.428422968 8.31E-05 ENSMUSG00000039782    Cpeb2    -0.354605197 0.0012313
ENSMUSG00000034271    Jdp2    -0.427641944 2.41E-06 ENSMUSG00000053398    Phgdh -0.354377614 1.25E-24
ENSMUSG00000021203    Otub2    -0.423009617 0.0006545 ENSMUSG00000074151    Nlrc5    -0.354193804 0.0044529
ENSMUSG00000044033    Ccdc141    -0.420084211 0.0002746 ENSMUSG00000006445    Epha2    -0.354121587 9.54E-07
ENSMUSG00000038292    Ccdc155    -0.418530005 2.43E-05 ENSMUSG00000050714    Zbtb26    -0.35366363 0.0009848
ENSMUSG00000056216    Cebpg -0.417111472 1.66E-10 ENSMUSG00000003032    Klf4    -0.352393758 0.000138
ENSMUSG00000030966    Trim21    -0.416865707 0.000805 ENSMUSG00000032724    Abtb2    -0.351124694 2.39E-05
ENSMUSG00000101431    Gm7901    -0.415139131 1.70E-07 ENSMUSG00000033909    Usp36    -0.350772456 8.72E-07
ENSMUSG00000042106    Fam212a -0.413250807 4.38E-06 ENSMUSG00000030747    Dgat2    -0.349868101 0.0044189
ENSMUSG00000024493    Lars -0.411795779 3.15E-24 ENSMUSG00000025375    Aatk -0.349786604 1.87E-05
ENSMUSG00000083716    Gm13436    -0.410042434 0.0002788 ENSMUSG00000061330    Gm11361    -0.347986162 1.46E-05
ENSMUSG00000027951    Adar -0.409456561 1.27E-10 ENSMUSG00000039221    Rpl22l1    -0.347631572 5.84E-09
ENSMUSG00000020707    Rnf135    -0.407724409 0.0006479 ENSMUSG00000037126    Psd -0.347455925 0.0015788
ENSMUSG00000021306    Gpr137b -0.407133259 3.78E-06 ENSMUSG00000055148    Klf2    -0.3472119 0.0050951
ENSMUSG00000095115    Itpripl2    -0.405846065 1.14E-15 ENSMUSG00000106714    RP23-76J15.4    -0.346242786 4.33E-05
ENSMUSG00000036528    Ppfibp2    -0.40569207 5.05E-11 ENSMUSG00000056758    Hmga2    -0.344993692 1.77E-30
ENSMUSG00000098234    Snhg6    -0.405625485 4.49E-05 ENSMUSG00000083022    Rps15a-ps6    -0.344656961 0.004938
ENSMUSG00000037820    Tgm2    -0.404868792 2.41E-05 ENSMUSG00000020334    Slc22a4    -0.34420456 0.0014302
ENSMUSG00000066000    2610305D13Rik -0.404818389 0.0001405 ENSMUSG00000031960    Aars -0.344150314 6.49E-23
ENSMUSG00000046798    Cldn12    -0.404328056 3.73E-20 ENSMUSG00000029826    Zc3hav1    -0.34346576 1.10E-07
ENSMUSG00000022346    Myc -0.40311586 1.96E-07 ENSMUSG00000030281    Il17rc -0.343426655 5.61E-05
ENSMUSG00000106968    RP23-276J7.2    -0.40259702 0.0004906 ENSMUSG00000020876    Snx11    -0.343082145 7.60E-05
ENSMUSG00000078435    AU041133    -0.402307323 0.0012051 ENSMUSG00000006273    Atp6v1b2    -0.342892418 7.49E-13
ENSMUSG00000007812    Zfp655    -0.401626373 4.11E-09 ENSMUSG00000073411    H2-D1    -0.34194583 0.0029143
ENSMUSG00000078922    Tgtp1    -0.400244724 8.12E-06 ENSMUSG00000027995    Tlr2    -0.341799712 0.0010277
ENSMUSG00000062054    Iah1    -0.400093608 0.0003674 ENSMUSG00000105134    RP23-328P19.4    -0.340865987 0.0004017
ENSMUSG00000074578    1500012F01Rik -0.398991535 2.12E-10 ENSMUSG00000097810    G730046D07Rik -0.340848599 0.0038857
ENSMUSG00000107092    RP23-57A17.2    -0.398909993 0.0007193 ENSMUSG00000039461    Tcta -0.340586373 0.0041419
ENSMUSG00000034708    Grn -0.398350976 1.38E-17 ENSMUSG00000027368    Dusp2    -0.340240983 0.0039799
ENSMUSG00000039158    Akna -0.396479799 0.0007748 ENSMUSG00000027603    Ggt7    -0.340204296 0.0003716
ENSMUSG00000029777    Gars -0.395808956 4.33E-35 ENSMUSG00000058922    Gm10052    -0.340115661 1.78E-05
ENSMUSG00000055301    Adh7    -0.395637636 3.84E-08 ENSMUSG00000057895    Zfp105    -0.340086279 0.001539
ENSMUSG00000025007    Aldh18a1    -0.395569181 3.70E-15 ENSMUSG00000015766    Eps8    -0.339993668 2.81E-30
ENSMUSG00000060487    Samd5    -0.392970009 4.32E-05 ENSMUSG00000038534    Osbpl7    -0.33892532 0.0001582
ENSMUSG00000025403    Shmt2    -0.390327485 9.57E-31 ENSMUSG00000021326    Trim27    -0.338840127 5.82E-08
ENSMUSG00000097772    5430416N02Rik -0.389603919 0.0005787 ENSMUSG00000056749    Nfil3    -0.338302389 0.0018152
ENSMUSG00000031530    Dusp4    -0.389128015 3.70E-06 ENSMUSG00000063652    Slc22a21    -0.338255299 0.00611
ENSMUSG00000091549    Gm6548    -0.389000288 0.0007812 ENSMUSG00000005951    Shpk -0.33804748 0.0042023
ENSMUSG00000037434    Slc30a1    -0.387825637 6.47E-05 ENSMUSG00000015652    Steap1    -0.337645691 2.09E-06
ENSMUSG00000034259    Exosc4    -0.384475903 2.51E-06 ENSMUSG00000082082    Gm13230    -0.336058089 5.38E-06
ENSMUSG00000041936    Agrn -0.384417695 2.40E-35 ENSMUSG00000062421    Arf2    -0.335384855 1.92E-07
ENSMUSG00000025854    Fam20c -0.383967042 1.15E-08 ENSMUSG00000097960    A330074K22Rik -0.335236044 0.0043743
ENSMUSG00000010755    Cars -0.383820509 7.23E-16 ENSMUSG00000040435    Ppp1r15a -0.334816285 0.0002189
ENSMUSG00000027122    Arl14ep -0.383095229 3.99E-09 ENSMUSG00000031431    Tsc22d3    -0.334651136 0.0004785
ENSMUSG00000001436    Slc19a1    -0.382082474 1.36E-06 ENSMUSG00000020099    Unc5b -0.334469723 1.88E-12
ENSMUSG00000049124    Gm8186    -0.381747529 0.0018733 ENSMUSG00000035064    Eef2k -0.334410838 1.44E-06
ENSMUSG00000028599    Tnfrsf1b -0.381161045 0.0001794 ENSMUSG00000057561    Eif1a -0.334328756 2.60E-15
ENSMUSG00000048065    Cyb5r2    -0.380693695 0.0004097 ENSMUSG00000024327    Slc39a7    -0.333097136 0.0002548
ENSMUSG00000053581    Zfand2a -0.379325525 1.10E-09 ENSMUSG00000048007    Timm8a1    -0.332835868 4.11E-05
ENSMUSG00000087590    Epb4.1l4aos -0.37888342 0.0005648 ENSMUSG00000002393    Nr2f6    -0.332343578 0.0002486
ENSMUSG00000058638    Zfp110    -0.377617995 3.62E-09 ENSMUSG00000107215    RP23-253G12.9    -0.332059231 0.0060316
ENSMUSG00000050796    B3galt6    -0.37672922 0.0002077 ENSMUSG00000000530    Acvrl1    -0.331300969 1.49E-07
ENSMUSG00000037411    Serpine1    -0.374734727 6.68E-31 ENSMUSG00000079225    Gm9531    -0.330842362 0.0004383
ENSMUSG00000032515    Csrnp1    -0.373073635 0.0001091 ENSMUSG00000068739    Sars -0.330744843 7.28E-22
ENSMUSG00000085385    Snhg17    -0.373031127 5.97E-06 ENSMUSG00000097195    Snhg5    -0.330741103 5.21E-07
ENSMUSG00000042997    Nhlrc3    -0.372993921 0.00025 ENSMUSG00000046269    Usp27x -0.328127718 0.003553
ENSMUSG00000026630    Batf3    -0.372830372 0.0027568 ENSMUSG00000084319    Tpt1-ps3    -0.327611687 4.61E-05
ENSMUSG00000026956    Uap1l1    -0.371664061 1.28E-07 ENSMUSG00000034957    Cebpa -0.327596473 0.0023606
ENSMUSG00000030268    Bcat1    -0.370588692 2.20E-13 ENSMUSG00000010601    Apol7a -0.327280232 0.00416
ENSMUSG00000078606    Gm4070    -0.370406252 0.0015231 ENSMUSG00000108218    Olfr1372-ps1    -0.327228415 0.0074648
ENSMUSG00000056501    Cebpb -0.369792355 0.0003086 ENSMUSG00000029019    Nppb -0.32712305 0.0043341
ENSMUSG00000032372    Plscr2    -0.369524743 8.75E-27 ENSMUSG00000012519    Mlkl -0.326941627 0.0001295
ENSMUSG00000022548    Apod -0.36847993 2.03E-36 ENSMUSG00000026942    Traf2    -0.326615887 0.0006387
ENSMUSG00000013415    Igf2bp1    -0.368418973 0.0030887 ENSMUSG00000000184    Ccnd2    -0.326560384 2.35E-11
ENSMUSG00000075609    Gm7935    -0.367206619 0.0020658 ENSMUSG00000046909    Tefm -0.326398581 0.001763
ENSMUSG00000047603    Zfp235    -0.366743471 0.0015239 ENSMUSG00000050212    Eva1b -0.326253654 0.0058359
ENSMUSG00000028059    Arhgef2    -0.366212383 3.25E-20 ENSMUSG00000053801    Grwd1    -0.325194064 1.67E-09
ENSMUSG00000053038    Gm6180    -0.365693371 0.0028947 ENSMUSG00000050621    Rps27rt -0.324025896 0.0049963
ENSMUSG00000027722    Spata5    -0.365038023 3.68E-07 ENSMUSG00000061286    Exosc5    -0.323185258 3.80E-05
ENSMUSG00000052861    Dnah6    -0.36442046 0.0031376 ENSMUSG00000032281    Acsbg1    -0.322821862 1.40E-05
ENSMUSG00000024079    Eif2ak2    -0.364239019 7.75E-09 ENSMUSG00000078349    AW011738    -0.320762248 0.0062624
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ENSMUSG00000000489    Pdgfb -0.320327309 0.0001937 ENSMUSG00000027435    Cd93    -0.289058086 0.01711
ENSMUSG00000068240    Gm11808    -0.319763686 0.0024509 ENSMUSG00000072621    Slfn10-ps -0.288728175 0.0177297
ENSMUSG00000022554    Hgh1    -0.317025261 1.30E-05 ENSMUSG00000038335    Tsr1    -0.288496614 1.82E-10
ENSMUSG00000034430    Zxdc -0.316963463 9.40E-05 ENSMUSG00000087141    Plcxd2    -0.288430067 0.0087461
ENSMUSG00000078851    Hist3h2a -0.316863476 0.0104914 ENSMUSG00000079491    H2-T10    -0.288302758 0.0168268
ENSMUSG00000046027    Stard5    -0.316830447 1.54E-05 ENSMUSG00000021266    Wars -0.287899279 4.17E-12
ENSMUSG00000048755    Mcat -0.315898769 0.0015934 ENSMUSG00000020121    Srgap1    -0.287737964 0.0089758
ENSMUSG00000098923    Tmem185b -0.315631701 0.0048581 ENSMUSG00000106549    RP23-332O18.2    -0.286771174 0.0059661
ENSMUSG00000029314    Agpat9    -0.314959076 0.0107317 ENSMUSG00000033793    Atp6v1h -0.286530452 9.92E-07
ENSMUSG00000022043    Trim35    -0.31482745 1.78E-06 ENSMUSG00000019558    Slc6a8    -0.286007531 1.18E-15
ENSMUSG00000038517    Tbkbp1    -0.313674102 0.0004956 ENSMUSG00000021226    Acot2    -0.285848776 0.0217776
ENSMUSG00000043289    Mei4    -0.313397692 0.0104476 ENSMUSG00000103009    Gm4430    -0.285717443 0.0099449
ENSMUSG00000097039    Pvt1    -0.313115152 0.0038354 ENSMUSG00000051675    Trim32    -0.285589083 0.0021006
ENSMUSG00000073002    Vamp5    -0.312947875 0.0002147 ENSMUSG00000032513    Gorasp1    -0.285441699 0.0033961
ENSMUSG00000020941    Map3k14    -0.312451806 0.0016859 ENSMUSG00000030057    Cnbp -0.285252913 1.79E-24
ENSMUSG00000031916    Cog8    -0.312283213 0.0012736 ENSMUSG00000046516    Cox17    -0.284964024 0.0011725
ENSMUSG00000030905    Crym -0.312001756 1.59E-06 ENSMUSG00000047767    Atg16l2    -0.284893132 0.0116728
ENSMUSG00000054203    Ifi205    -0.311983463 0.0026293 ENSMUSG00000022615    Tymp -0.284780024 0.0223121
ENSMUSG00000038037    Socs1    -0.311468406 0.0020679 ENSMUSG00000016534    Lamp2    -0.284759944 3.12E-12
ENSMUSG00000038550    Ciart -0.311431935 0.0089137 ENSMUSG00000022698    Naa50    -0.284740985 7.06E-17
ENSMUSG00000033538    Casp4    -0.311008564 0.0105016 ENSMUSG00000087396    4933407K13Rik -0.284728207 0.0223438
ENSMUSG00000034667    Xpot -0.309947682 3.77E-14 ENSMUSG00000031976    Urb2    -0.284380675 5.10E-06
ENSMUSG00000042419    Nfkbil1    -0.309500418 0.0025876 ENSMUSG00000026820    Ptges2    -0.283775424 0.0014704
ENSMUSG00000018405    Mrm1    -0.309064849 0.0059406 ENSMUSG00000001053    N4bp3    -0.283736084 0.0132789
ENSMUSG00000024883    Rin1    -0.308729667 1.05E-11 ENSMUSG00000014177    Tvp23b -0.283229595 0.0003387
ENSMUSG00000020715    Ern1    -0.308342509 0.0003932 ENSMUSG00000030782    Tgfb1i1    -0.283107476 0.0046302
ENSMUSG00000028811    Yars -0.308179603 4.72E-09 ENSMUSG00000045886    Gm9803    -0.282203029 0.0109237
ENSMUSG00000000791    Il12rb1    -0.308005821 0.0106966 ENSMUSG00000008435    Rdh13    -0.282042226 0.0004855
ENSMUSG00000030347    D6Wsu163e -0.30791469 7.36E-05 ENSMUSG00000101188    Eif4a-ps4    -0.282021353 4.99E-09
ENSMUSG00000068335    Dok1    -0.307727861 2.15E-06 ENSMUSG00000042549    Map2k3os -0.281726566 0.0085933
ENSMUSG00000006463    Zdhhc24    -0.307640475 0.0032814 ENSMUSG00000021458    2010111I01Rik -0.2815697 0.0001268
ENSMUSG00000090440    Gm9732    -0.30762307 0.0116752 ENSMUSG00000020629    Adi1    -0.281083271 1.12E-05
ENSMUSG00000089682    Bcl2l2    -0.307430896 0.0011425 ENSMUSG00000021770    Samd8    -0.28104422 0.0001542
ENSMUSG00000029173    Sepsecs -0.305545446 0.0004015 ENSMUSG00000000078    Klf6    -0.280710215 2.26E-08
ENSMUSG00000079009    Gm14139    -0.305302716 0.0017249 ENSMUSG00000037474    Dtl -0.280600179 2.56E-08
ENSMUSG00000053338    Tarm1    -0.305274777 0.014301 ENSMUSG00000026857    Ntmt1    -0.280533604 0.0016339
ENSMUSG00000099875    Gm15453    -0.305199688 0.0094736 ENSMUSG00000057101    Zfp180    -0.280515928 1.52E-06
ENSMUSG00000030042    Pole4    -0.30489992 2.92E-08 ENSMUSG00000012640    Zfp715    -0.280485135 0.0041797
ENSMUSG00000037104    Socs5    -0.304682992 1.92E-16 ENSMUSG00000040883    Tmem205    -0.2801093 0.0225619
ENSMUSG00000022792    Yars2    -0.302456038 3.40E-06 ENSMUSG00000032834    Pwp2    -0.27964085 3.41E-08
ENSMUSG00000028850    Gpatch3    -0.302210825 0.0137679 ENSMUSG00000045917    6330416G13Rik -0.27946082 0.0083708
ENSMUSG00000033467    Crlf2    -0.3018929 0.0126578 ENSMUSG00000058809    Hspd1-ps3    -0.278981195 0.0004527
ENSMUSG00000021759    Ppap2a -0.301791777 0.0002006 ENSMUSG00000028744    Pqlc2    -0.278718701 0.0252818
ENSMUSG00000049969    Plekhf2    -0.301702661 0.0018478 ENSMUSG00000043822    Adamtsl5    -0.278544971 0.0131718
ENSMUSG00000074876    Spata5l1    -0.301020224 0.011588 ENSMUSG00000051444    Bbs12    -0.278537123 0.0037189
ENSMUSG00000082809    Gm14150    -0.300336421 0.0117161 ENSMUSG00000027955    Fam198b -0.278346023 0.0111814
ENSMUSG00000033728    Lrrc14    -0.29891295 4.97E-05 ENSMUSG00000004446    Bid -0.278257171 0.0010371
ENSMUSG00000032952    Ap4b1    -0.298879656 0.016456 ENSMUSG00000094614    Gm21769    -0.278239597 0.0216555
ENSMUSG00000040521    Tsfm -0.298723554 8.59E-06 ENSMUSG00000031425    Plp1    -0.278210455 1.26E-09
ENSMUSG00000044716    Dok7    -0.298717062 0.0161546 ENSMUSG00000022299    Slc25a32    -0.278166203 0.0001519
ENSMUSG00000031691    Tnpo2    -0.29822189 2.05E-08 ENSMUSG00000041623    D11Wsu47e -0.278092524 0.0025158
ENSMUSG00000082319    Gm8822    -0.297807922 0.0080606 ENSMUSG00000048807    Slc35e4    -0.277544745 4.29E-06
ENSMUSG00000052751    Repin1    -0.297685835 1.47E-05 ENSMUSG00000035969    Rusc2    -0.27743052 2.48E-05
ENSMUSG00000035517    Tdrd7    -0.297424014 7.33E-05 ENSMUSG00000050721    Plekho2    -0.277425638 0.0004236
ENSMUSG00000047098    Rnf31    -0.297402655 0.0020754 ENSMUSG00000045822    Zswim3    -0.277296321 0.0158056
ENSMUSG00000006301    Tmbim1    -0.29715196 1.14E-08 ENSMUSG00000023883    Phf10    -0.277019777 7.28E-07
ENSMUSG00000036368    Rmdn2    -0.296844727 0.0143052 ENSMUSG00000068206    Pick1    -0.276878838 0.0001262
ENSMUSG00000047143    Dmrta2    -0.296785586 0.0140792 ENSMUSG00000015776    Med22    -0.276248672 1.17E-05
ENSMUSG00000025225    Nfkb2    -0.296475662 5.78E-07 ENSMUSG00000089728    Clec2f -0.275202987 0.02696
ENSMUSG00000078498    Gm13151    -0.29565548 0.0156778 ENSMUSG00000067203    H2-K2    -0.274481246 0.0073179
ENSMUSG00000036534    Slc38a7    -0.295071942 0.0064557 ENSMUSG00000002343    Armc6    -0.274232757 0.0021577
ENSMUSG00000037868    Egr2    -0.294453541 0.0178023 ENSMUSG00000002108    Nr1h3    -0.274055496 0.0045769
ENSMUSG00000021890    Eaf1    -0.294359642 9.27E-11 ENSMUSG00000091086    Gm5428    -0.274048428 0.0275417
ENSMUSG00000028345    Tex10    -0.293578979 8.39E-09 ENSMUSG00000027346    Gpcpd1    -0.273967053 0.0041368
ENSMUSG00000095588    Gm12350    -0.293162795 0.0071795 ENSMUSG00000028540    Dph2    -0.273955677 0.0005072
ENSMUSG00000091803    Cox16    -0.293054334 0.0080868 ENSMUSG00000069014    Gm5641    -0.273843259 0.0117905
ENSMUSG00000045455    Gm9797    -0.292490534 0.0187826 ENSMUSG00000017307    Acot8    -0.273206548 0.0270493
ENSMUSG00000045140    Pigw -0.29234715 0.0062889 ENSMUSG00000022365    Derl1    -0.273178328 2.11E-08
ENSMUSG00000035530    Eif1    -0.292321493 4.36E-24 ENSMUSG00000054793    Cadm4    -0.273004586 2.65E-19
ENSMUSG00000081999    Gm13461    -0.291274932 0.0190237 ENSMUSG00000034854    Mfsd12    -0.272918771 0.0003098
ENSMUSG00000040354    Mars -0.290561469 9.98E-13 ENSMUSG00000035397    Klf16    -0.272438734 0.0013993
ENSMUSG00000049957    Ccdc137    -0.290429174 3.32E-06 ENSMUSG00000003526    Prodh -0.272426928 0.0195574
ENSMUSG00000021079    Timm9    -0.290326207 0.0001937 ENSMUSG00000094497    Gm8210    -0.272280521 0.0004507
ENSMUSG00000071722    Spin4    -0.290204017 0.0196123 ENSMUSG00000030029    Lrig1    -0.272247768 3.40E-12
ENSMUSG00000091811    Inafm1    -0.290179577 0.0164887 ENSMUSG00000050335    Lgals3    -0.272094359 2.08E-27
ENSMUSG00000058838    Rps27a-ps2    -0.289861674 0.0055684 ENSMUSG00000038888    Ctu1    -0.271765558 0.0124256
ENSMUSG00000003948    Mmd -0.289769508 0.0024229 ENSMUSG00000045027    Prss22    -0.271512799 0.0288003
ENSMUSG00000027845    Dclre1b -0.289639935 0.0025355 ENSMUSG00000057411    Fam173a -0.2712561 0.0039446
ENSMUSG00000009292    Trpm2    -0.28962244 0.0198584 ENSMUSG00000066362    Rps13-ps1    -0.271152591 0.0211067
ENSMUSG00000018932    Map2k3    -0.289397796 4.51E-10 ENSMUSG00000079507    H2-Q1    -0.271090222 0.021646
ENSMUSG00000069972    Rps13-ps2    -0.289224894 0.01779 ENSMUSG00000021385    Ippk -0.270744571 0.0048576
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ENSMUSG00000042854    Trp53rkb -0.270556772 0.0291882 ENSMUSG00000023000    Dhh -0.25455891 0.0129126
ENSMUSG00000036067    Slc2a6    -0.270485156 0.0277036 ENSMUSG00000042178    Armc5    -0.254472512 0.0055606
ENSMUSG00000080848    Gm9385    -0.270354027 0.0140941 ENSMUSG00000001751    Naglu -0.254282794 0.0094678
ENSMUSG00000022241    Tars -0.270315893 5.50E-14 ENSMUSG00000024640    Psat1    -0.254102996 7.71E-19
ENSMUSG00000024593    Megf10    -0.27028186 8.46E-05 ENSMUSG00000079260    Tmppe -0.254052551 0.004513
ENSMUSG00000028708    Mknk1    -0.270212604 0.0058709 ENSMUSG00000026640    Plxna2    -0.253906887 0.002278
ENSMUSG00000020790    Ankfy1    -0.269859012 3.15E-10 ENSMUSG00000024785    Rcl1    -0.253573841 4.57E-05
ENSMUSG00000036106    Prr5    -0.269801161 0.0081893 ENSMUSG00000065999    Gm13154    -0.253564449 0.0206044
ENSMUSG00000007872    Id3    -0.269732181 1.46E-07 ENSMUSG00000032788    Pdxk -0.253481499 2.85E-07
ENSMUSG00000024276    Zfp397    -0.269617403 0.0003936 ENSMUSG00000083626    Gm4459    -0.253320415 0.0362535
ENSMUSG00000046731    Kctd11    -0.269410117 0.0132214 ENSMUSG00000029179    Zcchc4    -0.253018768 0.0013594
ENSMUSG00000002289    Angptl4    -0.269335761 8.14E-06 ENSMUSG00000024427    Spry4    -0.252881863 0.0241547
ENSMUSG00000055184    Fam72a -0.269161688 0.0119919 ENSMUSG00000022507    1810013L24Rik -0.252774778 5.95E-05
ENSMUSG00000041506    Rrp9    -0.269072606 1.96E-05 ENSMUSG00000066892    Fbxl12    -0.252429878 0.0356353
ENSMUSG00000027472    Pdrg1    -0.268891068 6.13E-06 ENSMUSG00000033918    Parl -0.252330676 8.40E-06
ENSMUSG00000082361    Btc -0.268851249 0.0304965 ENSMUSG00000078789    Dph1    -0.252330564 0.0046655
ENSMUSG00000001750    Tcirg1    -0.268670426 0.0002976 ENSMUSG00000043131    Mob1a -0.252194107 8.60E-12
ENSMUSG00000034998    Foxn2    -0.268529066 0.0001657 ENSMUSG00000087259    2610035D17Rik -0.251853573 0.0223943
ENSMUSG00000027395    Polr1b -0.268428736 3.70E-06 ENSMUSG00000034379    Wdr5b -0.251464323 0.0332211
ENSMUSG00000043801    Oaz1-ps -0.268421015 0.0309856 ENSMUSG00000048222    Mfap1b -0.251418418 0.0345869
ENSMUSG00000049323    Smcr8    -0.26829666 7.25E-07 ENSMUSG00000085101    Platr16    -0.251401924 0.0374632
ENSMUSG00000039774    Galnt12    -0.267608745 0.0306808 ENSMUSG00000024610    Cd74    -0.251049392 0.0032886
ENSMUSG00000001281    Itgb7    -0.267410877 0.0295784 ENSMUSG00000054716    Zfp771    -0.250923045 0.0100561
ENSMUSG00000062432    Cyp26c1    -0.267241706 0.0056608 ENSMUSG00000103965    Gm30173    -0.250601122 0.0322631
ENSMUSG00000027800    Tm4sf1    -0.267084281 3.21E-22 ENSMUSG00000066640    Fbxl18    -0.250579977 0.0005716
ENSMUSG00000032911    Cspg4    -0.267075342 4.31E-09 ENSMUSG00000041571    Sepw1    -0.250564085 6.62E-06
ENSMUSG00000026475    Rgs16    -0.26703365 1.74E-21 ENSMUSG00000027495    Fam210b -0.250462657 0.0016942
ENSMUSG00000038299    Wdr36    -0.266859519 2.58E-09 ENSMUSG00000040658    Dnph1    -0.250179127 0.0007856
ENSMUSG00000033386    Frrs1    -0.265984559 3.34E-05 ENSMUSG00000001166    Oas1c -0.250090117 0.0009107
ENSMUSG00000036867    Smad6    -0.264564673 0.0221858 ENSMUSG00000032044    Rpusd4    -0.249583425 0.0027707
ENSMUSG00000042410    Agps -0.264523306 1.51E-07 ENSMUSG00000029028    Lrrc47    -0.249256125 7.38E-05
ENSMUSG00000050846    Zfp623    -0.264322123 0.0067085 ENSMUSG00000022772    Senp5    -0.249179344 2.73E-05
ENSMUSG00000081272    Gm13509    -0.264036796 0.0077135 ENSMUSG00000083899    Gm12346    -0.249047666 0.0112665
ENSMUSG00000062382    Gm10116    -0.263746647 0.0003239 ENSMUSG00000026303    Mlph -0.248500722 0.0088153
ENSMUSG00000020397    Med7    -0.263179687 0.0085973 ENSMUSG00000044763    Trmt10c -0.248244201 0.0027204
ENSMUSG00000045374    Wdr81    -0.263135364 0.0022382 ENSMUSG00000035505    Cox18    -0.247815687 0.0066534
ENSMUSG00000037509    Arhgef4    -0.262983601 0.0297249 ENSMUSG00000046441    Cmtr2    -0.247757764 0.0060809
ENSMUSG00000034898    Filip1    -0.262894173 0.0190598 ENSMUSG00000030621    Me3    -0.247488534 0.031174
ENSMUSG00000066724    Gm10175    -0.262866928 0.0222463 ENSMUSG00000021311    Mtr -0.247478477 0.0036551
ENSMUSG00000085783    Gm9816    -0.262646996 0.0346081 ENSMUSG00000039384    Dusp10    -0.247458142 0.0125059
ENSMUSG00000043079    Synpo -0.262519025 5.34E-07 ENSMUSG00000021532    Fastkd3    -0.247391214 0.0164837
ENSMUSG00000034842    Art3    -0.262470748 0.018757 ENSMUSG00000026283    Ing5    -0.247184118 0.0005587
ENSMUSG00000075227    Znhit2    -0.262384372 0.0027212 ENSMUSG00000032531    Amotl2    -0.247005546 1.14E-08
ENSMUSG00000000555    Itga5    -0.260537373 1.07E-08 ENSMUSG00000079144    A130010J15Rik -0.24687357 0.0403859
ENSMUSG00000035735    Dagla -0.260534864 5.62E-07 ENSMUSG00000036061    Smug1    -0.246436841 0.0144147
ENSMUSG00000031770    Herpud1    -0.260517787 0.0010562 ENSMUSG00000029500    Pgam5    -0.246096875 0.0017134
ENSMUSG00000005413    Hmox1    -0.260482621 0.0015706 ENSMUSG00000000278    Scpep1    -0.245960865 1.75E-06
ENSMUSG00000079056    Kcnip3    -0.260158837 0.0255784 ENSMUSG00000101940    Akp-ps1    -0.245342654 0.0387467
ENSMUSG00000014599    Csf1    -0.25977207 3.42E-09 ENSMUSG00000029596    Sdsl -0.245253142 0.0331342
ENSMUSG00000005045    Chd5    -0.259646781 0.0342733 ENSMUSG00000020788    Atp2a3    -0.245198616 0.0011127
ENSMUSG00000070709    1700049G17Rik -0.259447146 0.0354948 ENSMUSG00000042719    Naa25    -0.244815118 1.65E-08
ENSMUSG00000022178    Ajuba -0.259248655 0.0004306 ENSMUSG00000021025    Nfkbia -0.244361342 0.001632
ENSMUSG00000061979    Wbscr16    -0.258972911 0.0003483 ENSMUSG00000070493    Chchd2    -0.244306838 5.17E-09
ENSMUSG00000002274    Metrn -0.258792021 0.0003852 ENSMUSG00000004221    Ikbkg -0.24415744 0.0001842
ENSMUSG00000027613    Eif6    -0.258754724 5.68E-08 ENSMUSG00000059588    Calcrl -0.244138657 0.0458232
ENSMUSG00000071256    Zfp213    -0.258567452 0.037979 ENSMUSG00000058173    Smco4    -0.244118603 0.0256946
ENSMUSG00000027534    Snx16    -0.258345934 0.0030649 ENSMUSG00000067787    Blcap -0.243952357 0.0035552
ENSMUSG00000040165    Cd209c -0.258120692 0.0142107 ENSMUSG00000032122    Slc37a2    -0.24393159 0.0261036
ENSMUSG00000075602    Ly6a -0.25810421 0.0031383 ENSMUSG00000025602    Zfp202    -0.243519723 0.0234611
ENSMUSG00000032508    Myd88    -0.257673858 0.0055791 ENSMUSG00000050891    Tatdn1    -0.243179888 0.0315735
ENSMUSG00000021282    Eif5    -0.257653626 2.41E-13 ENSMUSG00000045316    Fahd1    -0.242968528 0.0305006
ENSMUSG00000103041    Gm37305    -0.257023146 0.0391803 ENSMUSG00000048351    Coa7    -0.242932912 0.0094909
ENSMUSG00000030657    Xylt1    -0.256904513 0.022578 ENSMUSG00000046994    Mars2    -0.242928781 0.0014649
ENSMUSG00000050312    Nsun3    -0.256880321 0.0138229 ENSMUSG00000060548    Tnfrsf19    -0.242868345 0.0292149
ENSMUSG00000019122    Ccl9    -0.256753622 0.0247949 ENSMUSG00000026181    Ppm1f -0.242667018 2.07E-10
ENSMUSG00000020605    Hs1bp3    -0.256736904 0.0018013 ENSMUSG00000047368    Abhd17b -0.242516982 0.0015218
ENSMUSG00000031785    Adgrg1    -0.256656799 5.73E-06 ENSMUSG00000039512    Uhrf1bp1    -0.242374248 1.67E-05
ENSMUSG00000074811    Hps6    -0.256654738 0.0040319 ENSMUSG00000031387    Renbp -0.242168861 0.0016139
ENSMUSG00000056300    Gm13247    -0.256594768 0.03587 ENSMUSG00000030428    Ttyh1    -0.241873589 0.0149906
ENSMUSG00000021149    Gtpbp4    -0.256541539 1.94E-07 ENSMUSG00000039182    AW209491    -0.241359831 0.0111224
ENSMUSG00000022515    Anks3    -0.256398934 0.0092088 ENSMUSG00000105504    Gbp5    -0.24127343 0.0213179
ENSMUSG00000080776    Gm12174    -0.256214357 0.0313105 ENSMUSG00000036432    Siah2    -0.24125115 0.0108212
ENSMUSG00000026177    Slc11a1    -0.256180902 0.0032596 ENSMUSG00000067038    Rps12-ps3    -0.241068459 0.0052267
ENSMUSG00000048486    Fitm2    -0.256027146 0.0016038 ENSMUSG00000029560    Snx8    -0.240885804 7.87E-05
ENSMUSG00000024019    Cmtr1    -0.255879702 0.007598 ENSMUSG00000018143    Mafk -0.24064242 0.0005283
ENSMUSG00000038213    Tapbpl -0.25572967 0.0229592 ENSMUSG00000025138    Sirt7    -0.240608681 0.0201794
ENSMUSG00000020092    Pald1    -0.255369538 0.0012207 ENSMUSG00000098702    1500015A07Rik -0.240599749 0.0493515
ENSMUSG00000029060    Mib2    -0.2552655 0.0234322 ENSMUSG00000039826    Trub2    -0.240017615 0.0006598
ENSMUSG00000045896    Paip2b -0.255106286 1.72E-06 ENSMUSG00000046223    Plaur -0.239744484 1.31E-09
ENSMUSG00000051671    Coa6    -0.255030914 0.0184157 ENSMUSG00000031490    Eif4ebp1    -0.239673763 2.03E-07
ENSMUSG00000028857    Tmem222    -0.254944813 0.0023716 ENSMUSG00000090700    Cyp4f40    -0.239369741 0.0004609
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ENSMUSG00000107383    RP24-246N21.1    -0.239262887 1.59E-06 ENSMUSG00000039853    Trim14    -0.228050946 0.0465197
ENSMUSG00000040652    Oaz2    -0.239126088 0.000117 ENSMUSG00000070953    Rabepk -0.227756078 0.0181981
ENSMUSG00000070034    Sp110    -0.239009303 0.0280131 ENSMUSG00000025971    9430016H08Rik -0.227452263 0.0262403
ENSMUSG00000071456    1110002L01Rik -0.238988976 0.0347539 ENSMUSG00000027628    Aar2    -0.227291006 0.0011563
ENSMUSG00000041645    Ddx24        -0.238835388 5.29E-08 ENSMUSG00000020691    Mettl2    -0.227188702 0.0047532
ENSMUSG00000003949    Hlf -0.238528057 0.0468702 ENSMUSG00000054364    Rhob -0.226654362 1.04E-06
ENSMUSG00000094441    Zfp955a -0.238475355 0.0325182 ENSMUSG00000025384    Faap100    -0.226051518 0.0204459
ENSMUSG00000008136    Fhl2    -0.238341298 0.0383102 ENSMUSG00000034159    2310007B03Rik -0.226036883 0.0278664
ENSMUSG00000066800    Rnasel -0.238276518 0.0479737 ENSMUSG00000053080    2700081O15Rik -0.22582906 0.0027975
ENSMUSG00000037190    Cyb561d2    -0.238210294 0.0189735 ENSMUSG00000031875    Cmtm3    -0.22549842 0.0020103
ENSMUSG00000021908    Gm6768    -0.237960449 0.0487437 ENSMUSG00000063953    Amd2    -0.225307077 0.0261483
ENSMUSG00000024013    Fgd2    -0.237856261 0.0456719 ENSMUSG00000052253    Zfp622    -0.225205165 0.0011942
ENSMUSG00000096910    Zfp955b -0.237571477 0.0370897 ENSMUSG00000001588    Acap1    -0.22484507 8.31E-05
ENSMUSG00000022842    Ece2    -0.237235986 0.0006926 ENSMUSG00000074182    Znhit6    -0.224007041 0.004657
ENSMUSG00000026202    Tuba4a -0.237077392 0.0074668 ENSMUSG00000062661    Ncs1    -0.224007013 0.0111657
ENSMUSG00000031751    Amfr -0.236999091 2.16E-06 ENSMUSG00000072940    Gm10443    -0.223950472 0.0468054
ENSMUSG00000032714    Syde1    -0.236837504 0.000119 ENSMUSG00000042406    Atf4    -0.223886844 7.74E-12
ENSMUSG00000024164    C3    -0.236820505 0.0303929 ENSMUSG00000039463    Slc9a8    -0.223868457 0.0017707
ENSMUSG00000054072    Iigp1    -0.236487339 0.000643 ENSMUSG00000067825    Pex26    -0.223857766 0.0309749
ENSMUSG00000089824    Rbm12    -0.236478318 0.0101902 ENSMUSG00000028980    H6pd -0.223842199 0.0105469
ENSMUSG00000039754    Alkbh4    -0.236335602 0.0293832 ENSMUSG00000069020    Urm1    -0.223629766 0.0139566
ENSMUSG00000084384    Gm12251    -0.236122346 0.0242563 ENSMUSG00000031711    Zfp330    -0.222888045 0.0032359
ENSMUSG00000021280    Exoc3l4    -0.236043466 0.0486043 ENSMUSG00000038174    Fam126b -0.222515608 0.0326537
ENSMUSG00000015143    Actn1    -0.235890675 7.24E-07 ENSMUSG00000033983    Coil -0.222237547 0.0075617
ENSMUSG00000026142    Rhbdd1    -0.235723111 0.0011625 ENSMUSG00000041438    Cirh1a -0.222158115 9.51E-05
ENSMUSG00000039483    Asb6    -0.235165716 0.0022689 ENSMUSG00000032180    Tmed1    -0.222053969 0.0004281
ENSMUSG00000020544    Cox11    -0.234882931 0.0481576 ENSMUSG00000037594    BC022687    -0.221970317 0.0407613
ENSMUSG00000038172    Ttc39b -0.234782463 0.0006551 ENSMUSG00000066235    Pomgnt2    -0.221792766 0.0153267
ENSMUSG00000013076    Amotl1    -0.234459936 1.29E-07 ENSMUSG00000027170    Eif3m -0.221529294 1.28E-06
ENSMUSG00000033186    Mzt1    -0.234406313 0.0288488 ENSMUSG00000104960    Snhg8    -0.22147711 0.0042854
ENSMUSG00000020781    Tsen54    -0.234256146 0.0021919 ENSMUSG00000000561    Wdr77    -0.221338179 4.05E-05
ENSMUSG00000039474    Wfs1    -0.233914628 0.0070518 ENSMUSG00000030880    Polr3e -0.221293879 0.0004635
ENSMUSG00000054342    Kcnn4    -0.233765207 3.48E-08 ENSMUSG00000036908    Unc93b1    -0.221213569 0.0414308
ENSMUSG00000062168    Ppef1    -0.233683124 0.0296354 ENSMUSG00000043629    1700019D03Rik -0.220813617 0.0198629
ENSMUSG00000035378    Shq1    -0.233624188 0.0181253 ENSMUSG00000020692    Nle1    -0.220726663 0.001578
ENSMUSG00000025512    Chid1    -0.233603539 0.001275 ENSMUSG00000101892    9130401M01Rik -0.220587589 0.0191005
ENSMUSG00000025465    Echs1    -0.233328035 0.0008328 ENSMUSG00000056209    Npm3    -0.220222382 5.03E-06
ENSMUSG00000018169    Mfng -0.233260975 0.0431977 ENSMUSG00000043453    Magea10    -0.220083472 0.0090545
ENSMUSG00000023755    Rhebl1    -0.233098548 0.0497865 ENSMUSG00000026694    Mettl13    -0.219953198 0.0022893
ENSMUSG00000034429    Zfp707    -0.232995531 0.0370926 ENSMUSG00000028917    Plekhm2    -0.219829614 0.0077357
ENSMUSG00000066191    Anks6    -0.232788517 0.0494625 ENSMUSG00000021094    Dhrs7    -0.219682087 0.0493455
ENSMUSG00000046691    Chtf8    -0.232530536 2.49E-07 ENSMUSG00000031352    Hccs -0.219540832 0.0010997
ENSMUSG00000027808    Serp1    -0.232523717 3.27E-07 ENSMUSG00000001569    Nom1    -0.219284125 0.0001843
ENSMUSG00000046229    Scand1    -0.232474512 0.0229052 ENSMUSG00000030287    Itpr2    -0.219136468 0.0486582
ENSMUSG00000050271    D8Ertd82e -0.232437871 0.0111259 ENSMUSG00000029551    Psmg3    -0.219071251 0.0044852
ENSMUSG00000000058    Cav2    -0.232418092 0.0007175 ENSMUSG00000040464    Gtpbp10    -0.218977018 0.0024576
ENSMUSG00000107853    RP24-409C18.1    -0.232395717 0.0404559 ENSMUSG00000022108    Itm2b -0.218938624 0.0011882
ENSMUSG00000033722    BC034090    -0.231945961 0.004569 ENSMUSG00000030942    Thumpd1    -0.218575421 5.38E-05
ENSMUSG00000059423    Zfp933    -0.231805053 0.0361883 ENSMUSG00000026171    Rnf25    -0.218561476 0.0104956
ENSMUSG00000029544    Cabp1    -0.231704697 0.0074997 ENSMUSG00000038150    Ormdl3    -0.218513668 0.0009365
ENSMUSG00000085795    Zfp703    -0.231679973 0.0101667 ENSMUSG00000049482    Ctu2    -0.218498062 0.0104436
ENSMUSG00000022849    Hspbap1    -0.231548158 0.0160394 ENSMUSG00000025647    Shisa5    -0.218217214 7.41E-05
ENSMUSG00000096983    2010015M23Rik -0.23136072 0.0351601 ENSMUSG00000025722    Wdr73    -0.217661222 0.0118796
ENSMUSG00000024831    Ighmbp2    -0.231330743 0.0233858 ENSMUSG00000022150    Dab2    -0.217635712 0.0153527
ENSMUSG00000037242    Clic4    -0.231313883 2.01E-12 ENSMUSG00000042594    Sh2b3    -0.217484713 0.0001646
ENSMUSG00000020641    Rsad2    -0.231288762 0.0147547 ENSMUSG00000031832    Taf1c -0.216814465 0.0477589
ENSMUSG00000038742    Angptl6    -0.231123568 0.0450526 ENSMUSG00000000386    Mx1    -0.216660472 0.0009239
ENSMUSG00000064326    Siva1    -0.231081625 0.0003503 ENSMUSG00000067161    Gm5560    -0.216546413 0.0430845
ENSMUSG00000042211    Fbxo38    -0.230904356 0.0002136 ENSMUSG00000025198    Erlin1    -0.216212639 6.11E-05
ENSMUSG00000039518    Cdsn -0.23085365 0.0016741 ENSMUSG00000022718    Dgcr8    -0.216075817 0.000235
ENSMUSG00000030400    Ercc2    -0.230775331 0.0024763 ENSMUSG00000002808    Epdr1    -0.216012936 0.0188042
ENSMUSG00000000120    Ngfr -0.230718766 5.01E-13 ENSMUSG00000024732    Ccdc86    -0.215835631 0.0023114
ENSMUSG00000025485    Ric8    -0.230586048 0.0010029 ENSMUSG00000016496    Cd274    -0.215800298 0.0290401
ENSMUSG00000044636    Csrnp2    -0.230246078 0.0096995 ENSMUSG00000058392    Rrp1b -0.215587132 0.0002203
ENSMUSG00000026600    Soat1    -0.230133758 1.13E-08 ENSMUSG00000038806    Sde2    -0.215528372 0.0006914
ENSMUSG00000002763    Pex6    -0.230098526 0.0127121 ENSMUSG00000020528    Prpsap2    -0.215287701 0.0037316
ENSMUSG00000038214    Bend3    -0.230000363 0.0062708 ENSMUSG00000017677    Wsb1    -0.215204217 1.50E-05
ENSMUSG00000060708    Bloc1s4    -0.229920472 0.0302393 ENSMUSG00000049680    Urgcp -0.215136897 0.0006631
ENSMUSG00000006585    Cdt1    -0.229912699 1.06E-05 ENSMUSG00000045045    Lrfn4        -0.215076702 0.0004818
ENSMUSG00000007613    Tgfbr1    -0.229900352 0.0002268 ENSMUSG00000020087    Tysnd1    -0.214982933 0.0106847
ENSMUSG00000028339    Col15a1    -0.229717306 0.0413336 ENSMUSG00000096916    Zfp850    -0.214970496 0.0171177
ENSMUSG00000032712    2810474O19Rik -0.229443874 0.0055402 ENSMUSG00000022407    Adsl -0.214949191 9.04E-07
ENSMUSG00000041966    Dcaf17    -0.229347006 0.0107619 ENSMUSG00000022560    Slc52a2    -0.214874296 0.0012735
ENSMUSG00000073755    5730409E04Rik -0.228954224 0.0352796 ENSMUSG00000029397    Rchy1    -0.214268339 0.0173299
ENSMUSG00000029591    Ung -0.228941347 0.0021678 ENSMUSG00000032409    Atr -0.214229545 0.0004954
ENSMUSG00000026596    Abl2    -0.228931309 2.44E-08 ENSMUSG00000044768    D1Ertd622e -0.214070829 0.0091117
ENSMUSG00000068196    Col8a1    -0.228774023 4.56E-07 ENSMUSG00000098178    Yam1    -0.213700729 0.0423566
ENSMUSG00000007610    Gtpbp3    -0.228683646 0.0042211 ENSMUSG00000023990    Tfeb -0.213634128 0.0379693
ENSMUSG00000026000    Lancl1    -0.228677668 0.006009 ENSMUSG00000019261    Map1s -0.213563465 0.0065057
ENSMUSG00000008318    Relt -0.228555074 0.0034328 ENSMUSG00000020107    Anapc16    -0.213295576 0.0030277
ENSMUSG00000039005    Tlr4        -0.228410505 0.0447003 ENSMUSG00000032035    Ets1    -0.213203561 2.84E-10
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ENSMUSG00000036281    Snapc4    -0.212859111 0.016237 ENSMUSG00000024843    Chka -0.199689232 0.0343283
ENSMUSG00000043140    Tmem186    -0.212689356 0.0048629 ENSMUSG00000075419    Dolk -0.19966477 0.0409065
ENSMUSG00000069682    Gm10275    -0.212559436 0.0005902 ENSMUSG00000032633    Flcn -0.199526842 0.0125952
ENSMUSG00000062202    Btbd9    -0.211691082 0.0025637 ENSMUSG00000026806    Ddx31    -0.19951244 0.0302176
ENSMUSG00000062014    Gmfb -0.211386055 2.14E-05 ENSMUSG00000051067    Lingo3    -0.199433292 0.0192647
ENSMUSG00000029186    Pi4k2b -0.211298364 0.0004395 ENSMUSG00000030452    Nipa2    -0.19942066 0.0003093
ENSMUSG00000031482    Slc25a15    -0.211272789 0.0486991 ENSMUSG00000039623    Ap5z1    -0.19928478 0.0364221
ENSMUSG00000054099    Slc25a40    -0.211182656 0.0165571 ENSMUSG00000020534    Shmt1    -0.199217611 0.0003168
ENSMUSG00000036693    Nop14    -0.210934033 3.33E-05 ENSMUSG00000082016    Pgam1-ps2    -0.199072166 0.0090434
ENSMUSG00000030748    Il4ra -0.210528218 4.86E-05 ENSMUSG00000026520    Pycr2    -0.199022141 0.0006661
ENSMUSG00000040007    Bahd1    -0.210526003 0.0047593 ENSMUSG00000032733    Snx33    -0.198986907 0.0221243
ENSMUSG00000023905    Tnfrsf12a -0.210159882 1.35E-10 ENSMUSG00000049580    Tsku -0.198879393 0.0072708
ENSMUSG00000017830    Dhx58    -0.209657185 0.0422512 ENSMUSG00000017664    Slc35c2    -0.198760114 0.0032538
ENSMUSG00000079509    Zfx -0.209600164 0.000332 ENSMUSG00000024664    Fads3    -0.198672252 0.0002197
ENSMUSG00000007570    Fance -0.209471489 0.0214735 ENSMUSG00000079562    Maea -0.198371128 5.52E-06
ENSMUSG00000030161    Gabarapl1    -0.209410295 0.0061254 ENSMUSG00000018322    Tomm34    -0.198223093 0.005039
ENSMUSG00000032305    Fam219b -0.209330113 0.0191096 ENSMUSG00000029513    Prkab1    -0.198213379 0.0195839
ENSMUSG00000028381    Ugcg -0.209217277 0.0056104 ENSMUSG00000034203    Chchd4    -0.198089972 0.0024969
ENSMUSG00000030741    Spns1    -0.209139243 0.0075866 ENSMUSG00000028889    Yrdc -0.19791265 0.0059753
ENSMUSG00000020561    Twistnb -0.209130573 0.0040488 ENSMUSG00000020133    2310011J03Rik -0.197685243 0.0076977
ENSMUSG00000016206    H2-M3    -0.208880982 0.0468191 ENSMUSG00000056708    Ier5    -0.197564358 0.0078473
ENSMUSG00000024317    Rnf138    -0.208723648 0.011129 ENSMUSG00000067724    Gbx1    -0.197423655 0.0358363
ENSMUSG00000038323    1700066M21Rik -0.208580325 0.030205 ENSMUSG00000023009    Nckap5l -0.197353957 0.0269325
ENSMUSG00000029708    Gcc1    -0.208115625 0.0210282 ENSMUSG00000028688    Toe1    -0.197353247 0.0189029
ENSMUSG00000032014    Oaf -0.208054687 6.46E-06 ENSMUSG00000020289    Nprl3    -0.197057288 0.0182138
ENSMUSG00000035992    Fnip1    -0.208022084 0.0008661 ENSMUSG00000041747    Utp15    -0.197017199 0.0063913
ENSMUSG00000061878    Sphk1    -0.207835333 0.020359 ENSMUSG00000036992    Nxt1    -0.196966354 0.0075383
ENSMUSG00000040865    Ino80d -0.207709475 0.0143033 ENSMUSG00000071748    Gm14698    -0.196802495 0.0370605
ENSMUSG00000042328    Hps4    -0.207653235 0.0406778 ENSMUSG00000037344    Slc12a9    -0.19666576 0.023926
ENSMUSG00000037531    Mrpl47    -0.207494911 0.0086214 ENSMUSG00000006599    Gtf2h1    -0.196664647 5.76E-05
ENSMUSG00000040022    Rab11fip2    -0.20725231 0.044918 ENSMUSG00000094411    Snord16a -0.196662287 0.0499608
ENSMUSG00000060121    Gemin2    -0.207189118 0.0230235 ENSMUSG00000024486    Hbegf -0.196514946 0.0018157
ENSMUSG00000032020    Ubash3b -0.206995158 4.41E-05 ENSMUSG00000026289    Atg16l1    -0.195876727 0.0073669
ENSMUSG00000039130    Zc3hc1    -0.206708448 0.0027947 ENSMUSG00000002307    Daxx -0.19587248 0.0154515
ENSMUSG00000026535    Ifi202b -0.20660095 0.000724 ENSMUSG00000021147    Wdr37    -0.195870496 0.0426427
ENSMUSG00000025880    Smad7    -0.206493228 0.0028117 ENSMUSG00000026342    Slc35f5    -0.195746414 0.0295066
ENSMUSG00000025024    Smndc1    -0.206414836 0.0012791 ENSMUSG00000025511    Tspan4    -0.195621752 0.0001867
ENSMUSG00000026064    Ptp4a1    -0.206011618 1.98E-05 ENSMUSG00000018733    Pex12    -0.195530177 0.0354793
ENSMUSG00000044835    Ankrd45    -0.205839282 0.0045726 ENSMUSG00000034867    Ankrd27    -0.195436128 5.51E-05
ENSMUSG00000026315    Serpinb8    -0.205768219 0.0442108 ENSMUSG00000042793    Lgr6    -0.194961156 0.0068457
ENSMUSG00000029594    Rbm19    -0.205534306 4.35E-05 ENSMUSG00000079036    Alkbh1    -0.194906536 0.0216428
ENSMUSG00000061024    Rrs1    -0.205468799 7.57E-05 ENSMUSG00000079426    Arpc4    -0.194877788 0.0001628
ENSMUSG00000032902    Slc16a1    -0.205330837 2.18E-06 ENSMUSG00000001524    Gtf2h4    -0.194801913 0.010856
ENSMUSG00000019818    Cd164    -0.205088474 1.68E-08 ENSMUSG00000073771    Btbd19    -0.194661801 0.0401327
ENSMUSG00000090290    Gm17296    -0.205024184 0.0224426 ENSMUSG00000042729    Wdr74    -0.194509556 0.0013844
ENSMUSG00000027660    Skil -0.205010555 0.0002916 ENSMUSG00000015133    Lrrk1    -0.19438641 0.0001598
ENSMUSG00000022500    Litaf -0.205002926 2.11E-07 ENSMUSG00000053746    Ptrh1    -0.194069513 0.0204287
ENSMUSG00000071359    Tbpl1    -0.204669454 0.0063138 ENSMUSG00000063406    Tmed5    -0.193733133 0.0002776
ENSMUSG00000023977    Ubr2    -0.204488739 4.23E-05 ENSMUSG00000079478    Sssca1    -0.193629966 0.0045422
ENSMUSG00000092558    Med20    -0.204391836 0.0293451 ENSMUSG00000030469    Zfp719    -0.193559969 0.0422176
ENSMUSG00000084807    Gm13073    -0.204034897 0.0055011 ENSMUSG00000040663    Clcf1    -0.193508129 0.0040907
ENSMUSG00000048387    Osr1    -0.203900737 0.0176276 ENSMUSG00000004996    Mri1    -0.193482875 0.0426192
ENSMUSG00000038671    Arfrp1    -0.203758585 0.0122365 ENSMUSG00000024955    Esrra -0.193454803 0.0069668
ENSMUSG00000058979    Cecr5    -0.203339245 0.0344928 ENSMUSG00000030208    Emp1    -0.193451768 7.42E-08
ENSMUSG00000063235    Ptpmt1    -0.203176776 0.0041022 ENSMUSG00000030353    Tead4    -0.193287216 0.0273801
ENSMUSG00000047221    Fam185a -0.202739637 0.0248036 ENSMUSG00000019796    Lrp11    -0.193060746 0.0272131
ENSMUSG00000073490    AI607873    -0.202624833 0.0229949 ENSMUSG00000024132    Eci1    -0.192977064 0.0250998
ENSMUSG00000033213    AA467197    -0.202509699 0.0151751 ENSMUSG00000024188    Luc7l -0.192944163 0.0006985
ENSMUSG00000015790    Surf1    -0.20235942 0.0418643 ENSMUSG00000027276    Jag1    -0.192918041 0.0003077
ENSMUSG00000041153    Osgin2    -0.202226339 0.0237326 ENSMUSG00000080242    Gm15487    -0.192840613 0.0311954
ENSMUSG00000075040    Zfp408    -0.20214522 0.0419109 ENSMUSG00000026766    Mmadhc -0.19283731 0.0004154
ENSMUSG00000025612    Bach1    -0.202089498 0.0202415 ENSMUSG00000024780    Cdc37l1    -0.192811554 0.0067877
ENSMUSG00000027423    Snx5    -0.201820792 8.10E-11 ENSMUSG00000056952    Tatdn2    -0.192797992 0.0017605
ENSMUSG00000020000    Moxd1    -0.201796063 2.08E-09 ENSMUSG00000024841    Eif1ad -0.19273107 0.0006384
ENSMUSG00000039242    B3galnt2    -0.201654823 0.0099366 ENSMUSG00000038181    Chpf2    -0.192540895 0.0172674
ENSMUSG00000043858    Nup62    -0.201640185 5.61E-06 ENSMUSG00000020255    D10Wsu102e -0.192447289 0.001444
ENSMUSG00000000384    Tbrg4    -0.201509623 5.48E-05 ENSMUSG00000041390    Mdfic -0.192308669 0.0111154
ENSMUSG00000068742    Cry2    -0.201443187 0.0397721 ENSMUSG00000032344    Mb21d1    -0.192299304 0.0230681
ENSMUSG00000029128    Rab28    -0.200867635 0.0017721 ENSMUSG00000028423    Nfx1    -0.192150053 3.15E-07
ENSMUSG00000028431    Ikbkap -0.200829714 2.63E-05 ENSMUSG00000028948    Nol9    -0.192057691 0.0005397
ENSMUSG00000026615    Eprs -0.200653413 9.14E-10 ENSMUSG00000062510    Nsl1    -0.191790628 0.012857
ENSMUSG00000015750    Aph1a -0.200576552 0.0005592 ENSMUSG00000011179    Odc1    -0.191770674 3.93E-09
ENSMUSG00000081534    Slc48a1    -0.200546807 0.0056455 ENSMUSG00000069844    Sco1    -0.191525483 0.0148043
ENSMUSG00000055737    Ghr -0.200435818 0.0045476 ENSMUSG00000022837    Iqcb1    -0.191313597 0.0220358
ENSMUSG00000045409    Trim39    -0.200430462 0.0283906 ENSMUSG00000025185    Loxl4        -0.191261007 0.0352345
ENSMUSG00000092203    1110038B12Rik -0.200411825 5.65E-05 ENSMUSG00000038843    Gcnt1    -0.19111693 0.0107712
ENSMUSG00000036305    Rpl39-ps -0.200300474 0.0095645 ENSMUSG00000074405    Zfp865    -0.190754732 0.0333195
ENSMUSG00000029569    Tmem168    -0.200209493 0.0061117 ENSMUSG00000020032    Nuak1    -0.190627055 0.0001706
ENSMUSG00000030738    Eif3c -0.200156282 5.88E-14 ENSMUSG00000007836    Hnrnpa0    -0.190574054 1.03E-05
ENSMUSG00000039911    Spsb1    -0.199800345 0.0060137 ENSMUSG00000037885    Stk35    -0.190553977 0.003722
ENSMUSG00000027522    Stx16    -0.199789998 0.0028299 ENSMUSG00000078899    Gm4631    -0.19044717 0.0038285
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ENSMUSG00000025648    Pfkfb4    -0.190346048 0.0006237 ENSMUSG00000028967    Errfi1    -0.179402095 0.0031443
ENSMUSG00000021906    Oxnad1    -0.190140985 0.0149745 ENSMUSG00000039929    Urb1    -0.179347743 0.0285372
ENSMUSG00000003346    Abhd17a -0.18940306 0.0038292 ENSMUSG00000048429    1810026J23Rik -0.179316012 0.0078431
ENSMUSG00000024360    Etf1    -0.189160842 6.71E-10 ENSMUSG00000005057    Sh2b2    -0.179078456 0.0402394
ENSMUSG00000020300    Cpeb4    -0.189081682 0.0221194 ENSMUSG00000039753    Fbxl5    -0.178894483 0.0160826
ENSMUSG00000029408    Abcb9    -0.189002501 0.0042216 ENSMUSG00000027599    Armc1    -0.178819676 0.0007443
ENSMUSG00000037003    Tns2    -0.188975149 0.015804 ENSMUSG00000086150    Bach2os -0.178337237 0.0254754
ENSMUSG00000046675    Tmem251    -0.188843808 0.0222681 ENSMUSG00000028986    Klhl7    -0.178153893 0.015285
ENSMUSG00000024037    Wdr4    -0.188731619 0.0065818 ENSMUSG00000032112    Trappc4    -0.177948335 0.0014713
ENSMUSG00000002395    Use1    -0.188600765 0.0191132 ENSMUSG00000038462    Uqcrfs1    -0.177830764 0.0025672
ENSMUSG00000063019    Manbal -0.188462393 0.0333662 ENSMUSG00000001143    Lman2l -0.177703951 0.044553
ENSMUSG00000060038    Dhps -0.188134623 0.0422151 ENSMUSG00000036282    Naa30    -0.177439568 0.0409641
ENSMUSG00000019823    Mical1    -0.188120739 0.0225688 ENSMUSG00000027076    Timm10    -0.177375447 0.0373705
ENSMUSG00000070420    Zscan25    -0.188020145 0.0457994 ENSMUSG00000040631    Dok4    -0.177359286 0.0098704
ENSMUSG00000078440    Dohh -0.187884201 0.0023521 ENSMUSG00000022570    Tsta3    -0.177165264 0.003146
ENSMUSG00000079499    6530402F18Rik -0.187820994 0.0453239 ENSMUSG00000037921    Ddx60    -0.176833797 0.0090614
ENSMUSG00000020280    Pus10    -0.187801137 0.0044492 ENSMUSG00000022601    Zbtb11    -0.176804322 0.042825
ENSMUSG00000057359    Gm17494    -0.187504325 0.0433132 ENSMUSG00000038975    Rabggtb -0.17668422 6.62E-05
ENSMUSG00000055093    Gm8430    -0.187162486 0.0438816 ENSMUSG00000020310    Madcam1    -0.176648019 0.0033377
ENSMUSG00000024097    Srsf7    -0.186934845 1.35E-07 ENSMUSG00000022476    Polr3h -0.176312309 0.0002555
ENSMUSG00000057134    Ado -0.186923505 0.0039509 ENSMUSG00000021400    Wrnip1    -0.176237077 0.0107609
ENSMUSG00000035049    Rrp12    -0.186767125 0.0005835 ENSMUSG00000020937    Plcd3    -0.175871672 0.0488704
ENSMUSG00000059336    Slc14a1    -0.186140898 0.0068003 ENSMUSG00000021733    Slc4a7    -0.175830432 0.014457
ENSMUSG00000056220    Pla2g4a -0.186054315 0.0230097 ENSMUSG00000034157    Cipc -0.175794797 0.0022098
ENSMUSG00000036442    Thap11    -0.18584796 0.0180416 ENSMUSG00000032435    Dync1li1    -0.174829296 0.0006553
ENSMUSG00000000916    Nsun5    -0.185713925 0.0078291 ENSMUSG00000029507    Pus1    -0.174808694 0.0102435
ENSMUSG00000024359    Hspa9    -0.185619683 1.82E-12 ENSMUSG00000028403    Zdhhc21    -0.174784758 0.023572
ENSMUSG00000026889    Rbm18    -0.185410575 0.0234596 ENSMUSG00000024170    Telo2    -0.174778525 0.0186294
ENSMUSG00000051375    Pcdh1    -0.185384953 4.31E-06 ENSMUSG00000004393    Ddx56    -0.174635587 0.000593
ENSMUSG00000047843    Bri3    -0.185208855 0.0109638 ENSMUSG00000026413    Pkp1    -0.174579934 0.0149033
ENSMUSG00000033955    Tnks1bp1    -0.184984531 4.31E-05 ENSMUSG00000087153    Gm6483    -0.174293883 0.0472327
ENSMUSG00000002635    Pdcd2l -0.184857428 0.037239 ENSMUSG00000002017    Fam98a -0.174280193 0.0008066
ENSMUSG00000022369    Mtbp -0.184608025 0.0013823 ENSMUSG00000027944    Hax1    -0.174202883 0.0045537
ENSMUSG00000029415    Sdad1    -0.184534616 0.002431 ENSMUSG00000070730    Rmdn3    -0.174158277 0.0196766
ENSMUSG00000050812    AI314180    -0.184472169 4.64E-05 ENSMUSG00000036160    Surf6    -0.174046605 0.0191459
ENSMUSG00000045932    Ifit2    -0.184332119 0.0138774 ENSMUSG00000016252    Atp5e -0.17402035 0.0026707
ENSMUSG00000005779    Psmb4    -0.184224508 3.41E-05 ENSMUSG00000020530    Ggnbp2    -0.173937957 0.0007295
ENSMUSG00000037656    Slc20a2    -0.184210557 0.0001578 ENSMUSG00000021607    Mrpl36    -0.173714824 0.0333542
ENSMUSG00000039747    Orai2    -0.184035028 0.0087609 ENSMUSG00000051343    Rab11fip5    -0.173646427 0.0049254
ENSMUSG00000031750    Il34    -0.183787835 0.0277328 ENSMUSG00000084416    Rpl10a-ps1    -0.173390605 0.0102871
ENSMUSG00000037225    Fgf2    -0.183766156 0.0136038 ENSMUSG00000028140    Mrpl9    -0.173329525 0.0022977
ENSMUSG00000052419    2610001J05Rik -0.183667056 0.028934 ENSMUSG00000038028    Tigar -0.173242229 0.0302656
ENSMUSG00000020875    Hoxb9    -0.183592546 0.0256918 ENSMUSG00000022905    Kpna1    -0.173201719 7.99E-05
ENSMUSG00000092225    Gm2381    -0.183576501 0.0288994 ENSMUSG00000056536    Pign -0.172885334 0.0013897
ENSMUSG00000031007    Atp6ap2    -0.183456668 0.0008257 ENSMUSG00000047648    Fbxo30    -0.17271933 0.0326064
ENSMUSG00000020857    Nme2    -0.183428706 0.000594 ENSMUSG00000039841    Zfp800    -0.172706819 0.0424022
ENSMUSG00000005846    Rsl1d1    -0.183373085 5.12E-09 ENSMUSG00000059482    2610301B20Rik -0.17196754 0.0260116
ENSMUSG00000074221    Zfp568    -0.18329273 0.0226383 ENSMUSG00000041168    Lonp1    -0.171802459 6.62E-05
ENSMUSG00000025785    Exosc7    -0.183249512 0.0198441 ENSMUSG00000074892    B3galt5    -0.171769783 0.0362237
ENSMUSG00000060568    Fam78b -0.183210406 0.0122959 ENSMUSG00000007739    Cct4    -0.171392552 6.17E-10
ENSMUSG00000037419    Endod1    -0.1829502 0.0337638 ENSMUSG00000022031    Elp3    -0.171251739 0.0179089
ENSMUSG00000022257    Laptm4b -0.182796699 7.59E-05 ENSMUSG00000077737    Snord72    -0.171141757 0.0419035
ENSMUSG00000059713    Rcan3    -0.1827794 0.0113811 ENSMUSG00000051469    Zfp191    -0.171080241 0.0028207
ENSMUSG00000022770    Dlg1    -0.182760066 1.08E-05 ENSMUSG00000040236    Trappc5    -0.170926577 0.0462004
ENSMUSG00000049401    Ogfr -0.182325684 0.0003343 ENSMUSG00000084349    Rpl3-ps1    -0.170738044 0.0245646
ENSMUSG00000019920    Lims1    -0.182055433 0.000214 ENSMUSG00000019297    Nop9    -0.170700328 0.0104714
ENSMUSG00000096727    Psmb9    -0.181842733 0.0076851 ENSMUSG00000041057    Wdr43    -0.170533285 8.06E-06
ENSMUSG00000028617    Lrrc42    -0.181822693 0.0137099 ENSMUSG00000024953    Prdx5    -0.170479847 0.001939
ENSMUSG00000038170    Pde4dip -0.18171573 0.00614 ENSMUSG00000055707    Klhl26    -0.170314316 0.0281274
ENSMUSG00000060098    Prmt7    -0.181602033 0.0023557 ENSMUSG00000044030    Irf2bp1    -0.170313516 0.0105214
ENSMUSG00000012017    Scarf2    -0.181503885 0.0001655 ENSMUSG00000020453    Patz1    -0.17007431 0.020916
ENSMUSG00000035172    Plekhh3    -0.181499144 0.0124944 ENSMUSG00000106744    Riok2    -0.170040112 0.0150939
ENSMUSG00000028633    Ctps -0.181208364 2.06E-05 ENSMUSG00000026796    Fam129b -0.169518756 1.12E-06
ENSMUSG00000029344    Tpst2    -0.181131628 0.0034734 ENSMUSG00000049922    Slc35c1    -0.169501003 0.0442575
ENSMUSG00000042644    Itpr3    -0.181128958 0.0023803 ENSMUSG00000022884    Eif4a2    -0.169422139 4.05E-09
ENSMUSG00000083327    Vcp-rs -0.181073694 0.0022132 ENSMUSG00000041712    Ubr7    -0.169379147 0.002012
ENSMUSG00000027710    Acad9    -0.180861388 0.0045811 ENSMUSG00000027397    Slc20a1    -0.168622174 0.0077046
ENSMUSG00000003923    Tfam -0.180820657 0.0011716 ENSMUSG00000003438    Timm50    -0.168426141 0.002778
ENSMUSG00000023452    Pisd -0.18060993 0.0154572 ENSMUSG00000044986    Tst -0.168376161 0.0099781
ENSMUSG00000026960    Arl6ip6    -0.180592185 0.0075754 ENSMUSG00000017679    Ttpal -0.16778159 0.0175925
ENSMUSG00000026245    Farsb -0.180580284 9.43E-05 ENSMUSG00000034290    Nek9    -0.167527204 4.47E-05
ENSMUSG00000026885    Ttll11    -0.180342367 0.041422 ENSMUSG00000039699    Batf2    -0.167205124 0.016934
ENSMUSG00000063800    Prpf38a -0.180159515 0.0123277 ENSMUSG00000038615    Nfe2l1    -0.167199117 2.24E-06
ENSMUSG00000036430    Tbcc -0.180062314 0.0495775 ENSMUSG00000047044    D030056L22Rik -0.166560603 0.00905
ENSMUSG00000032997    Chpf -0.179890019 2.19E-05 ENSMUSG00000020694    Tlk2    -0.166471577 0.0033579
ENSMUSG00000033285    Wdr3    -0.17981743 5.65E-05 ENSMUSG00000027367    Stard7    -0.16637926 0.00011
ENSMUSG00000030872    Gga2    -0.179794342 0.0190775 ENSMUSG00000041548    Hspb8    -0.16630698 0.0018885
ENSMUSG00000053950    Adnp2    -0.179786717 0.0083062 ENSMUSG00000039630    Hnrnpu -0.166134439 0.0008409
ENSMUSG00000045598    Zfp553    -0.179681723 0.0176172 ENSMUSG00000024150    Mcfd2    -0.165809027 0.0023788
ENSMUSG00000039840    Epg5    -0.179645891 0.0365146 ENSMUSG00000025199    Chuk -0.165795559 0.0034272
ENSMUSG00000026248    Mrpl44    -0.179451017 0.0287934 ENSMUSG00000025544    Tm9sf2    -0.165647372 0.0025572
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ENSMUSG00000022564    Grina -0.165592899 0.0001904 ENSMUSG00000020817    Rabep1    -0.153231609 0.0028364
ENSMUSG00000023034    Nr4a1    -0.165562893 0.0025052 ENSMUSG00000000743    Chmp1a -0.153141668 0.0147362
ENSMUSG00000026726    Cubn -0.165405628 0.0118683 ENSMUSG00000020843    Timm22    -0.15302961 0.0210049
ENSMUSG00000028180    Zranb2    -0.164848607 0.000221 ENSMUSG00000045411    2410002F23Rik -0.15302209 0.0032402
ENSMUSG00000056121    Fez2    -0.164621226 0.0235103 ENSMUSG00000014550    Rbsn -0.152669376 0.0174578
ENSMUSG00000050229    Pigm -0.164532113 0.0362274 ENSMUSG00000024622    Hmgxb3    -0.152611374 0.0091918
ENSMUSG00000024142    Mlst8    -0.164516317 0.0372318 ENSMUSG00000024242    Map4k3    -0.152540549 0.0076934
ENSMUSG00000015806    Qdpr -0.164378538 0.0255773 ENSMUSG00000045629    Sh3tc2    -0.152356871 0.0488624
ENSMUSG00000074570    Cass4    -0.164343193 0.027116 ENSMUSG00000008035    Mid1ip1    -0.152325692 0.0198227
ENSMUSG00000020611    Gna13    -0.164077857 0.003561 ENSMUSG00000094870    Zfp131    -0.152292555 0.0477186
ENSMUSG00000017765    Slc12a4        -0.163922663 0.0110596 ENSMUSG00000020393    Kremen1    -0.151920675 0.0290615
ENSMUSG00000021952    Xpo4    -0.163755623 0.0357984 ENSMUSG00000025381    Cnpy2    -0.151795009 0.0059349
ENSMUSG00000075700    Selt -0.163483699 7.25E-06 ENSMUSG00000026761    Orc4    -0.151740665 0.0253511
ENSMUSG00000027312    Atrn -0.163475878 0.0010765 ENSMUSG00000025894    Aasdhppt -0.151565783 0.0343363
ENSMUSG00000029468    P2rx7    -0.163475448 0.008615 ENSMUSG00000054027    Nt5dc3    -0.151381137 0.030585
ENSMUSG00000027340    Slc23a2    -0.163468657 0.0018993 ENSMUSG00000043733    Ptpn11    -0.151355376 6.50E-06
ENSMUSG00000062190    Lancl2    -0.163302893 0.0296894 ENSMUSG00000037894    H2afz -0.151305955 6.35E-07
ENSMUSG00000042660    Wdr55    -0.163229604 0.010762 ENSMUSG00000033596    Rfwd3    -0.150940801 0.0044748
ENSMUSG00000025616    Usp16    -0.162862934 0.0108124 ENSMUSG00000009470    Tnpo1    -0.150799299 7.05E-05
ENSMUSG00000024764    Naa40    -0.162602391 0.0122305 ENSMUSG00000036718    Micall2    -0.150786125 0.0399063
ENSMUSG00000020422    Tns3    -0.16233556 2.43E-08 ENSMUSG00000022894    Adamts5    -0.15075673 0.0129087
ENSMUSG00000042046    Dstyk -0.162028345 0.0286083 ENSMUSG00000022503    Nubp1    -0.150689223 0.0221895
ENSMUSG00000020483    Dynll2    -0.162006641 0.000627 ENSMUSG00000020464    Pnpt1    -0.150347848 0.0017765
ENSMUSG00000056153    Socs6    -0.16144088 0.0225395 ENSMUSG00000071172    Srsf3    -0.150333475 7.27E-07
ENSMUSG00000030499    Kctd15    -0.161296146 0.0146388 ENSMUSG00000033706    Smyd5    -0.1502701 0.0152731
ENSMUSG00000044934    Zfp367    -0.160924618 0.0150674 ENSMUSG00000038650    Rnh1    -0.150115091 0.0072308
ENSMUSG00000005882    Uqcc1    -0.160715703 0.0215193 ENSMUSG00000038780    Smurf1    -0.150059347 1.78E-05
ENSMUSG00000035673    Sbno2    -0.160378797 0.0081571 ENSMUSG00000021189    Atxn3    -0.149887011 0.0478958
ENSMUSG00000041025    Iffo2    -0.160297065 0.0110319 ENSMUSG00000037851    Iars -0.149834918 3.31E-05
ENSMUSG00000026319    2310035C23Rik -0.160007072 0.0138449 ENSMUSG00000022412    Mief1    -0.148990014 0.0184258
ENSMUSG00000027309    4930402H24Rik -0.159949313 0.0098811 ENSMUSG00000048170    Mcmbp -0.148670252 0.0011583
ENSMUSG00000024293    Esco1    -0.159863152 0.0444403 ENSMUSG00000071793    2610005L07Rik -0.148561784 0.0428648
ENSMUSG00000015804    Med28    -0.159533109 0.008411 ENSMUSG00000046722    Cdc42se1    -0.148404569 1.27E-05
ENSMUSG00000046671    Mtfr1l -0.159457456 0.0075272 ENSMUSG00000051232    Tmem199    -0.148111706 0.0479061
ENSMUSG00000024580    Grpel2    -0.159241759 0.0239495 ENSMUSG00000020015    Cdk17    -0.147926021 0.0138495
ENSMUSG00000107470    CAAA01093177.1    -0.159057366 0.0402237 ENSMUSG00000017802    Fam134c -0.147847398 0.0236241
ENSMUSG00000028195    Cyr61    -0.159014528 0.0006625 ENSMUSG00000026112    Coa5    -0.14728639 0.0048489
ENSMUSG00000064080    Fbln2    -0.158660878 5.65E-10 ENSMUSG00000040390    Map3k10    -0.147218285 0.0270832
ENSMUSG00000017929    B4galt5    -0.158515123 0.000466 ENSMUSG00000000378    Ccm2    -0.14720108 0.0070215
ENSMUSG00000021701    Plk2    -0.158419676 0.0005916 ENSMUSG00000070462    Mesdc1    -0.147178814 0.0349566
ENSMUSG00000020413    Hus1    -0.15837201 0.0085827 ENSMUSG00000031904    Slc7a6    -0.147174374 0.0197278
ENSMUSG00000079297    Gm2223    -0.158297999 0.0472283 ENSMUSG00000078249    Hmga1-rs1    -0.146527505 0.040229
ENSMUSG00000026204    Ptprn -0.158285827 0.0129426 ENSMUSG00000029246    Ppat -0.14639193 0.0092131
ENSMUSG00000027822    Slc33a1    -0.158235473 0.0361948 ENSMUSG00000024589    Nedd4l -0.146341863 0.0006808
ENSMUSG00000026389    Steap3    -0.158181694 0.0006729 ENSMUSG00000047213    Ythdf3    -0.14630411 0.0066174
ENSMUSG00000091089    A930018M24Rik -0.158082041 0.018543 ENSMUSG00000053835    H2-T24        -0.14629517 0.0258821
ENSMUSG00000026135    Zfp142    -0.158054378 0.0207501 ENSMUSG00000024937    Ehbp1l1    -0.145808527 0.0076282
ENSMUSG00000040661    Rad54l2    -0.157993589 0.002127 ENSMUSG00000022528    Hes1    -0.145742596 0.0294124
ENSMUSG00000022514    Il1rap -0.157644317 5.25E-08 ENSMUSG00000026123    Plekhb2    -0.145725573 0.0238794
ENSMUSG00000018736    Ndel1    -0.157581108 0.0070482 ENSMUSG00000096458    Moap1    -0.145529087 0.0403894
ENSMUSG00000076437    2700094K13Rik -0.157385371 0.0048412 ENSMUSG00000010453    Kansl3    -0.145305076 0.0106253
ENSMUSG00000027787    Nmd3    -0.157158877 0.0048981 ENSMUSG00000047434    Xxylt1    -0.145288474 0.0153124
ENSMUSG00000022992    Kansl2    -0.157108745 0.0005283 ENSMUSG00000032386    Trip4    -0.145239787 0.0287273
ENSMUSG00000026663    Atf6    -0.157044482 0.0017969 ENSMUSG00000022426    Josd1    -0.1451623 0.0013552
ENSMUSG00000027488    Snta1    -0.156969333 0.0408207 ENSMUSG00000041801    Phlda3    -0.144994612 0.0021852
ENSMUSG00000040699    Limd2    -0.156901348 0.0419119 ENSMUSG00000022367    Has2    -0.144974414 0.0253111
ENSMUSG00000030403    Vasp -0.156775895 0.0042075 ENSMUSG00000024457    Trim26    -0.14491961 0.0499218
ENSMUSG00000040463    Mybbp1a -0.156523709 5.57E-10 ENSMUSG00000014030    Pax5    -0.14456865 0.0114498
ENSMUSG00000040688    Tbl3    -0.156436908 0.0012662 ENSMUSG00000022175    Lrp10    -0.143883144 0.0184196
ENSMUSG00000024404    Riok3    -0.156370583 0.0082716 ENSMUSG00000041135    Ripk2    -0.143834405 0.0495745
ENSMUSG00000002458    Rgs19    -0.156364887 0.0193521 ENSMUSG00000038305    Spats2l -0.143390539 0.0071585
ENSMUSG00000024778    Fas -0.156293245 0.0342803 ENSMUSG00000026674    Ddr2    -0.143257437 0.0046392
ENSMUSG00000052429    Prmt1    -0.156134741 6.53E-06 ENSMUSG00000021567    Nkd2    -0.143241699 0.0003371
ENSMUSG00000016477    E2f3    -0.156065136 0.0467025 ENSMUSG00000023087    Ccrn4l -0.143107607 0.0050536
ENSMUSG00000062397    Zfp706    -0.155700113 2.51E-05 ENSMUSG00000020386    Sar1b -0.143081036 0.0193811
ENSMUSG00000051256    Jagn1    -0.155629894 0.0231452 ENSMUSG00000015745    Plekho1    -0.143052704 0.0003889
ENSMUSG00000028514    Usp24    -0.155493393 0.0017243 ENSMUSG00000009585    Apobec3    -0.142936781 0.0475581
ENSMUSG00000016946    Kctd5    -0.15539754 0.0094904 ENSMUSG00000031365    Zfp275    -0.142837019 0.0134356
ENSMUSG00000033096    Apmap -0.155191135 0.0237763 ENSMUSG00000038047    Haus6    -0.14282981 0.0360742
ENSMUSG00000032369    Plscr1    -0.154877494 0.002102 ENSMUSG00000106106    Rn18s-rs5    -0.142722407 0.0009233
ENSMUSG00000033964    Zbtb41    -0.154648421 0.0060552 ENSMUSG00000003848    Nob1    -0.142475829 0.0210962
ENSMUSG00000058569    Tmed9    -0.15456738 0.0025125 ENSMUSG00000026974    Zmynd19    -0.142406175 0.022314
ENSMUSG00000024571    Gm16286    -0.154476132 0.0012264 ENSMUSG00000034707    Gns -0.142301436 0.0005738
ENSMUSG00000038855    Itpkb -0.154465471 0.0252192 ENSMUSG00000073700    Klhl21    -0.142059088 0.0008581
ENSMUSG00000034595    Ppp1r18    -0.154362596 3.76E-05 ENSMUSG00000038279    Nop2    -0.141907445 0.0003732
ENSMUSG00000047036    Zfp445    -0.154203013 0.0221436 ENSMUSG00000006418    Rnf114    -0.14180357 0.0199641
ENSMUSG00000032381    Fam96a -0.15397569 0.0119224 ENSMUSG00000026019    Wdr12    -0.141324398 0.0077531
ENSMUSG00000021018    Polr2h -0.153826535 0.0231111 ENSMUSG00000037315    Jade3    -0.141227958 0.0489537
ENSMUSG00000028318    Polr1e -0.153691701 0.0116745 ENSMUSG00000033161    Atp1a1    -0.141220346 1.86E-09
ENSMUSG00000037275    Gemin5    -0.153326804 4.50E-05 ENSMUSG00000034640    Tiparp -0.140896162 0.0479895
ENSMUSG00000027424    Mgme1    -0.153292396 0.0399478 ENSMUSG00000048782    Insc -0.140809525 0.0168353
 
 
 147 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Gene Log2 Fold Change pValue Gene Log2 Fold Change pValue
ENSMUSG00000020152    Actr2    -0.140688241 7.65E-08 ENSMUSG00000022704    Qtrtd1    -0.128170517 0.0196755
ENSMUSG00000019082    Slc25a22    -0.140190099 0.0478304 ENSMUSG00000005397    Nid1    -0.128050007 0.002194
ENSMUSG00000018171    Vmp1    -0.140048287 0.0005627 ENSMUSG00000020978    Klhdc2    -0.127992316 0.0145276
ENSMUSG00000033799    Fam208b -0.139820083 0.0211151 ENSMUSG00000049807    Arhgap23    -0.127894588 0.0463258
ENSMUSG00000028233    Tgs1    -0.139798839 0.0134023 ENSMUSG00000039703    Nploc4    -0.127815185 0.0064611
ENSMUSG00000018433    Nol11    -0.139637669 0.0009709 ENSMUSG00000055612    Cdca7    -0.127561108 0.0190798
ENSMUSG00000002602    Axl -0.139508646 1.08E-10 ENSMUSG00000035898    Uba6    -0.127513189 0.0298651
ENSMUSG00000026867    Gapvd1    -0.13933117 0.0105004 ENSMUSG00000033149    Phldb2    -0.12749859 0.0367185
ENSMUSG00000020570    Sypl -0.139258025 0.0123223 ENSMUSG00000035900    Gramd4    -0.12721566 0.0072044
ENSMUSG00000037855    Zfp365    -0.139225237 0.0275166 ENSMUSG00000027293    Ehd4    -0.126882036 0.0177459
ENSMUSG00000000399    Ndufa9    -0.139192152 0.0059353 ENSMUSG00000028557    Rnf11    -0.126759476 0.0156317
ENSMUSG00000028776    Tinagl1    -0.139167852 4.42E-05 ENSMUSG00000028468    Rgp1    -0.126734125 0.0346726
ENSMUSG00000035351    Nup37    -0.139004555 0.0147304 ENSMUSG00000022437    Samm50    -0.126722433 0.0032223
ENSMUSG00000024816    Frmd8    -0.138962053 0.0030263 ENSMUSG00000052397    Ezr -0.126679114 0.0024077
ENSMUSG00000026280    Atg4b -0.138918203 0.0284764 ENSMUSG00000032594    Ip6k1    -0.126614714 0.0208116
ENSMUSG00000042363    Lgalsl -0.138764252 0.0238962 ENSMUSG00000030126    Tmcc1    -0.126469426 0.0263615
ENSMUSG00000031917    Nip7    -0.138741347 0.025854 ENSMUSG00000026037    Orc2    -0.126336559 0.0074999
ENSMUSG00000029334    Prkg2    -0.138662217 0.0001541 ENSMUSG00000021140    Pcnx -0.126317809 0.0314112
ENSMUSG00000021102    Glrx5    -0.138421799 0.0211316 ENSMUSG00000026749    Nek6    -0.125931121 0.0107014
ENSMUSG00000033184    Tmed7    -0.138259352 0.0011333 ENSMUSG00000005813    Metap1    -0.125888772 0.0089382
ENSMUSG00000032244    Fem1b -0.138188309 0.0068811 ENSMUSG00000087445    Gm14286    -0.125685165 0.0402795
ENSMUSG00000039105    Atp6v1g1    -0.137943722 0.0091278 ENSMUSG00000035754    Wdr18    -0.125656473 0.0249015
ENSMUSG00000029134    Plb1    -0.137916028 0.0361881 ENSMUSG00000048039    Isg20l2    -0.125570492 0.046923
ENSMUSG00000023004    Tuba1b -0.137859704 6.02E-06 ENSMUSG00000071652    Ints5    -0.125495788 0.0228106
ENSMUSG00000031781    Ciapin1    -0.137806429 0.0311156 ENSMUSG00000041733    Coq5    -0.125237417 0.0385956
ENSMUSG00000039244    E130309D02Rik -0.137725978 0.0284811 ENSMUSG00000040620    Dhx33    -0.125143205 0.0167795
ENSMUSG00000094627    Gm10182    -0.137706692 0.0338023 ENSMUSG00000035614    Fam179b -0.125019253 0.0431155
ENSMUSG00000097346    Gm26619    -0.137610688 0.0358067 ENSMUSG00000020520    Galnt10    -0.125002045 0.001567
ENSMUSG00000045312    Lhfpl2    -0.137463728 0.0054799 ENSMUSG00000020388    Pdlim4    -0.124816278 0.0261341
ENSMUSG00000063317    Usp31    -0.13737167 0.0242052 ENSMUSG00000016664    Pacsin2    -0.124264156 0.000686
ENSMUSG00000052298    Cdc42se2    -0.137192548 0.0096837 ENSMUSG00000057497    Fam136a -0.124197985 0.0442406
ENSMUSG00000068922    Msto1    -0.137165023 0.013935 ENSMUSG00000038485    Socs7    -0.123783484 0.0226383
ENSMUSG00000051391    Ywhag -0.13703265 2.61E-06 ENSMUSG00000034612    Chst11    -0.123608914 0.0002098
ENSMUSG00000032773    Chrm1    -0.136790893 0.0372432 ENSMUSG00000020088    Sar1a -0.123585012 0.0016364
ENSMUSG00000021608    Lpcat1    -0.136710014 0.0172757 ENSMUSG00000030505    Prmt3    -0.123264471 0.0119707
ENSMUSG00000028896    Rcc1    -0.136513983 0.0051385 ENSMUSG00000022538    Lsg1    -0.123167097 0.0145357
ENSMUSG00000066232    Ipo7    -0.136471827 1.70E-06 ENSMUSG00000062611    Rps3a2    -0.122553009 0.0213775
ENSMUSG00000020642    Rnf144a -0.136372412 0.0329497 ENSMUSG00000033735    Spr -0.122500127 0.0463086
ENSMUSG00000026087    Mrpl30    -0.136225592 0.0190921 ENSMUSG00000046756    Mrps7    -0.122475207 0.014212
ENSMUSG00000038683    Pak1ip1    -0.135912823 0.0260683 ENSMUSG00000060636    Rpl35a -0.122437266 0.0011904
ENSMUSG00000046062    Ppp1r15b -0.135849143 0.008475 ENSMUSG00000017715    Pgs1    -0.122212446 0.0197023
ENSMUSG00000028273    Pdlim5    -0.135677282 0.0016277 ENSMUSG00000070436    Serpinh1    -0.122090123 5.08E-06
ENSMUSG00000001521    Tulp3    -0.135561627 0.0042813 ENSMUSG00000055491    Pprc1    -0.121725338 0.0032802
ENSMUSG00000021939    Ctsb -0.135491045 0.0003144 ENSMUSG00000042745    Id1    -0.121554338 0.0132837
ENSMUSG00000004054    Map3k11    -0.135386571 0.0428226 ENSMUSG00000022394    L3mbtl2    -0.121361841 0.0194494
ENSMUSG00000003518    Dusp3    -0.135369713 0.0285635 ENSMUSG00000040659    Efhd2    -0.121273744 0.0439167
ENSMUSG00000079104    Prps1l3    -0.134743289 0.0478722 ENSMUSG00000030753    Prkrir -0.121254191 0.0025025
ENSMUSG00000022551    Cyc1    -0.134715479 0.0005178 ENSMUSG00000011096    Akt1s1    -0.121119358 0.0233222
ENSMUSG00000026667    Uhmk1    -0.134563712 0.0033405 ENSMUSG00000052144    Ppp4r2    -0.121072046 0.0010753
ENSMUSG00000023307    March5    -0.134159575 0.0097071 ENSMUSG00000050244    Heatr1    -0.120585713 0.0116945
ENSMUSG00000074746    Pdzd8    -0.134134778 0.0203952 ENSMUSG00000001627    Ifrd1    -0.119961356 0.0227351
ENSMUSG00000030327    Necap1    -0.134038005 0.0174061 ENSMUSG00000025995    Wdr75    -0.119821114 0.0082304
ENSMUSG00000028945    Rheb -0.133916613 0.0069119 ENSMUSG00000047879    Usp14    -0.119489154 0.0047562
ENSMUSG00000051510    Mafg -0.133863101 0.0197256 ENSMUSG00000025858    Get4    -0.119469938 0.0103866
ENSMUSG00000104222    Gm7292    -0.133839691 0.0375553 ENSMUSG00000001785    Pwp1    -0.11910573 0.0146397
ENSMUSG00000037458    Azin1    -0.133546638 2.16E-06 ENSMUSG00000048332    Lhfp -0.119054374 0.0163771
ENSMUSG00000020592    Sdc1    -0.133534923 0.0029194 ENSMUSG00000020250    Txnrd1    -0.11904078 0.0002977
ENSMUSG00000022814    Umps -0.133385927 0.0005364 ENSMUSG00000009614    Sardh -0.11875328 0.04875
ENSMUSG00000071072    Ptges3    -0.133340279 2.87E-05 ENSMUSG00000019960    Dusp6    -0.118657957 0.006903
ENSMUSG00000044700    Tmem201    -0.132842202 0.02403 ENSMUSG00000062937    Mtap -0.118565768 0.0120228
ENSMUSG00000018398    Sept8    -0.132565437 0.0056983 ENSMUSG00000025651    Uqcrc1    -0.118338673 0.0016391
ENSMUSG00000027465    Tbc1d20    -0.132555091 0.0095207 ENSMUSG00000027646    Src -0.118272981 0.0363057
ENSMUSG00000028261    Ndufaf4    -0.132335812 0.024241 ENSMUSG00000022300    Dcaf13    -0.117972997 0.024108
ENSMUSG00000035342    Lzts2    -0.13186997 0.0078851 ENSMUSG00000054079    Utp18    -0.117822842 0.0205065
ENSMUSG00000028126    Pip5k1a -0.131400722 0.0311239 ENSMUSG00000050567    Maml1    -0.117391747 0.0449877
ENSMUSG00000040152    Thbs1    -0.130917299 7.05E-06 ENSMUSG00000007659    Bcl2l1    -0.117332029 0.0032754
ENSMUSG00000022881    Rfc4    -0.130687411 0.0246478 ENSMUSG00000030660    Pik3c2a -0.117148392 0.0099877
ENSMUSG00000020741    Cluh -0.130269545 0.0006122 ENSMUSG00000021072    Tmx1    -0.117109367 0.0247625
ENSMUSG00000029152    Ociad1    -0.130086118 0.0015235 ENSMUSG00000027601    Mtfr1    -0.116807194 0.0380594
ENSMUSG00000031993    Snx19    -0.129982109 0.0333508 ENSMUSG00000034120    Srsf2    -0.116717357 0.0015042
ENSMUSG00000020840    Blmh -0.129967496 0.0271283 ENSMUSG00000035770    Dync1li2    -0.116650282 0.0314069
ENSMUSG00000017831    Rab5a -0.129883545 0.0391398 ENSMUSG00000043683    Fem1a -0.116347292 0.0442234
ENSMUSG00000032058    Ppp2r1b -0.129777031 0.0118021 ENSMUSG00000011877    Git1    -0.116338225 0.0003584
ENSMUSG00000012422    Tmem167    -0.129640481 0.0411134 ENSMUSG00000027823    Gmps -0.116292861 0.0074904
ENSMUSG00000026374    Tsn -0.129554582 0.0042659 ENSMUSG00000029578    Wipi2    -0.116277681 0.0132708
ENSMUSG00000032869    Psmf1    -0.129335048 0.0477553 ENSMUSG00000020472    Zkscan17    -0.116211719 0.0478961
ENSMUSG00000027502    Rtfdc1    -0.129155321 0.0240118 ENSMUSG00000029703    Lrwd1    -0.116068897 0.0356531
ENSMUSG00000031657    Heatr3    -0.129000823 0.0073352 ENSMUSG00000046032    Snx12    -0.116004583 0.0359741
ENSMUSG00000024997    Prdx3    -0.128661042 0.0120481 ENSMUSG00000023025    Larp4        -0.115237663 0.0015696
ENSMUSG00000027575    Arfgap1    -0.128511476 0.0365729 ENSMUSG00000020219    Timm13    -0.115234099 0.0260324
ENSMUSG00000025178    Pi4k2a -0.128244406 0.0301042 ENSMUSG00000048029    Eno4    -0.115192652 0.0475703
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ENSMUSG00000019795    Pcmt1    -0.115098315 0.0251025 ENSMUSG00000001228    Uhrf1    -0.094905262 0.0027189
ENSMUSG00000030275    Etnk1    -0.114767211 0.0359138 ENSMUSG00000022010    Tsc22d1    -0.094896602 0.043184
ENSMUSG00000040857    Erf -0.114733958 0.0092886 ENSMUSG00000049553    Polr1a -0.094621816 0.0118433
ENSMUSG00000039405    Prss23    -0.114732079 0.0237958 ENSMUSG00000056429    Tgoln1    -0.094614996 0.0256092
ENSMUSG00000017943    Gdap1l1    -0.114647977 0.0171253 ENSMUSG00000028955    Vamp3    -0.094460115 0.0491417
ENSMUSG00000000168    Dlat -0.114360425 0.0150106 ENSMUSG00000018481    Appbp2    -0.094208543 0.0478042
ENSMUSG00000062929    Cfl2    -0.114320789 0.0353148 ENSMUSG00000026020    Nop58    -0.094030468 0.0052304
ENSMUSG00000024429    Gnl1    -0.114095801 0.0258822 ENSMUSG00000022438    Parvb -0.093776608 0.0379334
ENSMUSG00000061904    Slc25a3    -0.113993599 5.54E-05 ENSMUSG00000009376    Met -0.093134158 0.0159068
ENSMUSG00000093904    Tomm20    -0.113649844 0.0213977 ENSMUSG00000042506    Usp22    -0.092196314 0.0224898
ENSMUSG00000025856    Pdgfa -0.113590329 0.0002013 ENSMUSG00000021024    Psma6    -0.092065561 0.0216038
ENSMUSG00000039682    Lap3    -0.113282569 0.0140761 ENSMUSG00000020473    Aebp1    -0.092004735 5.10E-05
ENSMUSG00000015733    Capza2    -0.112694683 0.003624 ENSMUSG00000032480    Dhx30    -0.092001745 0.0311886
ENSMUSG00000015653    Steap2    -0.1125454 0.0441694 ENSMUSG00000022255    Mtdh -0.091838604 0.0141457
ENSMUSG00000025417    Pip4k2c -0.112499499 0.0232783 ENSMUSG00000000740    Rpl13    -0.091388715 0.0013768
ENSMUSG00000017861    Mybl2    -0.112439595 0.0354705 ENSMUSG00000078652    Psme3    -0.091332867 0.0126915
ENSMUSG00000021877    Arf4    -0.111869818 0.0074697 ENSMUSG00000042079    Hnrnpf -0.090964768 0.0008135
ENSMUSG00000023348    Trip6    -0.111732783 0.04265 ENSMUSG00000000753    Serpinf1    -0.090646449 0.0103571
ENSMUSG00000039001    Rps21    -0.111524622 0.0007374 ENSMUSG00000020114    Cand1    -0.090232555 0.0128528
ENSMUSG00000024120    Lrpprc -0.111345094 0.006824 ENSMUSG00000025047    Pdcd11    -0.090199424 0.0369465
ENSMUSG00000016559    H3f3b -0.111334125 6.26E-07 ENSMUSG00000029430    Ran -0.090060431 0.0003925
ENSMUSG00000086704    Gm14582    -0.11114366 0.04575 ENSMUSG00000022962    Gart -0.089640476 0.0410698
ENSMUSG00000066324    Impad1    -0.111025707 0.0041363 ENSMUSG00000020745    Pafah1b1    -0.089225592 0.0091326
ENSMUSG00000022295    Atp6v1c1    -0.110811472 0.016459 ENSMUSG00000026103    Gls -0.088276096 0.0431755
ENSMUSG00000017776    Crk -0.110798226 0.0018515 ENSMUSG00000036912    Piwil4    -0.088223476 0.0497369
ENSMUSG00000002059    Rab34    -0.11069879 0.020996 ENSMUSG00000104713    Gbp6    -0.087461771 0.0388856
ENSMUSG00000039804    Ncoa5    -0.110652089 0.0477481 ENSMUSG00000033813    Tcea1    -0.087368279 0.0237606
ENSMUSG00000025239    Limd1    -0.110638052 0.0251912 ENSMUSG00000024576    Csnk1a1    -0.086086148 0.0081217
ENSMUSG00000074656    Eif2s2    -0.110560423 0.0003055 ENSMUSG00000041459    Tardbp -0.085814857 0.0052665
ENSMUSG00000002741    Ykt6    -0.110354803 0.0058424 ENSMUSG00000023068    Nus1    -0.085214337 0.0167379
ENSMUSG00000007029    Vars -0.109775424 0.0006548 ENSMUSG00000039000    Ube3c -0.084891209 0.0222623
ENSMUSG00000030180    Kdm5a -0.109629635 0.0455916 ENSMUSG00000053332    Gas5    -0.08411424 0.029777
ENSMUSG00000018770    Atp5g3    -0.109494849 0.0018485 ENSMUSG00000005610    Eif4g2    -0.084032298 6.22E-05
ENSMUSG00000020097    Sgpl1    -0.109361493 0.0141563 ENSMUSG00000030884    Uqcrc2    -0.083350563 0.0163277
ENSMUSG00000051223    Bzw1    -0.109054439 0.0004063 ENSMUSG00000004356    Utp20    -0.083109876 0.0396398
ENSMUSG00000022629    Kif21a -0.109034383 0.0432829 ENSMUSG00000020372    Gnb2l1    -0.082919396 0.000277
ENSMUSG00000028314    Toporsl -0.109013537 0.0479056 ENSMUSG00000062825    Actg1    -0.081867184 0.0003025
ENSMUSG00000037857    Nufip2    -0.108907702 0.0312687 ENSMUSG00000046841    Ckap4    -0.081807042 0.0198611
ENSMUSG00000042747    Krtcap2    -0.108532136 0.0379323 ENSMUSG00000040945    Rcc2    -0.080408906 0.0031619
ENSMUSG00000020585    Laptm4a -0.108022034 0.0006263 ENSMUSG00000018583    G3bp1    -0.080237724 0.0027266
ENSMUSG00000020238    Ncln -0.107885083 0.0147157 ENSMUSG00000035242    Oaz1    -0.079640144 0.0110519
ENSMUSG00000021477    Ctsl -0.107670832 0.0008717 ENSMUSG00000082976    Gm15056    -0.079511395 0.0494384
ENSMUSG00000036167    Pphln1    -0.107660268 0.0136845 ENSMUSG00000071646    Mta2    -0.079285563 0.0455381
ENSMUSG00000010048    Ifrd2    -0.107640681 0.0417553 ENSMUSG00000003131    Pafah1b2    -0.078576184 0.0280735
ENSMUSG00000021484    Lman2    -0.107134207 0.0089597 ENSMUSG00000040952    Rps19    -0.078315446 0.0049825
ENSMUSG00000013662    Atad1    -0.107134075 0.0215134 ENSMUSG00000012848    Rps5    -0.077405675 0.0014697
ENSMUSG00000038774    Ascc3    -0.106929312 0.0492864 ENSMUSG00000018446    C1qbp -0.07531545 0.0222627
ENSMUSG00000022800    Fyttd1    -0.106286833 0.0171329 ENSMUSG00000026341    Actr3    -0.073993973 0.0247669
ENSMUSG00000017499    Cdc6    -0.106119409 0.0337388 ENSMUSG00000057863    Rpl36    -0.073343715 0.0279915
ENSMUSG00000014444    Piezo1    -0.105592672 0.0117319 ENSMUSG00000034993    Vat1    -0.073187222 0.0298837
ENSMUSG00000021039    Snw1    -0.105589505 0.0482032 ENSMUSG00000027404    Snrpb -0.073124726 0.0252369
ENSMUSG00000027889    Ampd2    -0.105582688 0.0386014 ENSMUSG00000001440    Kpnb1    -0.072588467 0.0011917
ENSMUSG00000030224    Strap -0.105526888 0.002135 ENSMUSG00000090862    Rps13    -0.072587282 0.0193257
ENSMUSG00000016487    Ppfibp1    -0.105470967 0.0001782 ENSMUSG00000022858    Tra2b -0.072560563 0.044809
ENSMUSG00000036990    Otud4    -0.105431531 0.020196 ENSMUSG00000062006    Rpl34    -0.071506243 0.0301468
ENSMUSG00000018921    Pelp1    -0.105385625 0.0497257 ENSMUSG00000018379    Srsf1    -0.069025089 0.0215649
ENSMUSG00000036707    Cab39    -0.104672929 0.0131046 ENSMUSG00000001416    Cct3    -0.068440179 0.0171743
ENSMUSG00000029621    Arpc1a -0.104555674 0.0083121 ENSMUSG00000028063    Lmna -0.068223517 0.0068751
ENSMUSG00000037503    Fam168b -0.104387124 0.0031958 ENSMUSG00000028234    Rps20    -0.066205216 0.0092201
ENSMUSG00000048852    Gm12185    -0.104332981 0.023365 ENSMUSG00000041734    Kirrel -0.065825627 0.0273137
ENSMUSG00000028430    Nol6    -0.103892299 0.0157902 ENSMUSG00000037236    Matr3    -0.065624647 0.0450122
ENSMUSG00000027782    Kpna4    -0.103856547 0.0195024 ENSMUSG00000008683    Rps15a -0.065323554 0.0135501
ENSMUSG00000020899    Pfas -0.10340507 0.0112466 ENSMUSG00000032135    Mcam -0.065054901 0.0388479
ENSMUSG00000032803    Cdv3    -0.102879184 0.0013471 ENSMUSG00000020361    Hspa4    -0.064101165 0.0156947
ENSMUSG00000056144    Trim34a -0.102703346 0.0402025 ENSMUSG00000037331    Larp1    -0.064036492 0.0232094
ENSMUSG00000005204    Senp3    -0.102307909 0.0110681 ENSMUSG00000025351    Cd63    -0.059928081 0.0295175
ENSMUSG00000032867    Fbxw8    -0.10217449 0.0225946 ENSMUSG00000029622    Arpc1b -0.056406833 0.0125219
ENSMUSG00000035885    Cox8a -0.101784695 0.0104061 ENSMUSG00000029447    Cct6a -0.052430118 0.0276991
ENSMUSG00000056537    Rlim -0.101699034 0.0388563 ENSMUSG00000054808    Actn4    0.048750091 0.0398528
ENSMUSG00000091957    Rps2-ps10    -0.100691944 0.0062057 ENSMUSG00000020460    Rps27a 0.048849628 0.037112
ENSMUSG00000030007    Cct7    -0.100585039 0.0004993 ENSMUSG00000061983    Rps12    0.050853564 0.0257895
ENSMUSG00000020708    Psmc5    -0.100501784 0.0168449 ENSMUSG00000025809    Itgb1    0.051213084 0.0269067
ENSMUSG00000067851    Arfgef1    -0.100185464 0.0415371 ENSMUSG00000078812    Eif5a 0.051791296 0.0228381
ENSMUSG00000023150    Ivns1abp -0.099948485 0.0022294 ENSMUSG00000074129    Rpl13a 0.054258971 0.0319998
ENSMUSG00000028455    Stoml2    -0.099902417 0.0397048 ENSMUSG00000062203    Gspt1    0.055086668 0.0437406
ENSMUSG00000030082    Sec61a1    -0.099706002 0.0031162 ENSMUSG00000034024    Cct2    0.05727966 0.0193269
ENSMUSG00000019132    BC005537    -0.099467373 0.0281471 ENSMUSG00000041841    Rpl37    0.061018163 0.0278106
ENSMUSG00000020598    Nrcam -0.09884229 0.0134582 ENSMUSG00000019432    Ddx39b 0.061520957 0.0458675
ENSMUSG00000020664    Dld -0.097803276 0.0092808 ENSMUSG00000032096    Arcn1    0.06173066 0.0399723
ENSMUSG00000025967    Eef1b2    -0.095986141 0.000245 ENSMUSG00000026478    Lamc1    0.062106586 0.0444485
ENSMUSG00000047180    Neurl3    -0.095984997 0.048494 ENSMUSG00000031167    Rbm3    0.062988191 0.007684
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ENSMUSG00000024063    Lbh 0.063569182 0.0428576 ENSMUSG00000005698    Ctcf 0.089989562 0.0496204
ENSMUSG00000057113    Npm1    0.064722916 0.0021854 ENSMUSG00000015120    Ube2i 0.089990055 0.0074706
ENSMUSG00000048076    Arf1    0.06512033 0.0121262 ENSMUSG00000018160    Med1    0.090423747 0.0353455
ENSMUSG00000010277    2610507B11Rik 0.066393399 0.0241795 ENSMUSG00000025510    Cd151    0.09056356 0.0202898
ENSMUSG00000020917    Acly 0.066789313 0.0418318 ENSMUSG00000039953    Clstn1    0.090639013 0.0194159
ENSMUSG00000030062    Rpn1    0.067252681 0.0269704 ENSMUSG00000029718    Pcolce 0.09067208 0.0028615
ENSMUSG00000030835    Nomo1    0.067754623 0.0362596 ENSMUSG00000030603    Psmc4    0.091082135 0.0225196
ENSMUSG00000040385    Ppp1ca 0.06820549 0.046277 ENSMUSG00000027566    Psma7    0.091227487 0.0183648
ENSMUSG00000033047    Eif3l 0.068338583 0.0194943 ENSMUSG00000029364    Wsb2    0.091706121 0.0301793
ENSMUSG00000005683    Cs 0.068542021 0.0101174 ENSMUSG00000020994    Pnn 0.092095123 0.005506
ENSMUSG00000032115    Hyou1    0.068720947 0.0100274 ENSMUSG00000027455    Nsfl1c 0.09211347 0.0458216
ENSMUSG00000020719    Ddx5    0.069514712 0.0057523 ENSMUSG00000033006    Sox10    0.092380257 0.0026543
ENSMUSG00000055065    Ddx17    0.069692891 0.0390253 ENSMUSG00000040667    Nup88    0.092389539 0.0333342
ENSMUSG00000025508    Rplp2    0.069719908 0.0074817 ENSMUSG00000058230    Arhgap35    0.092930083 0.0195634
ENSMUSG00000027828    Ssr3    0.070932439 0.0152063 ENSMUSG00000003360    Ddx23    0.092994409 0.0083284
ENSMUSG00000027342    Pcna 0.071306559 0.0282915 ENSMUSG00000037029    Zfp146    0.093023343 0.0459726
ENSMUSG00000018707    Dync1h1    0.071815846 0.0305963 ENSMUSG00000058655    Eif4b 0.093305366 2.69E-05
ENSMUSG00000071644    Eef1g 0.071939754 0.0016354 ENSMUSG00000017760    Ctsa 0.093387017 0.0497951
ENSMUSG00000004891    Nes 0.072456934 0.0072467 ENSMUSG00000036309    Skp1a 0.093585551 0.009138
ENSMUSG00000003534    Ddr1    0.072594886 0.0384903 ENSMUSG00000040212    Emp3    0.0940296 0.0177664
ENSMUSG00000037608    Bclaf1    0.073105279 0.024922 ENSMUSG00000001525    Tubb5    0.094188976 1.29E-05
ENSMUSG00000025332    Kdm5c 0.074372383 0.0377673 ENSMUSG00000028809    Srrm1    0.094536852 0.0201499
ENSMUSG00000063511    Snrnp70    0.075035798 0.0175595 ENSMUSG00000002297    Dbf4    0.094753395 0.0490675
ENSMUSG00000018293    Pfn1    0.075965033 0.0086946 ENSMUSG00000038467    Chmp4b 0.095031462 0.0256695
ENSMUSG00000031078    Cttn 0.07615013 0.0110858 ENSMUSG00000038762    Abcf1    0.095128844 0.0064098
ENSMUSG00000026623    Lpgat1    0.076452997 0.0218094 ENSMUSG00000038084    Opa1    0.09522926 0.0189302
ENSMUSG00000034892    Rps29    0.076496163 0.0071989 ENSMUSG00000001517    Foxm1    0.09526755 0.0048101
ENSMUSG00000022234    Cct5    0.076747519 0.0034664 ENSMUSG00000028367    Txn1    0.095289986 0.0293437
ENSMUSG00000060166    Zdhhc8    0.077843013 0.049082 ENSMUSG00000011257    Pabpc4    0.095291733 0.0045487
ENSMUSG00000007891    Ctsd 0.078084481 0.0185397 ENSMUSG00000052752    Traf7    0.095424395 0.031799
ENSMUSG00000020929    Eftud2    0.078200817 0.0060933 ENSMUSG00000026837    Col5a1    0.095552499 0.0079296
ENSMUSG00000022285    Ywhaz 0.078676338 0.0031975 ENSMUSG00000003810    Mast2    0.095682468 0.0385259
ENSMUSG00000028691    Prdx1    0.07922751 0.0024872 ENSMUSG00000020181    Nav3    0.095751034 0.0206012
ENSMUSG00000014769    Psmb1    0.079393074 0.043285 ENSMUSG00000024661    Fth1    0.096228265 3.22E-05
ENSMUSG00000006333    Rps9    0.079467585 0.0012547 ENSMUSG00000027363    Usp8    0.09628846 0.0404469
ENSMUSG00000036606    Plxnb2    0.079623575 0.0200893 ENSMUSG00000029767    Calu 0.096526273 0.0002715
ENSMUSG00000032216    Nedd4    0.079700562 9.83E-05 ENSMUSG00000031865    Dctn1    0.096633735 0.0470176
ENSMUSG00000024054    Smchd1    0.079948592 0.045094 ENSMUSG00000036781    Rps27l 0.097353735 0.0281172
ENSMUSG00000094483    Purb 0.080074097 0.0279508 ENSMUSG00000047676    Rpsa-ps10    0.097587972 0.0064999
ENSMUSG00000033228    Scaf11    0.080199233 0.0162833 ENSMUSG00000040054    Baz2a 0.097875881 0.0485025
ENSMUSG00000028330    Ncbp1    0.080605791 0.0350357 ENSMUSG00000019471    Cdc37    0.097877834 0.0029039
ENSMUSG00000032178    Ilf3    0.081558268 0.0261257 ENSMUSG00000040479    Dgkz 0.097916611 0.0146643
ENSMUSG00000005514    Por 0.081575973 0.0455367 ENSMUSG00000032228    Tcf12    0.098559542 0.0085
ENSMUSG00000024981    Acsl5    0.081785479 0.0329498 ENSMUSG00000041355    Ssr2    0.098639597 0.0170533
ENSMUSG00000017057    Il13ra1    0.082513968 0.0493907 ENSMUSG00000026260    Ndufa10    0.098818466 0.0299286
ENSMUSG00000026042    Col5a2    0.083146991 9.87E-05 ENSMUSG00000032397    Tipin 0.098877128 0.0414074
ENSMUSG00000033295    Ptprf 0.083186118 0.0234748 ENSMUSG00000017548    Suz12    0.099008062 0.0073421
ENSMUSG00000027763    Mbnl1    0.083284217 0.0265487 ENSMUSG00000026457    Adipor1    0.099229631 0.0222417
ENSMUSG00000025364    Pa2g4    0.083315009 0.0049419 ENSMUSG00000038690    Atp5j2    0.09953458 0.0170397
ENSMUSG00000020349    Ppp2ca 0.083396858 0.0056096 ENSMUSG00000009013    Dynll1    0.099752004 0.003491
ENSMUSG00000024991    Eif3a 0.083696498 0.0003379 ENSMUSG00000047945    Marcksl1    0.099783608 0.0428924
ENSMUSG00000031256    Cstf2    0.083746393 0.0320732 ENSMUSG00000031059    Ndufb11    0.100009722 0.0352758
ENSMUSG00000022185    Acin1    0.083939204 0.0311652 ENSMUSG00000031060    Rbm10    0.100078131 0.0391391
ENSMUSG00000014959    Gorasp2    0.083976736 0.0454431 ENSMUSG00000001016    Ilf2    0.100244499 0.0117134
ENSMUSG00000059005    Hnrnpa3    0.084589374 0.0008861 ENSMUSG00000053565    Eif3k 0.100301131 0.026194
ENSMUSG00000020720    Psmd12    0.085167189 0.0319001 ENSMUSG00000025204    Ndufb8    0.100516621 0.0353895
ENSMUSG00000055204    Ankrd17    0.085272194 0.022603 ENSMUSG00000068823    Csde1    0.10062723 0.0005814
ENSMUSG00000060938    Rpl26    0.085361207 0.0014892 ENSMUSG00000061518    Cox5b 0.100628661 0.0318716
ENSMUSG00000024870    Rab1b 0.085925534 0.0312889 ENSMUSG00000010205    Raver1    0.100676192 0.0096317
ENSMUSG00000012535    Tnpo3    0.085965269 0.0221613 ENSMUSG00000024507    Hsd17b4    0.100677025 0.0249093
ENSMUSG00000021012    Zc3h14    0.086183489 0.0388723 ENSMUSG00000009073    Nf2    0.100750397 0.004447
ENSMUSG00000031503    Col4a2    0.086203492 0.004727 ENSMUSG00000028149    Rap1gds1    0.100899824 0.0370409
ENSMUSG00000003345    Csnk1g2    0.08626891 0.0342958 ENSMUSG00000020538    Srebf1    0.101157531 0.0339991
ENSMUSG00000028745    Capzb 0.086344263 0.0368838 ENSMUSG00000022607    Ptk2    0.10128319 0.0079786
ENSMUSG00000056342    Usp34    0.086413653 0.0445419 ENSMUSG00000014077    Chp1    0.101404302 0.0273922
ENSMUSG00000028284    Map3k7    0.086517976 0.0397104 ENSMUSG00000027523    Gnas 0.101445946 0.0079144
ENSMUSG00000094195    Gm6509    0.087348546 0.0491729 ENSMUSG00000053617    Sh3pxd2a 0.101507931 0.0060686
ENSMUSG00000019189    Rnf145    0.087358754 0.0175086 ENSMUSG00000032875    Arhgef17    0.101622504 0.0230068
ENSMUSG00000020737    Hn1    0.087533547 0.0126474 ENSMUSG00000024392    Bag6    0.101646075 0.0092504
ENSMUSG00000027201    Myef2    0.088382432 0.0341039 ENSMUSG00000069662    Marcks 0.101723271 0.0030698
ENSMUSG00000031715    Smarca5    0.08842211 0.0316154 ENSMUSG00000018286    Psmb6    0.101759903 0.0112959
ENSMUSG00000010608    Rbm25    0.088697094 0.0286138 ENSMUSG00000040824    Snrpd2    0.102102792 0.0298827
ENSMUSG00000021178    Psmc1    0.088761176 0.0158676 ENSMUSG00000024659    Anxa1    0.102266949 4.04E-05
ENSMUSG00000027479    Mapre1    0.088897275 0.0214773 ENSMUSG00000029148    Nrbp1    0.102406089 0.0371718
ENSMUSG00000038677    Scube3    0.088982186 0.0063423 ENSMUSG00000026176    Ctdsp1    0.102431665 0.026204
ENSMUSG00000058799    Nap1l1    0.088991015 0.0001394 ENSMUSG00000036256    Igfbp7    0.102450572 0.0401792
ENSMUSG00000025503    Taldo1    0.089125486 0.0064306 ENSMUSG00000025083    Afap1l2    0.102571848 0.0350453
ENSMUSG00000061477    Rps7    0.089268703 0.000851 ENSMUSG00000039220    Ppp1r10    0.102600981 0.0498029
ENSMUSG00000007670    Khsrp 0.089375431 0.0145664 ENSMUSG00000057278    Snrpg 0.102810946 0.045114
ENSMUSG00000008690    Ncaph2    0.089765644 0.0112464 ENSMUSG00000094690    1600014C23Rik 0.103251048 0.047266
ENSMUSG00000023110    Prmt5    0.089946375 0.0468704 ENSMUSG00000000751    Rpa1    0.10326747 0.0035189
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ENSMUSG00000014226    Cacybp 0.103273877 0.0046474 ENSMUSG00000026083    Eif5b 0.114139503 0.000889
ENSMUSG00000041879    Ipo9    0.103478846 0.0025653 ENSMUSG00000027804    Ppid 0.114215586 0.0039846
ENSMUSG00000032458    Copb2    0.103512144 0.0089299 ENSMUSG00000020454    Eif4enif1    0.114276396 0.0121467
ENSMUSG00000029614    Rpl6    0.10395831 1.14E-05 ENSMUSG00000030852    Tacc2    0.11429381 0.0328231
ENSMUSG00000001833    Sept7    0.104099232 0.0010678 ENSMUSG00000046079    Lrrc8d 0.114325275 0.0263744
ENSMUSG00000056999    Ide 0.10413453 0.0151824 ENSMUSG00000047216    Cdh19    0.114496911 0.0325988
ENSMUSG00000031342    Gpm6b 0.10414494 0.0047294 ENSMUSG00000007564    Ppp2r1a 0.114541432 0.002455
ENSMUSG00000028343    Erp44    0.104344719 0.0457004 ENSMUSG00000023460    Rab12    0.114758664 0.0428433
ENSMUSG00000020392    Cdkn2aipnl 0.104419015 0.0494702 ENSMUSG00000008301    Phax 0.114822714 0.0394165
ENSMUSG00000039959    Hip1    0.104517666 0.0040628 ENSMUSG00000032399    Rpl4    0.114861967 1.51E-08
ENSMUSG00000033031    C330027C09Rik 0.104677268 0.0281568 ENSMUSG00000029613    Eif2ak1    0.114927269 0.0200831
ENSMUSG00000022378    Fam49b 0.10475083 0.0081771 ENSMUSG00000021377    Dek 0.115090927 0.0063161
ENSMUSG00000028937    Acot7    0.104836514 0.0151524 ENSMUSG00000044224    Dnajc21    0.115103901 0.0369496
ENSMUSG00000030216    Wbp11    0.104843511 0.0148493 ENSMUSG00000039148    Sart1    0.115277727 0.0260719
ENSMUSG00000057335    Cep170    0.104855387 0.0099699 ENSMUSG00000029550    Sppl3    0.115322565 0.0477297
ENSMUSG00000025132    Arhgdia 0.104928878 0.0003613 ENSMUSG00000001910    Nacc1    0.115354533 0.0063072
ENSMUSG00000020850    Prpf8    0.105353109 8.08E-06 ENSMUSG00000004937    Sgta 0.115456392 0.008598
ENSMUSG00000040785    Ttc3    0.106083518 0.0144981 ENSMUSG00000025935    Tram1    0.115687879 0.0298985
ENSMUSG00000029439    Sfswap 0.106171184 0.0250441 ENSMUSG00000060657    Marf1    0.11596481 0.0411613
ENSMUSG00000055319    Sec23ip 0.10628528 0.0241891 ENSMUSG00000034088    Hdlbp 0.116044475 2.03E-06
ENSMUSG00000037012    Hk1    0.106361376 0.0164059 ENSMUSG00000059273    Zc3h4    0.116054607 0.0106035
ENSMUSG00000028961    Pgd 0.106613911 0.0283895 ENSMUSG00000025027    Xpnpep1    0.116218662 0.0070541
ENSMUSG00000030605    Mfge8    0.106667603 0.0072556 ENSMUSG00000052146    Rps10    0.116466206 1.01E-05
ENSMUSG00000005161    Prdx2    0.106751794 0.0121816 ENSMUSG00000007041    Clic1    0.116496274 0.0144541
ENSMUSG00000026864    Hspa5    0.107312856 6.11E-06 ENSMUSG00000030654    Arl6ip1    0.116528305 0.0029392
ENSMUSG00000079487    Med12    0.107550301 0.0238476 ENSMUSG00000022148    Fyb 0.116606852 0.0137004
ENSMUSG00000001175    Calm1    0.107633518 0.0002079 ENSMUSG00000017721    Pigt 0.116664747 0.012011
ENSMUSG00000024083    Pja2    0.107649795 0.0369369 ENSMUSG00000000568    Hnrnpd 0.116691932 0.0009906
ENSMUSG00000045983    Eif4g1    0.10770643 2.27E-07 ENSMUSG00000031672    Got2    0.116745717 0.0036907
ENSMUSG00000001472    Tcf25    0.107740429 0.0096826 ENSMUSG00000057130    Txnl4a 0.116910089 0.045961
ENSMUSG00000022757    Tfg 0.107777775 0.0434445 ENSMUSG00000038664    Herc1    0.116998412 0.0489018
ENSMUSG00000028556    Dock7    0.107793545 0.0046572 ENSMUSG00000030557    Mef2a 0.117187147 0.0251975
ENSMUSG00000014606    Slc25a11    0.107917724 0.0412191 ENSMUSG00000027109    Sp3    0.117264955 0.0212342
ENSMUSG00000023106    Denr 0.107979463 0.0118593 ENSMUSG00000020922    Lsm12    0.117359357 0.0143913
ENSMUSG00000028790    Khdrbs1    0.10811385 0.0039551 ENSMUSG00000073838    Tufm 0.117371581 0.01446
ENSMUSG00000014195    Dnajc7    0.108141684 0.0045782 ENSMUSG00000029580    Actb 0.117373765 1.79E-10
ENSMUSG00000022912    Pros1    0.108144602 0.0102229 ENSMUSG00000049804    Armcx4    0.117499399 0.0334728
ENSMUSG00000006699    Cdc42    0.108399355 0.0022778 ENSMUSG00000007850    Hnrnph1    0.117529453 8.00E-05
ENSMUSG00000021546    Hnrnpk 0.108591186 5.76E-06 ENSMUSG00000040524    Zfp609    0.117663408 0.0194846
ENSMUSG00000024767    Otub1    0.10875085 0.0323244 ENSMUSG00000070544    Top1    0.117807988 0.0013315
ENSMUSG00000003099    Ppp5c 0.10875435 0.0203836 ENSMUSG00000030213    Atf7ip 0.117924255 0.0234636
ENSMUSG00000032418    Me1    0.109022856 0.0431936 ENSMUSG00000026728    Vim 0.11799488 1.49E-08
ENSMUSG00000052337    Immt 0.109023744 0.0010092 ENSMUSG00000021131    Erh 0.118000961 0.0055462
ENSMUSG00000071659    Hnrnpul2    0.109070458 0.001563 ENSMUSG00000056515    Rab31    0.118258074 0.0022338
ENSMUSG00000059552    Trp53    0.109202569 0.0070387 ENSMUSG00000023175    Bsg 0.118410663 6.01E-05
ENSMUSG00000030058    Copg1    0.109611969 0.0094091 ENSMUSG00000036241    Ube2r2    0.118422174 0.007201
ENSMUSG00000024941    Scyl1    0.109778197 0.0463381 ENSMUSG00000028960    Ube4b 0.11843411 0.023811
ENSMUSG00000027162    Lin7c 0.109841592 0.0116906 ENSMUSG00000019494    Cops6    0.118436111 0.0029517
ENSMUSG00000061315    Naca 0.110039786 8.05E-05 ENSMUSG00000004319    Clcn3    0.118694696 0.0475963
ENSMUSG00000029064    Gnb1    0.110080355 0.000108 ENSMUSG00000074797    Itpa 0.118728606 0.0267481
ENSMUSG00000054863    Fam19a5    0.110181419 0.0095188 ENSMUSG00000008475    Arpc5    0.118828954 0.0141761
ENSMUSG00000047675    Rps8    0.110257885 1.51E-05 ENSMUSG00000036087    Slain2    0.118836831 0.0303585
ENSMUSG00000022885    St6gal1    0.110343661 0.0480766 ENSMUSG00000043962    Thrap3    0.118879918 0.0022761
ENSMUSG00000013858    Tmem259    0.110528861 0.0299828 ENSMUSG00000061731    Ext1    0.119399473 0.0326471
ENSMUSG00000026509    Capn2    0.110850439 0.0022086 ENSMUSG00000027665    Pik3ca 0.119406233 0.0428123
ENSMUSG00000025982    Sf3b1    0.110855563 0.0002362 ENSMUSG00000022706    Mrpl40    0.119587006 0.0354764
ENSMUSG00000035227    Spcs2    0.111101043 0.0088257 ENSMUSG00000019969    Psen1    0.119621968 0.0436014
ENSMUSG00000022361    Zhx1    0.111184379 0.0254181 ENSMUSG00000001056    Nhp2    0.119705556 0.0005731
ENSMUSG00000027247    Arhgap1    0.11122457 0.0391068 ENSMUSG00000037933    Bicd2    0.119832219 0.0476666
ENSMUSG00000009035    Tmem184b 0.111318196 0.0104515 ENSMUSG00000040940    Arhgef1    0.119866521 0.0375635
ENSMUSG00000010663    Fads1    0.11135052 0.0121695 ENSMUSG00000022403    St13    0.120100116 2.34E-05
ENSMUSG00000021870    Slmap 0.111382631 0.0364604 ENSMUSG00000023932    Cdc5l 0.12026461 0.0076369
ENSMUSG00000062604    Srpk2    0.111394321 0.0356927 ENSMUSG00000004056    Akt2    0.120384161 0.0022756
ENSMUSG00000057363    Uxs1    0.111467368 0.032626 ENSMUSG00000001847    Rac1    0.120436861 2.38E-05
ENSMUSG00000039262    Prrc2b 0.111538392 0.0077301 ENSMUSG00000028081    Rps3a1    0.120504212 4.74E-07
ENSMUSG00000020716    Nf1    0.111559329 0.0269832 ENSMUSG00000018166    Erbb3    0.120519434 0.0023403
ENSMUSG00000028044    Cks1b 0.111599955 0.0172682 ENSMUSG00000000563    Atp5f1    0.120564922 0.000268
ENSMUSG00000036078    Sigmar1    0.111822502 0.0024095 ENSMUSG00000024533    Spire1    0.120616048 0.017033
ENSMUSG00000022710    Usp7    0.11191306 0.00114 ENSMUSG00000029822    Osbpl3    0.12061736 0.0415991
ENSMUSG00000028936    Rpl22    0.111928783 0.0012343 ENSMUSG00000036932    Aifm1    0.120628373 0.0098202
ENSMUSG00000002052    Supt6    0.111933373 0.0007545 ENSMUSG00000031703    Itfg1    0.120647836 0.0472727
ENSMUSG00000020368    Canx 0.112677816 1.68E-06 ENSMUSG00000052915    Msl1    0.120764565 0.0287595
ENSMUSG00000027198    Ext2    0.11268069 0.0109681 ENSMUSG00000024639    Gnaq 0.120863967 0.0412898
ENSMUSG00000078676    Casc3    0.112796951 0.0349984 ENSMUSG00000067367    Lyar 0.121155167 0.0068144
ENSMUSG00000054408    Spcs3    0.113220926 0.0433516 ENSMUSG00000048878    Hexim1    0.121175916 0.0114882
ENSMUSG00000028649    Macf1    0.113289573 0.0179517 ENSMUSG00000018042    Cyb5r3    0.12124552 6.45E-05
ENSMUSG00000029190    D5Ertd579e 0.113371406 0.0268276 ENSMUSG00000020358    Hnrnpab 0.121287438 1.17E-07
ENSMUSG00000006057    Atp5g1    0.113572112 0.0128383 ENSMUSG00000021756    Il6st 0.121317769 0.0006387
ENSMUSG00000032518    Rpsa 0.113727171 9.95E-09 ENSMUSG00000037364    Srrt 0.121334996 0.0003854
ENSMUSG00000024909    Efemp2    0.114019079 0.0191755 ENSMUSG00000029581    Fscn1    0.121868439 2.50E-05
ENSMUSG00000030663    1110004F10Rik 0.114073844 0.012821 ENSMUSG00000039128    Cdc123    0.121956321 0.035066
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ENSMUSG00000038502    Ptov1    0.122021945 0.0316311 ENSMUSG00000038025    Phf2    0.13029185 0.0300048
ENSMUSG00000020640    Itsn2    0.122023599 0.0109844 ENSMUSG00000031347    Cetn2    0.13030462 0.0359164
ENSMUSG00000030824    Nucb1    0.122083926 0.0013374 ENSMUSG00000002524    Puf60    0.130450698 6.35E-05
ENSMUSG00000030583    Sipa1l3    0.122149901 0.0082717 ENSMUSG00000017119    Nbr1    0.130523218 0.0021266
ENSMUSG00000021556    Golm1    0.12217468 0.0180193 ENSMUSG00000031790    Mmp15    0.130549531 0.0351155
ENSMUSG00000021823    Vcl 0.122201149 0.0298917 ENSMUSG00000027699    Ect2    0.130618481 0.0003368
ENSMUSG00000020476    Dbnl 0.122551572 0.0038875 ENSMUSG00000066037    Hnrnpr 0.130841122 0.0022102
ENSMUSG00000042489    Clspn 0.122696005 0.0167699 ENSMUSG00000020402    Vdac1    0.130964694 7.95E-06
ENSMUSG00000002833    Hdgfrp2    0.122863157 0.011431 ENSMUSG00000065979    Cpped1    0.130997172 0.0324797
ENSMUSG00000024833    Pola2    0.122958494 0.0267976 ENSMUSG00000073497    AA792892    0.131131997 0.0249065
ENSMUSG00000050424    Pnma5    0.12311062 0.0268701 ENSMUSG00000079029    Gm5662    0.131191622 0.0419299
ENSMUSG00000020705    Ddx42    0.123326411 0.0064162 ENSMUSG00000025134    Alyref 0.131197219 0.0044569
ENSMUSG00000035325    Sec31a 0.123386465 0.0011224 ENSMUSG00000029610    Aimp2    0.131496577 0.0301929
ENSMUSG00000022307    Oxr1    0.123464596 0.0116056 ENSMUSG00000038845    Phb 0.131736429 0.0012257
ENSMUSG00000052727    Map1b 0.123654052 0.0031405 ENSMUSG00000015149    Sirt2    0.132113993 0.026127
ENSMUSG00000040711    Sh3pxd2b 0.123767268 0.0011777 ENSMUSG00000019961    Tmpo 0.132312362 2.21E-05
ENSMUSG00000032855    Pkd1    0.123826668 0.0147948 ENSMUSG00000010097    Nxf1    0.132492429 0.0030313
ENSMUSG00000008373    Prpf31    0.12404413 0.0061678 ENSMUSG00000017670    Elmo2    0.132594975 0.0160268
ENSMUSG00000037286    Stag1    0.12412254 0.0059475 ENSMUSG00000039414    Heatr5b 0.132632615 0.0246029
ENSMUSG00000037935    Smarce1    0.124359929 0.0043805 ENSMUSG00000020536    Llgl1    0.132663076 0.0070959
ENSMUSG00000036398    Ppp1r11    0.124425037 0.0253448 ENSMUSG00000040446    Rprd1a 0.1327191 0.0091017
ENSMUSG00000014498    Ankrd52    0.124535303 0.0075907 ENSMUSG00000032966    Fkbp1a 0.132755303 7.80E-06
ENSMUSG00000038766    Gabpb2    0.12454946 0.0137721 ENSMUSG00000006304    Arpc2    0.132981578 8.50E-05
ENSMUSG00000057133    Chd6    0.12456441 0.0338413 ENSMUSG00000000028    Cdc45    0.133161564 0.0050133
ENSMUSG00000031065    Cdk16    0.124684985 0.0013097 ENSMUSG00000020018    Snrpf 0.133258427 0.0049484
ENSMUSG00000037533    Rapgef6    0.124753773 0.0168401 ENSMUSG00000020235    Fzr1    0.133266488 0.0226965
ENSMUSG00000001729    Akt1    0.124769469 3.07E-06 ENSMUSG00000035726    Supt16    0.133320952 0.0005806
ENSMUSG00000022477    Aco2    0.124796829 6.46E-05 ENSMUSG00000036523    Greb1    0.133404378 0.0123274
ENSMUSG00000009927    Rps25    0.12512541 5.46E-07 ENSMUSG00000004455    Ppp1cc 0.133476592 8.03E-05
ENSMUSG00000022191    Drosha 0.125247839 0.0021791 ENSMUSG00000020608    Smc6    0.133844903 0.0015168
ENSMUSG00000027108    Ola1    0.125265675 0.00097 ENSMUSG00000051768    Xrcc1    0.133918688 0.0108662
ENSMUSG00000068744    Psrc1    0.125363793 0.0467496 ENSMUSG00000031392    Irak1    0.134012032 0.0096106
ENSMUSG00000026028    Trak2    0.125370657 0.0122314 ENSMUSG00000042133    Ppig 0.134158461 0.0031428
ENSMUSG00000027180    Fbxo3    0.125371052 0.045385 ENSMUSG00000006307    Kmt2b 0.134204949 0.0098714
ENSMUSG00000024902    Mrpl11    0.125388851 0.0498823 ENSMUSG00000027649    Ctnnbl1    0.134394828 0.0326906
ENSMUSG00000015092    Edf1    0.125446839 0.0316049 ENSMUSG00000020471    Pold2    0.134484763 0.0116886
ENSMUSG00000031592    Pcm1    0.125488818 0.0147502 ENSMUSG00000025794    Rpl14    0.13498303 1.28E-08
ENSMUSG00000020224    Llph 0.125684544 0.0303889 ENSMUSG00000048874    Phf3    0.135041128 0.0041596
ENSMUSG00000003038    Hmgn2    0.126120465 0.0069234 ENSMUSG00000034675    Dbn1    0.135219816 0.0477538
ENSMUSG00000020484    Xbp1    0.126129728 0.038761 ENSMUSG00000027379    Bub1    0.135238867 0.0031933
ENSMUSG00000024844    Banf1    0.126192172 0.0025974 ENSMUSG00000036323    Srp72    0.135322666 0.00029
ENSMUSG00000005575    Ube2m 0.126390188 0.0018812 ENSMUSG00000001761    Smo 0.135409617 0.0004287
ENSMUSG00000028309    Rnf20    0.126699447 0.0042551 ENSMUSG00000008429    Herpud2    0.135427553 0.0497853
ENSMUSG00000037300    Ttc13    0.126729837 0.0250781 ENSMUSG00000019777    Hdac2    0.135464353 0.0002396
ENSMUSG00000049327    Setd8    0.126813127 0.0001956 ENSMUSG00000076431    Sox4    0.135669129 0.0112557
ENSMUSG00000099835    Gm29668    0.126951537 0.0380828 ENSMUSG00000074305    Peak1    0.135795874 0.0390146
ENSMUSG00000039523    Cep104    0.127024173 0.0328123 ENSMUSG00000040043    Rbms2    0.135834585 0.0085927
ENSMUSG00000036199    Ndufa13    0.127080338 0.049446 ENSMUSG00000036371    Serbp1    0.135942146 1.31E-07
ENSMUSG00000019977    Hbs1l 0.127160367 0.0161994 ENSMUSG00000022201    Zfr 0.136035295 0.0001173
ENSMUSG00000032621    Srek1    0.127196238 0.0466077 ENSMUSG00000057177    Gsk3a 0.136357549 0.0118954
ENSMUSG00000079139    Gm4204    0.127302398 0.007611 ENSMUSG00000025266    Gnl3l 0.136474892 0.0013272
ENSMUSG00000037876    Jmjd1c 0.127406651 0.0170234 ENSMUSG00000036273    Lrrk2    0.136598265 0.006963
ENSMUSG00000027774    Gfm1    0.127505585 0.0023129 ENSMUSG00000002233    Rhoc 0.136681356 0.0007455
ENSMUSG00000026305    Lrrfip1    0.127632858 6.14E-05 ENSMUSG00000024290    Rock1    0.136705854 0.0152188
ENSMUSG00000026944    Abca2    0.127817779 0.0230512 ENSMUSG00000002010    Idh3g 0.136759461 0.0026909
ENSMUSG00000005609    Ctr9    0.127846903 0.0102166 ENSMUSG00000051586    Mical3    0.136777811 0.0429808
ENSMUSG00000039218    Srrm2    0.127910101 4.79E-06 ENSMUSG00000028496    Mllt3    0.136991982 0.0201445
ENSMUSG00000059208    Hnrnpm 0.127965233 1.29E-05 ENSMUSG00000006941    Eif1b 0.137270362 0.0270841
ENSMUSG00000029571    Tmem106b 0.128034286 0.0472484 ENSMUSG00000019841    Rev3l 0.137464319 0.0385201
ENSMUSG00000022141    Nipbl 0.128053209 0.0137965 ENSMUSG00000056091    St3gal5    0.137492606 0.0070791
ENSMUSG00000027104    Atf2    0.128058646 0.040428 ENSMUSG00000037013    Ss18    0.137537131 0.0015602
ENSMUSG00000029761    Cald1    0.128180758 0.000643 ENSMUSG00000027111    Itga6    0.137540927 5.14E-06
ENSMUSG00000021427    Ssr1    0.128401298 0.0002648 ENSMUSG00000023272    Creld2    0.137588475 0.0054145
ENSMUSG00000031502    Col4a1    0.12840472 1.21E-06 ENSMUSG00000049751    Rpl36al 0.137781617 0.0003016
ENSMUSG00000021244    Ylpm1    0.128428643 0.0166114 ENSMUSG00000002102    Psmc3    0.137936871 0.0001616
ENSMUSG00000050379    Sept6    0.128513043 0.0480417 ENSMUSG00000009575    Cbx5    0.137964363 5.69E-06
ENSMUSG00000007050    Lsm2    0.128733342 0.0351219 ENSMUSG00000041890    Git2    0.138020683 0.0098288
ENSMUSG00000031358    Msl3    0.128815196 0.0295537 ENSMUSG00000029422    Rsrc2    0.138036016 0.0031421
ENSMUSG00000061306    Slc38a10    0.128857107 0.0129105 ENSMUSG00000036752    Tubb4b 0.138464973 3.66E-05
ENSMUSG00000033623    Pcgf3    0.128885667 0.0104282 ENSMUSG00000095180    Rhox5    0.138764567 1.11E-06
ENSMUSG00000034210    Efcab14    0.129076485 0.0434964 ENSMUSG00000031393    Mecp2    0.138861794 0.0173217
ENSMUSG00000026490    Cdc42bpa 0.129128264 0.0157628 ENSMUSG00000001280    Sp1    0.139021714 0.0007734
ENSMUSG00000042487    Leo1    0.12930591 0.0267984 ENSMUSG00000068747    Sort1    0.139036413 0.0102469
ENSMUSG00000021215    Net1    0.12939562 0.0211326 ENSMUSG00000007080    Pole 0.1392423 0.0018596
ENSMUSG00000000605    Clcn4-2    0.129413625 0.0447158 ENSMUSG00000061665    Cd2ap 0.13935145 0.0035471
ENSMUSG00000038482    Tfdp1    0.129600293 0.0015243 ENSMUSG00000055320    Tead1    0.139411617 0.0043355
ENSMUSG00000036026    Tmem63b 0.12966142 0.0052959 ENSMUSG00000024908    Ppp6r3    0.13948439 0.0004241
ENSMUSG00000026965    Anapc2    0.129982995 0.0428731 ENSMUSG00000025743    Sdc3    0.139560675 3.28E-05
ENSMUSG00000039765    Cc2d2a 0.130222562 0.0467708 ENSMUSG00000025261    Huwe1    0.139676739 2.24E-06
ENSMUSG00000028759    Hp1bp3    0.130249844 0.0042839 ENSMUSG00000066406    Akap13    0.139700536 0.0087386
ENSMUSG00000094635    Gm7104        0.130278654 0.0255782 ENSMUSG00000071655    Ubxn1    0.139785804 0.0012969
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ENSMUSG00000071054    Safb 0.139797979 0.0017282 ENSMUSG00000022186    Oxct1    0.148608104 1.17E-06
ENSMUSG00000027746    Ufm1    0.140016836 0.0271165 ENSMUSG00000022360    Atad2    0.14865109 4.33E-06
ENSMUSG00000025130    P4hb 0.140057756 8.33E-08 ENSMUSG00000035093    Secisbp2l 0.148745467 0.0004838
ENSMUSG00000022663    Atg3    0.140081806 0.0453487 ENSMUSG00000036372    Tmem258    0.148859094 0.0305125
ENSMUSG00000031221    Igbp1    0.140251433 0.0152769 ENSMUSG00000039108    Lsm14b 0.149109391 0.010006
ENSMUSG00000040322    Slc25a24    0.1402988 0.003533 ENSMUSG00000021500    Ddx46    0.14918462 0.0001154
ENSMUSG00000021760    Gpx8    0.140551759 0.0257509 ENSMUSG00000024393    Prrc2a 0.149248556 3.39E-10
ENSMUSG00000030779    Rbbp6    0.140829765 0.0015401 ENSMUSG00000056201    Cfl1    0.149646912 1.76E-11
ENSMUSG00000029657    Hsph1    0.140838784 4.53E-05 ENSMUSG00000003316    Glg1    0.1496816 0.0001691
ENSMUSG00000035493    Tgfbi 0.140997033 4.64E-05 ENSMUSG00000026730    Pter 0.14983529 0.039708
ENSMUSG00000022377    Asap1    0.141440126 0.0009305 ENSMUSG00000020823    Sec14l1    0.149843193 0.0091882
ENSMUSG00000022536    Glyr1    0.141523265 0.0003087 ENSMUSG00000025878    Uimc1    0.150095909 0.0343767
ENSMUSG00000048087    Gm4737    0.14154931 0.0417633 ENSMUSG00000001173    Ocrl 0.150099037 0.0182561
ENSMUSG00000030315    Vgll4        0.14171861 0.0151784 ENSMUSG00000006398    Cdc20    0.150115984 6.11E-05
ENSMUSG00000025224    Gbf1    0.141898639 0.0038872 ENSMUSG00000004099    Dnmt1    0.150146038 1.11E-06
ENSMUSG00000029552    Tes 0.142300145 0.0001813 ENSMUSG00000024302    Dtna 0.150163828 0.0298868
ENSMUSG00000041697    Cox6a1    0.142334178 0.0004916 ENSMUSG00000039585    Myo9a 0.15022653 0.0358941
ENSMUSG00000036591    Arhgap21    0.14237035 0.0216215 ENSMUSG00000037062    Sh3glb1    0.150855013 4.03E-05
ENSMUSG00000028873    Cdca8    0.142386151 0.0111093 ENSMUSG00000003458    Ncstn 0.150901038 0.0060215
ENSMUSG00000035851    Ythdc1    0.142568606 0.0067534 ENSMUSG00000030515    Tarsl2    0.150915136 0.0458389
ENSMUSG00000019179    Mdh2    0.142690931 1.56E-07 ENSMUSG00000029632    Ndufa4    0.150956818 0.0010878
ENSMUSG00000026134    Prim2    0.142924459 0.0146824 ENSMUSG00000027984    Hadh 0.151000062 0.0080388
ENSMUSG00000059495    Arhgef12    0.142949039 0.0007866 ENSMUSG00000067713    Prkag1    0.151027558 0.0407571
ENSMUSG00000004530    Coro1c 0.143024323 5.99E-05 ENSMUSG00000025781    Atp5c1    0.151036407 1.15E-05
ENSMUSG00000020321    Mdh1    0.143176309 0.0004871 ENSMUSG00000036550    Cnot1    0.151380243 8.71E-05
ENSMUSG00000032382    Snx1    0.143397551 0.0142677 ENSMUSG00000014551    Mrps25    0.151852365 0.0309716
ENSMUSG00000014504    Srp19    0.143774776 0.0258287 ENSMUSG00000004535    Tax1bp1    0.1521482 0.0002462
ENSMUSG00000028334    Nans 0.143908888 0.0061902 ENSMUSG00000039016    Timm8b 0.152216117 0.0263496
ENSMUSG00000023923    Tbc1d5    0.14394232 0.0183484 ENSMUSG00000043262    Uevld 0.152378505 0.038264
ENSMUSG00000042066    Tmcc2    0.14395877 0.0271136 ENSMUSG00000029017    Pmpcb 0.152550823 0.0022598
ENSMUSG00000018377    Vezf1    0.144454773 0.0197888 ENSMUSG00000055762    Eef1d 0.152681857 6.70E-07
ENSMUSG00000052539    Magi3    0.144539416 0.0488126 ENSMUSG00000005583    Mef2c 0.152892169 0.0076012
ENSMUSG00000055862    Izumo4    0.144606367 0.0423943 ENSMUSG00000050965    Prkca 0.152995945 0.0441183
ENSMUSG00000003039    Fam32a 0.144652109 0.0157117 ENSMUSG00000033565    Rbfox2    0.15305204 0.0014363
ENSMUSG00000003873    Bax 0.144783528 0.0014701 ENSMUSG00000028289    Epha7    0.153150067 0.0082868
ENSMUSG00000034109    Golim4    0.145113795 0.0019041 ENSMUSG00000006589    Aprt 0.153397266 0.00149
ENSMUSG00000022451    Twf1    0.145185546 0.0002876 ENSMUSG00000056050    Mia3    0.153512495 0.0088129
ENSMUSG00000000346    Dazap2    0.145258005 0.0002484 ENSMUSG00000020571    Pdia6    0.15360724 1.71E-08
ENSMUSG00000038708    Golga4    0.145390661 0.0029418 ENSMUSG00000060126    Tpt1    0.153657389 2.71E-08
ENSMUSG00000061119    Prcp 0.145659673 0.0418935 ENSMUSG00000042272    Sestd1    0.153750259 0.0468408
ENSMUSG00000020516    Rps6kb1    0.14572436 0.0022848 ENSMUSG00000004085    Zak 0.1538047 0.0395287
ENSMUSG00000034349    Smc4    0.145798221 5.17E-06 ENSMUSG00000030551    Nr2f2    0.153841283 0.0214851
ENSMUSG00000066979    Bub3    0.145800846 0.0002364 ENSMUSG00000057789    Bak1    0.154104697 0.0033584
ENSMUSG00000039298    Cdk5rap2    0.145800986 0.0202335 ENSMUSG00000025278    Flnb 0.154301211 6.04E-06
ENSMUSG00000024048    Myl12a 0.145829543 8.81E-06 ENSMUSG00000037400    Atp11b 0.154570817 0.0006201
ENSMUSG00000058407    Txndc9    0.145897288 0.0063802 ENSMUSG00000033307    Mif 0.154655989 0.039976
ENSMUSG00000004945    Tmem242    0.146016834 0.04236 ENSMUSG00000033671    Cep350    0.154736105 0.0403938
ENSMUSG00000039197    Adk 0.146196706 0.000828 ENSMUSG00000027533    Fabp5    0.154811838 0.0011716
ENSMUSG00000021156    Zmynd11    0.146343836 0.0053764 ENSMUSG00000034566    Atp5h 0.154812312 0.000493
ENSMUSG00000062353    Gm15772    0.146408074 0.0003895 ENSMUSG00000045039    Megf8    0.154831691 0.0003918
ENSMUSG00000025885    Myo5b 0.146438462 0.0001853 ENSMUSG00000048000    Gigyf2    0.154840719 0.0010994
ENSMUSG00000045180    Shroom2    0.146560874 0.0024172 ENSMUSG00000002778    Kdelr1    0.154872265 0.0032734
ENSMUSG00000029201    Ugdh 0.14674139 1.98E-05 ENSMUSG00000027010    Slc25a12    0.154878934 0.019799
ENSMUSG00000002885    Adgre5    0.146752213 0.0498719 ENSMUSG00000053931    Cnn3    0.155260551 7.46E-08
ENSMUSG00000024483    Ankhd1    0.146952316 0.0032249 ENSMUSG00000034254    Agpat1    0.155261196 0.0017065
ENSMUSG00000029106    Add1    0.146960678 0.001829 ENSMUSG00000037563    Rps16    0.15527597 1.95E-10
ENSMUSG00000027663    Zmat3    0.147035998 0.0150088 ENSMUSG00000027597    Ahcy 0.155323575 3.70E-05
ENSMUSG00000030342    Cd9    0.147152366 0.0016429 ENSMUSG00000052423    B4galt3    0.155425097 0.0439661
ENSMUSG00000020687    Cdc27    0.147352591 7.71E-05 ENSMUSG00000013698    Pea15a 0.155473065 1.27E-05
ENSMUSG00000027361    Gabpb1    0.147373373 0.0406741 ENSMUSG00000026039    Sgol2a 0.155655216 0.0467453
ENSMUSG00000042508    Dmtf1    0.147410007 0.0207219 ENSMUSG00000025810    Nrp1    0.155763166 0.0027075
ENSMUSG00000068284    Gm608    0.147461589 0.0473369 ENSMUSG00000027624    Epb4.1l1    0.155766732 0.0002819
ENSMUSG00000058318    Phf21a 0.147480973 0.0427727 ENSMUSG00000037712    Fermt2    0.155908928 0.0009265
ENSMUSG00000017485    Top2b 0.147491156 0.0021569 ENSMUSG00000028194    Ddah1    0.155972633 0.0008979
ENSMUSG00000041220    Elovl6    0.14757811 0.0194318 ENSMUSG00000038384    Setd1b 0.156021086 0.0400215
ENSMUSG00000034681    Rnps1    0.147610754 0.000268 ENSMUSG00000025758    Plk4    0.156225988 0.001323
ENSMUSG00000032582    Rbm6    0.147807327 0.0048627 ENSMUSG00000004364    Cul3    0.156239746 7.63E-05
ENSMUSG00000006931    P3h4    0.147962032 0.0033747 ENSMUSG00000038838    Vars2    0.156267905 0.0463054
ENSMUSG00000005374    Tbl2    0.14803112 0.0165107 ENSMUSG00000033788    Dysf 0.156386121 0.0348696
ENSMUSG00000040761    Spen 0.148049443 0.0073554 ENSMUSG00000030451    Herc2    0.156423865 0.0030312
ENSMUSG00000048668    Rhno1    0.148110208 0.0274508 ENSMUSG00000046574    Prr12    0.156697353 0.0090495
ENSMUSG00000041570    Camsap2    0.14811997 0.0090966 ENSMUSG00000008976    Gabpa 0.156744967 0.0057683
ENSMUSG00000026872    Zeb2    0.148149602 0.0006506 ENSMUSG00000028613    Lrp8    0.156838066 0.0054028
ENSMUSG00000022433    Csnk1e 0.148172345 0.0122521 ENSMUSG00000021830    Txndc16    0.156956064 0.0112712
ENSMUSG00000041702    Btbd7    0.148329785 0.0184095 ENSMUSG00000041235    Chd7    0.156971747 0.0326103
ENSMUSG00000058881    Zfp516    0.148356418 0.0169036 ENSMUSG00000024725    Ostf1    0.157112845 0.0269269
ENSMUSG00000028245    Nsmaf 0.148377487 0.0090967 ENSMUSG00000007815    Rhoa 0.157121229 1.92E-07
ENSMUSG00000068270    Shroom4    0.148459761 0.018685 ENSMUSG00000047547    Cltb 0.157318654 0.0067156
ENSMUSG00000020821    Kif1c 0.148483771 0.0001054 ENSMUSG00000030770    Parva 0.157319222 9.93E-05
ENSMUSG00000057000    Nxf3    0.14851507 0.0125335 ENSMUSG00000034902    Pip5k1c 0.157425935 0.0066964
ENSMUSG00000032570    Atp2c1    0.148565663 0.00212 ENSMUSG00000040204    2810417H13Rik 0.157772452 0.0002777
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ENSMUSG00000028394    Pole3    0.157807015 0.0051704 ENSMUSG00000041258    Zfp236    0.167039653 0.0055949
ENSMUSG00000037742    Eef1a1    0.157935536 1.60E-18 ENSMUSG00000020190    Mknk2    0.167079701 0.0006427
ENSMUSG00000026547    Tagln2    0.157996949 4.33E-07 ENSMUSG00000082895    Rpsa-ps9    0.167102994 0.0286602
ENSMUSG00000058600    Rpl30    0.158162824 1.56E-07 ENSMUSG00000031812    Map1lc3b 0.167297302 0.0299668
ENSMUSG00000101625    Gm29371    0.158216944 0.0366892 ENSMUSG00000021578    Ccdc127    0.167301734 0.0234009
ENSMUSG00000026116    Tmem131    0.158248314 0.0009384 ENSMUSG00000032479    Map4    0.167372713 6.10E-08
ENSMUSG00000085208    Brip1os 0.158285835 0.0015885 ENSMUSG00000019978    Epb4.1l2    0.167410955 1.83E-08
ENSMUSG00000022338    Eny2    0.158350359 0.004184 ENSMUSG00000037234    Hook3    0.167444876 0.0149629
ENSMUSG00000006005    Tpr 0.158373017 2.67E-06 ENSMUSG00000075229    Ccdc58    0.167554866 0.009904
ENSMUSG00000026496    Parp1    0.158603601 2.93E-06 ENSMUSG00000038872    Zfhx3    0.167720828 0.0498327
ENSMUSG00000006705    Pknox1    0.158690553 0.0273195 ENSMUSG00000031540    Kat6a 0.167763294 0.0005077
ENSMUSG00000039952    Dag1    0.1589132 2.17E-07 ENSMUSG00000022889    Mrpl39    0.167894532 0.0335496
ENSMUSG00000045128    Rpl18a 0.158978826 2.53E-09 ENSMUSG00000037860    Aim2    0.168009197 0.0387454
ENSMUSG00000029153    Ociad2    0.158998171 0.03576 ENSMUSG00000038241    Cep250    0.168135401 0.0063948
ENSMUSG00000034485    Uaca 0.159060696 7.43E-08 ENSMUSG00000033373    Fntb 0.168322655 0.0261656
ENSMUSG00000020492    Ska2    0.159099806 0.013762 ENSMUSG00000032547    Ryk 0.168505529 0.0001535
ENSMUSG00000020580    Rock2    0.15924297 2.31E-06 ENSMUSG00000070923    Klhl9    0.168516441 0.0030845
ENSMUSG00000022261    Sdc2    0.159367259 0.0265675 ENSMUSG00000044155    Lsm8    0.16858891 0.0050945
ENSMUSG00000023921    Mut 0.159392575 0.0292684 ENSMUSG00000032301    Psma4    0.168793568 2.59E-05
ENSMUSG00000020982    Nemf 0.159395873 0.0021723 ENSMUSG00000024966    Stip1    0.168861119 1.00E-10
ENSMUSG00000024960    Plcb3    0.159448841 0.0001815 ENSMUSG00000062169    Cnih4    0.16896292 0.0018485
ENSMUSG00000041974    Spidr 0.159514044 0.0120108 ENSMUSG00000003352    Cacnb3    0.169054955 0.009231
ENSMUSG00000029672    Fam3c 0.159752506 0.027485 ENSMUSG00000021963    Sap18    0.169149744 0.0227836
ENSMUSG00000024777    Ppp2r5b 0.159756526 0.0473973 ENSMUSG00000052516    Robo2    0.169193869 0.0469522
ENSMUSG00000022771    Ppil2    0.159911147 0.0028433 ENSMUSG00000024853    Sf3b2    0.16934295 1.25E-08
ENSMUSG00000035674    Ndufa3    0.160023888 0.0219079 ENSMUSG00000018648    Dusp14    0.169371692 0.0454705
ENSMUSG00000057738    Sptan1    0.160134748 6.76E-08 ENSMUSG00000032280    Tle3    0.169404291 0.0007072
ENSMUSG00000000600    Krit1    0.160266572 0.0316144 ENSMUSG00000029156    Sgcb 0.169543586 0.0350431
ENSMUSG00000033676    Gabrb3    0.160447948 0.0004917 ENSMUSG00000027854    Sike1    0.169602719 0.0374117
ENSMUSG00000020074    Ccar1    0.160565477 0.0001178 ENSMUSG00000028837    Psmb2    0.16982445 0.0008071
ENSMUSG00000033105    Lss 0.160698136 0.0294356 ENSMUSG00000053477    Tcf4    0.169838694 0.0005209
ENSMUSG00000045482    Trrap 0.160708432 7.99E-05 ENSMUSG00000037343    Taf2    0.169889331 0.0003332
ENSMUSG00000041203    2310036O22Rik 0.161143572 0.0100954 ENSMUSG00000054405    Dnajc8    0.169898013 0.0006107
ENSMUSG00000031154    Otud5    0.161395193 0.0052362 ENSMUSG00000031328    Flna 0.169929779 1.30E-15
ENSMUSG00000069565    Dazap1    0.161416526 0.0003957 ENSMUSG00000038886    Man2a2    0.170177598 0.0001831
ENSMUSG00000024304    Cdh2    0.161522006 1.26E-07 ENSMUSG00000030560    Ctsc 0.170203547 0.0074577
ENSMUSG00000039536    Stau1    0.161648137 0.0006072 ENSMUSG00000069769    Msi2    0.170236194 0.0040264
ENSMUSG00000024560    Cxxc1    0.161843134 0.0111638 ENSMUSG00000038871    Bpgm 0.170245483 0.0411954
ENSMUSG00000032743    D430042O09Rik 0.162066212 0.0448313 ENSMUSG00000028800    Hdac1    0.170450396 0.0020339
ENSMUSG00000022641    Bbx 0.162071672 0.0108293 ENSMUSG00000025352    Gdf11    0.170513739 0.0277908
ENSMUSG00000084786    Ubl5    0.162073192 0.0108606 ENSMUSG00000035632    Cnot3    0.170530551 0.0004732
ENSMUSG00000031848    Lsm4    0.162088022 0.0077543 ENSMUSG00000062762    Ei24    0.170593421 0.0014577
ENSMUSG00000030987    Stim1    0.162166822 0.0278392 ENSMUSG00000031660    Brd7    0.170748537 0.0064714
ENSMUSG00000016253    Nelfcd 0.162222347 0.0119405 ENSMUSG00000037071    Scd1    0.170894788 2.18E-05
ENSMUSG00000002812    Flii 0.16229942 0.0008024 ENSMUSG00000029250    Polr2b 0.170940934 2.26E-05
ENSMUSG00000071176    Arhgef10    0.162511844 0.0253958 ENSMUSG00000035268    Pkig 0.1709808 0.0383725
ENSMUSG00000061755    Bod1l 0.16260485 0.0014773 ENSMUSG00000024807    Syvn1    0.171007729 0.0110918
ENSMUSG00000039156    Stim2    0.162779918 0.0219345 ENSMUSG00000063694    Cycs 0.171053173 3.18E-05
ENSMUSG00000032253    Phip 0.162850142 0.0045726 ENSMUSG00000009030    Pdcl 0.171074951 0.0457174
ENSMUSG00000053898    Ech1    0.162985972 0.0307481 ENSMUSG00000031400    G6pdx 0.171110996 0.0010276
ENSMUSG00000027936    Crtc2    0.16299098 0.022696 ENSMUSG00000021824    Ap3m1    0.171136017 0.0010782
ENSMUSG00000038463    Olfml2b 0.163063681 0.003469 ENSMUSG00000035107    Dcbld2    0.171250392 0.0069767
ENSMUSG00000024346    Pfdn1    0.1630876 0.0005298 ENSMUSG00000107176    RP23-263B18.4    0.171766633 0.0015497
ENSMUSG00000040850    Psme4    0.163145364 0.0001935 ENSMUSG00000022283    Pabpc1    0.171853664 6.57E-19
ENSMUSG00000039050    Osbpl2    0.163295502 0.0195734 ENSMUSG00000036980    Taf6    0.171861949 0.0075172
ENSMUSG00000055024    Ep300    0.163301651 0.0004833 ENSMUSG00000005442    Cic 0.171882141 5.22E-07
ENSMUSG00000027742    Cog6    0.163619447 0.0215556 ENSMUSG00000036023    Parp2    0.171897873 0.0437864
ENSMUSG00000069939    Gm12070    0.163838284 0.0013249 ENSMUSG00000054452    Aes 0.171902948 9.72E-07
ENSMUSG00000025395    Prim1    0.163897161 0.0023097 ENSMUSG00000028675    Pnrc2    0.171962503 0.0338615
ENSMUSG00000039159    Ube2h 0.164035661 0.025607 ENSMUSG00000028080    Lrba 0.172126827 0.007945
ENSMUSG00000033769    Exoc6b 0.164182345 0.0086411 ENSMUSG00000031954    Cfdp1    0.172131778 0.0004135
ENSMUSG00000041238    Rbbp8    0.164259931 0.0070562 ENSMUSG00000026238    Ptma 0.172181572 3.12E-11
ENSMUSG00000017466    Timp2    0.164366327 8.64E-05 ENSMUSG00000021134    Srsf5    0.17221561 1.04E-05
ENSMUSG00000042323    Pbrm1    0.164532556 0.0005842 ENSMUSG00000030726    Pold3    0.172375251 0.0078215
ENSMUSG00000050953    Gja1    0.16483811 7.58E-06 ENSMUSG00000022312    Eif3h 0.17239944 2.95E-08
ENSMUSG00000071708    Sms 0.164977915 0.0105262 ENSMUSG00000053119    Chmp3    0.172410762 0.0006223
ENSMUSG00000023015    Racgap1    0.16503218 9.08E-08 ENSMUSG00000022635    Zcrb1    0.172457521 0.000989
ENSMUSG00000003402    Prkcsh 0.165091789 4.63E-05 ENSMUSG00000022841    Ap2m1    0.172823832 2.75E-09
ENSMUSG00000030291    Med21    0.165290362 0.0235095 ENSMUSG00000038291    Snx25    0.172975385 0.0439131
ENSMUSG00000020964    Sel1l 0.165510264 0.0003576 ENSMUSG00000031479    Vps36    0.173018543 0.0146236
ENSMUSG00000003778    Brd8    0.165519213 0.0029291 ENSMUSG00000002997    Prkar2b 0.173221918 0.0005958
ENSMUSG00000027171    Prrg4    0.165664113 0.0454308 ENSMUSG00000012483    Rpa3    0.173252094 0.039959
ENSMUSG00000028161    Ppp3ca 0.166028749 0.0004817 ENSMUSG00000003865    Gys1    0.173370676 0.0099504
ENSMUSG00000034390    Cmip 0.166042805 0.0294169 ENSMUSG00000031226    Pbdc1    0.173611065 0.0001269
ENSMUSG00000070343    Gm10288    0.166059257 0.0218379 ENSMUSG00000019539    Rcn3    0.173748798 0.0109752
ENSMUSG00000002996    Hbp1    0.166128379 0.0341128 ENSMUSG00000039347    Atp6v0e2    0.173782057 0.0031866
ENSMUSG00000029185    Fam114a1    0.16618632 0.0229186 ENSMUSG00000031216    Stard8    0.173899692 0.0183224
ENSMUSG00000028246    Faxc 0.166496679 0.0395362 ENSMUSG00000054272    Zscan4c 0.173929517 0.0199295
ENSMUSG00000004096    Cwc15    0.166704963 0.0003793 ENSMUSG00000042670    Immp1l 0.173959299 0.0297571
ENSMUSG00000037679    Inf2    0.166909907 4.49E-06 ENSMUSG00000048930    Tada3    0.173986783 0.0485758
ENSMUSG00000028581    Laptm5    0.166971987 0.0270973 ENSMUSG00000020288    Ahsa2    0.174010157 0.0133272
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ENSMUSG00000030516    Tjp1    0.174041682 5.35E-06 ENSMUSG00000078429    Ctdsp2    0.181899196 0.000152
ENSMUSG00000021248    Tmed10    0.174071848 3.05E-08 ENSMUSG00000041164    Zmiz2    0.182214922 7.84E-05
ENSMUSG00000063659    Zbtb18    0.174123953 0.0063556 ENSMUSG00000027883    Gpsm2    0.182297549 0.0043246
ENSMUSG00000040363    Bcor 0.174134015 0.014422 ENSMUSG00000018287    Spag7    0.182405877 0.0041874
ENSMUSG00000028821    Syf2    0.174420886 0.0176491 ENSMUSG00000035934    Pknox2    0.182500931 0.0105282
ENSMUSG00000000731    Aire 0.174453339 0.0495156 ENSMUSG00000027326    Casc5    0.182601157 0.0014858
ENSMUSG00000031278    Acsl4    0.174458051 1.16E-05 ENSMUSG00000029122    Evc 0.182609338 0.0171131
ENSMUSG00000042712    Wbp5    0.174482238 0.0017808 ENSMUSG00000040462    Os9    0.182678124 0.0002132
ENSMUSG00000030067    Foxp1    0.174526791 0.0039998 ENSMUSG00000023885    Thbs2    0.182689322 4.46E-11
ENSMUSG00000060206    Zfp462    0.174545926 3.57E-05 ENSMUSG00000022820    Ndufb4    0.182696642 0.0046303
ENSMUSG00000032512    Wdr48    0.174567384 0.0026689 ENSMUSG00000028433    Ubap2    0.183109955 8.73E-08
ENSMUSG00000025228    Actr1a 0.17460306 4.40E-05 ENSMUSG00000078453    Abracl 0.183286953 0.0146221
ENSMUSG00000021114    Atp6v1d 0.174695117 0.0032381 ENSMUSG00000043940    Wdfy3    0.183348422 0.0008608
ENSMUSG00000000759    Tubgcp3    0.174696671 0.0080468 ENSMUSG00000070733    Fryl 0.183514445 0.0176058
ENSMUSG00000064373    Sepp1    0.174697169 0.032478 ENSMUSG00000025040    Fundc1    0.183627004 0.0249915
ENSMUSG00000068184    Ndufaf2    0.174722418 0.0464055 ENSMUSG00000025260    Hsd17b10    0.183680998 0.0049212
ENSMUSG00000029993    Nfu1    0.174819741 0.0296409 ENSMUSG00000050668    Gpatch11    0.183837135 0.0477343
ENSMUSG00000039967    Zfp292    0.17487039 0.0086011 ENSMUSG00000026585    Kifap3    0.18384813 0.0063119
ENSMUSG00000035901    Dennd5a 0.17517495 3.87E-07 ENSMUSG00000027223    Mapk8ip1    0.183980332 0.0353867
ENSMUSG00000075232    Amd1    0.175227031 1.01E-06 ENSMUSG00000019362    D8Ertd738e 0.184377334 0.0065479
ENSMUSG00000027654    Fam83d 0.175341562 0.0268122 ENSMUSG00000024542    Cep192    0.184446963 0.0006791
ENSMUSG00000050148    Ubqln2    0.175376198 0.0098084 ENSMUSG00000034593    Myo5a 0.184474673 7.75E-09
ENSMUSG00000014402    Tsg101    0.175605246 0.0012201 ENSMUSG00000069729    Arid1b 0.184492637 0.0075474
ENSMUSG00000028849    Map7d1    0.17566786 0.0001652 ENSMUSG00000028998    Tomm7    0.184657335 0.0015214
ENSMUSG00000006390    Elovl1    0.175720025 0.003612 ENSMUSG00000027634    Ndrg3    0.184702916 0.0009835
ENSMUSG00000031668    Eif2ak3    0.175921804 0.0399451 ENSMUSG00000063077    Kif1b 0.184715924 0.0003384
ENSMUSG00000019813    Cep57l1    0.176202911 0.0322127 ENSMUSG00000028419    Chmp5    0.184819877 0.0005437
ENSMUSG00000017716    Birc5    0.176417635 9.40E-05 ENSMUSG00000049047    Armcx3    0.185037696 0.0114872
ENSMUSG00000018474    Chd3    0.176492897 1.47E-05 ENSMUSG00000019927    Ube2d1    0.18535066 0.0256758
ENSMUSG00000031441    Atp11a 0.176497895 0.0111106 ENSMUSG00000030591    Psmd8    0.185501857 3.49E-05
ENSMUSG00000038602    Slc35f1    0.176563609 2.69E-05 ENSMUSG00000036959    Bcorl1    0.186011872 0.0396159
ENSMUSG00000023050    Map3k12    0.176571583 0.0442507 ENSMUSG00000030417    Pdcd5    0.18618861 0.0002117
ENSMUSG00000042308    Setd1a 0.176580488 0.0175686 ENSMUSG00000019971    Cep290    0.186366234 0.0202265
ENSMUSG00000040990    Sh3kbp1    0.176635357 0.0005932 ENSMUSG00000028032    Papss1    0.186372095 6.80E-05
ENSMUSG00000035637    Grhpr 0.176726362 0.0405435 ENSMUSG00000039178    Tbc1d19    0.186424273 0.0408226
ENSMUSG00000039735    Fnbp1l 0.176747257 0.0002942 ENSMUSG00000028068    Iqgap3    0.186591872 0.0009383
ENSMUSG00000028034    Fubp1    0.176838388 1.05E-07 ENSMUSG00000032402    Smad3    0.186674405 0.0084644
ENSMUSG00000042918    Mamstr 0.177025071 0.0493836 ENSMUSG00000043154    Ppp2r3a 0.186762349 0.0320215
ENSMUSG00000040591    1110051M20Rik 0.177115271 0.0338044 ENSMUSG00000042978    Sbk1    0.18676571 0.0288262
ENSMUSG00000060743    H3f3a 0.177396098 3.13E-05 ENSMUSG00000033065    Pfkm 0.1868224 0.0019976
ENSMUSG00000041957    Pkp2    0.17779982 0.0020866 ENSMUSG00000060373    Hnrnpc 0.187027108 1.67E-10
ENSMUSG00000057841    Rpl32    0.177972354 1.05E-15 ENSMUSG00000021067    Sav1    0.187066614 0.0010822
ENSMUSG00000027187    Cat 0.178040609 0.0199224 ENSMUSG00000034621    Gpatch8    0.187384281 0.0003847
ENSMUSG00000060591    Ifitm2    0.178127988 0.0001623 ENSMUSG00000022205    Sub1    0.187492386 7.28E-06
ENSMUSG00000032481    Smarcc1    0.178265006 3.93E-08 ENSMUSG00000030718    Ppme1    0.187529013 0.0007128
ENSMUSG00000091625    Lsm5    0.178393476 0.029313 ENSMUSG00000017421    Zfp207    0.187655568 2.78E-08
ENSMUSG00000024099    Ndufv2    0.178440903 0.0001049 ENSMUSG00000031835    Mbtps1    0.187847923 2.70E-05
ENSMUSG00000021693    Kif2a 0.178444932 0.0033251 ENSMUSG00000060090    Rp2h 0.187911013 0.0134577
ENSMUSG00000001767    Crnkl1    0.178507542 0.0063121 ENSMUSG00000021318    Gli3    0.188066056 0.0084007
ENSMUSG00000048756    Foxo3    0.178559745 0.0187452 ENSMUSG00000061981    Flot2    0.188086238 0.0001826
ENSMUSG00000033589    Reep4    0.178670463 0.0223962 ENSMUSG00000042462    Dctpp1    0.18809863 0.0030496
ENSMUSG00000059409    Ppp2r5d 0.178714736 8.94E-05 ENSMUSG00000020111    Micu1    0.18828797 0.0096362
ENSMUSG00000030172    Erc1    0.179139494 0.0093204 ENSMUSG00000039031    Arhgap18    0.188296665 0.0285104
ENSMUSG00000028410    Dnaja1    0.17923424 2.35E-07 ENSMUSG00000004266    Ptpn6    0.188347757 0.010974
ENSMUSG00000012076    Brms1l 0.179272209 0.005722 ENSMUSG00000026239    Pde6d 0.188433856 0.009996
ENSMUSG00000017404    Rpl19    0.179318764 4.98E-15 ENSMUSG00000040481    Bptf 0.188450702 1.88E-06
ENSMUSG00000031229    Atrx 0.179341457 1.65E-05 ENSMUSG00000031996    Aplp2    0.188476851 9.99E-08
ENSMUSG00000041037    Irgq 0.17950209 0.0233176 ENSMUSG00000035696    Rnf38    0.18850429 0.0014152
ENSMUSG00000025151    Maged1    0.179553468 2.15E-09 ENSMUSG00000028538    St3gal3    0.18851307 0.0154037
ENSMUSG00000038374    Rbm8a 0.179698837 0.0001911 ENSMUSG00000027254    Map1a 0.188584164 0.0001057
ENSMUSG00000021366    Hivep1    0.180038281 0.0350503 ENSMUSG00000026571    Dcaf6    0.188593035 0.012219
ENSMUSG00000032231    Anxa2    0.180045818 8.46E-16 ENSMUSG00000061273    Mmgt1    0.188606482 9.69E-05
ENSMUSG00000001158    Snrnp27    0.180146436 0.0067745 ENSMUSG00000024942    Capn1    0.188699212 0.0315162
ENSMUSG00000033916    Chmp2a 0.18019421 0.0008654 ENSMUSG00000003037    Rab8a 0.188741429 0.0031234
ENSMUSG00000025745    Hadha 0.180218495 7.18E-06 ENSMUSG00000000197    Nalcn 0.189082122 0.0181187
ENSMUSG00000006498    Ptbp1    0.180221497 7.83E-11 ENSMUSG00000041219    Arhgap11a 0.189167358 4.24E-05
ENSMUSG00000030203    Dusp16    0.180300989 0.0268364 ENSMUSG00000021288    Klc1    0.189229455 1.87E-05
ENSMUSG00000029191    Rfc1    0.180340679 8.97E-06 ENSMUSG00000025103    Btbd1    0.189249368 0.004422
ENSMUSG00000022024    Sugt1    0.180356144 0.0497911 ENSMUSG00000024947    Men1    0.189265019 0.0014203
ENSMUSG00000068882    Ssb 0.180494415 2.57E-08 ENSMUSG00000035246    Pcyt1b 0.189338985 0.0021045
ENSMUSG00000032349    Elovl5    0.180623945 0.0001379 ENSMUSG00000033632    AW554918    0.189342372 0.0475065
ENSMUSG00000024666    Tmem138    0.180760247 0.0429302 ENSMUSG00000056073    Grik2    0.189505082 0.0475214
ENSMUSG00000054717    Hmgb2    0.180840515 1.50E-06 ENSMUSG00000005470    Asf1b 0.189649183 0.002962
ENSMUSG00000054196    Cthrc1    0.18085966 0.0037217 ENSMUSG00000028402    Mpdz 0.189670925 0.0104878
ENSMUSG00000021670    Hmgcr 0.180886865 0.0119638 ENSMUSG00000055053    Nfic 0.189683714 1.16E-07
ENSMUSG00000024283    Wac 0.181035795 0.0001705 ENSMUSG00000030246    Ldhb 0.189767074 0.0041886
ENSMUSG00000071533    Pcnp 0.181479627 0.0040311 ENSMUSG00000022322    Shcbp1    0.189824808 0.0067821
ENSMUSG00000038383    Pigu 0.181495025 0.0047334 ENSMUSG00000063787    Chchd1    0.189842602 0.0085032
ENSMUSG00000001985    Grik3    0.181584199 0.0452135 ENSMUSG00000031198    Fundc2    0.189998223 0.0011315
ENSMUSG00000002658    Gtf2f1    0.181653531 0.0001144 ENSMUSG00000021707    Dhfr 0.190439934 0.0053045
ENSMUSG00000021606    Ndufs6    0.181724084 0.0157905 ENSMUSG00000020803    Txndc17    0.190446446 0.0002165
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ENSMUSG00000027165    B230118H07Rik 0.190559121 0.0449773 ENSMUSG00000021466    Ptch1    0.198771305 0.0020755
ENSMUSG00000039219    Arid4b 0.190583575 0.0169393 ENSMUSG00000041870    Ankrd13a 0.198924331 6.65E-05
ENSMUSG00000051579    Tceal8    0.190589208 0.0012062 ENSMUSG00000037058    Paip2    0.198970853 0.0004236
ENSMUSG00000025525    Apool 0.190608986 0.0472212 ENSMUSG00000060601    Nr1h2    0.199295319 0.0056383
ENSMUSG00000022808    Snx4    0.190637637 2.81E-05 ENSMUSG00000028248    Pnisr 0.199315556 0.000165
ENSMUSG00000071866    Ppia 0.190741252 2.57E-21 ENSMUSG00000023048    Prr13    0.199356502 0.0442097
ENSMUSG00000019066    Rab3d 0.190747716 0.0310356 ENSMUSG00000024914    Drap1    0.199491073 2.43E-05
ENSMUSG00000039234    Sec24d 0.191459564 0.0028387 ENSMUSG00000002250    Ppard 0.199517953 0.0127812
ENSMUSG00000019738    Polr2i 0.191466669 0.0263976 ENSMUSG00000041431    Ccnb1    0.199631459 2.07E-05
ENSMUSG00000037020    Wdr62    0.191734306 0.0270724 ENSMUSG00000022329    Stk3    0.199883307 0.0037001
ENSMUSG00000074457    S100a16    0.191786582 0.0146409 ENSMUSG00000068036    Mllt4    0.199993109 0.0002736
ENSMUSG00000032580    Rbm5    0.191821957 0.0004576 ENSMUSG00000030323    Ift122    0.200127425 0.0425508
ENSMUSG00000046138    9930021J03Rik 0.192060404 0.0047856 ENSMUSG00000021957    Tkt 0.200232014 5.56E-07
ENSMUSG00000032060    Cryab 0.192067627 1.07E-07 ENSMUSG00000036599    Chst12    0.200331303 0.0069438
ENSMUSG00000042548    Asxl1    0.192270352 2.14E-05 ENSMUSG00000030868    Dctn5    0.200345719 0.0036431
ENSMUSG00000020462    Cfap36    0.192276504 0.000699 ENSMUSG00000031134    Rbmx 0.200357305 5.93E-06
ENSMUSG00000042606    Hirip3    0.192388378 8.04E-05 ENSMUSG00000036561    Ppp6r2    0.200377408 0.0201388
ENSMUSG00000091337    Eid1    0.192390995 0.0002419 ENSMUSG00000031626    Sorbs2    0.200421352 0.040608
ENSMUSG00000013033    Adgrl1    0.192549068 0.0153545 ENSMUSG00000024052    Lpin2    0.200478485 0.0029369
ENSMUSG00000025823    Pdia4    0.192561363 1.71E-08 ENSMUSG00000025757    Hspa4l 0.200527025 0.0004291
ENSMUSG00000020009    Ifngr1    0.193046795 0.044466 ENSMUSG00000039844    Rapgef1    0.200529492 1.24E-06
ENSMUSG00000007987    Ift22    0.193066071 0.0284197 ENSMUSG00000025736    Jmjd8    0.200571193 0.011766
ENSMUSG00000039117    Taf4a 0.193088863 0.0075345 ENSMUSG00000033938    Ndufb7    0.200658613 0.004824
ENSMUSG00000031295    Phka2    0.19318442 0.0142605 ENSMUSG00000048922    Cdca2    0.200750381 0.0161974
ENSMUSG00000038206    Fbxo8    0.193356973 0.0408826 ENSMUSG00000047248    C2cd3    0.200782672 0.0008387
ENSMUSG00000037622    Wdtc1    0.193444349 0.0239859 ENSMUSG00000030978    Rrm1    0.201189534 2.79E-12
ENSMUSG00000022817    Itgb5    0.19344863 5.85E-05 ENSMUSG00000058558    Rpl5    0.201222668 7.73E-18
ENSMUSG00000026853    Crat 0.19345882 0.0088351 ENSMUSG00000032047    Acat1    0.201333648 0.0006945
ENSMUSG00000018501    Ncor1    0.193573461 6.92E-09 ENSMUSG00000026043    Col3a1    0.201338096 0.0003052
ENSMUSG00000005871    Apc 0.193636323 1.71E-06 ENSMUSG00000030409    Dmpk 0.201416119 0.0097724
ENSMUSG00000066551    Hmgb1    0.193718415 1.08E-09 ENSMUSG00000073702    Rpl31    0.201439662 2.89E-13
ENSMUSG00000046111    Cep295    0.193803181 0.0014156 ENSMUSG00000029762    Akr1b8    0.201506123 4.99E-05
ENSMUSG00000024220    Zfp523    0.19405209 0.0072527 ENSMUSG00000002477    Snrpd1    0.201537115 1.27E-05
ENSMUSG00000060739    Nsa2    0.194121298 0.0001646 ENSMUSG00000015478    Rnf5    0.201625604 0.0053119
ENSMUSG00000045095    Magi1    0.194291142 0.001247 ENSMUSG00000031756    Cenpn 0.201729045 0.0173607
ENSMUSG00000047003    Zfp41    0.194305585 0.0372231 ENSMUSG00000020315    Sptbn1    0.201994274 3.35E-11
ENSMUSG00000053317    Sec61b 0.194368871 0.001005 ENSMUSG00000075470    Alg10b 0.202012528 4.93E-06
ENSMUSG00000014601    Strip1    0.194466866 0.0003612 ENSMUSG00000032551    1110059G10Rik 0.202045286 0.0492019
ENSMUSG00000014767    Tbp 0.194488437 0.0096793 ENSMUSG00000036968    Cnpy4    0.202331197 0.0063482
ENSMUSG00000038119    Cdon 0.19456562 0.0419839 ENSMUSG00000024913    Lrp5    0.202493139 6.37E-05
ENSMUSG00000045671    Spred2    0.19457692 0.0001047 ENSMUSG00000046435    Gm13078    0.202496337 0.0078333
ENSMUSG00000070047    Fat1    0.194627943 0.0003948 ENSMUSG00000024758    Rtn3    0.202535095 7.02E-08
ENSMUSG00000037815    Ctnna1    0.194656699 6.70E-11 ENSMUSG00000041444    Arhgap32    0.202677343 0.0008345
ENSMUSG00000021585    Cast 0.194735718 0.001144 ENSMUSG00000031146    Plp2    0.202688974 5.71E-07
ENSMUSG00000040359    Ufl1    0.194926271 0.0041252 ENSMUSG00000024810    Il33    0.202763301 0.0066757
ENSMUSG00000049916    2610318N02Rik 0.195310427 0.0415055 ENSMUSG00000010110    Stx5a 0.202859062 0.0089342
ENSMUSG00000006276    Eps15l1    0.195397081 0.0091941 ENSMUSG00000016427    Ndufa1    0.202898337 0.0028425
ENSMUSG00000026469    Xpr1    0.195521266 0.0010095 ENSMUSG00000015291    Gdi1    0.203233953 0.0001919
ENSMUSG00000021359    Tfap2a 0.195889261 0.0048489 ENSMUSG00000020738    Sumo2    0.203318899 1.80E-10
ENSMUSG00000031168    Ebp 0.195937068 0.0034492 ENSMUSG00000028495    Rps6    0.203534598 6.65E-16
ENSMUSG00000030077    Chl1    0.196258671 9.19E-07 ENSMUSG00000037628    Cdkn3    0.203788334 0.0370617
ENSMUSG00000020747    2310067B10Rik 0.1963163 0.0096586 ENSMUSG00000037361    Sf3b6    0.204082912 0.0004283
ENSMUSG00000015937    H2afy 0.196427737 0.0006254 ENSMUSG00000020827    Mink1    0.204178302 2.92E-06
ENSMUSG00000063410    Stk24    0.196428747 0.0058713 ENSMUSG00000020140    Lgr5    0.204240966 0.0466675
ENSMUSG00000022450    Ndufa6    0.196507901 0.0005203 ENSMUSG00000034544    Rsrc1    0.204392401 0.0009929
ENSMUSG00000045962    Wnk1    0.196508516 9.65E-10 ENSMUSG00000094973    Gm8994    0.204395248 0.0180948
ENSMUSG00000031516    Dctn6    0.196553554 0.0271238 ENSMUSG00000033306    Lpp 0.204479411 0.0010484
ENSMUSG00000039716    Dock3    0.197018689 0.0153469 ENSMUSG00000036955    Kif1bp 0.205012244 0.0029556
ENSMUSG00000008859    Rala 0.197029236 0.0015671 ENSMUSG00000004798    Ulk2    0.205104867 0.0043428
ENSMUSG00000037270    4932438A13Rik 0.197462723 0.0004129 ENSMUSG00000037221    Mospd3    0.205145196 0.0327861
ENSMUSG00000032330    Cox7a2    0.197471628 6.09E-05 ENSMUSG00000093760    Gm20678    0.205363335 0.0103023
ENSMUSG00000027679    Dnajc19    0.197495711 0.0058886 ENSMUSG00000049504    Proser1    0.205395005 0.0303592
ENSMUSG00000027074    Slc43a3    0.197505997 0.0013338 ENSMUSG00000033985    Tesk2    0.20543267 0.0428804
ENSMUSG00000039741    Bahcc1    0.19757399 0.0119239 ENSMUSG00000042605    Atxn2    0.205535402 2.49E-05
ENSMUSG00000030335    Mrpl51    0.197629842 6.59E-05 ENSMUSG00000023919    Cenpq 0.205594403 0.0063267
ENSMUSG00000021807    2700060E02Rik 0.197728861 7.62E-05 ENSMUSG00000027248    Pdia3    0.20566041 2.86E-20
ENSMUSG00000068917    Clk2    0.197762324 0.0155244 ENSMUSG00000027303    Ptpra 0.205731393 7.24E-06
ENSMUSG00000042557    Sin3a 0.197768753 0.0002606 ENSMUSG00000030120    Mlf2    0.205855207 5.13E-08
ENSMUSG00000040767    Snrnp25    0.197865435 0.0362772 ENSMUSG00000024002    Brd4    0.206091726 1.21E-06
ENSMUSG00000028576    Ift74    0.19787637 0.029633 ENSMUSG00000023170    Gps2    0.206132992 0.0174095
ENSMUSG00000025144    Stra13    0.197902022 0.0487231 ENSMUSG00000032562    Gnai2    0.20616603 4.24E-11
ENSMUSG00000039828    Wdr70    0.197931867 0.0045654 ENSMUSG00000043866    Taf10    0.206278276 4.14E-05
ENSMUSG00000010376    Nedd8    0.197950794 7.00E-05 ENSMUSG00000040407    Akap9    0.20630242 4.23E-05
ENSMUSG00000031153    Gripap1    0.19806504 0.0066258 ENSMUSG00000025571    Tnrc6c 0.206656248 0.0069678
ENSMUSG00000024949    Sf1    0.198142522 3.37E-08 ENSMUSG00000055538    Zcchc24    0.206843854 0.0001874
ENSMUSG00000020572    Nampt 0.19829133 3.96E-05 ENSMUSG00000020721    Helz 0.207005565 0.0003756
ENSMUSG00000032187    Smarca4    0.198304596 5.82E-10 ENSMUSG00000022385    Gtse1    0.207022421 1.78E-05
ENSMUSG00000048154    Kmt2d 0.198386091 0.034345 ENSMUSG00000000127    Fer 0.207118061 0.0189664
ENSMUSG00000031157    Pqbp1    0.198526407 0.0018732 ENSMUSG00000049288    Lix1l 0.207156614 1.13E-05
ENSMUSG00000032740    Ccdc88a 0.198715585 0.0054507 ENSMUSG00000024974    Smc3    0.207623479 4.89E-09
ENSMUSG00000015222    Map2    0.198738164 0.0002501 ENSMUSG00000032383    Ppib 0.207941124 9.96E-06
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ENSMUSG00000086151    Gm5698    0.208174796 0.0019242 ENSMUSG00000028832    Stmn1    0.21817378 4.67E-11
ENSMUSG00000028312    Smc2    0.208199543 1.50E-10 ENSMUSG00000025474    Tubgcp2    0.218182507 0.0028935
ENSMUSG00000020808    Fam64a 0.20835471 9.15E-05 ENSMUSG00000040084    Bub1b 0.218185723 3.97E-08
ENSMUSG00000029472    Anapc5    0.208569853 1.77E-12 ENSMUSG00000000282    Mnt 0.218255983 0.0209518
ENSMUSG00000030774    Pak1    0.208571976 0.0008157 ENSMUSG00000032186    Tmod2    0.218821011 0.006469
ENSMUSG00000034709    Ppp1r21    0.20870688 0.0051928 ENSMUSG00000014813    Stc1    0.219054618 0.0180299
ENSMUSG00000008200    Fnbp4    0.208731302 0.0017523 ENSMUSG00000074280    Gm6166    0.219102086 5.05E-06
ENSMUSG00000004667    Polr2e 0.208740527 2.76E-05 ENSMUSG00000040225    Prrc2c 0.219113553 7.44E-14
ENSMUSG00000018395    Kif3a 0.208970158 0.0023454 ENSMUSG00000045215    Asxl3    0.219122474 0.0020988
ENSMUSG00000000957    Mmp14    0.208997122 2.45E-09 ENSMUSG00000036572    Upf3b 0.219457785 0.0019561
ENSMUSG00000025574    Tk1    0.209392543 0.0002195 ENSMUSG00000001441    Npepps 0.219504261 4.20E-06
ENSMUSG00000040746    Rnf167    0.209472259 0.0242834 ENSMUSG00000058603    Rpl28-ps1    0.21951133 0.0010396
ENSMUSG00000029554    Mad1l1    0.209614746 0.0001393 ENSMUSG00000037703    Lzts3    0.219644598 0.0127908
ENSMUSG00000025868    Higd2a 0.20980854 0.020842 ENSMUSG00000029096    Htra3    0.219812405 0.0136047
ENSMUSG00000071415    Rpl23    0.209837481 2.32E-20 ENSMUSG00000066306    Numa1    0.219978255 2.57E-10
ENSMUSG00000036002    Fam214b 0.209879131 0.042213 ENSMUSG00000005198    Polr2a 0.220024162 7.73E-12
ENSMUSG00000031149    Praf2    0.210023216 0.0062038 ENSMUSG00000003228    Grk5    0.220100075 0.0320472
ENSMUSG00000020864    Ankrd40    0.210246632 6.82E-08 ENSMUSG00000039607    Rbms3    0.220140369 0.0119996
ENSMUSG00000017781    Pitpna 0.21025211 1.63E-07 ENSMUSG00000034295    Fhod3    0.220370392 0.0035657
ENSMUSG00000043456    Zfp536    0.210309185 0.0205994 ENSMUSG00000031378    Abcd1    0.220487228 0.0064756
ENSMUSG00000040151    Hs2st1    0.210337129 1.81E-10 ENSMUSG00000022428    Cby1    0.220663741 0.0197456
ENSMUSG00000034761    Map4k5    0.210950613 9.05E-05 ENSMUSG00000020935    Dcakd 0.220703723 0.0002441
ENSMUSG00000029623    Pdap1    0.211094896 7.71E-13 ENSMUSG00000036427    Gpi1    0.220729495 0.0023394
ENSMUSG00000037217    Syn1    0.211315237 0.0280901 ENSMUSG00000073434    Wdr90    0.220738598 0.0193598
ENSMUSG00000020986    Sec23a 0.211319359 0.0005078 ENSMUSG00000020173    Cobl 0.220750799 0.015926
ENSMUSG00000019942    Cdk1    0.211325603 3.04E-10 ENSMUSG00000070639    Lrrc8b 0.220844806 6.39E-05
ENSMUSG00000001151    Pcnt 0.211392759 3.25E-05 ENSMUSG00000035024    Ncapd3    0.220944243 8.59E-06
ENSMUSG00000005371    Fbxo11    0.211532717 0.000309 ENSMUSG00000019194    Scn1b 0.221105915 0.0279264
ENSMUSG00000045160    Bola3    0.211548394 0.0090646 ENSMUSG00000000804    Usp32    0.221200402 0.0002439
ENSMUSG00000044285    Gm1821    0.211581549 0.0469344 ENSMUSG00000021273    Fdft1    0.221255993 0.0169041
ENSMUSG00000041911    Dlx1    0.211670348 0.0102318 ENSMUSG00000002055    Spag5    0.221318882 3.94E-06
ENSMUSG00000028878    Fam76a 0.211678862 0.0390144 ENSMUSG00000024588    Fech 0.221336557 0.0005757
ENSMUSG00000034021    Pds5b 0.211766465 1.51E-07 ENSMUSG00000020814    Mxra7    0.221389839 0.0086989
ENSMUSG00000083670    Gm6829    0.211768587 0.0379806 ENSMUSG00000028484    Psip1    0.221470346 2.60E-08
ENSMUSG00000023904    Hcfc1r1    0.211895983 0.0072161 ENSMUSG00000009687    Fxyd5    0.221559154 1.33E-07
ENSMUSG00000028671    Gale 0.211960114 0.0451893 ENSMUSG00000028378    Ptgr1    0.221585192 0.0331902
ENSMUSG00000004698    Hdac9    0.212049325 0.0190367 ENSMUSG00000025357    Dgka 0.222042585 0.021509
ENSMUSG00000029461    Fam168a 0.212236408 0.0006876 ENSMUSG00000013367    Iglon5    0.222323521 0.0312556
ENSMUSG00000037621    Atoh8    0.212266474 0.0405854 ENSMUSG00000033282    Rpgrip1l 0.222443532 0.0279034
ENSMUSG00000061607    Mdc1    0.212330554 4.13E-07 ENSMUSG00000063065    Mapk3    0.222503258 2.08E-08
ENSMUSG00000030587    2200002D01Rik 0.212397118 0.0104034 ENSMUSG00000026779    Mastl 0.222645594 0.0053099
ENSMUSG00000035198    Tubg1    0.212443967 0.000171 ENSMUSG00000080893    Gm15920    0.222690839 0.0249453
ENSMUSG00000078180    Gm20900    0.212523984 0.0089695 ENSMUSG00000022139    Mbnl2    0.222715577 7.16E-05
ENSMUSG00000023072    Cep89    0.212800628 0.0038352 ENSMUSG00000056394    Lig1    0.22330003 9.18E-09
ENSMUSG00000049517    Rps23    0.212947439 2.96E-15 ENSMUSG00000031604    Msmo1    0.22338013 0.0025185
ENSMUSG00000042520    Ubap2l 0.212950237 1.24E-11 ENSMUSG00000022314    Rad21    0.223387866 1.65E-17
ENSMUSG00000056763    Cspp1    0.213496563 0.0119527 ENSMUSG00000027115    Kif18a 0.223676827 0.0008878
ENSMUSG00000020241    Col6a2    0.213542606 0.010767 ENSMUSG00000033278    Ptprm 0.223803332 0.0060957
ENSMUSG00000039270    Megf9    0.213748439 0.0031052 ENSMUSG00000022678    Nde1    0.223970871 1.97E-06
ENSMUSG00000024277    Mapre2    0.213970981 0.0020122 ENSMUSG00000063445    Nmral1    0.224030317 0.010259
ENSMUSG00000096284    Tcstv1    0.213973339 0.0039191 ENSMUSG00000070619    Gm13119    0.224032203 0.0085956
ENSMUSG00000024556    Me2    0.214112155 5.13E-06 ENSMUSG00000036295    Lrrn3    0.224128543 0.0311276
ENSMUSG00000040549    Ckap5    0.214126393 1.24E-10 ENSMUSG00000042331    Specc1    0.22424927 1.92E-07
ENSMUSG00000028718    Stil 0.214447235 0.0174344 ENSMUSG00000081406    Rps6-ps4    0.224315472 0.0002612
ENSMUSG00000024590    Lmnb1    0.214651051 1.28E-06 ENSMUSG00000024925    Rnaseh2c 0.224353271 0.0187051
ENSMUSG00000038648    Creb3l2    0.21474352 0.000267 ENSMUSG00000028134    Ptbp2    0.225087654 0.0006023
ENSMUSG00000001794    Capns1    0.214795232 2.32E-07 ENSMUSG00000027012    Dync1i2    0.225111336 3.60E-07
ENSMUSG00000031386    Hcfc1    0.215260408 1.03E-14 ENSMUSG00000030693    Klk10    0.225135511 1.35E-05
ENSMUSG00000008450    Nutf2    0.215403515 0.0002336 ENSMUSG00000025404    R3hdm2    0.225188878 2.48E-06
ENSMUSG00000070808    Gltscr1    0.215524004 0.0362421 ENSMUSG00000057388    Mrpl18    0.225208346 9.32E-06
ENSMUSG00000030035    Wbp1    0.215553201 0.0057626 ENSMUSG00000031762    Mt2    0.225323115 0.0032148
ENSMUSG00000027797    Dclk1    0.21566699 0.0026955 ENSMUSG00000024260    Sap130    0.225458575 8.49E-05
ENSMUSG00000105868    RP24-223I19.6    0.215740273 0.0404511 ENSMUSG00000032410    Xrn1    0.225525378 0.0001732
ENSMUSG00000090841    Myl6    0.216080843 0.0140356 ENSMUSG00000048118    Arid4a 0.225528826 0.0201613
ENSMUSG00000035357    Pdzrn3    0.216167571 5.84E-05 ENSMUSG00000026797    Stxbp1    0.225573966 0.0022613
ENSMUSG00000042284    Itga1    0.216259832 4.56E-05 ENSMUSG00000027330    Cdc25b 0.225652678 2.03E-05
ENSMUSG00000019302    Atp6v0a1    0.216280911 0.0123062 ENSMUSG00000029135    Fosl2    0.225656279 5.01E-05
ENSMUSG00000005447    Pafah1b3    0.216601308 0.0018952 ENSMUSG00000053137    Mapk11    0.225749528 0.0221475
ENSMUSG00000077450    Rab11b 0.216994367 5.74E-05 ENSMUSG00000029101    Rgs12    0.225812169 0.0135588
ENSMUSG00000018750    Zbtb4    0.217077144 0.0132726 ENSMUSG00000020485    Supt4a 0.226069874 0.0015494
ENSMUSG00000062933    Gm10123    0.217137163 0.0137926 ENSMUSG00000028412    Slc44a1    0.226319123 1.33E-07
ENSMUSG00000038072    Galnt11    0.217168043 0.0066522 ENSMUSG00000038065    Mturn 0.226608817 0.0490654
ENSMUSG00000021127    Zfp36l1    0.217170359 0.00999 ENSMUSG00000032355    Mlip 0.226817906 0.0246526
ENSMUSG00000021068    Nin 0.217365354 0.0001586 ENSMUSG00000007817    Zmiz1    0.227041332 6.03E-06
ENSMUSG00000039686    Zer1    0.217422227 0.0487613 ENSMUSG00000030701    Plekhb1    0.227373949 0.0002542
ENSMUSG00000025374    Nabp2    0.217609592 0.0023644 ENSMUSG00000031391    L1cam 0.227736947 6.32E-07
ENSMUSG00000024989    Cep55    0.217726864 4.35E-05 ENSMUSG00000058239    Usf2    0.227746318 5.47E-05
ENSMUSG00000020859    Spag9    0.217737005 2.93E-06 ENSMUSG00000067288    Rps28    0.22776661 2.96E-13
ENSMUSG00000020776    Fbf1    0.217899361 0.0061611 ENSMUSG00000054199    Gon4l 0.227861084 0.0003324
ENSMUSG00000013236    Ptprs 0.217946134 2.23E-05 ENSMUSG00000061533    Cep128    0.227909486 0.009047
ENSMUSG00000021196    Pfkp 0.218170064 0.0376001 ENSMUSG00000020932    Gfap 0.227910576 1.31E-11
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ENSMUSG00000046364    Rpl27a 0.228227576 7.98E-24 ENSMUSG00000064351    mt-Co1    0.243465525 5.36E-47
ENSMUSG00000073987    Ggh 0.22830973 0.0464787 ENSMUSG00000001383    Zmat2    0.243550077 1.50E-06
ENSMUSG00000026879    Gsn 0.228643703 0.000691 ENSMUSG00000035683    Melk 0.243560135 1.33E-05
ENSMUSG00000040725    Hnrnpul1    0.228972542 2.10E-11 ENSMUSG00000020375    Rufy1    0.243634465 0.0012085
ENSMUSG00000046753    Ccdc66    0.229052848 0.0196496 ENSMUSG00000032575    Manf 0.243647149 1.06E-09
ENSMUSG00000056211    R3hdm1    0.229053127 4.43E-07 ENSMUSG00000040721    Zfhx2    0.243835504 0.0455284
ENSMUSG00000061028    Clasrp 0.229263755 0.0046102 ENSMUSG00000067925    Cxx1a 0.243864707 0.0322663
ENSMUSG00000024646    Cyb5a 0.229271665 0.0438815 ENSMUSG00000034401    Spata6    0.244381686 0.0094976
ENSMUSG00000057963    Itpk1    0.22960994 0.0005295 ENSMUSG00000078193    Gm2000    0.244460623 0.0032062
ENSMUSG00000035051    Dhx57    0.230158787 0.0094364 ENSMUSG00000028969    Cdk5    0.244589964 0.0005559
ENSMUSG00000043987    Cep164    0.230281486 0.0012596 ENSMUSG00000028799    Zfp362    0.24520216 0.0139232
ENSMUSG00000039477    Tnrc18    0.23032416 8.58E-08 ENSMUSG00000026851    BC005624    0.245261769 0.0008992
ENSMUSG00000017843    Ppp2r5c 0.230876834 1.96E-06 ENSMUSG00000075590    Nrbp2    0.245366973 0.0409819
ENSMUSG00000024269    Tpgs2    0.231147601 0.0017374 ENSMUSG00000024018    Ccdc167    0.245847838 0.0432777
ENSMUSG00000008575    Nfib 0.231614844 0.0066145 ENSMUSG00000000711    Rab5b 0.246059344 3.71E-06
ENSMUSG00000038717    Atp5l 0.231689653 1.56E-05 ENSMUSG00000033460    Armcx1    0.246152123 0.0351686
ENSMUSG00000019370    Calm3    0.231729469 5.51E-12 ENSMUSG00000031879    Fam96b 0.246287925 0.007922
ENSMUSG00000078695    Cisd3    0.231736077 0.0305246 ENSMUSG00000062691    Cebpzos 0.246324099 0.0307114
ENSMUSG00000026074    Map4k4    0.231928707 3.47E-10 ENSMUSG00000034520    Gjc1    0.246344719 0.0025158
ENSMUSG00000058325    Dock1    0.231979777 5.93E-07 ENSMUSG00000024498    Tcerg1    0.246366846 9.18E-09
ENSMUSG00000064302    Clasp1    0.232247138 1.33E-06 ENSMUSG00000063382    Bcl9l 0.246585749 1.71E-05
ENSMUSG00000027994    Ccdc109b 0.232298889 0.0325719 ENSMUSG00000030867    Plk1    0.246606328 5.47E-11
ENSMUSG00000041997    Tlk1    0.232400042 6.39E-06 ENSMUSG00000019804    Snx3    0.246664472 4.50E-08
ENSMUSG00000105388    Rpl36a-ps2    0.232896582 0.0036423 ENSMUSG00000024056    Ndc80    0.246713214 8.61E-05
ENSMUSG00000044674    Fzd1    0.232952215 0.0002818 ENSMUSG00000052331    Ankrd44    0.246878007 0.006619
ENSMUSG00000028760    Eif4g3    0.233196204 3.12E-08 ENSMUSG00000026790    Odf2    0.247081066 9.53E-05
ENSMUSG00000010751    Tnfrsf22    0.233346422 7.33E-05 ENSMUSG00000061288    Taok3    0.247539741 0.0138362
ENSMUSG00000021262    Evl 0.233350702 0.0013566 ENSMUSG00000064193    Gm4735    0.24764698 0.0112492
ENSMUSG00000037313    Tacc3    0.23364818 1.86E-06 ENSMUSG00000022013    Dnajc15    0.247678539 0.0218744
ENSMUSG00000020185    E2f7    0.233863873 0.0049733 ENSMUSG00000020024    Cep83    0.247744615 0.0006686
ENSMUSG00000005233    Spc25    0.233940267 0.0006321 ENSMUSG00000058056    Palld 0.247755677 0.0353383
ENSMUSG00000026473    Glul 0.234125453 0.0016474 ENSMUSG00000031708    Tecr 0.247857552 2.63E-06
ENSMUSG00000023067    Cdkn1a 0.234234224 1.42E-06 ENSMUSG00000078427    Sarnp 0.247910691 5.34E-07
ENSMUSG00000027940    Tpm3    0.234980966 2.50E-08 ENSMUSG00000062248    Cks2    0.248261053 4.38E-05
ENSMUSG00000028609    Magoh 0.235409385 0.0004841 ENSMUSG00000039781    Cep131    0.248355628 0.0120294
ENSMUSG00000020849    Ywhae 0.235453926 5.03E-23 ENSMUSG00000002546    Golga2    0.248432562 5.53E-05
ENSMUSG00000072594    Gm16439    0.2354691 0.0402839 ENSMUSG00000034205    Loxl2    0.24848243 0.0454574
ENSMUSG00000078923    Ube2v1    0.235490156 0.0343649 ENSMUSG00000073177    Gm773    0.248609183 1.57E-06
ENSMUSG00000020163    Uqcr11    0.235910213 9.79E-06 ENSMUSG00000068923    Syt11    0.24903653 0.0001959
ENSMUSG00000027997    Casp6    0.235963239 0.0088946 ENSMUSG00000006800    Sulf2    0.249244957 9.11E-11
ENSMUSG00000032238    Rora 0.236192345 0.0432607 ENSMUSG00000038379    Ttk 0.249441542 2.81E-05
ENSMUSG00000031207    Msn 0.236275065 1.74E-26 ENSMUSG00000031232    Magt1    0.249490027 1.54E-05
ENSMUSG00000003031    Cdkn1b 0.236434813 0.0030427 ENSMUSG00000034341    Wbp2    0.249547178 2.13E-06
ENSMUSG00000003437    Paf1    0.236618003 1.90E-05 ENSMUSG00000018449    Rpain 0.249571249 0.0186755
ENSMUSG00000063229    Ldha 0.237201879 0.0160158 ENSMUSG00000051154    Commd3    0.249724439 1.95E-05
ENSMUSG00000029705    Cux1    0.23734647 1.10E-05 ENSMUSG00000031683    Lsm6    0.249729027 0.0001726
ENSMUSG00000030096    Slc6a6    0.237789189 1.14E-12 ENSMUSG00000029512    Ulk1    0.249732857 0.0011243
ENSMUSG00000058454    Dhcr7    0.237907018 0.0054902 ENSMUSG00000038332    Sesn1    0.250180895 0.030253
ENSMUSG00000038256    Bcl9    0.238070712 2.88E-05 ENSMUSG00000021591    Glrx 0.250342162 0.0392698
ENSMUSG00000059518    Znhit1    0.238132048 0.0002785 ENSMUSG00000009418    Nav1    0.250345839 3.90E-05
ENSMUSG00000053580    Tanc2    0.238142476 4.07E-05 ENSMUSG00000041559    Fmod 0.250456702 0.0201014
ENSMUSG00000028843    Sh3bgrl3    0.238187763 0.0035557 ENSMUSG00000085289    Gm15337    0.25049557 0.0430977
ENSMUSG00000037960    1110007C09Rik 0.238187935 0.0019735 ENSMUSG00000035545    Leng8    0.250671293 0.0001549
ENSMUSG00000057110    Cntrl 0.238387363 0.0007811 ENSMUSG00000068740    Celsr2    0.25077704 0.0313736
ENSMUSG00000058258    Idi1    0.238923614 0.0007946 ENSMUSG00000018567    Gabarap 0.250814897 6.24E-07
ENSMUSG00000063457    Rps15    0.23939081 1.64E-20 ENSMUSG00000074884    Serf2    0.250819474 2.60E-08
ENSMUSG00000028647    Mycbp 0.239406471 0.0105516 ENSMUSG00000006191    Cdkal1    0.251046574 0.0173307
ENSMUSG00000027304    Rtf1    0.239545886 1.04E-05 ENSMUSG00000039849    Pcif1    0.251154396 0.0001043
ENSMUSG00000024795    Kif20b 0.239550536 4.05E-06 ENSMUSG00000031558    Slit2    0.251302976 9.29E-12
ENSMUSG00000027860    Vangl1    0.239637632 0.0019396 ENSMUSG00000005732    Ranbp1    0.251311902 2.16E-19
ENSMUSG00000004270    Lpcat3    0.239655639 0.0034618 ENSMUSG00000026492    Tfb2m 0.25140345 0.0014604
ENSMUSG00000025154    Arhgap19    0.239857569 0.0147666 ENSMUSG00000044022    Pcdhb21    0.251567229 0.0428181
ENSMUSG00000032064    Dixdc1    0.239860911 0.0021266 ENSMUSG00000054942    Fam73a 0.251672883 7.03E-08
ENSMUSG00000024067    Dpy30    0.239925563 0.0001233 ENSMUSG00000056962    Jmjd6    0.251965632 1.67E-05
ENSMUSG00000031311    Nono 0.240078463 1.86E-23 ENSMUSG00000074637    Sox2    0.252145009 1.91E-08
ENSMUSG00000041133    Smc1a 0.240240886 1.94E-12 ENSMUSG00000100005    B130024G19Rik 0.252184281 0.0245927
ENSMUSG00000039542    Ncam1    0.240468847 1.76E-06 ENSMUSG00000046519    Golph3l 0.252255269 0.0068466
ENSMUSG00000027966    Col11a1    0.240701372 2.91E-15 ENSMUSG00000040621    Gemin8    0.252455169 0.0104851
ENSMUSG00000007880    Arid1a 0.240763808 6.40E-08 ENSMUSG00000070890    Gm12794    0.252597379 0.0095018
ENSMUSG00000038518    Jarid2    0.241001542 0.0344177 ENSMUSG00000015668    Pdzd11    0.252942212 7.31E-06
ENSMUSG00000022174    Dad1    0.241030166 8.69E-05 ENSMUSG00000032249    Anp32a 0.253034875 4.11E-11
ENSMUSG00000045679    Pqlc3    0.241188903 0.043055 ENSMUSG00000058135    Gstm1    0.253088683 0.0421121
ENSMUSG00000037111    Setd7    0.241278823 6.19E-07 ENSMUSG00000022957    Itsn1    0.253172792 2.62E-05
ENSMUSG00000022449    Adamts20    0.241717982 0.0135744 ENSMUSG00000020091    Eif4ebp2    0.253329962 6.58E-05
ENSMUSG00000038967    Pdk2    0.241886237 0.0497932 ENSMUSG00000083261    Gm7816    0.253726695 0.0282792
ENSMUSG00000024201    Kdm4b 0.241910447 0.0020812 ENSMUSG00000020048    Hsp90b1    0.25403545 4.10E-39
ENSMUSG00000064127    Med14    0.242428368 2.24E-08 ENSMUSG00000031314    Taf1    0.254149652 7.19E-08
ENSMUSG00000027993    Trim2    0.243048233 0.0020369 ENSMUSG00000036678    Aaas 0.254212696 2.85E-08
ENSMUSG00000028678    Kif2c 0.243116598 6.53E-08 ENSMUSG00000055200    Sertad3    0.254277633 0.0412842
ENSMUSG00000053333    Dis3l2    0.243152845 0.0066978 ENSMUSG00000026147    Col9a1    0.254310599 0.0108954
ENSMUSG00000037426    Depdc5    0.243307488 0.0007859 ENSMUSG00000105263    RP24-230J14.5    0.254530192 2.81E-11
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ENSMUSG00000017314    Mpp2    0.255001001 0.032157 ENSMUSG00000026032    Ndufb3    0.272361306 0.0005949
ENSMUSG00000061079    Zfp143    0.255005989 0.001188 ENSMUSG00000031839    Hsbp1    0.272541631 3.69E-05
ENSMUSG00000025558    Dock9    0.255417534 0.0003232 ENSMUSG00000038369    Ncoa6    0.272649045 1.55E-08
ENSMUSG00000024968    Rcor2    0.255474765 3.20E-06 ENSMUSG00000041498    Kif14    0.272735661 2.73E-05
ENSMUSG00000036777    Anln 0.255607659 1.54E-18 ENSMUSG00000029661    Col1a2    0.272926378 2.83E-38
ENSMUSG00000009828    Ick 0.255608633 0.0031584 ENSMUSG00000020267    Hint1    0.272954388 8.16E-13
ENSMUSG00000020180    Snrpd3    0.255808965 6.26E-10 ENSMUSG00000044927    H1fx 0.273069731 8.02E-05
ENSMUSG00000030541    Idh2    0.25581591 9.55E-15 ENSMUSG00000073590    3222401L13Rik 0.273164631 0.0282059
ENSMUSG00000031634    Ufsp2    0.255818852 0.0018656 ENSMUSG00000027641    Rbl1    0.273173651 3.71E-06
ENSMUSG00000030095    Tmem43    0.256060557 1.57E-05 ENSMUSG00000095339    Zscan4b 0.273219537 0.0026656
ENSMUSG00000026708    Cenpl 0.256256403 0.0081421 ENSMUSG00000024660    Incenp 0.273674267 3.12E-12
ENSMUSG00000018965    Ywhah 0.256326341 1.05E-11 ENSMUSG00000079435    Rpl36a 0.274753123 9.12E-23
ENSMUSG00000097439    Gm16754    0.256525148 0.0304088 ENSMUSG00000062380    Tubb3    0.275181593 0.0001088
ENSMUSG00000039599    Fam149b 0.256569996 0.007425 ENSMUSG00000034243    Golgb1    0.275434415 4.25E-06
ENSMUSG00000020456    Ogdh 0.257090855 1.56E-14 ENSMUSG00000032845    Alpk2    0.275983005 0.0126415
ENSMUSG00000027985    Lef1    0.257162182 0.0197575 ENSMUSG00000090247    Bloc1s1    0.27629903 0.000723
ENSMUSG00000071653    1810009A15Rik 0.257364834 0.0046321 ENSMUSG00000035401    2210018M11Rik 0.276348537 1.79E-05
ENSMUSG00000010830    Kdelr3    0.25738486 0.0327527 ENSMUSG00000024474    Ik 0.276592547 2.26E-11
ENSMUSG00000081007    Gm11543    0.257413385 0.0014159 ENSMUSG00000062070    Pgk1    0.276651999 0.0051369
ENSMUSG00000026727    Rsu1    0.257693827 6.35E-08 ENSMUSG00000025066    Sfr1    0.276966789 3.33E-10
ENSMUSG00000001025    S100a6    0.257833679 8.34E-14 ENSMUSG00000011884    Gltp 0.277407073 1.23E-06
ENSMUSG00000005774    Rfx5    0.257865884 0.024448 ENSMUSG00000072235    Tuba1a 0.277695012 1.04E-16
ENSMUSG00000001120    Pcbp3    0.258137857 0.0024754 ENSMUSG00000048108    Tmem72    0.277916406 0.0249756
ENSMUSG00000020277    Pfkl 0.258453335 0.0272931 ENSMUSG00000025212    Sfxn3    0.278227446 1.09E-05
ENSMUSG00000015932    Dstn 0.258492257 1.62E-10 ENSMUSG00000084304    Gm6142    0.278443609 0.0247004
ENSMUSG00000020758    Itgb4    0.258814083 2.14E-07 ENSMUSG00000032316    Clk3    0.278501191 0.0008635
ENSMUSG00000029436    Mmp17    0.258986591 1.89E-09 ENSMUSG00000030555    Ttc23    0.278571965 0.0014913
ENSMUSG00000020593    Lpin1    0.259204558 0.024272 ENSMUSG00000021975    Ints9    0.279090618 0.0101151
ENSMUSG00000035835    Lppr3    0.259705715 2.23E-05 ENSMUSG00000048747    E130114P18Rik 0.279289174 0.0234125
ENSMUSG00000042510    AA986860    0.259828521 0.0368713 ENSMUSG00000027605    Acss2    0.279361648 0.0249812
ENSMUSG00000003779    Kif20a 0.260242946 2.70E-09 ENSMUSG00000033429    Mcee 0.279382157 0.0189026
ENSMUSG00000007721    Ccdc124    0.260305135 7.80E-05 ENSMUSG00000051989    Smim11    0.279686926 0.00608
ENSMUSG00000101970    1810026B05Rik 0.261012984 0.0172439 ENSMUSG00000022956    Atp5o 0.279782735 8.99E-11
ENSMUSG00000066456    Hmgn3    0.261033516 1.22E-05 ENSMUSG00000006567    Atp7b 0.280076045 0.021926
ENSMUSG00000067279    Ppp1r3c 0.261088405 0.0199366 ENSMUSG00000021643    Serf1    0.280140226 0.0196943
ENSMUSG00000027977    Ndst3    0.261147991 0.0078273 ENSMUSG00000027715    Ccna2    0.280575217 9.52E-21
ENSMUSG00000008398    Elk3    0.261551856 1.38E-07 ENSMUSG00000032294    Pkm 0.280612147 5.09E-09
ENSMUSG00000021537    Cetn3    0.261687209 0.0002362 ENSMUSG00000040048    Ndufb10    0.28064006 3.34E-06
ENSMUSG00000026817    Ak1    0.262036986 2.46E-06 ENSMUSG00000059291    Rpl11    0.280671424 1.80E-21
ENSMUSG00000054428    Atpif1    0.262251843 2.35E-05 ENSMUSG00000028639    Ybx1    0.281582475 2.40E-27
ENSMUSG00000039943    Plcb4    0.262291337 0.0081192 ENSMUSG00000019873    Reep3    0.281704601 8.91E-09
ENSMUSG00000030695    Aldoa 0.262543379 0.0025579 ENSMUSG00000009569    Mkl2    0.281737738 3.24E-06
ENSMUSG00000049775    Tmsb4x 0.262653627 6.26E-18 ENSMUSG00000019124    Scrn1    0.282065341 2.34E-10
ENSMUSG00000025207    Sema4g 0.262696084 0.0265896 ENSMUSG00000031125    3830403N18Rik 0.28236488 1.91E-05
ENSMUSG00000009739    Pou6f1    0.26273438 0.0218424 ENSMUSG00000036854    Hspb6    0.282588296 0.0009614
ENSMUSG00000031166    Wdr13    0.263112095 0.0006509 ENSMUSG00000022982    Sod1    0.282670709 2.23E-11
ENSMUSG00000003033    Ap1m1    0.264443276 3.45E-05 ENSMUSG00000046711    Hmga1    0.282708828 1.37E-24
ENSMUSG00000019883    Echdc1    0.264616516 0.0047322 ENSMUSG00000020801    Med31    0.282976912 0.0088419
ENSMUSG00000063524    Eno1    0.265247663 0.0011753 ENSMUSG00000048764    Tmprss11f 0.283460808 0.0128079
ENSMUSG00000067924    Cxx1b 0.265534701 0.0086973 ENSMUSG00000024206    Rfx2    0.283770618 0.0226774
ENSMUSG00000035048    Anapc13    0.265645685 0.0060081 ENSMUSG00000036223    Ska1    0.283855074 0.0009605
ENSMUSG00000030847    Bag3    0.26585153 5.24E-08 ENSMUSG00000028398    Tmem261    0.284198676 0.0023907
ENSMUSG00000034413    Neurl1b 0.266278923 0.0103855 ENSMUSG00000019055    Plod1    0.284545235 8.55E-10
ENSMUSG00000031590    Frg1    0.266306805 0.0016559 ENSMUSG00000026578    Ccdc181    0.284657451 0.0109588
ENSMUSG00000028040    Efna4    0.266400272 0.0318559 ENSMUSG00000002732    Fkbp7    0.284716415 0.0206708
ENSMUSG00000029763    Exoc4    0.266469871 1.64E-07 ENSMUSG00000022051    Bnip3l 0.284741227 5.90E-05
ENSMUSG00000033237    Arid2    0.266667437 5.06E-08 ENSMUSG00000031666    Rbl2    0.284809987 0.0089215
ENSMUSG00000047123    Ticam1    0.266768173 0.0191061 ENSMUSG00000018909    Arrb1    0.285481617 0.0114858
ENSMUSG00000029231    Pdgfra 0.266775995 0.0319479 ENSMUSG00000038252    Ncapd2    0.285596274 2.27E-12
ENSMUSG00000038965    Ube2l3    0.266921342 9.22E-15 ENSMUSG00000030677    Kif22    0.286196598 1.52E-08
ENSMUSG00000022280    Rnf19a 0.267563683 0.0004542 ENSMUSG00000022321    Cdh10    0.286270968 0.0020652
ENSMUSG00000051550    Zfp579    0.26820358 0.0254569 ENSMUSG00000039168    Dap 0.286507284 1.46E-06
ENSMUSG00000069910    Spdl1    0.268311476 9.20E-06 ENSMUSG00000037544    Dlgap5    0.286998627 2.76E-07
ENSMUSG00000032220    Myo1e 0.268393916 4.21E-10 ENSMUSG00000096210    H1f0    0.287039009 1.28E-39
ENSMUSG00000003814    Calr 0.268526787 9.06E-30 ENSMUSG00000062901    Klhl24    0.287260269 0.0021519
ENSMUSG00000020897    Aurkb 0.268819213 5.47E-08 ENSMUSG00000006476    Nsmf 0.287363532 2.02E-06
ENSMUSG00000037605    Adgrl3    0.269215592 1.13E-05 ENSMUSG00000100967    Gm29666    0.288078988 0.004153
ENSMUSG00000042312    S100a13    0.269462318 0.0295646 ENSMUSG00000026932    Nacc2    0.288474879 1.48E-07
ENSMUSG00000056671    Prelid2    0.269812526 0.0293559 ENSMUSG00000013921    Clip3    0.28884044 2.41E-06
ENSMUSG00000097055    Gm4419    0.27005326 0.0089676 ENSMUSG00000056629    Fkbp2    0.289227731 0.0004266
ENSMUSG00000037890    Wdr19    0.270183564 0.0144001 ENSMUSG00000079480    Pin4    0.289270408 0.0006868
ENSMUSG00000034818    Celf5    0.270390197 0.0070566 ENSMUSG00000030432    Rpl28    0.289370294 3.28E-26
ENSMUSG00000022034    Esco2    0.270993695 0.008932 ENSMUSG00000041959    S100a10    0.290227836 5.41E-21
ENSMUSG00000051378    Kif18b 0.271348175 3.02E-07 ENSMUSG00000021838    Samd4    0.290562922 1.04E-05
ENSMUSG00000037325    Bbs7    0.271416248 0.008127 ENSMUSG00000027160    Ccdc34    0.291392082 3.86E-05
ENSMUSG00000082908    Gm13736    0.271428211 0.0253162 ENSMUSG00000019230    Lhx9    0.291658533 0.0192075
ENSMUSG00000047534    Mis18bp1    0.271445857 3.99E-06 ENSMUSG00000036438    Calm2    0.291933774 7.32E-26
ENSMUSG00000027102    Hoxd8    0.271680069 0.0005222 ENSMUSG00000050908    Tvp23a 0.292146919 0.0001862
ENSMUSG00000046330    Rpl37a 0.271869238 2.84E-19 ENSMUSG00000027130    Slc12a6    0.293039356 0.002683
ENSMUSG00000029516    Cit 0.27197219 0.0002889 ENSMUSG00000022707    Gbe1    0.293161305 0.0009884
ENSMUSG00000004032    Gstm5    0.272261824 0.0212682 ENSMUSG00000028218    Fam92a 0.293198941 1.84E-09
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ENSMUSG00000021485    Mxd3    0.293277052 0.0015618 ENSMUSG00000020493    Prr11    0.319301183 5.71E-12
ENSMUSG00000041895    Wipi1    0.2934047 0.000548 ENSMUSG00000031231    Cox7b 0.319660843 1.50E-13
ENSMUSG00000036565    Ttyh3    0.293478959 1.24E-07 ENSMUSG00000056055    Sag 0.319751558 0.0017632
ENSMUSG00000023055    Calcoco1    0.293771012 0.0002308 ENSMUSG00000032527    Pccb 0.319782918 0.0007733
ENSMUSG00000015656    Hspa8    0.29453256 1.69E-37 ENSMUSG00000022351    Sqle 0.319871127 7.78E-09
ENSMUSG00000102700    Gm38312    0.294658681 1.75E-05 ENSMUSG00000048388    Fam171b 0.320063696 0.0006662
ENSMUSG00000079884    Gm10698    0.294937878 0.0010848 ENSMUSG00000078566    Bnip3    0.320635134 0.0078187
ENSMUSG00000066043    Phactr4    0.294963842 0.0002544 ENSMUSG00000004151    Etv1    0.320640792 0.0069356
ENSMUSG00000012609    Ttll5    0.295466472 0.0001528 ENSMUSG00000026987    Baz2b 0.320705655 0.0001489
ENSMUSG00000021486    Prelid1    0.295529949 4.20E-14 ENSMUSG00000022421    Nptxr 0.321403908 9.59E-10
ENSMUSG00000001467    Cyp51    0.29592032 1.40E-05 ENSMUSG00000038481    Cdk19    0.321788097 0.000251
ENSMUSG00000038126    Mphosph9    0.296337649 3.41E-05 ENSMUSG00000038371    Sbf2    0.322405778 2.30E-11
ENSMUSG00000069601    Ank3    0.297018661 7.94E-10 ENSMUSG00000028645    Slc2a1    0.322995835 0.0068067
ENSMUSG00000003153    Slc2a3    0.297383259 0.0147251 ENSMUSG00000064339    mt-Rnr2    0.323134179 8.70E-12
ENSMUSG00000023505    Cdca3    0.297625124 1.91E-07 ENSMUSG00000071547    Nt5dc2    0.323391036 1.05E-11
ENSMUSG00000036667    Tcaf1    0.297680297 4.25E-05 ENSMUSG00000092166    Gm7942    0.323863362 0.0001614
ENSMUSG00000071528    Usmg5    0.298037783 2.02E-06 ENSMUSG00000083773    Gm13394    0.324398533 0.0048234
ENSMUSG00000041126    H2afv 0.298257352 4.87E-05 ENSMUSG00000041064    Pif1    0.32504649 8.44E-05
ENSMUSG00000032883    Acsl3    0.298501583 1.68E-06 ENSMUSG00000021754    Map3k1    0.325637168 0.0015537
ENSMUSG00000032218    Ccnb2    0.298668246 2.47E-10 ENSMUSG00000063450    Syne2    0.325932548 1.53E-08
ENSMUSG00000030321    Efcab12    0.29873109 0.0157075 ENSMUSG00000023089    Ndufa5    0.326029543 3.24E-07
ENSMUSG00000001289    Pfdn5    0.298958953 6.06E-09 ENSMUSG00000025203    Scd2    0.32624725 4.55E-10
ENSMUSG00000027496    Aurka 0.29951365 6.73E-11 ENSMUSG00000044627    Swi5    0.327013954 4.38E-14
ENSMUSG00000029910    Mad2l1    0.299520614 3.86E-11 ENSMUSG00000021520    Uqcrb 0.327092277 5.55E-08
ENSMUSG00000037725    Ckap2    0.299645013 3.71E-08 ENSMUSG00000026193    Fn1    0.327353138 1.32E-42
ENSMUSG00000068391    Chrac1    0.299874196 4.94E-05 ENSMUSG00000034192    Lsm3    0.327680875 4.38E-09
ENSMUSG00000033685    Ucp2    0.300249394 1.40E-11 ENSMUSG00000032377    Plscr4    0.328162169 0.0047656
ENSMUSG00000032782    Cntrob 0.300394543 1.45E-05 ENSMUSG00000047604    Frat2    0.328405664 0.0075744
ENSMUSG00000001403    Ube2c 0.301103522 1.48E-13 ENSMUSG00000093674    Rpl41    0.328886329 2.80E-43
ENSMUSG00000022463    Srebf2    0.302135922 4.48E-13 ENSMUSG00000036242    3632451O06Rik 0.32959721 0.0081648
ENSMUSG00000018678    Sp2    0.30315056 4.77E-06 ENSMUSG00000039771    Polr2j 0.329941752 1.31E-10
ENSMUSG00000036985    Zdhhc9    0.303617428 0.000223 ENSMUSG00000066553    Gm6969    0.330620791 0.0028718
ENSMUSG00000050334    C130071C03Rik 0.303755099 0.0148044 ENSMUSG00000091537    Tma7    0.331862413 5.92E-08
ENSMUSG00000029465    Arpc3    0.304230435 1.25E-11 ENSMUSG00000018593    Sparc 0.331920833 1.87E-45
ENSMUSG00000027952    Pmvk 0.304453484 0.0020009 ENSMUSG00000029022    Miip 0.332088931 0.0003292
ENSMUSG00000056904    Gm5620    0.304507418 0.013595 ENSMUSG00000024376    Epb4.1l4a 0.33221461 1.62E-05
ENSMUSG00000048644    Ctxn1    0.304575546 0.0120504 ENSMUSG00000002409    Dyrk1b 0.332360745 0.0075152
ENSMUSG00000042116    Vwa1    0.306188672 0.0031083 ENSMUSG00000015944    Gatsl2    0.332520393 1.73E-05
ENSMUSG00000053470    Kdm3a 0.306206107 0.0058631 ENSMUSG00000030103    Bhlhe40    0.333629513 0.0027743
ENSMUSG00000062647    Rpl7a 0.306278414 1.11E-29 ENSMUSG00000068397    Gm10240    0.333895411 6.03E-10
ENSMUSG00000084159    Gm12696    0.306510358 0.0028593 ENSMUSG00000025369    Smarcc2    0.333929435 1.99E-18
ENSMUSG00000083563    Gm13340    0.306686885 0.0099458 ENSMUSG00000068220    Lgals1    0.334801987 2.28E-48
ENSMUSG00000031155    Pim2    0.307577653 0.0026456 ENSMUSG00000104413    Gm37065    0.335228552 0.0045837
ENSMUSG00000027331    Knstrn 0.307612758 3.84E-15 ENSMUSG00000005125    Ndrg1    0.335888969 0.0070241
ENSMUSG00000001119    Col6a1    0.307818456 1.03E-11 ENSMUSG00000035919    Bbs9    0.33613089 0.0025346
ENSMUSG00000033276    Stk36    0.308163913 0.0116408 ENSMUSG00000072214    Sept5    0.336261201 2.30E-05
ENSMUSG00000037573    Tob1    0.308659618 4.23E-05 ENSMUSG00000030022    Adamts9    0.33630205 0.0003137
ENSMUSG00000001131    Timp1    0.308720579 2.52E-14 ENSMUSG00000035834    Polr3g 0.337330563 9.78E-05
ENSMUSG00000025035    Arl3    0.309169842 0.0004527 ENSMUSG00000027469    Tpx2    0.33777417 5.88E-26
ENSMUSG00000042804    Gpr153    0.309443891 0.0045315 ENSMUSG00000042541    Shfm1    0.33842989 5.30E-13
ENSMUSG00000015217    Hmgb3    0.30946547 2.27E-09 ENSMUSG00000036768    Kif15    0.338696573 2.85E-10
ENSMUSG00000034771    Tle2    0.309526754 0.0110363 ENSMUSG00000004267    Eno2    0.339574748 0.0062039
ENSMUSG00000048148    Nwd1    0.309550394 0.0116003 ENSMUSG00000031799    Tpm4    0.339931856 8.50E-28
ENSMUSG00000031843    Mphosph6    0.309567258 0.0012134 ENSMUSG00000005682    Pan2    0.340075085 7.47E-05
ENSMUSG00000019837    Gtf3c6    0.309865617 5.94E-05 ENSMUSG00000085787    Gm13092    0.340395535 0.0059356
ENSMUSG00000081128    Gm13328    0.310196067 0.0127408 ENSMUSG00000018906    P4ha2    0.340652834 0.0004954
ENSMUSG00000024975    Pdcd4        0.310365315 0.0052437 ENSMUSG00000020022    Ndufa12    0.341328026 1.56E-10
ENSMUSG00000046179    E2f8    0.310517768 2.28E-07 ENSMUSG00000034906    Ncaph 0.34340848 2.32E-11
ENSMUSG00000019820    Utrn 0.31058429 2.14E-13 ENSMUSG00000050555    Hyls1    0.343843863 0.0004379
ENSMUSG00000051285    Pcmtd1    0.310588642 0.0011027 ENSMUSG00000012443    Kif11    0.344296791 4.20E-17
ENSMUSG00000020109    Dnajb12    0.310956168 5.41E-07 ENSMUSG00000028211    Trp53inp1    0.344327383 0.000142
ENSMUSG00000047146    Tet1    0.311829144 0.0118695 ENSMUSG00000046432    Ngfrap1    0.344419365 1.63E-12
ENSMUSG00000034868    Myl12b 0.312180097 2.13E-12 ENSMUSG00000062981    Mrpl42    0.34455256 1.38E-13
ENSMUSG00000037060    Prkcdbp 0.313319679 2.00E-09 ENSMUSG00000020949    Fkbp3    0.34488777 1.02E-12
ENSMUSG00000061887    Ssbp3    0.313770667 2.72E-05 ENSMUSG00000025791    Pgm2    0.345154054 4.47E-08
ENSMUSG00000037706    Cd81    0.314095712 6.25E-12 ENSMUSG00000021697    Depdc1b 0.345281885 0.0025632
ENSMUSG00000096472    Cdkn2d 0.314337455 0.0001455 ENSMUSG00000018362    Kpna2    0.345735646 9.29E-27
ENSMUSG00000028463    Car9    0.315360711 0.0108251 ENSMUSG00000037235    Mxd4        0.345799398 0.000134
ENSMUSG00000027778    Ift80    0.31561182 3.14E-05 ENSMUSG00000045294    Insig1    0.346508635 3.83E-07
ENSMUSG00000025978    Rftn2    0.315713137 0.0038775 ENSMUSG00000032254    Kif23    0.346862803 1.16E-19
ENSMUSG00000036882    Arhgap33    0.315753067 0.0112797 ENSMUSG00000028943    Espn 0.347801096 4.61E-10
ENSMUSG00000040624    Plekhg1    0.315771524 0.0007659 ENSMUSG00000021097    Clmn 0.348550964 0.0007696
ENSMUSG00000025006    Sorbs1    0.315877304 1.94E-14 ENSMUSG00000055675    Kbtbd11    0.348983389 2.85E-05
ENSMUSG00000026131    Dst 0.316163527 0.0006105 ENSMUSG00000023456    Tpi1    0.349022004 8.21E-05
ENSMUSG00000078300    Gm2606    0.316678003 0.0027418 ENSMUSG00000051517    Arhgef39    0.349087272 4.55E-05
ENSMUSG00000023064    Sncg 0.316892606 0.006334 ENSMUSG00000097796    Gm16702    0.349155201 0.0025691
ENSMUSG00000026335    Pam 0.317447584 6.19E-22 ENSMUSG00000059401    Mamld1    0.349387053 0.0002954
ENSMUSG00000054626    Xlr 0.31769859 9.97E-06 ENSMUSG00000020330    Hmmr 0.349632224 2.17E-20
ENSMUSG00000043073    Usp17le 0.318009324 0.0009516 ENSMUSG00000050856    Atp5k 0.350000706 1.06E-06
ENSMUSG00000062328    Rpl17    0.318206705 2.10E-40 ENSMUSG00000031617    Tmem184c 0.353362269 8.98E-07
ENSMUSG00000090394    4930523C07Rik 0.31899104 0.0020543 ENSMUSG00000019916    P4ha1    0.3535996 0.0005502
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ENSMUSG00000032398    Snapc5    0.353789174 0.0003863 ENSMUSG00000020427    Igfbp3    0.450255365 2.63E-23
ENSMUSG00000074802    Gas2l3    0.355625885 1.77E-18 ENSMUSG00000031245    Hmgn5    0.451586868 3.76E-14
ENSMUSG00000060429    Sntb1    0.356408527 3.59E-11 ENSMUSG00000100801    Gm15459    0.451889317 9.74E-26
ENSMUSG00000097554    Gm26825    0.358727649 9.48E-20 ENSMUSG00000028464    Tpm2    0.452450625 5.16E-12
ENSMUSG00000075610    Tmem92    0.359367821 0.0004082 ENSMUSG00000047557    Lxn 0.45495059 2.26E-13
ENSMUSG00000090714    Zscan4d 0.359718958 0.0009232 ENSMUSG00000020601    Trib2    0.45614354 2.10E-05
ENSMUSG00000074506    Gm10705    0.36113103 0.0023395 ENSMUSG00000037010    Apln 0.456986438 0.000202
ENSMUSG00000020150    Gamt 0.361957224 4.82E-05 ENSMUSG00000001870    Ltbp1    0.457888604 5.65E-11
ENSMUSG00000025290    Rps24    0.362065618 4.92E-45 ENSMUSG00000020263    Appl2    0.458760223 1.80E-08
ENSMUSG00000046329    Slc25a23    0.362160502 7.37E-10 ENSMUSG00000050914    Ankrd37    0.462803241 0.0001273
ENSMUSG00000034311    Kif4    0.362490148 1.88E-14 ENSMUSG00000033952    Aspm 0.463333419 2.07E-26
ENSMUSG00000025362    Rps26    0.362920399 1.01E-51 ENSMUSG00000021253    Tgfb3    0.467246627 6.58E-05
ENSMUSG00000032332    Col12a1    0.362927729 0.0009663 ENSMUSG00000087687    Pet100    0.468238267 6.40E-05
ENSMUSG00000055415    Atp10b 0.363184312 0.0001647 ENSMUSG00000020326    Ccng1        0.470461284 3.04E-32
ENSMUSG00000029209    Gnpda2    0.363190913 0.0001711 ENSMUSG00000000056    Narf 0.470944481 8.73E-05
ENSMUSG00000064372    mt-Tp 0.365154709 0.0002125 ENSMUSG00000029385    Ccng2    0.474152871 1.41E-08
ENSMUSG00000026768    Itga8    0.367569433 0.0010103 ENSMUSG00000029304    Spp1    0.47931031 3.99E-89
ENSMUSG00000074968    Ano3    0.368033564 0.0030136 ENSMUSG00000106334    WI1-49P9.2    0.480495257 5.77E-57
ENSMUSG00000031765    Mt1    0.368310958 1.20E-11 ENSMUSG00000055435    Maf 0.480744667 2.11E-07
ENSMUSG00000031987    Egln1    0.369542348 1.26E-10 ENSMUSG00000032193    Ldlr 0.483947608 1.05E-20
ENSMUSG00000090137    Uba52    0.369573648 6.60E-18 ENSMUSG00000062997    Rpl35    0.491120144 5.06E-46
ENSMUSG00000037613    Tnfrsf23    0.369726707 6.62E-14 ENSMUSG00000041453    Rpl21    0.498354569 2.14E-20
ENSMUSG00000004558    Ndrg2    0.370226578 0.0027983 ENSMUSG00000081455    Hmgb1-ps3    0.507663957 1.38E-05
ENSMUSG00000048327    Ckap2l 0.370248939 6.85E-19 ENSMUSG00000035105    Egln3    0.513738146 1.32E-05
ENSMUSG00000036977    Anapc10    0.37085065 0.0004041 ENSMUSG00000048758    Rpl29    0.516669545 3.48E-24
ENSMUSG00000027210    Meis2    0.371528424 9.70E-05 ENSMUSG00000038375    Trp53inp2        0.52545131 8.37E-14
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closely analogous licensable use plus Rightsholder's and/or CCC's costs and expenses
incurred in collecting such payment.
8. Miscellaneous.
8.1 User acknowledges that CCC may, from time to time, make changes or additions to the
Service or to these terms and conditions, and CCC reserves the right to send notice to the
User by electronic mail or otherwise for the purposes of notifying User of such changes or
additions; provided that any such changes or additions shall not apply to permissions already
secured and paid for.
8.2 Use of User-related information collected through the Service is governed by CCC’s
privacy policy, available online here:
http://www.copyright.com/content/cc3/en/tools/footer/privacypolicy.html.
8.3 The licensing transaction described in the Order Conﬁrmation is personal to User.
Therefore, User may not assign or transfer to any other person (whether a natural person or
an organization of any kind) the license created by the Order Conﬁrmation and these terms
and conditions or any rights granted hereunder; provided, however, that User may assign
such license in its entirety on written notice to CCC in the event of a transfer of all or
substantially all of User’s rights in the new material which includes the Work(s) licensed
under this Service.
8.4 No amendment or waiver of any terms is binding unless set forth in writing and signed
by the parties. The Rightsholder and CCC hereby object to any terms contained in any
writing prepared by the User or its principals, employees, agents or afﬁliates and purporting
to govern or otherwise relate to the licensing transaction described in the Order
Conﬁrmation, which terms are in any way inconsistent with any terms set forth in the Order
Conﬁrmation and/or in these terms and conditions or CCC's standard operating procedures,
whether such writing is prepared prior to, simultaneously with or subsequent to the Order
Conﬁrmation, and whether such writing appears on a copy of the Order Conﬁrmation or in a
separate instrument.
8.5 The licensing transaction described in the Order Conﬁrmation document shall be
governed by and construed under the law of the State of New York, USA, without regard to
the principles thereof of conﬂicts of law. Any case, controversy, suit, action, or proceeding
arising out of, in connection with, or related to such licensing transaction shall be brought, at
CCC's sole discretion, in any federal or state court located in the County of New York, State
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of New York, USA, or in any federal or state court whose geographical jurisdiction covers
the location of the Rightsholder set forth in the Order Conﬁrmation. The parties expressly
submit to the personal jurisdiction and venue of each such federal or state court.If you have
any comments or questions about the Service or Copyright Clearance Center, please contact
us at 978-750-8400 or send an e-mail to info@copyright.com.
v 1.1
Questions?  customercare@copyright.com  or  +1-­855-­239-­3415  (toll  free  in  the  US)  or
+1-­978-­646-­2777.
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Terms  and  Conditions
INTRODUCTION
1. The publisher for this copyrighted material is Elsevier.  By clicking "accept" in connection
with completing this licensing transaction, you agree that the following terms and conditions
apply to this transaction (along with the Billing and Payment terms and conditions
established by Copyright Clearance Center, Inc. ("CCC"), at the time that you opened your
Rightslink account and that are available at any time at http://myaccount.copyright.com).
GENERAL TERMS
2. Elsevier hereby grants you permission to reproduce the aforementioned material subject to
the terms and conditions indicated.
3. Acknowledgement: If any part of the material to be used (for example, ﬁgures) has
appeared in our publication with credit or acknowledgement to another source, permission
must also be sought from that source.  If such permission is not obtained then that material
may not be included in your publication/copies. Suitable acknowledgement to the source
must be made, either as a footnote or in a reference list at the end of your publication, as
follows:
"Reprinted from Publication title, Vol /edition number, Author(s), Title of article / title of
chapter, Pages No., Copyright (Year), with permission from Elsevier [OR APPLICABLE
SOCIETY COPYRIGHT OWNER]." Also Lancet special credit - "Reprinted from The
Lancet, Vol. number, Author(s), Title of article, Pages No., Copyright (Year), with
permission from Elsevier."
4. Reproduction of this material is conﬁned to the purpose and/or media for which
permission is hereby given.
5. Altering/Modifying Material: Not Permitted. However ﬁgures and illustrations may be
altered/adapted minimally to serve your work. Any other abbreviations, additions, deletions
and/or any other alterations shall be made only with prior written authorization of Elsevier
Ltd. (Please contact Elsevier at permissions@elsevier.com). No modiﬁcations can be made
to any Lancet ﬁgures/tables and they must be reproduced in full.
6. If the permission fee for the requested use of our material is waived in this instance,
please be advised that your future requests for Elsevier materials may attract a fee.
7. Reservation of Rights: Publisher reserves all rights not speciﬁcally granted in the
combination of (i) the license details provided by you and accepted in the course of this
licensing transaction, (ii) these terms and conditions and (iii) CCC's Billing and Payment
terms and conditions.
8. License Contingent Upon Payment: While you may exercise the rights licensed
immediately upon issuance of the license at the end of the licensing process for the
transaction, provided that you have disclosed complete and accurate details of your proposed
use, no license is ﬁnally effective unless and until full payment is received from you (either
by publisher or by CCC) as provided in CCC's Billing and Payment terms and conditions.  If
full payment is not received on a timely basis, then any license preliminarily granted shall be
deemed automatically revoked and shall be void as if never granted.  Further, in the event
that you breach any of these terms and conditions or any of CCC's Billing and Payment
terms and conditions, the license is automatically revoked and shall be void as if never
granted.  Use of materials as described in a revoked license, as well as any use of the
materials beyond the scope of an unrevoked license, may constitute copyright infringement
and publisher reserves the right to take any and all action to protect its copyright in the
materials.
9. Warranties: Publisher makes no representations or warranties with respect to the licensed
material.
10. Indemnity: You hereby indemnify and agree to hold harmless publisher and CCC, and
their respective ofﬁcers, directors, employees and agents, from and against any and all
claims arising out of your use of the licensed material other than as speciﬁcally authorized
pursuant to this license.
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11. No Transfer of License: This license is personal to you and may not be sublicensed,
assigned, or transferred by you to any other person without publisher's written permission.
12. No Amendment Except in Writing: This license may not be amended except in a writing
signed by both parties (or, in the case of publisher, by CCC on publisher's behalf).
13. Objection to Contrary Terms: Publisher hereby objects to any terms contained in any
purchase order, acknowledgment, check endorsement or other writing prepared by you,
which terms are inconsistent with these terms and conditions or CCC's Billing and Payment
terms and conditions.  These terms and conditions, together with CCC's Billing and Payment
terms and conditions (which are incorporated herein), comprise the entire agreement
between you and publisher (and CCC) concerning this licensing transaction.  In the event of
any conﬂict between your obligations established by these terms and conditions and those
established by CCC's Billing and Payment terms and conditions, these terms and conditions
shall control.
14. Revocation: Elsevier or Copyright Clearance Center may deny the permissions described
in this License at their sole discretion, for any reason or no reason, with a full refund payable
to you.  Notice of such denial will be made using the contact information provided by you. 
Failure to receive such notice will not alter or invalidate the denial.  In no event will Elsevier
or Copyright Clearance Center be responsible or liable for any costs, expenses or damage
incurred by you as a result of a denial of your permission request, other than a refund of the
amount(s) paid by you to Elsevier and/or Copyright Clearance Center for denied
permissions.
LIMITED LICENSE
The following terms and conditions apply only to speciﬁc license types:
15. Translation: This permission is granted for non-exclusive world English rights only
unless your license was granted for translation rights. If you licensed translation rights you
may only translate this content into the languages you requested. A professional translator
must perform all translations and reproduce the content word for word preserving the
integrity of the article.
16. Posting licensed content on any Website: The following terms and conditions apply as
follows: Licensing material from an Elsevier journal: All content posted to the web site must
maintain the copyright information line on the bottom of each image; A hyper-text must be
included to the Homepage of the journal from which you are licensing at
http://www.sciencedirect.com/science/journal/xxxxx or the Elsevier homepage for books at
http://www.elsevier.com; Central Storage: This license does not include permission for a
scanned version of the material to be stored in a central repository such as that provided by
Heron/XanEdu.
Licensing material from an Elsevier book: A hyper-text link must be included to the Elsevier
homepage at http://www.elsevier.com . All content posted to the web site must maintain the
copyright information line on the bottom of each image.
Posting licensed content on Electronic reserve: In addition to the above the following
clauses are applicable: The web site must be password-protected and made available only to
bona ﬁde students registered on a relevant course. This permission is granted for 1 year only.
You may obtain a new license for future website posting.
17. For journal authors: the following clauses are applicable in addition to the above:
Preprints:
A preprint is an author's own write-up of research results and analysis, it has not been peer-
reviewed, nor has it had any other value added to it by a publisher (such as formatting,
copyright, technical enhancement etc.).
Authors can share their preprints anywhere at any time. Preprints should not be added to or
enhanced in any way in order to appear more like, or to substitute for, the ﬁnal versions of
articles however authors can update their preprints on arXiv or RePEc with their Accepted
Author Manuscript (see below).
 
 
 173 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
If accepted for publication, we encourage authors to link from the preprint to their formal
publication via its DOI. Millions of researchers have access to the formal publications on
ScienceDirect, and so links will help users to ﬁnd, access, cite and use the best available
version. Please note that Cell Press, The Lancet and some society-owned have different
preprint policies. Information on these policies is available on the journal homepage.
Accepted Author Manuscripts: An accepted author manuscript is the manuscript of an
article that has been accepted for publication and which typically includes author-
incorporated changes suggested during submission, peer review and editor-author
communications.
Authors can share their accepted author manuscript:
immediately
via their non-commercial person homepage or blog
by updating a preprint in arXiv or RePEc with the accepted manuscript
via their research institute or institutional repository for internal institutional
uses or as part of an invitation-only research collaboration work-group
directly by providing copies to their students or to research collaborators for
their personal use
for private scholarly sharing as part of an invitation-only work group on
commercial sites with which Elsevier has an agreement
After the embargo period
via non-commercial hosting platforms such as their institutional repository
via commercial sites with which Elsevier has an agreement
In all cases accepted manuscripts should:
link to the formal publication via its DOI
bear a CC-BY-NC-ND license - this is easy to do
if aggregated with other manuscripts, for example in a repository or other site, be
shared in alignment with our hosting policy not be added to or enhanced in any way to
appear more like, or to substitute for, the published journal article.
Published journal article (JPA): A published journal article (PJA) is the deﬁnitive ﬁnal
record of published research that appears or will appear in the journal and embodies all
value-adding publishing activities including peer review co-ordination, copy-editing,
formatting, (if relevant) pagination and online enrichment.
Policies for sharing publishing journal articles differ for subscription and gold open access
articles:
Subscription Articles: If you are an author, please share a link to your article rather than the
full-text. Millions of researchers have access to the formal publications on ScienceDirect,
and so links will help your users to ﬁnd, access, cite, and use the best available version.
Theses and dissertations which contain embedded PJAs as part of the formal submission can
be posted publicly by the awarding institution with DOI links back to the formal
publications on ScienceDirect.
If you are afﬁliated with a library that subscribes to ScienceDirect you have additional
private sharing rights for others' research accessed under that agreement. This includes use
for classroom teaching and internal training at the institution (including use in course packs
and courseware programs), and inclusion of the article for grant funding purposes.
Gold Open Access Articles: May be shared according to the author-selected end-user
license and should contain a CrossMark logo, the end user license, and a DOI link to the
formal publication on ScienceDirect.
Please refer to Elsevier's posting policy for further information.
18. For book authors the following clauses are applicable in addition to the above:  
Authors are permitted to place a brief summary of their work online only. You are not
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allowed to download and post the published electronic version of your chapter, nor may you
scan the printed edition to create an electronic version. Posting to a repository: Authors are
permitted to post a summary of their chapter only in their institution's repository.
19. Thesis/Dissertation: If your license is for use in a thesis/dissertation your thesis may be
submitted to your institution in either print or electronic form. Should your thesis be
published commercially, please reapply for permission. These requirements include
permission for the Library and Archives of Canada to supply single copies, on demand, of
the complete thesis and include permission for Proquest/UMI to supply single copies, on
demand, of the complete thesis. Should your thesis be published commercially, please
reapply for permission. Theses and dissertations which contain embedded PJAs as part of
the formal submission can be posted publicly by the awarding institution with DOI links
back to the formal publications on ScienceDirect.
 
Elsevier Open Access Terms and Conditions
You can publish open access with Elsevier in hundreds of open access journals or in nearly
2000 established subscription journals that support open access publishing. Permitted third
party re-use of these open access articles is deﬁned by the author's choice of Creative
Commons user license. See our open access license policy for more information.
Terms & Conditions applicable to all Open Access articles published with Elsevier:
Any reuse of the article must not represent the author as endorsing the adaptation of the
article nor should the article be modiﬁed in such a way as to damage the author's honour or
reputation. If any changes have been made, such changes must be clearly indicated.
The author(s) must be appropriately credited and we ask that you include the end user
license and a DOI link to the formal publication on ScienceDirect.
If any part of the material to be used (for example, ﬁgures) has appeared in our publication
with credit or acknowledgement to another source it is the responsibility of the user to
ensure their reuse complies with the terms and conditions determined by the rights holder.
Additional Terms & Conditions applicable to each Creative Commons user license:
CC BY: The CC-BY license allows users to copy, to create extracts, abstracts and new
works from the Article, to alter and revise the Article and to make commercial use of the
Article (including reuse and/or resale of the Article by commercial entities), provided the
user gives appropriate credit (with a link to the formal publication through the relevant
DOI), provides a link to the license, indicates if changes were made and the licensor is not
represented as endorsing the use made of the work. The full details of the license are
available at http://creativecommons.org/licenses/by/4.0.
CC BY NC SA: The CC BY-NC-SA license allows users to copy, to create extracts,
abstracts and new works from the Article, to alter and revise the Article, provided this is not
done for commercial purposes, and that the user gives appropriate credit (with a link to the
formal publication through the relevant DOI), provides a link to the license, indicates if
changes were made and the licensor is not represented as endorsing the use made of the
work. Further, any new works must be made available on the same conditions. The full
details of the license are available at http://creativecommons.org/licenses/by-nc-sa/4.0.
CC BY NC ND: The CC BY-NC-ND license allows users to copy and distribute the Article,
provided this is not done for commercial purposes and further does not permit distribution of
the Article if it is changed or edited in any way, and provided the user gives appropriate
credit (with a link to the formal publication through the relevant DOI), provides a link to the
license, and that the licensor is not represented as endorsing the use made of the work. The
full details of the license are available at http://creativecommons.org/licenses/by-nc-nd/4.0.
Any commercial reuse of Open Access articles published with a CC BY NC SA or CC BY
NC ND license requires permission from Elsevier and will be subject to a fee.
Commercial reuse includes:
Associating advertising with the full text of the Article
Charging fees for document delivery or access
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Article aggregation
Systematic distribution via e-mail lists or share buttons
Posting or linking by commercial companies for use by customers of those companies.
 
20. Other Conditions:
 
v1.9
Questions?  customercare@copyright.com  or  +1-­855-­239-­3415  (toll  free  in  the  US)  or
+1-­978-­646-­2777.
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NATURE  PUBLISHING  GROUP  LICENSE
  TERMS  AND  CONDITIONS
Oct  11,  2017
This Agreement between James Case ("You") and Nature Publishing Group ("Nature
Publishing Group") consists of your license details and the terms and conditions provided by
Nature Publishing Group and Copyright Clearance Center.
License  Number 4206110969024
License  date Oct  11,  2017
Licensed  Content  Publisher Nature  Publishing  Group
Licensed  Content  Publication Nature  Reviews  Microbiology
Licensed  Content  Title SARS  and  MERS:  recent  insights  into  emerging  coronaviruses
Licensed  Content  Author Emmie  de  Wit,  Neeltje  van  Doremalen,  Darryl  Falzarano,  Vincent  J.
Munster
Licensed  Content  Date Jun  27,  2016
Licensed  Content  Volume 14
Licensed  Content  Issue 8
Type  of  Use reuse  in  a  dissertation  /  thesis
Requestor  type academic/educational
Format print  and  electronic
Portion figures/tables/illustrations
Number  of
figures/tables/illustrations
1
High-­res  required no
Figures Figure  1b
Author  of  this  NPG  article no
Your  reference  number
Title  of  your  thesis  /
dissertation
Roles  of  the  Coronavirus  3'-­to-­5'  Exoribonuclease  and  N7-­
Methyltransferase  in  Counteracting  Innate  Immunity
Expected  completion  date May  2018
Estimated  size  (number  of
pages)
180
Requestor  Location James  Case
  Vanderbilt  University  Medical  Center
  MCN  D-­6221
  1161  21st  Avenue  South
  NASHVILLE,  TN  37232
  United  States
  Attn:  James  Case
Billing  Type Invoice
Billing  Address James  Case
  Vanderbilt  University  Medical  Center
  MCN  D-­6221
  1161  21st  Avenue  South
  NASHVILLE,  TN  37232
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United  States
  Attn:  James  B  Case
Total 0.00  USD
Terms  and  Conditions
Terms and Conditions for Permissions
Nature Publishing Group hereby grants you a non-exclusive license to reproduce this
material for this purpose, and for no other use,subject to the conditions below:
1.  NPG  warrants  that  it  has,  to  the  best  of  its  knowledge,  the  rights  to  license  reuse  of  this
material.  However,  you  should  ensure  that  the  material  you  are  requesting  is  original  to
Nature  Publishing  Group  and  does  not  carry  the  copyright  of  another  entity  (as  credited  in
the  published  version).  If  the  credit  line  on  any  part  of  the  material  you  have  requested
indicates  that  it  was  reprinted  or  adapted  by  NPG  with  permission  from  another  source,
then  you  should  also  seek  permission  from  that  source  to  reuse  the  material.
    
2.  Permission  granted  free  of  charge  for  material  in  print  is  also  usually  granted  for  any
electronic  version  of  that  work,  provided  that  the  material  is  incidental  to  the  work  as  a
whole  and  that  the  electronic  version  is  essentially  equivalent  to,  or  substitutes  for,  the
print  version.Where  print  permission  has  been  granted  for  a  fee,  separate  permission  must
be  obtained  for  any  additional,  electronic  re-­use  (unless,  as  in  the  case  of  a  full  paper,  this
has  already  been  accounted  for  during  your  initial  request  in  the  calculation  of  a  print
run).NB:  In  all  cases,  web-­based  use  of  full-­text  articles  must  be  authorized  separately
through  the  'Use  on  a  Web  Site'  option  when  requesting  permission.
    
3.  Permission  granted  for  a  first  edition  does  not  apply  to  second  and  subsequent  editions  and
for  editions  in  other  languages  (except  for  signatories  to  the  STM  Permissions  Guidelines,
or  where  the  first  edition  permission  was  granted  for  free).
    
4.  Nature  Publishing  Group's  permission  must  be  acknowledged  next  to  the  figure,  table  or
abstract  in  print.  In  electronic  form,  this  acknowledgement  must  be  visible  at  the  same
time  as  the  figure/table/abstract,  and  must  be  hyperlinked  to  the  journal's  homepage.
5.  The  credit  line  should  read:
  Reprinted  by  permission  from  Macmillan  Publishers  Ltd:  [JOURNAL  NAME]  (reference
citation),  copyright  (year  of  publication)
  For  AOP  papers,  the  credit  line  should  read:
  Reprinted  by  permission  from  Macmillan  Publishers  Ltd:  [JOURNAL  NAME],  advance  online
publication,  day  month  year  (doi:  10.1038/sj.[JOURNAL  ACRONYM].XXXXX)
  
Note:  For  republication  from  the  British  Journal  of  Cancer,  the  following  credit
lines  apply.
  Reprinted  by  permission  from  Macmillan  Publishers  Ltd  on  behalf  of  Cancer  Research  UK:
[JOURNAL  NAME]  (reference  citation),  copyright  (year  of  publication)For  AOP  papers,  the
credit  line  should  read:
  Reprinted  by  permission  from  Macmillan  Publishers  Ltd  on  behalf  of  Cancer  Research  UK:
[JOURNAL  NAME],  advance  online  publication,  day  month  year  (doi:  10.1038/sj.[JOURNAL
ACRONYM].XXXXX)  
  
  
6.  Adaptations  of  single  figures  do  not  require  NPG  approval.  However,  the  adaptation  should
be  credited  as  follows:
  
Adapted  by  permission  from  Macmillan  Publishers  Ltd:  [JOURNAL  NAME]  (reference
citation),  copyright  (year  of  publication)
  
Note:  For  adaptation  from  the  British  Journal  of  Cancer,  the  following  credit  line
applies.
  Adapted  by  permission  from  Macmillan  Publishers  Ltd  on  behalf  of  Cancer  Research  UK:
[JOURNAL  NAME]  (reference  citation),  copyright  (year  of  publication)
    
7.  Translations  of  401  words  up  to  a  whole  article  require  NPG  approval.  Please  visit
http://www.macmillanmedicalcommunications.com  for  more  information.Translations  of  up
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to  a  400  words  do  not  require  NPG  approval.  The  translation  should  be  credited  as  follows:
  
Translated  by  permission  from  Macmillan  Publishers  Ltd:  [JOURNAL  NAME]  (reference
citation),  copyright  (year  of  publication).
  
Note:  For  translation  from  the  British  Journal  of  Cancer,  the  following  credit  line
applies.
  Translated  by  permission  from  Macmillan  Publishers  Ltd  on  behalf  of  Cancer  Research  UK:
[JOURNAL  NAME]  (reference  citation),  copyright  (year  of  publication)
We are certain that all parties will beneﬁt from this agreement and wish you the best in the
use of this material. Thank you.
Special Terms:
v1.1
Questions?  customercare@copyright.com  or  +1-­855-­239-­3415  (toll  free  in  the  US)  or
+1-­978-­646-­2777.
 
 
 179 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
NATURE  PUBLISHING  GROUP  LICENSE
  TERMS  AND  CONDITIONS
Oct  12,  2017
This Agreement between James B Case ("You") and Nature Publishing Group ("Nature
Publishing Group") consists of your license details and the terms and conditions provided by
Nature Publishing Group and Copyright Clearance Center.
License  Number 4206600479276
License  date Oct  12,  2017
Licensed  Content  Publisher Nature  Publishing  Group
Licensed  Content  Publication Nature  Reviews  Microbiology
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